Conditions: Hypertension
Keywords: Hypertension Combination Therapy Zofenopril Nebivolol Fixed Dose Combination
Allocation: NON_RANDOMIZED | Intervention model: SEQUENTIAL
Enrollment: 277
Healthy volunteers: no

Brief summary:
Study to assess the anti-hypertensive efficacy and safety of the extemporaneous combination of Zofenopril 30 mg in combination with Amlodipine 5 mg or AML 10 mg in lowering the sitting diastolic BP after 8 weeks of treatment in patients with uncontrolled BP previously treated with Zofenopril or Amlodipine (5 mg) monotherapies for at least 4 weeks.

Detailed description:
Approximately 290 patients are planned to be screened to ensure at least 216 patients complete the run-in period and start with the assessment period.

Patients with Grade 1-2 hypertensive patients (blood pressure \[BP\] ranging from ≥140/90 mmHg to ≤179/109 mmHg) on treatment with any angiotensin converting enzyme inhibitors (ACE-i) including Zofenopril (ZOF)30 mg or with calcium channel blockers (CCBs) including Amlodipine (AML)5 mg will be screened for eligibility (Visit 1).

Allowed CCBs: Felodipine, isradipine, lacidipine, lercanidipine, nicardipine, nifedipine, and nisoldipine. Patients treated with other dosages of ZOF (other than 30 mg) are not allowed to be screened. After screening, on the same day, eligible patients, will enter into a 4-week run-in period, during which patients on other ACE-i will be assigned to monotherapy with ZOF 30 mg while patients on CCBs will be assigned to monotherapy with AML 5 mg for 4 weeks. Patients with on-going treatment zofenopril 30 mg and amlodipine 5mg will continue on the same treatment for 4 weeks.

After the run-in period (4 weeks ± 2 days), BP will be further assessed (Visit 2), if BP levels are over the defined controlled target goal, sitting Systolic Blood Pressure (SBP)/Diastolic Blood Pressure (DBP) \>130/80 mmHg, treatment is well tolerated and adherence to the treatments ranges from 80% to 120%, patients will enter the assessment period, where they will be assigned to the extemporaneous combination of ZOF 30 mg and AML 5 mg. At Visit 2 patients with SBP/DBP values classified as Grade 3 (SBP ≥ 180 or DBP ≥ 110 mmHg) hypertension will be withdrawn from the study.

If patients, at Visit 2, after the run-in period, have a controlled BP (sitting SBP/DBP≤130/80 mmHg) or do not tolerate the treatment or have an adherence range below 80% or superior to 120%, they will be withdrawn from the study.

The patients will be assessed for further 8 weeks (assessment period). After 4 weeks ± 2 days from Visit 2,during the assessment period patients receiving the extemporaneous combination of ZOF 30 mg and AML 5 mg, will be further evaluated (Visit 3): controlled patients (sitting SBP/DBP ≤130/80 mmHg) will continue the same extemporaneous combination for additional 4 weeks ± 2 days, while uncontrolled patients (sitting SBP/DBP \>130/80 mmHg) will be up-titrated from ZOF/AML 30/5 mg to ZOF/AML 30/10 mg for further 4 weeks ± 2 days. At Visit 3 patients with SBP/DBP values classified as Grade 3 (SBP ≥ 180 or DBP ≥ 110 mmHg) hypertension will be withdrawn from the study. If patients at Visit 3, do not tolerate the extemporaneous combination treatment or they have an adherence range below 80% or superior to 120%, they will be withdrawn from the study.

At the end of the assessment period (8 weeks ± 4 days) at Visit 4, the anti-hypertensive effect of the extemporaneous combination (ZOF/AML 30/5 mg and ZOF/AML 30/10 mg) will be evaluated.

Efforts will be made to achieve 1:1 ratio in the enrolment of patients receiving any ACE-i or allowed CCBs (refer to section Subject Study Phases Duration for allowed CCBs). At Visit 2, a minimum of 45% of uncontrolled patients receiving treatment with ZOF 30 mg or AML 5 mg are required to enter the assessment period, in order to maintain a balance between the 2 treatments during the assessment period.

Arms:
arm 1: Single dose Phase (4 weeks): patients will be treated with Zofenopril 30 mg. Combination Phase (8 weeks) uncontrolled patients will be treated with the extemporaneous combination of Zofenopril 30 mg and Amlodipine 5mg for 4 weeks. Amlodipine 10mg will replace Amlodipine 5mg in uncontrolled patients for further 4 weeks while controlled patients with Zofenopril 30mg/Amlodipine 5mg will continue with the same therapy. arm 2: Single dose Phase (4 weeks): patients will be treated with Amlodipine 5 mg. Combination Phase (8 weeks) uncontrolled patients will be treated with the extemporaneous combination of Zofenopril 30 mg and Amlodipine 5mg for 4 weeks. Amlodipine 10mg will replace Amlodipine 5mg in uncontrolled patients for further 4 weeks while controlled patients with Zofenopril 30mg/Amlodipine 5mg will continue with the same therapy.

Interventions: intervention 1: Zofenopril intervention 2: Amlodipine
Intervention descriptions: intervention 1: Film-Coated tablets administered orally once daily according instructions provided by Principal Investigator. intervention 2: Tablets of 5mg and 10mg administered orally once daily according instructions provided by Principal Investigator.

Protocol document:
Prot_000.pdf: 
 
Corporate Medical Department 
Protocol Template 
Identification Number 
Version Number 
State 
Effective date 
FORM-000050125 
2.0, CURRENT 
Effective 
08, Jan 2021 
Enclosure to:   □ Guideline              □ Policy              x Procedure            □ Working Instruction 
 
Sponsor: Menarini International Operations Luxembourg SA 
Study Code: : MEIN/20/ZoAm-Hyp/001 
Protocol Version 1 .0   of 1     23/04/2021 
  
 
Pag. 1 a 91 
 
 
PROTOCOL TITLE 
CLINICAL STUDY PROTOCOL 
 
 
Interventional clinical trial to assess efficacy and safety of the extemporaneous combination of 
zofenopril calcium and amlodipine in grade 1-2 hypertensive patients versus each monotherapy – 
(MASOLINO Study) 
 
 
Protocol Code  
 
MEIN/20/ZoAm-Hyp/001 
 
EudraCT (or National Clinical 
Trial Identified Number) 
2021-000745-40 
Protocol Phase (if applicable) 
IV 
Study type and design 
Interventional, multi-centre, open-label study 
Protocol Version Number 
1.0 
Protocol Version Date 
23 April 2021 
Sponsor and address 
Menarini International Operations Luxembourg SA 
Registered Offices: 1, Avenue de la Gare L-1611 Luxembourg 
Operative Offices: 5D, Rue Eugene Ruppert L-2453 Luxembourg 
 
Ph. (+352) 2649761 - Fax (+352) 26497649 
Coordinating Investigator 
Professor Massimo Volpe 
Via Di Grottarossa, 1035 Roma 
 
CRO 
BIORASI 


 
Corporate Medical Department 
 
Identification Number 
Version Number 
State 
Effective date 
FORM-000050125 
2.0, CURRENT 
Effective 
08, Jan 2021 
 
Sponsor: Menarini International Operations Luxembourg SA 
Study Code: : MEIN/20/ZoAm-Hyp/001 
Protocol Version 1.0   of 1     23/04/2021 
  
 
Pag. 2 a 91 
 
 
SUMMARY OF CHANGES FROM PREVIOUS VERSION 
 
Affected Section(s) 
Summary of Revisions Made 
Rationale 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 


 
Corporate Medical Department 
 
Identification Number 
Version Number 
State 
Effective date 
FORM-000050125 
2.0, CURRENT 
Effective 
08, Jan 2021 
 
Sponsor: Menarini International Operations Luxembourg SA 
Study Code: : MEIN/20/ZoAm-Hyp/001 
Protocol Version 1.0   of 1     23/04/2021 
  
 
Pag. 3 a 91 
 
TABLE OF CONTENTS 
 
SUMMARY OF CHANGES FROM PREVIOUS VERSION .................................................. 2 
TABLE OF CONTENTS ........................................................................................................... 3 
LIST OF ABBREVIATIONS AND DEFINITION OF TERMS .............................................. 6 
1 
RESPONSIBILITIES .......................................................................................................... 8 
2 
PROTOCOL SYNOPSIS .................................................................................................... 9 
Inclusion Criteria ............................................................................................................ 12 
Exclusion Criteria ........................................................................................................... 13 
2.1 
Study Scheme ............................................................................................................. 17 
2.2 
Study Flow Chart ....................................................................................................... 19 
3 
STUDY RATIONALE AND BACKGROUND INFORMATION .................................. 22 
3.1 
Assessment of Potential Risks and Benefits .............................................................. 23 
4 
TRIAL OBJECTIVES AND ENDPOINTS...................................................................... 24 
5 
STUDY DESIGN .............................................................................................................. 28 
5.1 
Procedures and Study Visits ...................................................................................... 29 
6 
SELECTION OF SUBJECTS ........................................................................................... 33 
6.1 
Informed Consent Process ......................................................................................... 33 
6.2 
Inclusion and Exclusion Criteria ................................................................................ 33 
 Inclusion Criteria ................................................................................................ 33 
 Exclusion Criteria ............................................................................................... 34 
 Screening Failures ............................................................................................... 36 
7 
STUDY TREATMENT .................................................................................................... 36 
7.1 
Study Treatment Formulation, Appearance, Packaging, and Labeling ..................... 36 
7.2 
Study Treatment Distribution and Return / Destruction ............................................ 40 
7.3 
Product Storage and Stability ..................................................................................... 40 
7.4 
Study Product Compliance ......................................................................................... 41 
7.5 
Concomitant Therapy(ies) .......................................................................................... 41 
7.6 
Not permitted medications ......................................................................................... 42 
7.7 
Rescue Medicine ........................................................................................................ 42 
8 
STUDY ASSESSMENT AND PROCEDURES .............................................................. 42 
8.1 
Assessment of Efficacy .............................................................................................. 46 
8.2 
Assessment of Safety ................................................................................................. 46 
9 
SAFETY DATA MANAGEMENT .................................................................................. 52 
9.1 
Adverse Event (AE) ................................................................................................... 52 
9.2 
Drug Relationship ...................................................................................................... 52 
9.3 
Adverse Drug Reaction (ADR) .................................................................................. 53 
9.4 
Seriousness ................................................................................................................. 54 
9.5 
Adverse Event / Adverse Drug Reaction Intensity .................................................... 54 


 
Corporate Medical Department 
 
Identification Number 
Version Number 
State 
Effective date 
FORM-000050125 
2.0, CURRENT 
Effective 
08, Jan 2021 
 
Sponsor: Menarini International Operations Luxembourg SA 
Study Code: : MEIN/20/ZoAm-Hyp/001 
Protocol Version 1.0   of 1     23/04/2021 
  
 
Pag. 4 a 91 
 
9.6 
Adverse Event / Adverse Drug Reaction Expectedness ............................................ 55 
9.7 
Serious Unexpected Adverse Drug Reaction (SUSAR) ............................................ 55 
9.8 
Individual Case Safety Report (ICSR) ....................................................................... 55 
9.9 
Collection, Recording and Reporting of AEs ............................................................ 55 
9.10 Management of Serious AEs (SAEs) including laboratory abnormalities ................ 56 
9.10.1 Reporting Duties of the Investigator ................................................................... 56 
9.10.2 Reporting Duties of the Sponsor ......................................................................... 56 
9.11 Management of Non-serious AEs (NSAEs) including laboratory abnormalities ...... 57 
9.11.1 Reporting Duties of the Investigator ................................................................... 57 
9.12 Management of any laboratory abnormality .............................................................. 57 
9.13 Management of pregnancy exposure cases ................................................................ 58 
10 WITHDRAWAL CRITERIA ........................................................................................... 59 
11 LOST TO FOLLOW UP ................................................................................................... 61 
12 STATISTIC ....................................................................................................................... 61 
12.1 Statistical Methods (Blinding and Randomization) ................................................... 61 
12.2 Determination of Sample Size ................................................................................... 62 
12.3 Analysis Populations .................................................................................................. 62 
12.4 Analysis Variables ..................................................................................................... 63 
12.5 Statistical Analysis ..................................................................................................... 63 
 Descriptive statistics ........................................................................................... 63 
 Primary (efficacy) analysis ................................................................................. 63 
 Sensitivity analysis .............................................................................................. 64 
 Secondary (efficacy) analysis ............................................................................. 64 
 Exploratory (efficacy) analysis ........................................................................... 65 
 Subgroup analysis ............................................................................................... 65 
 Safety analysis .................................................................................................... 65 
 Interim analysis and stopping rules ..................................................................... 65 
 Data imputations ................................................................................................. 65 
12.6 Protocol Deviations and Protocol Amendments ........................................................ 66 
12.7 End of Study Visit ...................................................................................................... 66 
12.8 Statistical Analysis Plan ............................................................................................. 66 
13 STUDY DISCONTINUATION AND CLOSURE ........................................................... 67 
14 DIRECT ACCESS TO SOURCE DATA / DOCUMENTS ............................................. 68 
15 QUALITY CONTROL AND QUALITY ASSURANCE ................................................ 68 
15.1 Study Monitoring / Data Quality Control .................................................................. 68 
15.2 Case Report Forms ..................................................................................................... 69 
15.3 Quality Assurance ...................................................................................................... 70 
16 ETHICS ASPECTS ........................................................................................................... 70 
16.1 Ethics Committees ..................................................................................................... 71 


 
Corporate Medical Department 
 
Identification Number 
Version Number 
State 
Effective date 
FORM-000050125 
2.0, CURRENT 
Effective 
08, Jan 2021 
 
Sponsor: Menarini International Operations Luxembourg SA 
Study Code: : MEIN/20/ZoAm-Hyp/001 
Protocol Version 1.0   of 1     23/04/2021 
  
 
Pag. 5 a 91 
 
16.2 Subject’s Insurance .................................................................................................... 71 
17 PERSONAL DATA PROTECTION SECTION .............................................................. 71 
17.1 General Principles on Personal Data Compliance ..................................................... 71 
17.2 Acknowledgment ....................................................................................................... 72 
17.3 Data Controllers and Data Processors ........................................................................ 72 
17.4 Duties of the Parties involved in the performance of the study ................................. 73 
17.5 Archiving of the clinical trial master file and code pairing list ................................. 75 
17.6 Information notice on personal data protection and pseudo-anonymisation ............. 78 
17.7 Genetic Data ............................................................................................................... 79 
17.8 Transfer of subjects’ data outside the European union .............................................. 79 
17.9 Exercise of subjects’ data privacy rights .................................................................... 79 
17.10 Future research ........................................................................................................... 80 
18 PUBLICATION POLICY AND RESULTS ..................................................................... 80 
19 REFERENCES .................................................................................................................. 81 
20 PROTOCOL APPROVAL PAGE .................................................................................... 83 
21 INVESTIGATOR’S APPROVAL PAGE ........................................................................ 84 
22 APPENDICES................................................................................................................... 85 
 
 


 
Corporate Medical Department 
 
Identification Number 
Version Number 
State 
Effective date 
FORM-000050125 
2.0, CURRENT 
Effective 
08, Jan 2021 
 
Sponsor: Menarini International Operations Luxembourg SA 
Study Code: : MEIN/20/ZoAm-Hyp/001 
Protocol Version 1.0   of 1     23/04/2021 
  
 
Pag. 6 a 91 
 
LIST OF ABBREVIATIONS AND DEFINITION OF TERMS 
 
ABBREVIATION DEFINITION 
ACE 
Angiotensin Converting Enzyme 
ACE-i 
Angiotensin Converting Enzyme inhibitors 
ADR 
Adverse Drug Reaction 
AE 
Adverse Event 
ALT 
Alanine aminotransferase 
AST 
Aspartate aminotransferase 
AML  
Amlodipine  
ATC 
Anatomical Therapeutic Chemical 
BP 
Blood Pressure 
CCBs 
Calcium Beta Blocker  
eCRF 
Electronic Case Report Form 
CRO 
Contract Research Organization 
CV 
Cardiovascular Event 
DBP 
Diastolic Blood Pressure 
ECG 
Electrocardiogram 
EDC 
Electronic Data Capture 
eCRF 
Electronic Case Report Form 
FDC 
Fixed Dose Combination 
FPI 
First Patient In  
IMP 
Investigational Medicinal Product 
ISCR 
Individual Case Safety Report 
IUD  
Intrauterine Device  
IUS 
Intrauterine hormone-releasing system 
IWRS 
Interactive Web Response System 
MACE 
Major Adverse Cardiovascular Events 
NSAE 
Non-Serious Adverse Events 
PP 
Protocol Population 
PDE 
Phosphodiesterase inhibitors 
RCT 
Randomized controlled trial 
SAE 
Serious Adverse Events 
SBP 
Systolic Blood Pressure 
SD  
Standard deviation  
SS 
Sample Size 
SUSAR 
Suspected Unexpected Serious Adverse Reaction 


 
Corporate Medical Department 
 
Identification Number 
Version Number 
State 
Effective date 
FORM-000050125 
2.0, CURRENT 
Effective 
08, Jan 2021 
 
Sponsor: Menarini International Operations Luxembourg SA 
Study Code: : MEIN/20/ZoAm-Hyp/001 
Protocol Version 1.0   of 1     23/04/2021 
  
 
Pag. 7 a 91 
 
TEAE 
Treatment Emergent Adverse Event 
UNL 
Upper Normal Limit  
UPT 
Urine Pregnancy Test 
ZOF  
Zofenopril  
 
 
 


 
Corporate Medical Department 
 
Identification Number 
Version Number 
State 
Effective date 
FORM-000050125 
2.0, CURRENT 
Effective 
08, Jan 2021 
 
Sponsor: Menarini International Operations Luxembourg SA 
Study Code: : MEIN/20/ZoAm-Hyp/001 
Protocol Version 1.0   of 1     23/04/2021 
  
 
Pag. 8 a 91 
 
1 
 
RESPONSIBILITIES 
 
Sponsor:  
 
 
 
Name:  Menarini International Operations 
Luxembourg SA 
Address: 1, Avenue de la Gare L-1611 Luxembourg 
Phone:     +352 2649761                 
Fax +352 26497649 
Clinical Trial Coordinator:               
 
  
              
Name: Sabrina Vignolo 
Address: Via Sette Santi 1-3, 50131, Firenze 
Phone:  +39 055 56809145                 
  
  e-mail: svignolo@menarini.it 
Study Medical Expert (SME):               
Name:  Marco Salvatore 
 
Address: Via dei sette santi 1-3, 50131, Firenze 
Phone:  +39 055 56809581                 
  
  e-mail: msalvatore@menarini.it 
Study Drug Safety Manager (SDSM):  
Name:  Jaleh Khabirinejad 
 
Address: 5D, Rue Eugene Ruppert L-2453 
Luxembourg 
Phone:  +352 26497696                
  
  e-mail: jkhabirinejad@menarini.lu 
Coordinating Investigator  
Name:  Professor Massimo Volpe 
 
Address: Via Di Grottarossa, 1035 Roma 
Phone: 06 33775654                   
  
  e-mail: massimo.volpe@uniroma1.it 
CRO  
Name:  Biorasi  
 
Address: 18851 NE 29th Ave #800, Aventura, FL 
33180 USA 
Phone:                 +1 (786) 388-0700 
  
  e-mail:  masolino@biorasi.com  
Statistician  
Name 
John Reber 
 
Address: Statistician and SAS Programmer, 
Consultant. Foxhound Analytics LLC 
Phone: (218) 770-8145                  
  
  e-mail: jreber@foxhound-analytics.com  
 
 


 
Corporate Medical Department 
 
Identification Number 
Version Number 
State 
Effective date 
FORM-000050125 
2.0, CURRENT 
Effective 
08, Jan 2021 
 
Sponsor: Menarini International Operations Luxembourg SA 
Study Code: : MEIN/20/ZoAm-Hyp/001 
Protocol Version 1.0   of 1     23/04/2021 
  
 
Pag. 9 a 91 
 
2 
PROTOCOL SYNOPSIS 
 
Title 
 
 
Acronym  
Sponsor Study 
Code  
Interventional clinical trial to assess efficacy and safety of the 
extemporaneous combination of zofenopril calcium and amlodipine 
in grade 1-2 hypertensive patients versus each monotherapy  
 
MASOLINO Study 
MEIN/20/ZoAm-Hyp/001 
 
Study product, 
Dosage and 
Regimen:  
-Investigational 
Product 
-Reference 
Therapy 
(comparator) 
 
Extemporaneous combination of Zofenopril (ZOF) 30 mg (ATC 
code: C09AA15) with Amlodipine (AML) 5 mg (ATC code: 
C08CA01) or Amlodipine (AML) 10 mg (ATC code: C08CA01) will 
be administered orally once daily. 
Study Type and 
Design 
This study is a phase IV, open-label, multicentre, multinational study 
with two study periods, treating patients with grade 1-2 hypertension, 
blood pressure (BP) ranging from ≥140/90 mmHg to ≤179/109 
mmHg while on treatment with any angiotensin converting enzyme-
inhibitors (ACE-i) or Calcium Channel Blockers (CCBs) including 
ZOF  30 mg or AML 5 mg respectively.  
The study is designed with a run-in period of 4 weeks and an 
assessment period of 8 weeks.  
  
Phase 
Phase IV 
Objectives* 
 
 
Primary Objective: To assess the anti-hypertensive efficacy of the 
extemporaneous combination of ZOF 30 mg with AML 5 mg or 
AML 10 mg in lowering the sitting diastolic BP between Visit 2 
(Week 0) and Visit 4 (Week 8) in patients with uncontrolled BP 


 
Corporate Medical Department 
 
Identification Number 
Version Number 
State 
Effective date 
FORM-000050125 
2.0, CURRENT 
Effective 
08, Jan 2021 
 
Sponsor: Menarini International Operations Luxembourg SA 
Study Code: : MEIN/20/ZoAm-Hyp/001 
Protocol Version 1.0   of 1     23/04/2021 
  
 
Pag. 10 a 91 
 
previously treated with ZOF (30 mg) or AML (5 mg) monotherapies 
for at least 4 weeks.  
 
Secondary objectives:  
●To assess the antihypertensive efficacy of the extemporaneous 
combination of ZOF 30 mg in combination with AML 5 mg or AML 
10 mg in lowering sitting systolic BP between Visit 2 (Week 0) and 
Visit 4 (Week 8) in patients with uncontrolled BP previously treated 
with ZOF 30 mg or AML 5 mg  monotherapies for at least 4 weeks. 
●To assess the antihypertensive efficacy of the extemporaneous 
combination of ZOF/AML 30/10 mg vs. ZOF/AML 30/5 mg, in 
lowering sitting DBP and SBP between Visit 3 (Week 4) and Visit 4 
(Week 8) in patients with uncontrolled BP previously treated with 
ZOF or AML 5 mg monotherapies for at least 4 weeks.  
●To evaluate the total number and percentage of patients who 
achieved the BP goal (sitting BP ≤130/80 mmHg) at Visit 2 (Week 
0), at Visit 3 (Week 4) and at Visit 4 (Week 8). 
●To assess the compliance to the treatment (percentage of actual 
doses taken versus doses to be taken) at Visit 2 (Week 0), at Visit 3 
(Week 4) and at Visit 4 (Week 8).    
●To evaluate the safety and tolerability of the monotherapies (ZOF 
30 mg and AML 5 mg) and of the extemporaneous combinations 
(ZOF 30 mg and AML 5 mg or AML 10 mg) after 8 weeks of 
treatment. 
 
Endpoints* 
 
 
 
Primary Efficacy Endpoint: 
●Change in mean sitting DBP between Visit 2 (Week 0) and Visit 4 
(Week 8). 
 
Secondary Efficacy Endpoint: 
●Change in mean sitting SBP between Visit 2 (Week 0) and Visit 4 
(Week 8). 


 
Corporate Medical Department 
 
Identification Number 
Version Number 
State 
Effective date 
FORM-000050125 
2.0, CURRENT 
Effective 
08, Jan 2021 
 
Sponsor: Menarini International Operations Luxembourg SA 
Study Code: : MEIN/20/ZoAm-Hyp/001 
Protocol Version 1.0   of 1     23/04/2021 
  
 
Pag. 11 a 91 
 
●Change in mean sitting DBP and SBP between Visit 3 (week4) and 
4 (Week 8) in patients on combination of ZOF/AML 30/5 with 
uncontrolled BP at Visit 3 and up titrated to the extemporaneous 
combination of ZOF/AML 30/10 mg 
●Number and proportion of patients achieving the BP goal (sitting 
BP≤130/80 mmHg) at Visit 2 (Week 0), Visit 3 (Week 4) and Visit 4 
(Week 8). 
●Adherence to the treatments (% of doses taken/ doses to be taken) at 
Visit 2 (Week 0), Visit 3 (Week 4) and Visit 4 (Week 8). 
●Safety and tolerability of the monotherapies (ZOF 30 mg and AML 
5 mg) and of the extemporaneous combination (ZOF 30 mg and 
AML 5 mg or AML 10 mg) after eight weeks of treatment.  
 
Exploratory Efficacy Endpoint:  
●Change in mean sitting SBP and DBP between Visit 1 (week -4) 
and Visit 2 (Week 0), visit 3 (Week 4) and Visit 4 (Week 8).: 
o in the group of patients who were on ZOF and AML 5 mg at 
Visit 1 and started ZOF 30 mg or continued the same therapy 
AML 5 mg at Visit 1  
o in the group of patients who switched to ZOF 30 mg or AML 
5 mg from any other ACE-i or CCBs at Visit 1 
●Change in mean sitting SBP and DBP for uncontrolled patients at 
Visit 3 (Week 4), between Visit 2 (Week 0) and Visit 3 (Week 4)   
●Number and proportion of patients achieving the BP goal (sitting 
BP ≤130/80 mmHg) at Visit 2 (Week 0) and Visit 3 (Week 4):  
o in the group of patients who were on and AML 5 mg at Visit 
1(Week -4) and started ZOF 30 mg or continued the same 
therapy AML 5 mg 
o in the group of patients who switched to ZOF 30 mg or AML 
5 mg from any other ACE-i or CCBs at Visit 1 (Week- 4)   
●Number and proportion of patients divided in subgroup by the 
hypertension grade, the presence of diabetes and/or of 


 
Corporate Medical Department 
 
Identification Number 
Version Number 
State 
Effective date 
FORM-000050125 
2.0, CURRENT 
Effective 
08, Jan 2021 
 
Sponsor: Menarini International Operations Luxembourg SA 
Study Code: : MEIN/20/ZoAm-Hyp/001 
Protocol Version 1.0   of 1     23/04/2021 
  
 
Pag. 12 a 91 
 
hypercholesterolemia achieving the BP goal (sitting BP ≤130/80 
mmHg) at Visit 2 (Week 0), Visit 3 (Week 4)  and Visit 4 (Week 8) 
o in the group of patients who were on ZOF and AML 5 mg at 
Visit 1 (Week -4) and continued AML 5 mg and started ZOF 
30 mg 
o in the group of patients, who switched to ZOF 30 mg or AML 
5 mg from any other ACE-i or CCBs at Visit 1 (Week 4) 
 
Study Population: 
Subjects 
characteristics 
Number of 
Subjects 
●Male or female, Grade 1-2 uncontrolled hypertensive patients ≥18 
and ≤65 years of age 
●Considering a screening failure and a drop-out rate of 25%, the 
overall number of patients to be screened is 290. 
●216 patients are needed to complete the run- in period and start the 
assessment period to guarantee powered results  
 
Inclusion Criteria 
 
A patient will be considered eligible for inclusion in the study only if 
all the following criteria are met:   
1. Male or female Grade 1-2hypertensive patients:  with mean 
sitting SBP ≥140 mmHg and ≤179 mmHg and/or mean sitting 
DBP ≥ 90 mmHg and ≤109 mmHg at Screening, with ≥18 
and ≤65 years of age, in monotherapy either with ZOF 30 mg 
or AML 5 mg, or any other ACE-I or CCBs (Felodipine, 
isradipine, lacidipine, lercanidipine, nicardipine, nifedipine, 
and nisoldipine) for at least 1 months  before Visit 1 
(Screening). 
2. Patients who are able to understand and give written informed 
consent at Screening 
3. Patients who are available for the entire trial period and willing 
to adhere to the protocol requirements  
4. Ability to take oral medication and willing to adhere to the drug 
regimen 


 
Corporate Medical Department 
 
Identification Number 
Version Number 
State 
Effective date 
FORM-000050125 
2.0, CURRENT 
Effective 
08, Jan 2021 
 
Sponsor: Menarini International Operations Luxembourg SA 
Study Code: : MEIN/20/ZoAm-Hyp/001 
Protocol Version 1.0   of 1     23/04/2021 
  
 
Pag. 13 a 91 
 
5. Female patients are eligible to participate if not pregnant, or not 
breastfeeding and must refrain from donating or storing eggs. 
For females of reproductive potential: use of highly effective 
contraception (e.g., method of birth control throughout the 
study period and for 4 weeks after study completion defined as 
a method which results in a failure rate of less than 1% per year) 
such as: 
• Combined (estrogen- and progestogen-containing) 
hormonal contraception associated with inhibition of 
ovulation (oral, intravaginal, transdermal) 
• Progestogen-only hormonal contraception associated 
with 
inhibition 
of 
ovulation 
(oral, 
injectable, 
implantable) 
• Intrauterine device (IUD) 
• Intrauterine hormone-releasing system (IUS) 
• Bilateral tubal occlusion 
• Vasectomized partner (performed at least 2 months 
before screening) (if partner is the sole sexual partner 
of the trial participant and that the vasectomized partner 
has received medical assessment of the surgical 
success) 
6. A male patient must agree to use contraception during the 
whole study period and for at least 1 week after the last dose of 
study treatment and refrain from donating sperms during this 
period 
 
Exclusion Criteria 
Any patient who meets any of the following criteria will not qualify 
for entry into the study: 
 
1. Known contraindications, presence of not recommended / 
contraindicated concomitant therapy allergies, or significant 
history of hypersensitivity to zofenopril, amlodipine, other ACE-


 
Corporate Medical Department 
 
Identification Number 
Version Number 
State 
Effective date 
FORM-000050125 
2.0, CURRENT 
Effective 
08, Jan 2021 
 
Sponsor: Menarini International Operations Luxembourg SA 
Study Code: : MEIN/20/ZoAm-Hyp/001 
Protocol Version 1.0   of 1     23/04/2021 
  
 
Pag. 14 a 91 
 
inhibitors or dihydropyridines calcium channel blockers, or any 
related products (including excipients of the formulations as 
outlined in the Investigator’s Brochure [IB]) or), summary of 
product characteristics (SmPCs) or local package inserts for AML 
and ZOF 
2. Patients with serious disorders (in the opinion of the Investigator) 
which may limit the ability to evaluate the efficacy or safety of the 
tested medications, including cerebrovascular, cardiovascular, 
renal, respiratory, hepatic, gastrointestinal, endocrine/ or 
metabolic, haematological, or oncological, neurological, and 
psychiatric diseases. The same applies for immunocompromised 
and/or neutropenic patients 
3. Patients having a history of the following within the last 6 months: 
myocardial infarction, unstable angina pectoris, percutaneous 
coronary intervention, bypass surgery, valve replacement 
(transcatheter 
aortic 
valve 
implantation, 
MitraClip), 
cerebrovascular accident (stroke, heart failure, hypertensive 
encephalopathy, cerebrovascular accident (stroke), or transient 
ischemic attack. Patients with who have undergone other surgery 
that in the in the opinion of the Investigator may limit the ability to 
evaluate the efficacy or safety of the tested medications. 
4. Patients with secondary hypertension of any aetiology such as 
renal 
diseases, 
pheochromocytoma, 
Cushing’s 
syndrome 
hyperaldosteronism, renovascular disease, thyroid disorders  
5. Patients with severe heart failure (New York Heart Association 
classification III-IV), a narrowing of the aortic or bicuspid valve, 
an obstruction of cardiac outflow (obstructive, hypertrophic 
cardiomyopathy) or symptomatic coronary disease 
6. Patients with clinical evidence of renal disease as per the 
Investigator’s judgement (including renovascular occlusive 
disease, nephrectomy and/or renal transplant, bilateral renal artery 
stenosis or unilateral renal artery stenosis in a solitary kidney, or 
severe renal impairment) 


 
Corporate Medical Department 
 
Identification Number 
Version Number 
State 
Effective date 
FORM-000050125 
2.0, CURRENT 
Effective 
08, Jan 2021 
 
Sponsor: Menarini International Operations Luxembourg SA 
Study Code: : MEIN/20/ZoAm-Hyp/001 
Protocol Version 1.0   of 1     23/04/2021 
  
 
Pag. 15 a 91 
 
7. Patients with history of angioneurotic oedema 
8. Patients with clinically relevant hepatic impairment  
9. Patients with sick sinus syndrome, including sino-atrial block 
10. Patients with second- or third-degree heart block (without a 
pacemaker) 
11. Participation in any other interventional drug trial or exposure to 
other investigational agents within 30 days before Screening (Visit 
1)  
12. Inability to cooperate or any condition that, in the opinion of the 
Investigator, could increase the patient’s risk of participating in the 
study or confound the outcome of the study 
13. Patients with conditions that, in the opinion of the Investigator, 
would prevent a careful adherence to the protocol 
14. Patients with severe hypotension  
15. Patients who suffer from shock (including cardiogenic shock) 
16. Patients treated with Amlodipine 10 mg and Zofenopril (other 
than 30 mg) 
 
Clinical Sites 
Number of Centres  
● 
Approximately 28 clinical sites 
List of Countries 
Russia, Hungary, Italy 
Study Duration 
(specify different 
study phases): 
 
• Screening Visit 1, (Week -4) 
• Run-in period from Visit 1(Week -4) to Visit 2 (Week 0) 
• Assessment period from Visit 2 (Week 0) to Visit 4 (Week 8): 
 
Subject Study 
Phases Duration 
 
The overall duration of the study will be 12 weeks. 
Screening Visit 1, (Week -4): Grade 1-2 hypertensive patients with 
blood pressure [BP] ranging from ≥140/90 mmHg to ≤179/109 
mmHg)  in treatment with any ACE-i or CCBs*, including ZOF 30 
mg or AML 5 mg (only dosage allowed) for at least one month prior 
to Visit 1 will be screened for eligibility. 
Run-in period from Visit 1(Week -4) to Visit 2 (Week 0): eligible 
patients will enter a 4 weeks run-in period on the same day of the 


 
Corporate Medical Department 
 
Identification Number 
Version Number 
State 
Effective date 
FORM-000050125 
2.0, CURRENT 
Effective 
08, Jan 2021 
 
Sponsor: Menarini International Operations Luxembourg SA 
Study Code: : MEIN/20/ZoAm-Hyp/001 
Protocol Version 1.0   of 1     23/04/2021 
  
 
Pag. 16 a 91 
 
screening visit. Patients previously receiving ZOF 30 mg or AML 5 
mg will continue the same treatment, patients receiving other ACE-i 
will be switched to ZOF 30 mg, while patients receiving CCBs will 
receive AML 5 mg. Patients entering this phase in therapy with ZOF 
30 mg or AML 5 mg should be in a 1:1 ratio. 
Assessment period from Visit 2 (Week 0) to Visit 4 (Week 8): 
patients having uncontrolled BP at Visit 2, will be assigned to the 
extemporaneous combination of ZOF 30 mg and AML 5 mg. After 4 
Weeks ± 2 days the BP will be assessed again (Visit 3): controlled 
patients (SBP/DBP ≤  130/80 mmHg)  will continue the same 
extemporaneous combination, while uncontrolled (SBP/DBP 
>130/80 mmHg)   patients will be up-titrated from extemporaneous 
combination ZOF/AML 30/5 mg to extemporaneous combination of 
ZOF/AML 30/10 mg for further 4 weeks ± 2 days (Visit 4, Week 8). 
 
At Visit 2 and Visit 3 patients with SBP/DBP value classified as 
Grade 3 (SBP ≥ 180 or DBP ≥ 110 mmHg) hypertension will be 
withdrawn from the study.  
 
*To be enrolled in the study, patients could be in monotherapy with 
one of the listed CCBs: felodipine, isradipine, lacidipine, lercanidipine, 
nicardipine, nifedipine, and nisoldipine.  
 
Statistical 
Assumptions 
 
 
 
 
 
 
The primary endpoint will be assessed before and after assessment 
period at Week 8, by a paired t-test using the Intention-to-treat (ITT) 
population and the Per-Protocol (PP) population. 
All the other continuous secondary/exploratory endpoints will be 
assessed before (Week 0) and after treatment (at Week 8) by a paired 
t-test. 
All secondary/exploratory endpoints related to proportion of patients 
achieving the BP goal at Week 4 and Week 8 will be analysed 
descriptively producing also the relative 95% CI to assess if there is a 
significant difference from Week 0 where all patients were 
uncontrolled. 


 
Corporate Medical Department 
 
Identification Number 
Version Number 
State 
Effective date 
FORM-000050125 
2.0, CURRENT 
Effective 
08, Jan 2021 
 
Sponsor: Menarini International Operations Luxembourg SA 
Study Code: : MEIN/20/ZoAm-Hyp/001 
Protocol Version 1.0   of 1     23/04/2021 
  
 
Pag. 17 a 91 
 
A total sample size of 216 patients is required to achieve 90% power 
at a 5% significance level assuming a difference in mean DBP from 
baseline (Visit 2) to 8 weeks (Visit 4) of 4 mmHg and a standard 
deviation (SD) for this difference of 10 mmHg. The mean change in 
DBP for the null hypothesis is set equal to 2 mmHg. 
 
2.1 
Study Scheme 
 
 
 
# There is not a randomization procedure 
 
§Allowed CCBs at screening: Felodipine, isradipine, lacidipine, lercanidipine, nicardipine, nifedipine, and 
nisoldipine.  
Subjects treated with Amlodipine 10 mg or Zofenopril other than 30 mg will not undergo screening procedures. 
Grade 1-2 hypertensive patients mean: Blood pressure [BP] ranging from ≥140/90 mmHg to ≤179/109 
mmHg) 


 
Corporate Medical Department 
 
Identification Number 
Version Number 
State 
Effective date 
FORM-000050125 
2.0, CURRENT 
Effective 
08, Jan 2021 
 
Sponsor: Menarini International Operations Luxembourg SA 
Study Code: : MEIN/20/ZoAm-Hyp/001 
Protocol Version 1.0   of 1     23/04/2021 
  
 
Pag. 18 a 91 
 
Uncontrolled patients with Grade 1-2 hypertension mean: Sitting SBP/DBP >130/80 mmHg.  Patients with 
Grade 3 (SBP ≥ 180 or DBP ≥ 110 mmHg) hypertension will be withdrawn from the study at Visit 2 and Visit 3   
Controlled patients mean: SBP/DBP ≤130/80 mmHg 
 
 


 
Corporate Medical Department 
 
Identification Number 
Version Number 
State 
Effective date 
FORM-000050125 
2.0, CURRENT 
Effective 
08, Jan 2021 
 
Sponsor: Menarini International Operations Luxembourg SA 
Study Code: MEIN/20/ZoAm-Hyp/001 
Protocol Version 1.0 of 1     23/04/2021 
  
 
Pag. 19 a 91 
 
2.2 
Study Flow Chart 
The assessment schedule lists all the assessments and when they are performed. All data 
obtained from these assessments mut be supported in the subject’s source documentation. 
Subjects who prematurely discontinued the study for any reason should be scheduled for a visit 
as soon as possible.  All the assessments listed for the final visit (Visit 4) will be performed. At 
this final visit, all dispensed investigational treatment should be reconciled, and the adverse 
events and concomitant medications recorded in the eCRF. 
 
Informed consent must be signed prior to any study-related procedure.  


 
Corporate Medical Department 
 
Identification Number 
Version Number 
State 
Effective date 
FORM-000050125 
2.0, CURRENT 
Effective 
08, Jan 2021 
 
Sponsor: Menarini International Operations Luxembourg SA 
Study Code: MEIN/20/ZoAm-Hyp/001 
Protocol Version 1.0 of 1     23/04/2021 
  
 
Pag. 20 a 91 
 
 
VISIT 1 / WEEK -4 
VISIT 2 / 
WEEK 0± 2 
days 
VISIT 3 / 
WEEK 4± 2 
days 
VISIT 4 / WEEK 
8± 2 days 
Informed consent submitted  
 
 
 
 
IWRSf registration 
 
 
 
 
Inclusion/exclusion criteria 
 
 
 
 
Medical history 
 
 
 
 
Prior medications 
 
 
 
 
Demographic information 
(for more details see section 8) 
 
 
 
 
 
Concurrent diseases and medical 
conditions 
 
 
 
 
Monotherapy of ZOF 30 mg or AML 5 
mg dispensinga 
 
 
 
 
Extemporaneous combination of 
ZOF/AML 30/5 mg dispensing 
 
 
b 
 
Extemporaneous combination of 
ZOF/AML 30/10 mg dispensing 
 
 
c 
 
Study drug return/accounting 
(Compliance assessment) 
 
 
 
 
Concomitant medications 
 
 
 
 
Urine Pregnancy test 
 
 
 
 
Physical examination 
(for more details see section 8) 
 
 
 
 
Vital signs 
(for more details see section 8) 
 
 
 
 
Laboratory testsd 
 
 
 
 
Blood pressure assessment 
 
 
 
 
ECG 
 
 
 
 
AE/SAE assessmente 
 
 
 
 


Corporate Medical Department 
Identification Number 
Version Number 
State 
Effective date 
FORM-000050125 
2.0, CURRENT 
Effective 
08, Jan 2021 
Sponsor: Menarini International Operations Luxembourg SA 
Study Code: MEIN/20/ZoAm-Hyp/001 
Protocol Version 1.0 of 1     23/04/2021 
Pag. 21 a 91 
a. Patients on ZOF 30 mg or AML 5 mg will continue the same therapy for 4 weeks. Patients on any other 
ACE-i will be assigned to monotherapy with ZOF 30 mg and the patients on other CCBs (the allowed CCBs 
are: felodipine, isradipine, lacidipine, lercanidipine, nicardipine, nifedipine, and nisoldipine) will be assigned 
to monotherapy with AML 5 mg
b. Only patients controlled at Visit 3 will receive ZOF/AML 30/5 mg
c. Only patients uncontrolled at Visit 3 will receive ZOF/AML 30/10 mg. 
d. To ensure patient safety, the patients will be contacted over phone within 24 hours, in case of any 
abnormality and clinically relevant laboratory test according to the Investigator’s judgement at any visit
e. The Investigator is expected to also record any AE which was ongoing at the last treatment dose and a
follow-up phone call should be made after 2 weeks from the last study visit.
In case AE was ongoing, the Investigator is expected to follow-up until the outcome of the AE has been
determined.
f. IWRS- Interactive Web Response System
g. The following procedure is applied only in case of COVID-19 restrictions.
h. Patients will be provided with an automatic blood pressure device to be used in case they are not able to go
to the study centre due to Covid-19 pandemic situation.
i. The patient will return the device at the last visit at the site
BP device provided to patientsh 
 
Patient diary provided to patientsg 
 
 
 
Patient diary to be returned by patient if 
used g 
 
 
BP device returned to sitei 



 
Corporate Medical Department 
 
Identification Number 
Version Number 
State 
Effective date 
FORM-000050125 
2.0, CURRENT 
Effective 
08, Jan 2021 
 
Sponsor: Menarini International Operations Luxembourg SA 
Study Code: MEIN/20/ZoAm-Hyp/001 
Protocol Version 1.0 of 1     23/04/2021 
  
 
Pag. 22 a 91 
 
3 
STUDY RATIONALE AND BACKGROUND INFORMATION 
 
The global prevalence of hypertension was estimated to be 1.13 billion in 2015, with a 
prevalence of over 150 million in central and eastern Europe. The overall prevalence of 
hypertension in adults is around 30 - 45%1. Elevated blood pressure (BP) was the leading 
global contributor to premature death in 2015, accounting for almost 10 million deaths and over 
200 million disability-adjusted life years2. 
There are two well-established strategies to lower BP: lifestyle interventions and drug 
treatment3. 
The drug treatment of hypertension is founded on very solid evidence, supported by the largest 
number of outcomes based RCTs in clinical medicine. Meta-analyses of RCTs including 
several hundred thousand patients have shown that a 10 mmHg reduction in SBP or a 5 mmHg 
reduction in DBP is associated with significant reductions in all major CV events (MACE) by 
20%, all-cause mortality by 10 - 15%, stroke by 35%, coronary events by 20%, and heart 
failure by 40%4,5. 
Guidelines have generated a variety of different strategies to initiate and escalate BP-lowering 
medication to improve BP control rates. In previous 2013 Guidelines, the emphasis was on 
initial use of different monotherapies, increasing their dose, or substituting for another 
monotherapy3.  
However, increasing the dose of monotherapy produces little improvement in lowering the BP 
and may increase the risk of adverse effects, whilst switching from one monotherapy to another 
is frustrating, time consuming, and often ineffective. Due to these reasons, 2018 ESC/ESH 
Guidelines have increasingly focused on the stepped care approach, initiating treatment with 
different monotherapies and then sequentially adding other drugs until BP control is achieved3. 
Despite this, BP control rates have remained poor worldwide, only 40% of patients with 
hypertension being treated and of these, only 35% being controlled to a BP of <140/90 mmHg1. 
This has become an even more pressing matter because, based on new evidence, current 
guidelines are recommending more stringent BP targets (on-treatment values of <130/80 
mmHg in the general population and <140/90 mmHg in older hypertensive people), which will 
make the achievement of BP control even more challenging3. 
Patients with hypertension are generally treated with multiple pharmaceutical products, Fixed 
Dose Combinations (FDC) have generated increasing interest and have been recommended in 
treatment guidelines due to advantages in dosing and compliance, leading to improved 
treatment outcomes 10,11. 


 
Corporate Medical Department 
 
Identification Number 
Version Number 
State 
Effective date 
FORM-000050125 
2.0, CURRENT 
Effective 
08, Jan 2021 
 
Sponsor: Menarini International Operations Luxembourg SA 
Study Code: MEIN/20/ZoAm-Hyp/001 
Protocol Version 1.0 of 1     23/04/2021 
  
 
Pag. 23 a 91 
 
One of the main reasons why the current treatment strategy has failed to achieve better BP 
control rates is the insufficient use of the combination treatment10,11. 
Blood Pressure is a multi-regulated variable depending on many compensating pathways. 
Consequently, combinations of drugs, working through different mechanisms, are required to 
reduce BP in most people with hypertension. Thus, monotherapy is likely to be inadequate 
therapy in most patients. Indeed, almost all patients in RCTs have required combinations of 
drugs to control their BP6. 
Zofenopril has been widely investigated for the treatment of patients with hypertension and its 
BP lowering effect has been compared with either placebo or with all the classes of 
antihypertensive drugs currently recommended for the treatment of hypertension. Although 
there are data in literature showing an added antihypertensive effect of Amlodipine or 
Zofenopril to other antihypertensive treatment,9 there is scarce evidence at the moment on the 
antihypertensive effect of the extemporaneous combination of ZOF and AML versus each 
monotherapy. The trial will be conducted in compliance with the protocol, GCP and the 
applicable regulatory requirements. 
Amlodipine (a CCB) and Zofenopril (an ACE inhibitor) are antihypertensive drugs widely 
prescribed as monotherapies in the real world, according to treatment guidelines. Both drugs 
have specific benefit-risk profiles with different mechanism of action9.  
Amlodipine belongs to the dihydropyridine class of calcium channel blockers7. Amlodipine, 
like other calcium channel blockers, acts primarily by inhibiting extracellular calcium influx 
through cardiac and vascular smooth muscle cell membranes; this inhibition is achieved mainly 
by blockade of L-type 'voltage operated' calcium channels. Its main site of action is the 
peripheral vasculature, although it also produces vasodilation in coronary vascular beds. In 
patients with mild to moderate essential hypertension, amlodipine had a sustained and gradual 
onset of antihypertensive effect, when assessed by 24-hour ambulatory or intra-arterial blood 
pressure monitoring7.  
 
3.1 
Assessment of Potential Risks and Benefits 
Extemporaneous combination of ACE-i and CCBs are often prescribed to control BP without 
major reported risks. Several clinical studies have demonstrated how this combination is 
effective in lowering BP12,13. Furthermore, the combination does not significantly increase the 
incidence of adverse events compared with either agent alone12,13. In many cases, combination 
therapy improves rates of BP control and requires less time to achieve target BP with 
equivalent or better tolerability than higher dose monotherapy15. Hypertension to goal blood 


 
Corporate Medical Department 
 
Identification Number 
Version Number 
State 
Effective date 
FORM-000050125 
2.0, CURRENT 
Effective 
08, Jan 2021 
 
Sponsor: Menarini International Operations Luxembourg SA 
Study Code: MEIN/20/ZoAm-Hyp/001 
Protocol Version 1.0 of 1     23/04/2021 
  
 
Pag. 24 a 91 
 
pressure (BP) is an important objective. Approximately, 70% of patients with hypertension 
require 2 or more agents to achieve their target BP16. Beyond improving compliance, 
combination therapy in the setting of hypertension management allows for decreased BP 
variability. Variability in SBP and DBP is associated with an increased risk of myocardial 
infarction and stroke17.  
 
 
4 
TRIAL OBJECTIVES AND ENDPOINTS 
 
OBJECTIVES 
ENDPOINTS 
JUSTIFICATION FOR 
ENDPOINTS 
Primary 
• 
To 
assess 
the 
anti-
hypertensive efficacy of the 
extemporaneous 
combination of ZOF 30 mg 
in combination with AML 5 
mg or AML 10 mg in 
lowering 
the 
sitting 
diastolic BP between Visit 2 
(Week 0) and Visit 4 (Week 
8) 
in 
patients 
with 
uncontrolled BP previously 
treated with Zofenopril or 
Amlodipine 
(5 
mg) 
monotherapies for at least 4 
weeks. 
 
• 
Change in mean sitting DBP 
between Visit 2 (Week 0) 
and Visit 4 (Week 8) 
 
 
• 
The association between 
elevated DBP and 
increased mortality risk has 
been reported several times 
in literature15,  
Secondary 
 
• 
To 
assess 
the 
antihypertensive efficacy of 
the 
extemporaneous 
combination of ZOF 30 mg 
in combination with AML 5 
mg or AML 10 mg in 
lowering sitting systolic BP 
(SBP) between Visit 2 
(Week 0) and Visit 4 (Week 
 
• 
Change in mean sitting SBP 
between Visit 2 (Week 0) 
and Visit 4 (Week 8). 
 
 
 
 
 
 
 
• 
Change in SBP after 8 
weeks 
of 
treatment 
is 
intended to show the added 
efficacy 
of 
the 
extemporaneous 
combination also on SBP 
considering its link to the 
cardiovascular 
disease 
(CVD) 


 
Corporate Medical Department 
 
Identification Number 
Version Number 
State 
Effective date 
FORM-000050125 
2.0, CURRENT 
Effective 
08, Jan 2021 
 
Sponsor: Menarini International Operations Luxembourg SA 
Study Code: MEIN/20/ZoAm-Hyp/001 
Protocol Version 1.0 of 1     23/04/2021 
  
 
Pag. 25 a 91 
 
OBJECTIVES 
ENDPOINTS 
JUSTIFICATION FOR 
ENDPOINTS 
8) 
in 
patients 
with 
uncontrolled BP previously 
treated with ZOF or AML 5 
mg  monotherapies for at 
least 4 weeks. 
 
• 
To 
assess 
the 
antihypertensive efficacy of 
the 
extemporaneous 
combination of ZOF/AML 
30/10 mg vs. ZOF/AML 
30/5 mg, in lowering sitting 
DBP and SBP between 
Visit 3 (Week 4) and Visit 4 
(Week 8) in patients with 
uncontrolled BP previously 
treated with ZOF or AML 5 
mg monotherapies for at 
least 4 weeks 
 
• 
To 
evaluate 
the 
total 
number and percentage of 
patients who achieved the 
BP goal (sitting BP ≤130/80 
mmHg) at Visit 2 (Week 0), 
at Visit 3 (Week 4) and at 
Visit 4 (Week 8) 
 
• 
To assess the compliance to 
the treatment (percentage of 
actual doses taken versus 
doses to be taken) at Visit 2 
(Week 0), at Visit 3 (Week 
4) and at Visit 4 (Week 8).   
 
• 
To evaluate the safety and 
tolerability 
of 
the 
monotherapies (ZOF 30 mg 
and AML 5 mg) after 4 
 
 
 
 
 
 
• 
Change in mean sitting DBP 
and SBP between Visit 3 
(Week 4) and 4 (Week 8) in 
patients on combination of 
ZOF/AML 
30/5 
with 
uncontrolled BP at Visit 3 
and up titrated to the 
extemporaneous 
combination of ZOF/AML 
30/10 mg 
 
 
 
 
• 
Number and proportion of 
patients achieving the BP 
goal (sitting BP≤130/80 
mmHg) at Visit 2 (Week 0), 
Visit 3 (Week 4) and Visit 4 
(Week 8). 
 
 
• 
Adherence to the treatments 
(percentage (%) of doses 
taken/ doses to be taken) at 
Visit 2 (Week 0), Visit 3 
(Week 4) and Visit 4 (Week 
8). 
 
• 
Safety and tolerability   of 
the monotherapies (ZOF 30 
mg and AML 5 mg) after 4 
weeks of therapy and of the 
 
 
 
 
 
 
 
• 
The number and proportion 
of 
patients 
with 
uncontrolled BP following 
the shift from ZOF/AML 
30/5 mg to ZOF/AML 
30/10 mg is very important 
to assess the contribution by 
AML 10 mg in reaching the 
BP target 
 
 
 
 
 
• 
The proportion of patients at 
target is a very important 
clinical 
indicator 
of 
therapeutic success  
 
 
 
 
• 
Monitoring compliance is 
extremely 
important 
to 
better 
understand 
the 
efficacy and tolerability of 
the 
extemporaneous 
combination 
 
• 
Incidence of ADRs, AEs, 
SAEs, vital signs, physical 
examination, 
ECG, 
and 


 
Corporate Medical Department 
 
Identification Number 
Version Number 
State 
Effective date 
FORM-000050125 
2.0, CURRENT 
Effective 
08, Jan 2021 
 
Sponsor: Menarini International Operations Luxembourg SA 
Study Code: MEIN/20/ZoAm-Hyp/001 
Protocol Version 1.0 of 1     23/04/2021 
  
 
Pag. 26 a 91 
 
OBJECTIVES 
ENDPOINTS 
JUSTIFICATION FOR 
ENDPOINTS 
weeks of therapy and of the 
extemporaneous 
combinations (ZOF 30 mg 
and AML 5 mg or AML 10 
mg) after 8 weeks of 
treatment. These objectives 
should be the same as the 
objectives contained in the 
body of the protocol. 
extemporaneous 
combination (ZOF 30 mg 
and AML 5 mg or AML 10 
mg) after eight weeks of 
treatment.    
 
concomitant 
medications 
needs to be studied to 
address 
safety 
and 
tolerability 
of 
the 
extemporaneous 
combination for a safe and 
optimal use of the treatment 
 
 
 
Exploratory objective 
• 
To assess change in mean 
sitting SBP and DBP 
between Visit 1 (week -4) 
and Visit 2 (Week 0), Visit 
3 (Week 4) and Visit 4 
(Week 8): 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
• 
Change in mean sitting 
SBP and DBP between 
Visit 1 (week -4) and Visit 
2 (Week 0), Visit 3 (Week 
4) and Visit 4 (Week 8): 
 
In the group of patients who 
were on ZOF 30 mg and 
AML 5 mg at Visit 1 and 
continued 
the 
same 
therapies at Visit 1  
o In the group of patients 
who switched to ZOF 30 mg 
or AML 5 mg from any 
other ACE-i or CCBs at 
Visit 1 
o Change in mean sitting 
SBP 
and 
DBP, 
for 
uncontrolled 
patients 
at 
Visit 3 (Week 4), between 
Visit 2 (Week 0) and Visit 3 
(Week 4) 
 
• 
Number and proportion of 
patients achieving the BP 
goal (sitting BP ≤130/80 
mmHg) at Visit 2 (Week 0) 
and Visit 3 (Week 4):  
• 
Evaluation of the 
antihypertensive efficacy of 
monotherapies and 
combination therapy in 
patients with different 
associated CV risk factors 
(Hypertension grade, 
presence of diabetes, and/or 
hypercholesterolemia) 
• 
 


 
Corporate Medical Department 
 
Identification Number 
Version Number 
State 
Effective date 
FORM-000050125 
2.0, CURRENT 
Effective 
08, Jan 2021 
 
Sponsor: Menarini International Operations Luxembourg SA 
Study Code: MEIN/20/ZoAm-Hyp/001 
Protocol Version 1.0 of 1     23/04/2021 
  
 
Pag. 27 a 91 
 
OBJECTIVES 
ENDPOINTS 
JUSTIFICATION FOR 
ENDPOINTS 
 
 
 
 
 
 
 
 
 
 
 
 
• 
To assess the 
antihypertensive efficacy at 
different time points in 
patients who (1) received 
ZOF or AMLO 
monotherapies before the 
run-in period, (2) received 
any other ACE-i or CCB 
monotherapies before the 
run-in period 
 
o In the group of patients 
who were on ZOF 30 mg 
and AML 5 mg at Visit 1 
(week -4) and continued 
with the same therapies  
o In the group of patients 
who switched to ZOF 30 
mg or AML 5 mg from any 
other ACE-i or CCBs at 
Visit 1 (week -4)   
 
 
• 
Number and proportion of 
patients divided in 
subgroup by the 
hypertension grade, the 
presence of diabetes and/or 
of hypercholesterolemia 
achieving the BP goal 
(sitting BP ≤130/80 
mmHg) at Visit 2 (Week 
0), Visit 3 (Week 4)  and 
Visit 4 (Week 8) 
o In the group of patients 
who were on ZOF 30 mg 
and AML 5 mg at Visit 1 
(Week -4) and continued 
on the same therapies  
o In the group of patients, 
who switched to ZOF 30 
mg or AML 5 mg from any 
other ACE-i or CCBs at 
Visit 1 (Week 4) 
 
 
 
 
 
 


 
Corporate Medical Department 
 
Identification Number 
Version Number 
State 
Effective date 
FORM-000050125 
2.0, CURRENT 
Effective 
08, Jan 2021 
 
Sponsor: Menarini International Operations Luxembourg SA 
Study Code: MEIN/20/ZoAm-Hyp/001 
Protocol Version 1.0 of 1     23/04/2021 
  
 
Pag. 28 a 91 
 
5 
STUDY DESIGN 
 
This is a phase IV, open-label, multicentre, multinational study with 2 study periods: a 4-week 
run-in period and an 8-week assessment period.  
Approximately 290 patients are planned to be screened to ensure at least 216 patients complete 
the run-in period and start with the assessment period.  
Patients with Grade 1-2 hypertensive patients (blood pressure [BP] ranging from ≥140/90 
mmHg to ≤179/109 mmHg) on treatment with any angiotensin converting enzyme inhibitors 
(ACE-i) including Zofenopril 30 mg or with calcium channel blockers (CCBs) including 
Amlodipine 5 mg will be screened for eligibility (Visit 1).  
Allowed CCBs: Felodipine, isradipine, lacidipine, lercanidipine, nicardipine, nifedipine, and 
nisoldipine. Patients treated with other dosages of Zofenopril (other than 30 mg) are not 
allowed to be screened. 
After screening, on the same day, eligible patients, will enter into a 4-week run-in period, 
during which patients on other ACE-i  will be assigned to monotherapy with ZOF 30 mg while 
patients on CCBs§ will be assigned to monotherapy with AML 5 mg for 4 weeks. Patients with 
on-going treatment zofenopril 30 mg and amlodipine 5mg will continue on the same treatment 
for 4 weeks. 
 
After the run-in period (4 weeks ± 2 days), BP will be further assessed (Visit 2), if BP levels 
are over the defined controlled target goal  (sitting SBP/DBP >130/80 mmHg), treatment is 
well tolerated and adherence to the treatments ranges from 80% to 120%, patients will enter the 
assessment period, where they will be assigned to the extemporaneous combination of ZOF 30 
mg and AML 5 mg. At Visit 2 patients with SBP/DBP values classified as Grade 3 (SBP ≥ 180 
or DBP ≥ 110 mmHg) hypertension will be withdrawn from the study.  
 
If patients, at Visit 2, after the run-in period, have a controlled BP (sitting SBP/DBP≤130/80 
mmHg) or do not tolerate the treatment or have an adherence range below 80% or superior to 
120%, they will be withdrawn from the study. 
 
The patients will be assessed for further 8 weeks (assessment period). 
After 4 weeks ± 2 days from Visit 2,during  the assessment period patients receiving the 
extemporaneous combination of ZOF 30 mg and AML 5 mg, will be further evaluated (Visit 
3):  controlled patients (sitting SBP/DBP ≤130/80 mmHg) will continue the same 


 
Corporate Medical Department 
 
Identification Number 
Version Number 
State 
Effective date 
FORM-000050125 
2.0, CURRENT 
Effective 
08, Jan 2021 
 
Sponsor: Menarini International Operations Luxembourg SA 
Study Code: MEIN/20/ZoAm-Hyp/001 
Protocol Version 1.0 of 1     23/04/2021 
  
 
Pag. 29 a 91 
 
extemporaneous combination for additional 4 weeks ± 2 days, while uncontrolled patients 
(sitting SBP/DBP >130/80 mmHg) will be up-titrated from ZOF/AML 30/5 mg to ZOF/AML 
30/10 mg for further 4 weeks ± 2 days.   
At Visit 3 patients with SBP/DBP values classified as Grade 3 (SBP ≥ 180 or DBP ≥ 110 
mmHg) hypertension will be withdrawn from the study. 
If patients at Visit 3, do not tolerate the extemporaneous combination treatment or they have an 
adherence range below 80% or superior to 120%, they will be withdrawn from the study. 
At the end of the assessment period (8 weeks ± 4 days) at Visit 4, the anti-hypertensive effect 
of the extemporaneous combination (ZOF/AML 30/5 mg and ZOF/AML 30/10 mg) will be 
evaluated. 
Efforts will be made to achieve 1:1 ratio in the enrolment of patients receiving any ACE-i or 
allowed CCBs (refer to section Subject Study Phases Duration for allowed CCBs). At Visit 2, a 
minimum of 45% of uncontrolled patients receiving treatment with ZOF 30 mg or AML 5 mg 
are required to enter the assessment period, in order to maintain a balance between the 2 
treatments during the assessment period. 
 
5.1 
Procedures and Study Visits 
 
Patients will attend a total of four visits during the study for a duration of 12 weeks. A total 
number of 290 patients will be screened considering 25% of drop-out rate, to obtain at least 216 
patients complete the run-in period and start with the assessment period. The description of the 
activities, procedures, and tests to be performed at each visit is detailed below:   
Screening Visit 1 (Week -4) 
The following procedures/assessments will be performed during the Screening Visit 1: 
• Informed consent 
• Interactive Web Response System (IWRS) registration to register the treatment 
allocation  
• Verification of inclusion and exclusion criteria 
• Collection and review of Medical history 
• Collection and review of Prior and concomitant medications 
• Collection of Demographic data 
• Recording of concurrent diseases and medical conditions 


 
Corporate Medical Department 
 
Identification Number 
Version Number 
State 
Effective date 
FORM-000050125 
2.0, CURRENT 
Effective 
08, Jan 2021 
 
Sponsor: Menarini International Operations Luxembourg SA 
Study Code: MEIN/20/ZoAm-Hyp/001 
Protocol Version 1.0 of 1     23/04/2021 
  
 
Pag. 30 a 91 
 
• Physical Examination 
• Vital sign measurements 
• BP Measurement 
• ECG 
• Perform Urine Pregnancy Test (UPT) to female of child-bearing potential 
• Perform Local Laboratory Tests 
• Adverse Event (AE) and Serious Adverse Event (SAE) Assessment 
• Paper instruction to use automatic blood pressure device, including patient’s diary 
provided to the patient 
• Automatic blood pressure device provided to patients: to be used in case of Covid-19 
pandemic situation emergency procedures (Section 2.3) 
 
Patients meeting all inclusion criteria and none of the exclusion criteria will enter the run-in 
period on the same day and will receive monotherapy of ZOF 30 mg or AML 5 mg. 
 
• Patients who are already on therapy with ZOF 30 mg or AML 5 mg will be 
provided with the same medication 
• Patients taking any other CCBs (refer to section Subject Study Phases 
Duration for allowed CCBs) will be provided with AML 5 mg, and patients 
taking any other ACE-i will be provided with ZOF 30 mg. Patients entering 
this phase in therapy with ZOF 30 mg or AML 5 mg should be as close as 
possible to a 1:1 ratio. 
Visit 2 (Week 0 ± 2 days):  
The following procedures/assessments will be performed at Visit 2: 
• Recording of concurrent diseases and medical conditions  
• Concomitant medications 
• Vital sign measurements 
• Physical Examination 
• BP Measurement 
• Urine pregnancy test (UPT) 


 
Corporate Medical Department 
 
Identification Number 
Version Number 
State 
Effective date 
FORM-000050125 
2.0, CURRENT 
Effective 
08, Jan 2021 
 
Sponsor: Menarini International Operations Luxembourg SA 
Study Code: MEIN/20/ZoAm-Hyp/001 
Protocol Version 1.0 of 1     23/04/2021 
  
 
Pag. 31 a 91 
 
• Study Drug Compliance assessment by return of monotherapy ZOF and AML tablets 
(also empty blister) and IP accountability 
• AEs and serious adverse events (SAEs) assessment 
• IWRS update 
• Patient’s instruction to use the automatic blood pressure device, including patient’s diary 
to be returned at site by the patient 
 
The patients with uncontrolled BP (SBP/DBP >130/80 mmHg), who tolerated the treatment 
and whose adherence to the therapy ranges from 80% to 120%, will enter the assessment period 
and at this visit will be dispensed with extemporaneous combination of ZOF 30 mg and AML 
5 mg.  
To correctly evaluate the additional effect of the combination therapy, the number of patients 
with uncontrolled BP on AML or ZOF monotherapy needs to be balanced at Visit 2. In order to 
maintain a 1:1 ratio during the assessment period, a cap of 110 patients for each arm (i.e., AML 
and ZOF) will be included at Visit 2 in order to maintain a balanced number of uncontrolled 
patients entering the assessment period for each drug (please refer to section 8 IWRS 
registration). The evaluation will be done every 50 patients. If the rate of entrance in the 
assessment period for one of the 2 tested drugs will deviate more than 5%, a corrective measure 
will be initiated: according to the enrolment site statistics, one or more sites will be informed to 
enrol a greater number of patients being treated with the least represented drug in the 
assessment period. 
Visit 3 (Week 4 ± 2 days) 
The following procedures/assessments will be performed at Visit 3: 
• Recording of concurrent diseases and medical conditions  
• Concomitant medications 
• Vital sign measurements 
• Physical Examinations 
• BP Measurement 
• Urine pregnancy test (UPT) 
• Study 
Drug 
Compliance 
assessment 
(Study 
Drug 
Compliance 
assessment 
extemporaneous combination of ZOF 30 mg and AML 5 mg) return (also empty blisters) 
and IP accountability 


 
Corporate Medical Department 
 
Identification Number 
Version Number 
State 
Effective date 
FORM-000050125 
2.0, CURRENT 
Effective 
08, Jan 2021 
 
Sponsor: Menarini International Operations Luxembourg SA 
Study Code: MEIN/20/ZoAm-Hyp/001 
Protocol Version 1.0 of 1     23/04/2021 
  
 
Pag. 32 a 91 
 
• AEs and serious adverse events (SAEs) assessment 
• IWRS updates 
• Patient’s instruction to use the automatic blood pressure device, including patient’s diary 
to be returned at site by the patient 
At Visit 3, BP will be assessed, and controlled patients will continue the same extemporaneous 
combination from ZOF/AML 30/5 mg, while uncontrolled patients (SBP/DBP >130/80 mmHg) 
will be up titrated to ZOF/AML 30/10 mg for a further 4 weeks 
Visit 4 (Week 8 ± 2 days) 
 The following procedures/assessments will be performed at Visit 4: 
• Recording of concurrent diseases and medical conditions 
• Concomitant medications 
• Vital sign measurements 
• Physical Examinations 
• BP Measurement 
• ECG 
• Perform Urine Pregnancy Test (UPT) 
• Perform Local Laboratory Tests 
• Patient’s instruction to use the automatic blood pressure device, including patient’s 
diary to be returned at site by the patient 
• Patients return of the automatic BP device to the site 
• Study Drug Compliance assessment [extemporaneous combination of ZOF 30 mg 
and AML 5 mg/10 mg) return (also empty blisters) and IP accountability] 
• AEs and serious adverse events (SAEs) assessment:  
In case of any patients having an ongoing AE or SAE at the end of the treatment, 
there will be a follow-up telephone call after 2 weeks to ensure patient safety  
 
The Investigator is expected to record any AE which was ongoing at the last treatment dose and 
a follow-up phone call should be made after 2 weeks from the last study visit. 
In case of an ongoing AE, the Investigator is expected to follow-up until the outcome of the AE 
has been determined. 
 


 
Corporate Medical Department 
 
Identification Number 
Version Number 
State 
Effective date 
FORM-000050125 
2.0, CURRENT 
Effective 
08, Jan 2021 
 
Sponsor: Menarini International Operations Luxembourg SA 
Study Code: MEIN/20/ZoAm-Hyp/001 
Protocol Version 1.0 of 1     23/04/2021 
  
 
Pag. 33 a 91 
 
The details of the study visits are described in the Study Flow Chart Section 2.3. 
 
6 
SELECTION OF SUBJECTS 
The following subject will be screened: 
 
• Male or female, (Grade 1-2), uncontrolled hypertensive patients ≥18 and ≤65 years of 
age 
• Considering a screening failure and a drop-out rate of 25%, the overall number of 
patients to be screened is 290. 
• 216 patients needed to complete the run-in period and enter the assessment period to 
guarantee powered results  
 
6.1 
Informed Consent Process 
Prior to the subject’s enrolment into the study and before performing any study-related 
procedures, the Investigator - or its authorized delegate - shall obtain the subject’s written, 
dated and signed informed consent to participate into the study and process personal data  for 
processing and transferring necessary documentation of the subject’s health and personal data 
to the CRO, Sponsor and its Affiliates, the competent Health Authorities and any other 
institutions, as legally required and in accordance with the local applicable privacy laws (for 
the Privacy information to be reported on the ICF refer to Section 17 PERSONAL DATA 
PROTECTION  ). 
Institution and Investigator undertake to duly inform subjects about personal data processing 
and the relevant applicable privacy rights before their participation into the study. 
 
After being duly informed and interviewed by the Investigator, . The subject freely has to date 
and sign the ICF before being enrolled into the study and before undergoing any study 
procedure. The Investigator must store the originally signed ICF in the Investigator’s File, and 
the subject will be provided with a copy of it. 
If a protocol amendment would affect the terms of the ICF, it will be revised to reflect the 
protocol change and submitted to EC for approval. 
The Investigator will ensure that this new consent form is signed by all subjects subsequently 
entered in the study and those currently in the study, if affected by the amendment. 
 
6.2 
Inclusion and Exclusion Criteria 
 
 Inclusion Criteria 
 


 
Corporate Medical Department 
 
Identification Number 
Version Number 
State 
Effective date 
FORM-000050125 
2.0, CURRENT 
Effective 
08, Jan 2021 
 
Sponsor: Menarini International Operations Luxembourg SA 
Study Code: MEIN/20/ZoAm-Hyp/001 
Protocol Version 1.0 of 1     23/04/2021 
  
 
Pag. 34 a 91 
 
A patient will be considered eligible for inclusion in the study only if all the following criteria 
are met:   
1. Male or female Grade 1-2 hypertensive patients:  with mean sitting SBP ≥140 mmHg 
and ≤179 mmHg and/or mean sitting DBP ≥ 90 mmHg and ≤109 mmHg at Screening, 
with ≥18 and ≤65 years of age, on monotherapy either with ZOF 30 mg or AML 5mg or 
any other ACE-I or CCBs (Felodipine, isradipine, lacidipine, lercanidipine, nicardipine, 
nifedipine, and nisoldipine) for at least 1 month before Visit 1 (Screening). 
2. Patients who are able to understand and give written informed consent at Screening 
3. Patients who are available for the entire trial period and willing to adhere to the protocol 
requirements  
4. Ability to take oral medication and willing to adhere to the drug regimen 
5. Female patients are eligible to participate if not pregnant, or not breastfeeding and must 
refrain from donating or storing eggs. For females of reproductive potential: use of highly 
effective contraception (e.g., method of birth control throughout the study period and for 
4 weeks after study completion defined as a method which results in a failure rate of less 
than 1% per year) such as: 
• Combined (estrogen- and progestogen-containing) hormonal contraception 
associated with inhibition of ovulation (oral, intravaginal, transdermal) 
• Progestogen-only hormonal contraception associated with inhibition of ovulation 
(oral, injectable, implantable) 
• Intrauterine device (IUD) 
• Intrauterine hormone-releasing system (IUS) 
• Bilateral tubal occlusion 
• Vasectomized partner (performed at least 2 months before screening) (if the 
partner is the sole sexual partner of the trial participant and that the vasectomized 
partner has received medical assessment of the surgical success) 
6. A male patient must agree to use contraception during the whole study period and for at 
least 1 week after the last dose of study treatment and refrain from donating sperms during 
this period 
 
 Exclusion Criteria 
Any patient who meets any of the following criteria will not qualify for entry into the study: 
 


 
Corporate Medical Department 
 
Identification Number 
Version Number 
State 
Effective date 
FORM-000050125 
2.0, CURRENT 
Effective 
08, Jan 2021 
 
Sponsor: Menarini International Operations Luxembourg SA 
Study Code: MEIN/20/ZoAm-Hyp/001 
Protocol Version 1.0 of 1     23/04/2021 
  
 
Pag. 35 a 91 
 
1. Known contraindications, presence of not recommended/contraindicated concomitant 
therapy allergies, or significant history of hypersensitivity to zofenopril, amlodipine, other 
ACE-inhibitors or dihydropyridines, or any related products (including excipients of the 
formulations as outlined in the Investigator’s Brochure [IB]), or summary of product 
characteristics (SmPCs) or local package inserts for AML and ZOF  
2. Patients with serious disorders (in the opinion of the Investigator) which may limit the ability 
to evaluate the efficacy or safety of the tested medications, including cerebrovascular, 
cardiovascular, renal, respiratory, hepatic, gastrointestinal, endocrine/ or metabolic, 
haematological, or oncological, neurological, and psychiatric diseases. The same applies for 
immunocompromised and/or neutropenic patients 
3. Patients having a history of the following within the last 6 months: myocardial infarction, 
unstable angina pectoris, percutaneous coronary intervention, bypass surgery, valve 
replacement (transcatheter aortic valve implantation, mitraclip),cerebrovascular accident 
(stroke, heart failure, hypertensive encephalopathy, cerebrovascular accident (stroke), or 
transient ischemic attack. Patients with who have undergone other surgery that in the in the 
opinion of the Investigator may limit the ability to evaluate the efficacy or safety of the tested 
medications. 
4. Patients with secondary hypertension of any aetiology such as renal diseases, 
pheochromocytoma, Cushing’s syndrome hyperaldosteronism, renovascular disease, thyroid 
disorders  
5. Patients with severe heart failure (New York Heart Association classification III-IV), a 
narrowing of the aortic or bicuspid valve, an obstruction of cardiac outflow (obstructive, 
hypertrophic cardiomyopathy) or symptomatic coronary disease 
6. Patients with clinical evidence of renal disease as per the Investigator’s judgement (including 
renovascular occlusive disease, nephrectomy and/or renal transplant, bilateral renal artery 
stenosis or unilateral renal artery stenosis in a solitary kidney, or severe renal impairment) 
7. Patients with history of angioneurotic oedema 
8. Patients with clinically relevant hepatic impairment  
9. Patients with sick sinus syndrome, including sino-atrial block 
10. Patients with second- or third-degree heart block (without a pacemaker) 
11. Participation in any other interventional drug trial or exposure to other investigational agents 
within 30 days before Screening (Visit 1)  
12. Inability to cooperate or any condition that, in the opinion of the Investigator, could increase 
the patient’s risk of participating in the study or confound the outcome of the study 


 
Corporate Medical Department 
 
Identification Number 
Version Number 
State 
Effective date 
FORM-000050125 
2.0, CURRENT 
Effective 
08, Jan 2021 
 
Sponsor: Menarini International Operations Luxembourg SA 
Study Code: MEIN/20/ZoAm-Hyp/001 
Protocol Version 1.0 of 1     23/04/2021 
  
 
Pag. 36 a 91 
 
13. Patients with conditions that, in the opinion of the Investigator, would prevent a careful 
adherence to the protocol 
14. Patients with severe hypotension  
15. Patients who suffer from shock (including cardiogenic shock) 
16. Patients treated with Amlodipine 10 mg and Zofenopril (other than 30 mg) 
 
 Screening Failures 
 
All patients who have signed an informed consent form but do not enter into the Run-in period 
(failure to meet at least one of the inclusion criteria and/or met at least 1 of the exclusion 
criteria) will be classified as a screening failure. Screening failures need to have the screening 
completion eCRF for run-in period, demographics, inclusion / exclusion criteria and any SAE 
collected. There will be no re-screening allowed for screening failure patients.  
 
7 
STUDY TREATMENT 
 
 
7.1 
Study Treatment Formulation, Appearance, Packaging, and Labeling 
 
Zofenopril calcium will be provided as 30 mg film coated tablets 
 
Amlodipine (as besylate) will be provided as 5 mg and 10 mg tablets 
 
The treatments administered during the run-in period of the study are AML 5 mg tablets or 
ZOF 30 mg film-coated tablets. The patients who are eligible (uncontrolled hypertension with 
sitting BP of SBP/DBP >130/80 mmHg, who tolerated the treatment and whose adherence to 
the therapies ranges from 80% to 120%) for the assessment period will be given a combination 
of AML 5 mg and ZOF 30 mg or AML 10 mg and ZOF 30 mg. Details on the study design is 
provided in Section 5. 
 


 
Corporate Medical Department 
 
Identification Number 
Version Number 
State 
Effective date 
FORM-000050125 
2.0, CURRENT 
Effective 
08, Jan 2021 
 
Sponsor: Menarini International Operations Luxembourg SA 
Study Code: MEIN/20/ZoAm-Hyp/001 
Protocol Version 1.0 of 1     23/04/2021 
  
 
Pag. 37 a 91 
 
Study Treatment Name: 
Amlodipine 
Marketing Authorisation Holder:  
EG S.p.A. 
Via Pavia, 6 
20136 Milano 
Italy 
Zofenopril calcium 
Marketing Authorisation Holder: 
Laboratori Guidotti S.p.A. - Via 
Livornese 897, PISA – La Vettola 
Concessionario per la vendita: A. 
Menarini Industrie Farmaceutiche 
Riunite s.r.l., Via Sette Santi, 3 – 
Firenze, Italy 
Dosage Formulation: 
Tablets 
Film-coated tablets 
Unit Dose Strength(s)/Dosage 
Level(s): 
5 mg once daily 
10 mg once daily 
30 mg once daily 
Route of Administration:  
Oral 
Oral 
Dosing Instructions*: 
1 tablet of study medication to be 
administered with water, once daily 
and according to instructions provided 
by Principal Investigator 
1 tablet of study medication to be 
administered with water, once daily and 
according to instructions provided by 
Principal Investigator 
Packaging and Labelling: 
Study medication will be provided in 
its original marketed PVC//Aluminium 
blisters 
Study medication will be provided in its 
original marketed a 
PVDC/PVC//Aluminium blisters 
Storage Conditions:  
All study treatment must be stored in 
its original packaging and kept in a 
secure area (in a dry place and 
protected from light and in accordance 
with the label’s instructions) with 
access limited to the Investigator and 
authorized site staff. No other special 
storage conditions are needed.  
All study treatment must be stored in its 
original packaging and kept in a secure 
area (in a dry place and protected from 
light and in accordance with the label’s 
instructions) with access limited to the 
Investigator and authorized site staff. No 
other special storage conditions are 
needed. 
 
Study treatment dosage form, strength, formulation: 
Amlodipine 5 mg: AML 5 mg is white, round, tablet  
Amlodipine 10 mg: AML 10 mg is white, round, tablet with one break on one side  


 
Corporate Medical Department 
 
Identification Number 
Version Number 
State 
Effective date 
FORM-000050125 
2.0, CURRENT 
Effective 
08, Jan 2021 
 
Sponsor: Menarini International Operations Luxembourg SA 
Study Code: MEIN/20/ZoAm-Hyp/001 
Protocol Version 1.0 of 1     23/04/2021 
  
 
Pag. 38 a 91 
 
Zofenopril calcium 30 mg: ZOF 30 mg is white, oblong film-coated tablet with break marks on 
both sides. 
 
Study treatment manufacturing 
The AML 5/10 tablets and ZOF 30 mg film-coated tablets will be sourced as authorized EU 
marketed products from a commercial supplier in the European market. 
Marketing Authorization Holders (MAH) are reported in relative SmPC7,8. 
 
Study treatment packaging and labelling 
The study treatment packaging and labelling operations are performed by A. Menarini 
Manufacturing Logistics and Services S.R.L. (Menarini Group), Via Sette Santi, 3 50131-
Florence (Italy). 
 
The study treatment packaging and labelling operations will be performed in compliance with 
all applicable regulatory requirements and Good Manufacturing Practice guidelines, as well as 
any additional national requirement and Standard Operative Procedures (SOPs). 
The label wording will be in the local language for each country and will report the contents of 
the boxes and the instructions on how to administer and store the study medication. 
 
Study treatment packaging description 
 
Both ZOF 30 mg and AML 5/10 mg will be provided in dedicated treatment Patient Kits to be 
dispensed at Visit 1 (Run In) and at Visit 2 and Visit 3 (Assessment). 
 
Visit 1 (Screening- start Run In) 
• ZOF 30 mg: each trial participant is provided with one labelled Patient Kit (blue label) 
containing 42 film-coated tablets (3 blisters of 14 tablets each) of zofenopril calcium 30 
mg. 
• AML 5 mg: each trial participant is provided with one labelled Patient Kit (yellow 
label) containing 42 tablets (3 blisters of 14 tablets each) of amlodipine 5 mg. 
 
Trial participant must be instructed by Investigator to take one tablet of ZOF 30 mg or AML  5 
mg, according to Study Protocol. 
 


 
Corporate Medical Department 
 
Identification Number 
Version Number 
State 
Effective date 
FORM-000050125 
2.0, CURRENT 
Effective 
08, Jan 2021 
 
Sponsor: Menarini International Operations Luxembourg SA 
Study Code: MEIN/20/ZoAm-Hyp/001 
Protocol Version 1.0 of 1     23/04/2021 
  
 
Pag. 39 a 91 
 
Visit 2 (start of Assessment) 
Participants with uncontrolled BP (>130/80 mmHg) will be provided with ZOF 30 mg and 
AML 5 mg while participants with controlled BP (≤130/80 mmHg) will be withdrawn from the 
study  
Each trial participant is provided with one treatment Patient Kit made up by 
• ZOF 30 mg: one labelled box (white label) containing 42 film-coated tablets (3 blisters 
with 14 film coated tablets each) of zofenopril calcium 30 mg 
• AML 5 mg: one labelled box (white label) containing 42 tablets (3 blisters with 14 
tablets each) of amlodipine 5 mg. 
 
The two white labelled boxes are then sealed together into a transparent plastic film to realize 
the treatment Patient Kit. 
Trial participant must be carefully instructed by Investigator to take simultaneously (at the 
same time): ZOF 30 mg (zofenopril calcium 30 mg) as one oblong film-coated tablet and AML 
5 mg (amlodipine 5 mg) as one round tablet, according to Study Protocol. 
 
Visit 3 (Assessment) 
Participants with controlled BP (≤130/80 mmHg) are provided with one treatment kit made 
up by: 
• ZOF 30 mg: one labelled box (white label) containing 42 film-coated tablets (3 blisters 
with 14 film coated tablets each) of zofenopril calcium 30 mg 
• AML 5 mg: one labelled box (white label) containing 42 tablets (3 blisters with 14 
tablets each) of amlodipine 5 mg. 
The two white labelled boxes are then sealed together into a transparent plastic film to realize 
the treatment kit. 
Trial participant must be carefully instructed by Investigator to take simultaneously (at the 
same time): ZOF 30 mg (zofenopril calcium 30 mg) as one oblong film-coated tablet and AML 
5 mg (amlodipine 5 mg) as one round tablet, according to Study Protocol. 
 
Participants with SBP/DBP values classified as Grade 3 hypertension will be withdrawn from 
the study 
Participants with uncontrolled BP (>130/80 mmHg) are provided with one treatment Patient 
Kit made up by: 


 
Corporate Medical Department 
 
Identification Number 
Version Number 
State 
Effective date 
FORM-000050125 
2.0, CURRENT 
Effective 
08, Jan 2021 
 
Sponsor: Menarini International Operations Luxembourg SA 
Study Code: MEIN/20/ZoAm-Hyp/001 
Protocol Version 1.0 of 1     23/04/2021 
  
 
Pag. 40 a 91 
 
o 
ZOF 30 mg: one labelled box (green label) containing 42 film-coated tablets (3 blisters 
with 14 film coated tablets each) of zofenopril calcium 30 mg 
o 
AML 10 mg: one labelled box (green label) containing 42 tablets (3 blisters with 14 
tablets each) of amlodipine 10 mg. 
The two green labelled boxes are then sealed together into a transparent plastic film to identify 
the treatment Patient Kit. 
Trial participant must be carefully instructed by Investigator to take simultaneously (at the 
same time): ZOF 30 mg (zofenopril calcium 30 mg) as one oblong film-coated tablet and AML  
10 mg (amlodipine 10 mg) as one round tablet (with one break on one side), according to Study 
Protocol 
 
7.2 
Study Treatment Distribution and Return / Destruction 
 
All the study drugs must be retained at the investigational site for accountability, destruction 
and return of study supplies.  
The investigator or designee will acknowledge receipt of the investigational product, 
documenting shipment content and condition.  
Accurate records of all investigational product dispensed, used, returned, and/or destroyed must 
be maintained.  
The investigator is responsible for ensuring the retrieval of all study supplies from patients. 
 
At the conclusion of the study, any unused investigational product will either be destroyed at 
the investigator site or be returned to the Sponsor or its designee for destruction and destruction 
will be documented appropriately.  
If no supplies remain, this fact will be documented appropriately 
Destruction of returned investigational products must carried out after written authorization of 
the Sponsor 
 
7.3 
Product Storage and Stability 
 
No special storage conditions are required. However, the verification of the storage conditions 
along with the relevant records will be monitored at the trial site. 
 


 
Corporate Medical Department 
 
Identification Number 
Version Number 
State 
Effective date 
FORM-000050125 
2.0, CURRENT 
Effective 
08, Jan 2021 
 
Sponsor: Menarini International Operations Luxembourg SA 
Study Code: MEIN/20/ZoAm-Hyp/001 
Protocol Version 1.0 of 1     23/04/2021 
  
 
Pag. 41 a 91 
 
All study treatment must be stored in its original packaging and kept in a secure area (in a dry 
place and protected from light and in accordance with the label’s instructions) with access 
limited to the Investigator and authorized site staff. 
 
7.4 
Study Product Compliance 
 
The investigator must promote compliance by instructing the patient to the study treatment 
exactly as prescribed and by stating the compliance is necessary for the patient’s safety and the 
validity of the study. The investigator has to instruct patients to return the study treatment (if 
any or empty boxes for accountability) at each visit.  
 
Investigator should instruct the patient to take the study drug at the same time every day, in the 
morning. On the days of the patient’s visits, the investigator should instruct the patient to not 
take the study drug at home.  
 
In case a patient forgets to take a dose, he/she can by take the study drug the same day. Patients 
should not take the study drug after 16.00 (4 pm) on the visit days. The investigator should 
instruct the patient to not take the dose at home. 
 
The compliance to the treatment (percentage of actual doses taken versus doses to be taken) 
will be assessed by the investigator and/or study personnel at Visit 2 (Week 0), at Visit 3 
(Week 4) and at Visit 4 (Week 8).  This information should be captured in the source document 
and in the eCRFs at each visit.  
 
Adherence to treatment will be measured through treatment compliance which is 100 × (actual 
doses taken/planned dose). 
A patient who has taken at least 80% and no more than 120% of the required study medication 
intake since the last visit will be considered as compliant. 
 
7.5 
Concomitant Therapy(ies) 
 
The investigator must instruct the patient to notify the study site about any new medication 
he/she takes after being enrolled into the study. All medication, procedures and significant non-
drug therapies administered after the patient was enrolled at the study must be recorded in the 


 
Corporate Medical Department 
 
Identification Number 
Version Number 
State 
Effective date 
FORM-000050125 
2.0, CURRENT 
Effective 
08, Jan 2021 
 
Sponsor: Menarini International Operations Luxembourg SA 
Study Code: MEIN/20/ZoAm-Hyp/001 
Protocol Version 1.0 of 1     23/04/2021 
  
 
Pag. 42 a 91 
 
appropriate eCRF. Each concomitant drug must be individually assessed against all exclusion 
criteria/prohibited medication. If the patient is already enrolled, please contact BIORASI to 
determine if the patient should continue participation in the study. 
 
7.6 
Not permitted medications 
 
Blood pressure modifying drugs,  even though used for other indications like alpha receptor 
blockers and agonists, beta receptor blockers and agonists, calcium antagonists, angiotensin 
converting enzyme (ACE) inhibitors, diuretics, centrally acting antihypertensives (e.g. 
clonidine, methyldopa, guanfacine), reserpine, moxonidine, chronic nitrate treatment (e.g. 
isosorbide dinitrate or isosorbide mononitrate), potassium sparing diuretics, potassium 
supplements, potassium-containing salt substitutes or other agents that increase serum 
potassium, PDE - inhibitors and angiotensin II antagonists will be prohibited during the study.  
 
The Investigator has to instruct patients to refer to the study doctor before they administer any 
medicinal substances or products listed in section 4.5 of the Zofenopril and Amlodipine 
SmPC7,8.    
 
7.7 
Rescue Medicine 
 
Not Applicable. 
 
8 
STUDY ASSESSMENT AND PROCEDURES 
 
The following study assessment and procedures will proceed according to the Study Flow 
Chart in Section 2.3.  
 
Informed Consent 
 
A signed and dated, study-specific, Independent Ethics Committee (IEC) approved consent 
form must be obtained from each patient at the Screening Visit and prior to performing any 
study related procedures. No study related procedures or activities may be performed until each 
patient is fully informed and the consent form is duly read, understood, signed and dated. All 
patients will be given a copy of the signed and dated consent form. The Investigator must store 


 
Corporate Medical Department 
 
Identification Number 
Version Number 
State 
Effective date 
FORM-000050125 
2.0, CURRENT 
Effective 
08, Jan 2021 
 
Sponsor: Menarini International Operations Luxembourg SA 
Study Code: MEIN/20/ZoAm-Hyp/001 
Protocol Version 1.0 of 1     23/04/2021 
  
 
Pag. 43 a 91 
 
the originally signed ICF in the Investigator’s File, and the patient will be provided with a copy 
of it. For more details, please refer to Section 6.   
 
 Inclusion/Exclusion Criteria 
 
All patients who sign the ICF will be evaluated for inclusion and exclusion criteria to determine 
patient eligibility as described in Section 6.1. If the patient is determined to be ineligible prior 
to enrolment, the reason(s) for ineligibility must be documented by the Investigator. 
Verification of all inclusion and exclusion criteria, including all baseline assessments, will take 
place at the Screening Visit.  
 
Medical History 
A complete medical history for each patient will be recorded at the Screening Visit. A complete 
review of all current diseases, history of hypertension, and their respective durations and 
treatments will be conducted, and the relevant documentations will be filed in the Source 
Documentation.  
 
Prior medication 
 
 
At the Screening Visit, all medications taken within the 30 days prior to the start of the study 
will be recorded as Prior Medication with the corresponding indication, start and stop dates. 
Prior medications may include prescription, over-the counter (OTC) and all dietary 
supplements. A particular focus will be on prior medication to treat hypertension including 
zofenopril or amlodipine status and dosage.  
 
Demography 
 
After the informed consent has been signed and the patient’s eligibility to participate in the 
study has been determined at the Screening Visit, basic demographic information, including 
age, gender, race, height, and weight. The BMI (kg/m2) will be calculated will be recorded. 
Smoking status will be documented in the source documents and Ecrf. For female patients, the 
menopausal status would also be documented. 
 
IWRS registration: 


 
Corporate Medical Department 
 
Identification Number 
Version Number 
State 
Effective date 
FORM-000050125 
2.0, CURRENT 
Effective 
08, Jan 2021 
 
Sponsor: Menarini International Operations Luxembourg SA 
Study Code: MEIN/20/ZoAm-Hyp/001 
Protocol Version 1.0 of 1     23/04/2021 
  
 
Pag. 44 a 91 
 
 
At Visit 1 all screened patients will be registered via Interactive (IWRS) to one of the allocated 
treatments: zofenopril 30 mg and amlodipine 5 mg. The investigator or his/her delegate will 
contact the IWRS after confirming that the patient fulfils all the inclusion /exclusion criteria. 
The percentage of enrolled patients coming from each monotherapy treatment, Zofenopril 30 
mg / Amlodipine 5 mg will be capped at 50% at Visit 2. 
IWRS must be updated at each visit, registering the status of the patient (failure, ongoing and 
which therapy the patient’s is administering) 
 
Concurrent diseases and medical conditions 
 
At each of the study visits (1, 2, 3, and 4) current diseases and medical conditions will be 
recorded including their date/time of diagnosis, duration, and treatment. Adverse event will be 
conditions arising after the start of the study, which should be recorded as adverse events as 
described in Section 9.1.  
 
Monotherapy of zofenopril 30 mg or amlodipine 5 mg dispensing 
 
• At the Screening Visit (Visit 1): 
o Patients who are currently being treated with zofenopril (ZOF) 30 mg or 
amlodipine (AML) 5 mg will continue the same therapy for 4 weeks.  
o Patients on any other ACE-i will be assigned to monotherapy with ZOF 30 mg 
for 4 weeks.  
o Patients on other CCBs (the allowed CCBs are: felodipine, isradipine, 
lacidipine, lercanidipine, nicardipine, nifedipine, and nisoldipine) will be 
assigned to monotherapy with AML 5 mg for 4 weeks. 
 
The study drugs will be dispensed such that patients have sufficient supply to last until the next 
visit (Visit 2). All patients will be counselled to keep the packaging and any remaining drug to 
be surrendered during Visit 2.  
Extemporaneous combination of ZOF/AML 30/5 mg dispensing 
 
At Visit 2 (after the run-in period (4 weeks ± 2 days) of monotherapy) if BP remains 
uncontrolled (sitting SBP/DBP >130/80 mmHg), treatment is well tolerated and adherence to 


 
Corporate Medical Department 
 
Identification Number 
Version Number 
State 
Effective date 
FORM-000050125 
2.0, CURRENT 
Effective 
08, Jan 2021 
 
Sponsor: Menarini International Operations Luxembourg SA 
Study Code: MEIN/20/ZoAm-Hyp/001 
Protocol Version 1.0 of 1     23/04/2021 
  
 
Pag. 45 a 91 
 
the treatments ranges from 80% to 120%,  patients will enter the assessment period, where they 
will be assigned to the extemporaneous combination of ZOF 30 mg and AML 5 mg.  The study 
drugs will be dispensed such that patients have sufficient supply to last until the next visit (Visit 
3). All patients will be counselled to keep the packaging and remaining drug to be collected 
during Visit 3.  
At Visit 2 patients with SBP/DBP values classified as Grade 3 hypertension (SBP ≥ 180 or 
DBP ≥ 110 mmHg) will be withdrawn from the study. 
 
At Visit 3, if BP is controlled (≤130/80 mmHg), patients will continue the same 
extemporaneous combination ZOF/AML 30/5 mg for additional 4 weeks ± 2 days (Visit 4).   
 
Extemporaneous combination of ZOF/AML 30/10 mg dispensing 
 
At Visit 3, if BP is controlled, patients will continue the same extemporaneous combination for 
additional 4 weeks ± 2 days (Visit 4).  Uncontrolled patients (sitting SBP/DBP >130/80 
mmHg), will be up titrated from AML 5 mg to AML 10 mg for further 4 weeks ± 2 days (Visit 
4).  
At Visit 3 patients with SBP/DBP values classified as Grade 3 (SBP ≥ 180 or DBP ≥ 110 
mmHg) hypertension will be withdrawn from the study 
 
Study drug return/accounting (Compliance assessment) 
 
The study drugs will be dispensed on site such that patients have sufficient supply to last until 
the next visit. All patients will be counselled to keep the packaging and remaining drug to be 
returned to the site staff at the subsequent visit.  Site staff will collect the unused drug and 
packaging and provide an assessment of compliance at Visits 2, 3, and 4.  
 
Concomitant medications 
Any medication that the patient was receiving at the time of enrolment, and the other regular or 
occasional use of any concomitant medication during the study will be recorded in the source 
documents and in the eCRF. The concomitant medications will be recorded at the Screening 
Visit and each subsequent visit during the study.  
 


 
Corporate Medical Department 
 
Identification Number 
Version Number 
State 
Effective date 
FORM-000050125 
2.0, CURRENT 
Effective 
08, Jan 2021 
 
Sponsor: Menarini International Operations Luxembourg SA 
Study Code: MEIN/20/ZoAm-Hyp/001 
Protocol Version 1.0 of 1     23/04/2021 
  
 
Pag. 46 a 91 
 
8.1 
Assessment of Efficacy 
 
The primary objective of this study is to assess the anti-hypertensive efficacy of the 
extemporaneous combination of ZOF 30 mg in combination with AML 5 mg or AML 10 mg in 
lowering the sitting diastolic BP between Visit 2 (Week 0) and Visit 4 (Week 8) in patients 
with uncontrolled BP previously treated with Zofenopril or Amlodipine (5 mg) monotherapies 
for at least 4 weeks. The primary efficacy endpoint is change in mean sitting DBP between 
Visit 2 (Week 0) and Visit 4 (Week 8). To achieve this objective, the efficacy parameter BP 
will be measured at all visits as described below.  
 
Blood Pressure (BP) 
 
BP will be measured in both arms at the screening visit (Visit 1) to detect possible between-arm 
differences. The arm with the higher value of mean DBP will be identified as the reference arm 
and will be used at all subsequent visits for BP monitoring. Blood pressure measurements 
should be performed as nearly as possible at the same time of the day (7:00 – 12:00 a.m.), on 
the same arm, and using the same calibrated equipment at each visit.  
All BP measurements will be performed after at least 10 minutes rest in sitting position in 
triplicate (spaced by at least 1 minute) and once standing using an automatic device provided 
by MENARINI. The mean of the three recordings in sitting position will be used as the BP 
value for that visit and recorded in the source document and in the eCRF. All BP measurements 
during the treatment phase will be performed as through readings (i.e. 24 + 2 h after the last 
drug intake). Thus, the study drug should be taken at morning time Post-BP measurement.   
For this purpose, patients will be instructed to take study treatment at the same time each day 
except on the days of study visits when study treatment will be taken after all visit evaluations 
have been performed. 
 
8.2 
Assessment of Safety 
 
Safety will be assessed through collection of treatment-emergent AEs, serious AEs (SAE), , 
that started after the first dose of study treatments (incidence, severity, seriousness, treatment 
causality), and physical examination (, vital signs, BP, and heart rate). Safety assessments will 
be performed at time points as described in Section  9. 
 


 
Corporate Medical Department 
 
Identification Number 
Version Number 
State 
Effective date 
FORM-000050125 
2.0, CURRENT 
Effective 
08, Jan 2021 
 
Sponsor: Menarini International Operations Luxembourg SA 
Study Code: MEIN/20/ZoAm-Hyp/001 
Protocol Version 1.0 of 1     23/04/2021 
  
 
Pag. 47 a 91 
 
Urine Pregnancy test 
 
Study medication should not be given to pregnant female. Therefore, Urine Pregnancy tests 
will be performed in all females of childbearing potential at Screening and each subsequent 
visit during the study.  
 
Physical examination 
 
The Investigator (or site staff) must perform a complete physical examination at Screening and 
each subsequent visit during the study.  At the Screening visit height, weight (in indoor 
clothing but without shoes) and body mass index [BMI] calculation will be recorded. At all 
visits, the physical examination will include general appearance, skin, head, neck, ear-nose-
throat (ENT), heart, lungs, abdomen, extremities, neurological, musculoskeletal and lymph 
nodes. Information pertaining to physical examinations must be included in the source 
documentation at the study site. Any new finding, or worsening of a previous finding, should 
be reported as a new AE. 
 
Vital Signs 
 
Body temperature (°C) and heart rate will be measured under the same conditions at Screening 
and all subsequent visits (Visit 2, Visit 3, and Visit 4). If possible, vital sign assessment should 
be performed by the same study site staff member using the same validated device throughout 
the study. Blood pressure will also be measured at all visits as described above.  
Vital signs should be performed prior to taking the blood samples. 
 
Electrocardiograms 
 
In this study, Local ECG will be used and will be performed by a qualified clinical site 
physician. All 12-lead electrocardiogram (ECG) will be standardized recordings. Single 12-lead 
ECGs will be performed at Screening (Visit 1) and at Visit 4. Additional 12-lead ECG will be 
performed at other times if judged to be clinically appropriate or if the on-going review of the 
data suggests a more detailed assessment of ECG is required. ECGs will be performed in 
triplicate at Visit 1 and Visit 4.  
 


 
Corporate Medical Department 
 
Identification Number 
Version Number 
State 
Effective date 
FORM-000050125 
2.0, CURRENT 
Effective 
08, Jan 2021 
 
Sponsor: Menarini International Operations Luxembourg SA 
Study Code: MEIN/20/ZoAm-Hyp/001 
Protocol Version 1.0 of 1     23/04/2021 
  
 
Pag. 48 a 91 
 
The patient must rest in a supine position for 5 minutes before the ECG is obtained. ECG 
tracings (paper or electronic) should be reviewed and interpreted by the Investigator or a 
qualified clinician. ECG parameters including ventricular rate, RR-Interval [ms], PR-Interval 
[ms], Rhythm (sinusal - other), PR, QRS, QT, QTcF, and QTcB intervals will be recorded. 
 
If QTcF > 450 ms, it should be evaluated and used for clinical decision: another triplicate ECG 
is indicated and if required should be discussed with the Sponsor and/or medical monitor.  
 
The original ECGs must be appropriately signed, collected and archived at the study site.  
Printouts and related copies for each ECG will include date, time, initials of the 
technician/nurse, and initials of the Investigator who reviewed the printout and should be 
properly archived at site. 
Clinically relevant abnormalities should be recorded first on the source documents by the PI 
and then on the relevant section of the eCRFs. 
 
Laboratory tests 
 
A local laboratory will be used for laboratory evaluation. Clinical laboratory tests (chemistry 
and haematology) will be conducted at Screening (Visit 1) and Visit 4. Blood and urine 
samples for pregnancy test will be collected, processed, and analysed locally and in accordance 
to the research site’s SOPs. 
 
The maximum volume of blood to be taken is approximately 40 mL, which will be the total 
blood collected during the study.  
 
The results should be evaluated for criteria defining AE and reported as such if the criteria are 
met. In all cases, the investigator must document in the source documents, the clinical 
considerations (i.e. results were or was not was clinically significant and/or medically relevant) 
in allowing or disallowing the patient to continue in the study. 
 
To ensure patient safety, the patients will be contacted over phone within 24 hours, in case of 
any abnormality and clinically relevant laboratory test according to the Investigator’s 
judgement at any visit. The results of laboratory tests will be returned to the Investigator, who 
is responsible for 


 
Corporate Medical Department 
 
Identification Number 
Version Number 
State 
Effective date 
FORM-000050125 
2.0, CURRENT 
Effective 
08, Jan 2021 
 
Sponsor: Menarini International Operations Luxembourg SA 
Study Code: MEIN/20/ZoAm-Hyp/001 
Protocol Version 1.0 of 1     23/04/2021 
  
 
Pag. 49 a 91 
 
reviewing and filing these results. Note: Patients who will be reported with an abnormal renal 
function (creatinine clearance <30 mL/min) and/or abnormal liver enzyme parameters (alanine 
aminotransferase [ALT] or aspartate aminotransferase [AST] level of >2.5 × upper limit of 
normal [ULN] or bilirubin level >1.5 × ULN) will be withdrawn from treatment and study. 
 
The following parameters Haematology and Serum Chemistry parameters will be assessed: 
 
Haematology 
Serum Chemistry 
Red blood cell 
White blood cell 
Haemoglobin 
Haematocrit 
Platelets 
Neutrophils 
Lymphocytes 
Monocytes 
Eosinophils 
Basophils 
Neutrophils absolute 
Lymphocytes absolute 
Monocytes absolute 
Eosinophils absolute  
Basophils absolute 
 
 
ALT 
Albumin 
Alkaline phosphatase 
AST  
Direct bilirubin 
Total bilirubin 
Total protein 
Creatinine 
Blood urea nitrogen 
Creatine kinase 
GGT 
Triglycerides 
Cholesterol 
High- and low-density lipoprotein 
Chloride     
eGFR 
Blood glucose 
Potassium 
Uric acid  
 
 
AE/SAE Assessments 
 
The assessment of adverse events (AEs) by seriousness and relationship will be performed at 
all visits. AEs that occur after a patient has signed the ICF and prior to exposure to study drug 
will be recorded on the case report form and will not be considered treatment emergent adverse 
events (TEAEs).  
 
 


 
Corporate Medical Department 
 
Identification Number 
Version Number 
State 
Effective date 
FORM-000050125 
2.0, CURRENT 
Effective 
08, Jan 2021 
 
Sponsor: Menarini International Operations Luxembourg SA 
Study Code: MEIN/20/ZoAm-Hyp/001 
Protocol Version 1.0 of 1     23/04/2021 
  
 
Pag. 50 a 91 
 
Management of clinical trial during Pandemic COVID-19 
Since December 2019, an outbreak of respiratory disease caused by a novel coronavirus, first 
detected in Wuhan City, Hubei Province, China, has been detected in nearly all countries of the 
world. The virus has been named “SARS-CoV-2” and the disease it causes has been named 
“Coronavirus Disease 2019” (COVID-19). On 08 March 2020, the World Health Organization 
(WHO) declared the COVID-19 outbreak a global pandemic. 
 
The COVID-19 public health emergency may impact the conduct of clinical trials of medical 
products. In response to the pandemic, various health authorities have issued guidelines to 
maintain the integrity of ongoing clinical studies 
 
Summary of Changes in Study-Related Procedures as a Result of the COVID-19 Pandemic 
 
To assure the safety of study participants, maintain compliance with GCP, and minimize risks 
to study integrity, if necessary, the method of assessments may be changed at the discretion of 
the Sponsor. In addition, site visits may be replaced with home visits, telephone, or internet-
based video-conferencing applications. For this study, except in an urgent situation, changes in 
study conduct need to be approved by the Sponsor before being initiated. The specific changes 
to be implemented will be based on the current conditions in the country/region and will be 
reassessed on an ongoing basis. Not all countries or all sites in a country may be impacted. 
Normal procedures, as described in this protocol, will be resumed as soon as possible 
thereafter. 
This section describes the COVID-19 mitigation plans for MASOLINO study. The following 
mitigation measures will be implemented in study-related procedures as a result of the COVID-
19 pandemic. 
Clinical investigators should document in site files and in source documents as appropriate how 
restrictions related to COVID-19 originated changes to the study conduct, duration of changes, 
and which participants were affected by such changes. Communications with Sponsor 
regarding the implementation of the herein described mitigation measures should be 
documented in the source documents. 
 
Informed consent 
 
 


 
Corporate Medical Department 
 
Identification Number 
Version Number 
State 
Effective date 
FORM-000050125 
2.0, CURRENT 
Effective 
08, Jan 2021 
 
Sponsor: Menarini International Operations Luxembourg SA 
Study Code: MEIN/20/ZoAm-Hyp/001 
Protocol Version 1.0 of 1     23/04/2021 
  
 
Pag. 51 a 91 
 
This paragraph is applicable only in case a patient needs to re-consent in study participation. 
Initial informed consent signature must be provided at site during Visit 1 (Screening) 
Each participant must be provided with new information that might impact their willingness to 
participate in the study in a timely manner. Should the participant need to re-consent if 
permitted by investigative site procedures and local regulations, the informed consent form can 
be mailed to the participant. 
The participant can sign the consent form at home and mail it to the study site. Alternatively, 
the PI or designee can visit the participant at home to present the changes to the study and 
obtain the informed consent form signature at the participant’s home. If the participant has any 
questions about the changes to the study prior to providing their signature, they will be 
provided with an opportunity to discuss these questions with the PI or designee. 
After having obtained the consent, a copy of the signed consent must be sent to or stay with the 
participant. 
 
Study Treatment Distribution and Return 
 
 
This paragraph is not applicable for Visit 1 (screening) but only for the subsequent visits. 
Due to social restriction measures, the participant may not be able to reach the study site. In 
such cases, the study treatment will not be dispensed to the participants at the site. Instead, the 
study treatment may be distributed to the participants’ home at the times defined in the Study 
flow chart by the designated site staff or by a distributor independent from and acting on behalf 
of the sponsor in line with national law or temporary national emergency measures. Participants 
will be informed and trained on the new dispensing procedures. Participants will be instructed 
to keep unused study treatment, which will be collected by the designated site staff on the 
earliest possible time or agreed with the participant to return to site via courier. 
 
Study assessment and procedures 
 
The Screening visit is a mandatory in clinic/hospital visit and therefore should be performed at 
the site. The Principal Investigator continues to be responsible for reviewing all study -related 
assessments. 
The participant may not be able to reach the site to perform blood pressure (BP) measurement 
for primary and secondary analysis, clinical laboratory tests, vital sign and physical 
examination, electrocardiogram (ECG), or other assessments required by the study flow chart 


 
Corporate Medical Department 
 
Identification Number 
Version Number 
State 
Effective date 
FORM-000050125 
2.0, CURRENT 
Effective 
08, Jan 2021 
 
Sponsor: Menarini International Operations Luxembourg SA 
Study Code: MEIN/20/ZoAm-Hyp/001 
Protocol Version 1.0 of 1     23/04/2021 
  
 
Pag. 52 a 91 
 
In such cases, these assessments will be performed by the health care professionals (study staff 
or qualified designee) at participant’s home, if allowed per country regulations. 
 
At Visit 1 patients will be provided with an automatic BP device, instructions, on how to 
measure BP, and a diary to record the relevant BP values. In the case of COVID-19 restrictions, 
all patients will be able to measure BP themselves. All patients will be fully trained by the 
investigator or delegated site staff and training will be recorded in the relevant source 
documentation. Patients will note the BP measurements in the diary and communicate it to the 
appropriate site staff. The diary will be returned at the first on-site visit if possible or it will be 
delivered via mail/e-mail.  
 
9 
SAFETY DATA MANAGEMENT 
 
9.1 
Adverse Event (AE) 
 
Any untoward medical occurrence in a subject or clinical trial subject administered a medicinal 
product and which does not necessarily have a causal relationship with this treatment. 
An AE can therefore be any unfavourable and unintended sign (including an abnormal 
laboratory finding), symptom, or disease temporally associated with the use of a medicinal 
product, whether considered related to the medicinal product. 
 
9.2 
Drug Relationship 
 
The relationship between an AE and study drugs will be judged according to the following 
categories: 
− 
Certain: The AE occurs in a plausible time relation to the administration of the drug and 
cannot be explained by a concurrent disease or other drugs or chemicals. The response to 
withdrawal of the drug (dechallenge) should be clinically plausible. The event must be 
definitive pharmacologically or phenomenologically, using a satisfactory rechallenge 
procedure if necessary. 
− 
Probable: The AE occurs in a reasonable time relation to the administration of the drug, 
it is unlikely to be attributed to a concurrent disease or other drugs or chemicals and it 
follows a clinically reasonable response on withdrawal (dechallenge). Rechallenge 


 
Corporate Medical Department 
 
Identification Number 
Version Number 
State 
Effective date 
FORM-000050125 
2.0, CURRENT 
Effective 
08, Jan 2021 
 
Sponsor: Menarini International Operations Luxembourg SA 
Study Code: MEIN/20/ZoAm-Hyp/001 
Protocol Version 1.0 of 1     23/04/2021 
  
 
Pag. 53 a 91 
 
information (AE reappearance after drug reintroduction) is not required to fulfil this 
definition. 
− 
Possible: The AE occurs with a reasonable time relation to the administration of the drug, 
but it could also be explained by a concurrent disease or other drugs or chemicals. 
Information on drug withdrawal (dechallenge) may be lacking or unclear. 
− 
Unassessable: The relationship cannot be judged, because of the information is 
insufficient or contradictory and cannot be supplemented or verified. 
− 
Unlikely: A causal relationship cannot be definitively ruled out, but: 
− 
other drugs, chemicals, or underlying disease provide plausible explanations and / or 
− 
the temporal relation to the administration of the drug makes a causal relation 
improbable. 
− 
Not Related: Any of the following are present: 
− existence of a clear alternative explanation, and / or 
− unreasonable temporal relationship between Drug and Event, and / or 
− non-plausibility. 
 
9.3 
Adverse Drug Reaction (ADR) 
 
An ADR is any untoward and unintended response to an investigational medicinal product 
related to any dose administered. 
The definition implies a reasonable possibility of a causal relationship between the event and 
the Investigational Medicinal Product (IMP). This means that there are facts (evidence) or 
arguments to suggest a causal relationship. 
An ADR is considered any AE for which the relationship is considered as: 
1. 
Certain 
2. 
Probable 
3. 
Possible 
4. 
Un-assessable 
 
An AE is not considered as ADR when the relationship is judged as: 
1. 
Unlikely 
2. 
Not related 
 


 
Corporate Medical Department 
 
Identification Number 
Version Number 
State 
Effective date 
FORM-000050125 
2.0, CURRENT 
Effective 
08, Jan 2021 
 
Sponsor: Menarini International Operations Luxembourg SA 
Study Code: MEIN/20/ZoAm-Hyp/001 
Protocol Version 1.0 of 1     23/04/2021 
  
 
Pag. 54 a 91 
 
9.4 
Seriousness 
 
An AE/ADR is considered Serious when: 
1. 
Results in death; 
2. 
Is life-threatening. 
 
Note: Life-threatening is considered any AE in which the patient was at risk of death at the 
time of the event; it does not refer to an event which hypothetically might have caused death if 
it were more severe. 
 
− 
requires inpatient hospitalisation or prolongation of existing hospitalisation; 
− 
results in persistent or significant disability / incapacity; 
− 
is a congenital anomaly/birth defect; 
− 
is another medically important condition that may jeopardise the patient or may require 
intervention to prevent one of the outcomes listed above. Any suspected transmission of 
an infectious agent via a medicinal product is considered serious and should be assessed 
under the category of medically important events in the absence of other seriousness 
criteria. 
 
An AE / ADR is considered non-serious when it does not fulfil the conditions for the definition 
of Serious AE / ADR. 
 
9.5 
Adverse Event / Adverse Drug Reaction Intensity 
 
The intensity level of a Serious or a Non-serious AE or ADR is attributed according to the 
following definitions: 
− 
Mild: does not interfere with routine activities; in case of laboratory tests, when there is a 
mild abnormality. 
− 
Moderate: interferes with the routine activities; in case of laboratory tests, when there is 
a moderate abnormality. 
− 
Severe: makes it impossible to perform routine activities; in case of laboratory tests, 
when there is a significant abnormality. 
 


 
Corporate Medical Department 
 
Identification Number 
Version Number 
State 
Effective date 
FORM-000050125 
2.0, CURRENT 
Effective 
08, Jan 2021 
 
Sponsor: Menarini International Operations Luxembourg SA 
Study Code: MEIN/20/ZoAm-Hyp/001 
Protocol Version 1.0 of 1     23/04/2021 
  
 
Pag. 55 a 91 
 
9.6 
Adverse Event / Adverse Drug Reaction Expectedness 
 
An AE/ADR is considered Unexpected when the nature, severity, or outcome of the 
AE/ADR is not consistent with the information provided in the Reference Safety Document 
(summary of product characteristics for Zofenopril and Amlodipine)7,8. 
 
9.7 
Serious Unexpected Adverse Drug Reaction (SUSAR) 
 
Any SAE judged by the Investigator or the Sponsor as drug-related (see Section 9.3) and 
considered as unexpected qualifies as a SUSAR. 
SUSARs are subject to expedited reporting, as specified in Section 9.10, as having a 
“Reasonable Possibility” of relationship with the IMP. 
 
9.8 
Individual Case Safety Report (ICSR) 
 
Format and content provided to describe one or several AEs or a disease experience that occur 
to an individual subject at a particular point of time. 
 
9.9 
Collection, Recording and Reporting of AEs 
 
At each visit the Investigator will collect and assess any occurred subjective or objective AE 
occurred to each subject after his / her signature of the informed consent. 
The Investigator should manage as AE any laboratory test abnormality (newly occurring after 
the IMP administration or worsening of previously known abnormalities) considered as 
clinically relevant: i.e. values significantly above or under normal range or which require an 
intervention or diagnostic tests, or may result in the IMP discontinuation. 
Any AE communicated by the subject or by the subject’s relatives or delegates through phone 
calls, letters or e-mails will also be collected and assessed. 
The Investigator shall record on the respective eCRF AE recording pages / AE form any 
recognised AE identifying an ICSR, both serious and non-serious, whether or not thought to be 
drug-related, observed in or reported by the subject (or relatives / delegates), specifying the 
judgement on the causal relationship with the study treatment. 
Any available information and diagnostic measure (laboratory and instrumental tests, 
procedures, etc.) shall be recorded in and / or attached to the concerned eCRF pages / sections. 


 
Corporate Medical Department 
 
Identification Number 
Version Number 
State 
Effective date 
FORM-000050125 
2.0, CURRENT 
Effective 
08, Jan 2021 
 
Sponsor: Menarini International Operations Luxembourg SA 
Study Code: MEIN/20/ZoAm-Hyp/001 
Protocol Version 1.0 of 1     23/04/2021 
  
 
Pag. 56 a 91 
 
The Investigator is expected to also record any AE which was ongoing at the last treatment 
dose and a follow-up phone call should be made after 2 weeks from the last study visit. 
The Investigator is expected to follow up any AE occurred during the study, including the 
follow-up period, until the outcome of the AE has been determined. 
The Investigator must report all the collected information on any ICSR with Serious and 
Non Serious AE (whether or not thought to be related to the investigational drug), providing 
the concerned eCRF-AE pages/ by alert email), after the first knowledge of the occurrence 
of the case, to: 
 
When relevant, also the eCRF pages concerning medical history, concomitant medication, and 
laboratory tests will be placed at Sponsor disposal by email. 
 
9.10 Management of Serious AEs (SAEs) including laboratory abnormalities 
 
9.10.1 Reporting Duties of the Investigator 
The Investigator must report all the collected information on any eCRF with SAE (whether 
or not thought to be related to the investigational drug), as above specified, no later than 24 
hours after the first knowledge of the occurrence of the case. 
Any further information and supporting documentation that become available (copies of 
laboratory reports, tests, procedures, autopsy evidence of the cause of death, etc.) shall be 
provided no later than 24 hours after the knowledge, by the Investigator to the CRO by 
email (MEIN/20/ZoAm-Hyp/001-safety@biorasi.com) to be forwarded to the Sponsor. 
The Investigator must also comply with the local applicable obligation(s) on the reporting of 
ADRs to the local concerned Regulatory Authority/Ethics Committee. 
 
9.10.2 Reporting Duties of the Sponsor 
The Sponsor shall ensure that all relevant information about any SUSAR, is expeditiously 
reported to the competent Authorities and Ethics Committees as required, with these deadlines 
CRO Pharmacovigilance Officer: 
 
Email:  MEIN/20/ZoAm-Hyp/001-safety@biorasi.com 
 
Fax: +1 (786) 221-3531 
 
Tel: +1 (786) 388-0700 
 
Mobile: N/A 


 
Corporate Medical Department 
 
Identification Number 
Version Number 
State 
Effective date 
FORM-000050125 
2.0, CURRENT 
Effective 
08, Jan 2021 
 
Sponsor: Menarini International Operations Luxembourg SA 
Study Code: MEIN/20/ZoAm-Hyp/001 
Protocol Version 1.0 of 1     23/04/2021 
  
 
Pag. 57 a 91 
 
after the first knowledge, intended as the day when the CRO receives the notification of the 
SUSAR: 
 
− 
Fatal and life-threatening unexpected cases, no later than 7 days. 
− 
Other unexpected serious cases, no later than 15 days. 
 
The Sponsor shall ensure that all relevant information and supporting documentation that 
subsequently becomes available, is also expeditiously reported as follow-up information 
according to the above-mentioned deadlines. 
 
Furthermore, the following safety issues will be subjected to expedited management for the 
identification of possible necessary actions: 
 
− 
SAEs associated with the trial procedures. 
− 
Potential clinically significant findings emerging from non-clinical studies. 
− 
An anticipated end or suspension for safety reasons of another trial with the same study 
drug. 
 
When appropriate and applicable the Sponsor will arrange the adequate information also to the 
Investigators. 
 
9.11 Management of Non-serious AEs (NSAEs) including laboratory abnormalities 
 
9.11.1 Reporting Duties of the Investigator 
The Investigator must report all the collected information on any eCRF with NSAE (whether 
or not thought to be related to the investigational drug), as above specified, no later than 5 
Calendar days after the first knowledge of the occurrence of the case. 
Any further information and supporting documentation that become available (copies of 
laboratory reports, tests, procedures, etc.) shall be provided no later than 24 hours after the 
knowledge, by the Investigator to the CRO by email, to be forwarded to the Sponsor. 
 
9.12 Management of any laboratory abnormality 
 


 
Corporate Medical Department 
 
Identification Number 
Version Number 
State 
Effective date 
FORM-000050125 
2.0, CURRENT 
Effective 
08, Jan 2021 
 
Sponsor: Menarini International Operations Luxembourg SA 
Study Code: MEIN/20/ZoAm-Hyp/001 
Protocol Version 1.0 of 1     23/04/2021 
  
 
Pag. 58 a 91 
 
Any laboratory test abnormality which is considered by the Investigator as AE is to be 
managed as above detailed (refer to Section 9.9). 
However, all “out of range” values should be collected and reviewed periodically every 2 
months by the CRO and the Sponsor. 
 
 
9.13 Management of pregnancy exposure cases 
 
The Investigator is expected to record in the provided form ( Pregnancy Exposure Form)any 
case of pregnancy exposure occurring in a female subject or in a male subject’s partner during 
the treatment and follow-up periods, sending it within 5 days after being made aware of the 
pregnancy, to the CRO by email, to be forwarded to the Sponsor. 
The Investigator is requested to follow each case of pregnancy exposure until the outcome. 
If the pregnancy results in an abnormal outcome, this will be recorded in the eCRF as a SAE 
and managed as above described. 
 
Eligibility of a woman of childbearing potential (WOCBP) will be considered as described in 
Section 6.2.  
 
A woman is considered fertile following menarche and until becoming postmenopausal unless 
permanently sterile as described below. 
 
Women in the following categories are not considered WOCBP if: 
• Premenarchal 
• Premenopausal female with one of the following: 
o Documented hysterectomy. 
o Documented bilateral salpingectomy. 
o Documented bilateral oophorectomy. 
 
Note: Documentation can come from the study centre personnel’s: review of the patient’s 
medical records, medical examination, or medical history interview. 
 
Postmenopausal female: A postmenopausal state is defined as no menses for 12 
months without an alternative medical cause. A high follicle stimulating hormone (FSH) 


 
Corporate Medical Department 
 
Identification Number 
Version Number 
State 
Effective date 
FORM-000050125 
2.0, CURRENT 
Effective 
08, Jan 2021 
 
Sponsor: Menarini International Operations Luxembourg SA 
Study Code: MEIN/20/ZoAm-Hyp/001 
Protocol Version 1.0 of 1     23/04/2021 
  
 
Pag. 59 a 91 
 
level to 30 mIU/mL or higher may be used to confirm a postmenopausal state in women 
not using hormonal contraception or hormonal replacement therapy (HRT). However, in 
the absence of 12 months of amenorrhea, a single FSH measurement is insufficient. 
Females on HRT and whose menopausal status is in doubt will be required to use one of 
the non-estrogen hormonal highly effective contraception methods if they wish to continue 
their HRT during the study. Otherwise, they must discontinue HRT to allow confirmation of 
postmenopausal status before study enrolment. 
 
10 WITHDRAWAL CRITERIA 
 
Patients are free to discontinue the trial at any time without giving their reasons without losing 
the right to future medical care. Patients who withdraw from the trial will also be withdrawn 
from the investigational medicinal product.  
 Patients who voluntarily withdraw their consent can do so for any of the following reasons: 
 
• 
Does not want to participate in the study anymore 
• 
Does not permit further collection of personal data 
 
The investigator should make a reasonable effort to understand the primary reason for the 
patient’s decision to withdraw his/her consent and record this information. 
 
Study participants may, at any moment, be withdrawn by the Investigator, if considered 
appropriate. Patients can be withdrawn for any of, but not limited to, the following reasons: 
 
• 
If the patient meets an exclusion criterion (newly developed or not previously 
recognized) that precludes further study participation 
• 
Adverse events: when during the conduct of the study, adverse events occur 
that, in the Investigator’s judgement, are of such a nature or severity to 
recommend treatment withdrawal 
• 
Failure to comply with requirements of the protocol including, but not limited 
to evidence of non-compliance with inclusion/exclusion criteria during the 
study or patient non-compliance with key study procedures 


 
Corporate Medical Department 
 
Identification Number 
Version Number 
State 
Effective date 
FORM-000050125 
2.0, CURRENT 
Effective 
08, Jan 2021 
 
Sponsor: Menarini International Operations Luxembourg SA 
Study Code: MEIN/20/ZoAm-Hyp/001 
Protocol Version 1.0 of 1     23/04/2021 
  
 
Pag. 60 a 91 
 
• 
By request of the patient including explicit withdrawal of patient’s consent to 
participate  
• 
Patient’s failure to report to study visits 
• 
Patient’s loss to follow-up (for guidance see Section 11) 
• 
Withdrawal by Investigator’s judgement: Investigator may choose to withdraw 
a patient from the study if the Investigator deems it in the best interest of the 
patient to discontinue. 
 
Patients who satisfy the following criteria will also be withdrawn from the study:  
 
• 
If at Visit 2 patients have a controlled BP (sitting SBP/DBP ≤130/80 mmHg) 
or do not tolerate the treatment or have an adherence range below 80% or 
superior to 120%.  
• 
If at Visit 3 the patients do not tolerate the extemporaneous combination 
treatment or have an adherence range below 80% or superior to 120%.  
• 
Patients with abnormal renal function (creatinine clearance <30 mL/min) 
and/or abnormal liver enzyme parameters (alanine aminotransferase [ALT] or 
aspartate aminotransferase [AST] level of >2.5 × upper limit of normal [ULN] 
or total bilirubin level >1.5 × ULN). 
 
If a patient has been withdrawn due to an AE, the Investigator must immediately contact the 
relevant pharmacovigilance contact (see Safety Data Management section). The reason for 
patient withdrawal must be well-documented in the Electronic Case Report Form (eCRF). 
The eCRF should capture the date and specific underlying reason for discontinuation of 
study product or patient discontinuation/withdrawal. Study treatment must be discontinued, 
and no further assessment conducted, and the data that would have been collected at 
subsequent visit will be considered missing.  Further attempts to contact the patient are not 
allowed unless safety findings require communication or follow-up. All effort should be 
made to complete the assessment prior to study withdrawal. A final evaluation at the time of 
the patient’s study withdrawal should be made as detailed in Early termination visit 
scheduled assessment.  
Patients who discontinue from the study early will complete an early termination visit.  
 


 
Corporate Medical Department 
 
Identification Number 
Version Number 
State 
Effective date 
FORM-000050125 
2.0, CURRENT 
Effective 
08, Jan 2021 
 
Sponsor: Menarini International Operations Luxembourg SA 
Study Code: MEIN/20/ZoAm-Hyp/001 
Protocol Version 1.0 of 1     23/04/2021 
  
 
Pag. 61 a 91 
 
Subjects who prematurely withdrawn from study medication or from the study will not be 
replaced. These subjects will not be considered lost to follow-up. 
 
11 LOST TO FOLLOW UP 
 
A patient will be considered lost to follow-up if he or she fails to return for 2 or more scheduled 
visits and is unable to be contacted by the study site staff.  
 
The following actions must be taken if a patient fails to return to the clinic for a required study 
visit.  
The site staff will attempt to contact the patient and reschedule the missed visit within 2 business 
days. Site staff will counsel the patient on the importance of maintaining the assigned visit 
schedule and ascertain if the patient wishes to and/or should continue in the study.  
 
Before a patient is deemed lost to follow-up, the investigator or designee will make every effort 
(e.g. letters, telephone calls) to regain contact with the patient.  Each contact attempt should be 
documented in the patient’s medical record or study file.  
 
12 STATISTIC 
 
This section outlines the major features of statistical analyses. More detailed methodology for 
summary and statistical analysis of data collected in this study will be documented in the 
statistical analysis plan (SAP), which will be maintained by the sponsor and completed prior to 
locking the database. The SAP may modify the plans outlined in the protocol; however, any 
major modifications of the primary endpoint definition and/or its analysis will also be reflected 
in a protocol amendment.  
 
Any additional or supplemental data analyses performed independently by the investigator 
should be submitted to the Sponsor. 
 
12.1 Statistical Methods (Blinding and Randomization) 
 
This is a non-randomized, unblinded study. Unless specified otherwise, all statistical testing 
will be two-sided and will be performed using a significance (alpha) level of 0.05. 


 
Corporate Medical Department 
 
Identification Number 
Version Number 
State 
Effective date 
FORM-000050125 
2.0, CURRENT 
Effective 
08, Jan 2021 
 
Sponsor: Menarini International Operations Luxembourg SA 
Study Code: MEIN/20/ZoAm-Hyp/001 
Protocol Version 1.0 of 1     23/04/2021 
  
 
Pag. 62 a 91 
 
 
12.2 Determination of Sample Size 
 
A total sample size of 216 patients is required to achieve 90% power at a 5% significance level 
assuming a difference in mean DBP from baseline (Visit 2) to 8 weeks (Visit 4) of 4 mmHg 
and a standard deviation (SD) for this difference of 10 mmHg. The mean change in DBP for 
the null hypothesis is set equal to 2 mmHg. To achieve this, a total of 290 patients will be 
enrolled, allowing for a 25% withdrawal rate. 
 
12.3 Analysis Populations 
 
A total of three populations will be used for all summaries and analyses. Study participants 
who have satisfied the population criteria will be classified in the designated population and 
will only be included in analyses for which they have available data. 
 
Data analysis will be performed using the following analysis sets. 
 
The Safety Population 
The Safety population is defined as all study participants who sign the informed consent, meet 
all screening criteria, are enrolled, and receive at least one dose of the assigned treatment 
during the run-in period. This population will be used for safety analyses. 
 
The Efficacy Population 
The Efficacy population is defined as all study participants in the Safety population who 
complete the 4-week run-in period and the Visit 2 blood pressure assessment.  This will be 
population for efficacy analysis. 
 
The Per-Protocol Population  
The Per-Protocol (PP) population is defined as all study participants in the Efficacy population 
who were dosed according to protocol, complete the required study visits, and do not 
experience any major protocol deviations that may impact the primary efficacy assessment 
through end of treatment.   


 
Corporate Medical Department 
 
Identification Number 
Version Number 
State 
Effective date 
FORM-000050125 
2.0, CURRENT 
Effective 
08, Jan 2021 
 
Sponsor: Menarini International Operations Luxembourg SA 
Study Code: MEIN/20/ZoAm-Hyp/001 
Protocol Version 1.0 of 1     23/04/2021 
  
 
Pag. 63 a 91 
 
12.4 Analysis Variables 
The primary endpoint (i.e. change in sitting Diastolic Blood Pressure from Visit 2 to Visit 
4) and primary statistical analysis specifications will be detailed in 12.5.2. Secondary endpoints 
and their respective statistical analyses are summarized in 12.5.4 while safety analyses in 
12.5.7. Data handling and imputation methods are reported in 12.5.9. 
 
12.5 Statistical Analysis 
 Descriptive statistics 
Descriptive statistics for categorical variables (such as gender, race, and ethnicity) will include 
the number and percent of study participants with each characteristic. Percentages will be 
based on the number of study participants with non-missing values. Descriptive statistics for 
ordinal and continuous variables will include the number of study participants with non-
missing values, mean, median, standard deviation, minimum value, and maximum value. 
Intervals representing 95% confidence will be presented when appropriate. Graphical displays 
will be present when appropriate. 
 
All relevant data collected in the eCRF will be shown for each study participant in the 
individual study participant data listings. 
 
Disposition 
 
A tabulation of the disposition of study participants will be presented, including the number 
enrolled, the number treated, and the reasons for study discontinuation. Summaries of the 
number in each analysis set will be presented. Entry criteria violations and protocol deviations 
will be listed. 
 
Demographics and Baseline 
Demographic and baseline characteristic data summarization will be performed. Data to be 
tabulated will include study site, gender, age, race, and ethnicity, as well as baseline 
characteristics related to medical history. 
 
 Primary (efficacy) analysis 
For the primary efficacy analysis of the primary endpoint, the change in sitting Diastolic Blood 
Pressure (DBP) from Visit 2 to Visit 4 will be assessed using a paired t-test. A Type I error 


 
Corporate Medical Department 
 
Identification Number 
Version Number 
State 
Effective date 
FORM-000050125 
2.0, CURRENT 
Effective 
08, Jan 2021 
 
Sponsor: Menarini International Operations Luxembourg SA 
Study Code: MEIN/20/ZoAm-Hyp/001 
Protocol Version 1.0 of 1     23/04/2021 
  
 
Pag. 64 a 91 
 
threshold of 0.05 will be used to test the null hypothesis that the mean reduction in DBP is 0 
mmHg against a two-sided alternative. The Efficacy population will be used to analyse the 
primary endpoint. 
 
 Sensitivity analysis 
A sensitivity analysis for the primary endpoint will be conducted by replicating the primary 
endpoint analysis under each of the following: 
1. Per-protocol population 
2. Imputation of missing data using last-observation-carried-forward (LOCF) 
3. Analysis stratified by study site 
4. Analysis stratified by gender 
5. Analysis stratified by age group 
Further details of these analyses will be presented in the SAP 
 
 Secondary (efficacy) analysis 
The secondary efficacy endpoints are derived from the primary objective and will be used to 
support the conclusion of the primary efficacy endpoint, provided that the primary efficacy 
endpoint is met. The secondary endpoints will be analysed as follows: 
 
1. Change in mean sitting SBP between Visit 2 (Week 0) and Visit 4 (Week 8). 
Endpoint (1) will be analysed using a paired t-test with the null hypothesis that the 
mean change in SBP is 0 mmHg from Visit 2 to Visit 4.  
 
2. Change in mean sitting DBP and SBP between Visit 3 (week4) and Visit 4 (Week 8) in 
patients uncontrolled at Visit 3 and up titrated to the extemporaneous combination of 
ZOF/AML 30/10 mg. 
Endpoint (2) will be analysed using paired t-test for DBP and SBP with null hypotheses 
of 0 mmHg mean change from Visit 3 to Visit 4.  
 
3. Number and proportion of patients achieving the BP goal (sitting BP≤130/80 mmHg) at 
Visit 2 (Week 0), Visit 3 (Week 4) and Visit 4 (Week 8). 
 Endpoint (3) will be analysed using a 95% binomial confidence interval for adherence 
for each visit. 
 


 
Corporate Medical Department 
 
Identification Number 
Version Number 
State 
Effective date 
FORM-000050125 
2.0, CURRENT 
Effective 
08, Jan 2021 
 
Sponsor: Menarini International Operations Luxembourg SA 
Study Code: MEIN/20/ZoAm-Hyp/001 
Protocol Version 1.0 of 1     23/04/2021 
  
 
Pag. 65 a 91 
 
4. Adherence to the treatments (% of doses taken/ doses to be taken) at Visit 2 (Week 0), 
Visit 3 (Week 4) and Visit 4 (Week 8). 
 Endpoint (4) will be analysed using a 95% binomial confidence interval for adherence 
for each visit.  
 
In addition, all continuous efficacy variables will be summarized for all study visits using 
descriptive statistics for both actual values and change-from-baseline values. The Efficacy 
population will be used to analyse the secondary endpoints. 
 
 Exploratory (efficacy) analysis 
The exploratory efficacy endpoints assessing change-from-baseline BP will be analysed using 
mixed models for repeated measured (MMRM). The models will include treatment subgroup, 
analysis visit, treatment subgroup-by-visit interaction, the baseline BP value as a covariate, and 
patient as a random effect. An unstructured covariance structure was used to model the within-
patient errors. The exploratory efficacy endpoint for proportion of patients achieving controlled 
BP will be analysed using a logistic MMRM with similar terms. 
 
Additional details will be summarized in the Statistical Analysis Plan. 
 
 Subgroup analysis 
Further subgroups analyses besides those described in the exploratory endpoints will be defined 
in the Statistical Analysis Plan. 
 
 Safety analysis 
Safety and tolerability of the monotherapies (ZOF 30 mg and AML 5 mg) and of the 
extemporaneous combination (ZOF 30 mg and AML 5 mg or AML 10 mg) will be evaluated 
using the Safety population. The variables for this safety endpoint are laboratory tests, physical 
examination, vital signs, 12-lead ECG, and incidence of AEs and SAEs. 
 
 Interim analysis and stopping rules 
There will be no interim analyses for this study. 
 
 Data imputations 
Missing BP values that occur after baseline will be imputed for the sensitivity analysis using 
LOCF (see 12.5.3).  Any missing data for BP at baseline will not be imputed. No other standard 


 
Corporate Medical Department 
 
Identification Number 
Version Number 
State 
Effective date 
FORM-000050125 
2.0, CURRENT 
Effective 
08, Jan 2021 
 
Sponsor: Menarini International Operations Luxembourg SA 
Study Code: MEIN/20/ZoAm-Hyp/001 
Protocol Version 1.0 of 1     23/04/2021 
  
 
Pag. 66 a 91 
 
imputations of missing efficacy data will be applied unless it is described later in the SAP in 
the respective data section. 
 
12.6 Protocol Deviations and Protocol Amendments 
 
No deviations from the Protocol should be initiated without prior approval by EC/HA of a 
Protocol Amendment according to applicable Regulations, except in case of emergency or 
when the change involves only logistical or administrative aspects of the trial. 
Any deviation from the Protocol, SOPs, GCP and applicable Regulatory Requirements should 
be immediately reported to the Sponsor. 
Changes in the study protocol will require a protocol amendment. Such amendments will be 
agreed upon and approved in writing by all signatories of the protocol. 
If amendments are substantial, i.e. are likely to have an impact on the safety of the subjects, or 
to change the interpretation of the scientific documents in support of the conduct of the study, 
or if they are otherwise significant, the ECs and the CAs in the participating countries have to 
approve these amendments before implementation, according to applicable Regulatory 
Requirements. 
Changes which have no significant impact on medical or scientific validity of the study will be 
agreed upon and approved in writing by all signatories of the protocol and the EC will be 
notified of this protocol amendment. 
Any substantial amendments of the protocol will be integrated in an updated study protocol. 
The Principal Investigator must ensure full compliance with the updated study protocol. 
 
12.7 End of Study Visit  
The final subject last visit that occurs on Week 8 ± 2 days will be considered to be end of 
study. 
 
12.8 Statistical Analysis Plan 
The statistical analysis plan (SAP) will be finalized before the study. The SAP will describe in 
detail study endpoints and statistical analyses, including the analysis of the primary as well as 
additional endpoints. In case changes of the original primary endpoint or of the original 
primary analyses will occur during the study, these changes will be the subject of a substantial 
protocol amendment. 
All statistical analyses not pre-specified and run after additional/exploratory analyses. 


 
Corporate Medical Department 
 
Identification Number 
Version Number 
State 
Effective date 
FORM-000050125 
2.0, CURRENT 
Effective 
08, Jan 2021 
 
Sponsor: Menarini International Operations Luxembourg SA 
Study Code: MEIN/20/ZoAm-Hyp/001 
Protocol Version 1.0 of 1     23/04/2021 
  
 
Pag. 67 a 91 
 
13 STUDY DISCONTINUATION AND CLOSURE 
 
Menarini International Operations may discontinue this study prematurely for reasonable 
cause. Possible reasons for early termination or temporary suspension of the study include, 
but is not limited to: 
• 
Study closure based on PI decision and/or 
• 
Study closure based on Sponsor decision and/or 
• 
Study closure based on Regulatory or other oversight bodies initiation and/or 
• 
Review of serious, unexpected, and related AEs and/or 
• 
Non-compliance.  
 
In case this study was temporarily suspended or prematurely terminated, written notification 
documenting the reason for study suspension or termination will be provided by the 
suspending or terminating party at a reasonable time in advance of the intended termination.  
 
The Investigator may also discontinue this study at his/her site for reasonable cause after 
notifying the IEC and providing written notice to Menarini International Operations at a 
reasonable time in advance of the intended termination.  
 
Please note advanced notice is not required by either party if the study is stopped due to safety 
concerns.  
 
Menarini International Operations and the Investigator should take the following steps to 
follow up on patient safety and ensure data integrity: 
 
• 
Immediately notify the pharmacovigilance officer at Biorasi 
• 
Notify the IEC within 24 hours 
• 
Contact all patients by phone and distribute written communication that the study has 
been stopped  
• 
Advise all patients to report for an early termination visit 
• 
Make plans to follow all patients for AEs for two months after the study has been 
stopped or for as long as it takes for any AE/SAEs to resolve, whichever is longer 
• 
Instruct study staff to enter all data in the case report form and ensure their completion 
 


 
Corporate Medical Department 
 
Identification Number 
Version Number 
State 
Effective date 
FORM-000050125 
2.0, CURRENT 
Effective 
08, Jan 2021 
 
Sponsor: Menarini International Operations Luxembourg SA 
Study Code: MEIN/20/ZoAm-Hyp/001 
Protocol Version 1.0 of 1     23/04/2021 
  
 
Pag. 68 a 91 
 
14 DIRECT ACCESS TO SOURCE DATA / DOCUMENTS 
 
The Investigator and/or Institution will permit trial related monitoring, audits, EC review, and 
regulatory inspections, providing direct access to source data/documents upon request. 
 
15 QUALITY CONTROL AND QUALITY ASSURANCE 
 
15.1 Study Monitoring / Data Quality Control 
 
Site monitoring is conducted to ensure that the rights and well-being of trial subjects are 
protected, that the reported trial data are accurate, complete, and verifiable, and that the conduct 
of the trial is in compliance with the currently approved protocol / amendment(s), with ICH 
GCP, and with applicable regulatory requirement(s). 
 
The monitoring of the conduct of the study and progress of the clinical investigation will 
proceed in accordance to the Monitoring Plan. The purpose of the Monitoring Plan is to 
establish guidelines for managing, monitoring, and working with Investigational Sites for this 
study. 
The Monitoring Plan provides information that will be used by Clinical Research Associates 
(CRAs) to ensure the quality of the data including the type, frequency, and extent of 
monitoring, who will be provided reports of monitoring and whether independent audits of the 
monitoring activities will be conducted. The Monitoring Plan also provides detailed 
information about the number of study sites, Site Initiation Visits (SIVs), Study Site Visits 
(SSVs), Interim monitoring visits (IMVs), and close-out visits. 
 
The Investigator will be contacted by the study monitor on a regular basis. The monitor will 
have the responsibility of reviewing the ongoing study with the Investigator to verify adherence 
to the protocol and to deal with any problems. 
 
Quality checks that will be performed on trial documents and on the collected data include, but 
is not limited to, ICF review and source data verification.  Detailed information can be found in 
the Monitoring Plan.   
 


 
Corporate Medical Department 
 
Identification Number 
Version Number 
State 
Effective date 
FORM-000050125 
2.0, CURRENT 
Effective 
08, Jan 2021 
 
Sponsor: Menarini International Operations Luxembourg SA 
Study Code: MEIN/20/ZoAm-Hyp/001 
Protocol Version 1.0 of 1     23/04/2021 
  
 
Pag. 69 a 91 
 
The Investigator agrees to allow access to all study materials needed for the proper review of 
study conduct. The Investigator agrees to assist the monitor in resolving any problem that may 
be detected during the monitoring visit or data cleaning process. 
 
15.2 Case Report Forms 
 
Patient data will be entered into the IBM Clinical Development electronic data capture (EDC) 
system.  
 
Menarini International Operations, or its designee, will supply to the site personnel access to 
the electronic case report forms. These forms will be used to transmit information collected 
during the study to Menarini International Operations or its designee and regulatory authorities, 
as applicable. The Investigator may formally designate authority to complete eCRFs to 
qualified staff by completing the signature log and requesting access rights to the EDC system 
for the designee. Every user of the system will be made aware of the fact that username and 
password should never be shared, and their electronic signature constitutes the legally binding 
equivalent of a hand-written signature.  
Electronic CRFs (eCRFs) must be completed for each patient who signs the ICF for the study. 
Screening study data will be collected on the eCRF for all patients only. The system 
automatically records all changes in an electronic audit trail and requires a “reason for change” 
to be picked from a pre-defined list. If the reason for the correction is not obvious, a brief 
explanation (e.g. transcription error) should accompany the change. All information recorded 
on the eCRF forms must reflect the information in the patient source documents.  
For screen failed patients, the Investigator or designee will capture in source the patient’s 
demographic data, data collected from all completed screening procedures, and reason for 
screen failure. Only the patient’s demographic data, informed consent, reason for screen failure 
and SAEs will be entered in the EDC. 
 
Data collected during the study will be recorded in the eCRF. Data reported on the eCRF have 
to be consistent with the source documents. The Investigator must ensure the accuracy, the 
completeness and the consistency of the data entered in the eCRF. 
 
The Investigator will review the eCRFs for completeness and accuracy and electronically sign 
each set of eCRFs. Menarini International Operations personnel (or their representatives) will 


 
Corporate Medical Department 
 
Identification Number 
Version Number 
State 
Effective date 
FORM-000050125 
2.0, CURRENT 
Effective 
08, Jan 2021 
 
Sponsor: Menarini International Operations Luxembourg SA 
Study Code: MEIN/20/ZoAm-Hyp/001 
Protocol Version 1.0 of 1     23/04/2021 
  
 
Pag. 70 a 91 
 
periodically review the eCRFs for completeness and accuracy. Menarini International 
Operations personnel (or their representatives) will be allowed access to all source documents 
in order to verify eCRF entries.  
On the eCRF, patients will be identified by the patient number/code, assigned at the Screening 
Visit. The patient number/code will be assigned as stipulated in the Data Management Plan.   
During the conduct of the clinical part of the study, the eCRF must be available and up to date, 
so that it always reflects the latest observations on the respective patient. The data entry 
expectations are that the eCRFs will be entered within 5 business days of a patient’s visit. Any 
eCRF queries should be answered by the site within 5 business days.  SAE/Coding queries 
must be answered by the site within 3 business days.  
The Investigator will be responsible for entering study data into the eCRF in accordance to the 
eCRF user guidelines.  
 
15.3  Quality Assurance 
 
Quality Control will be performed according to applicable SOPs. The study may be audited by 
Quality Assurance representatives of Menarini International Operations (or their designee). All 
necessary related data and documents will be made available for inspection.    
 
All clinical activities conducted under this protocol is subject to GCP regulations. This includes 
audits / inspections by the Sponsor, and / or by national / international Health Authority 
representatives at any time. Principal Investigators must agree to the inspection of the study 
site, facilities, and of study related records by the Health Authority representatives and / or by 
the Sponsor, and / or its delegates, which must be performed in accordance with national laws 
concerning personal data protection. 
 
16 ETHICS ASPECTS 
 
This study will be conducted in compliance with this study protocol, the recommendations on 
biomedical research on human subjects of the Declaration of Helsinki, International Conference 
of Harmonisation – Good Clinical Practices (ICH-GCP) Guidelines, EU-Directives and 
Regulations and national requirements for the participating countries.  
 


 
Corporate Medical Department 
 
Identification Number 
Version Number 
State 
Effective date 
FORM-000050125 
2.0, CURRENT 
Effective 
08, Jan 2021 
 
Sponsor: Menarini International Operations Luxembourg SA 
Study Code: MEIN/20/ZoAm-Hyp/001 
Protocol Version 1.0 of 1     23/04/2021 
  
 
Pag. 71 a 91 
 
16.1  Ethics Committees 
 
Before starting the study in a study site, Study Protocol and relevant documentation (Subject 
information leaflet, Informed Consent Form and the Investigator’s Brochure and other 
documents, according to National Regulations) must be submitted to and approved by the 
Ethics Committees (EC) and the Health Authorities (HAs) of the participating countries. 
In addition, all local national legal requirements for the conduct of a clinical study have to be 
followed. Any amendment to the protocol will be submitted to the ECs and HAs before 
implementation. 
Furthermore, the HAs and ECs of the participating countries will be informed about the study 
start, the end of the study, or the premature study termination as appropriate and within the 
requested time period. 
 
16.2 Subject’s Insurance 
 
For subjects participating in the study, Sponsor will issue an insurance policy in accordance 
with local regulatory requirements. 
Details on the insurance company, the insurance number and conditions will be made available 
to subjects in the ICF and / or provided as a separate document, in accordance with national 
requirements. Insurance policy will be submitted for approval to the ECs along with the other 
study documents. 
A copy of the insurance certificate will be provided to each Investigator and will be filed in the 
Investigator’s File at the sites and in the study’s Trial Master File (TMF). 
The Investigator must notify to Sponsor immediately upon notice of any claims or lawsuits. 
 
17 PERSONAL DATA PROTECTION SECTION 
 
17.1 General Principles on Personal Data Compliance 
 
All clinical trial information shall be recorded, processed, handled, and stored in such a way 
that it can be accurately reported, interpreted and verified; at the same time, the confidentiality 
of records and of the personal data of the patients shall remain protected in accordance with the 
applicable law on personal data protection such as the EU General Data Protection Regulation 
679/2016, the EU Regulation on clinical trials on medicinal products for human use 536/2014, 


 
Corporate Medical Department 
 
Identification Number 
Version Number 
State 
Effective date 
FORM-000050125 
2.0, CURRENT 
Effective 
08, Jan 2021 
 
Sponsor: Menarini International Operations Luxembourg SA 
Study Code: MEIN/20/ZoAm-Hyp/001 
Protocol Version 1.0 of 1     23/04/2021 
  
 
Pag. 72 a 91 
 
laws applicable in countries where the data subject is based –i.e.., Russian privacy laws, 
particularly Data Protection Act No. 152 FZ dated 27 July 2006 (“DPA”) and various 
regulatory acts adopted to implement the DPA”. This section defines the appropriate technical 
and organisational measures that shall be implemented to protect information and personal data 
processed against unauthorised or unlawful access, disclosure, dissemination, alteration, or 
destruction or accidental loss as well as to assure the fulfilment of subjects’ privacy rights. 
 
17.2 Acknowledgment 
 
The Site, the Principal investigator, the Local Laboratory, the CRO - as well as their appointed 
staff and service providers acknowledge that: (a) the performance of the study  will imply 
processing of sensitive personal data; (b) personal data processing is regulated by the 
applicable  European (i.e. the EU General Data Protection Regulation 679/2016 and the EU 
Regulation on clinical trials on medicinal products for human use 536/2014) and laws 
applicable in countries where the data patient is based –i.e.., Russian privacy laws, particularly 
Data Protection Act No. 152 FZ dated 27 July 2006 (“DPA”) and various regulatory acts 
adopted to implement the DPA and local laws (i.e. the laws of all the countries where the study 
is conducted) as well as by the Sponsor’s national legislation. In particular, it is hereby 
acknowledged that being the Sponsor a company incorporated under Luxemburg law, it has to 
mandatorily comply with Luxemburgish and EU laws  on data protection: therefore The Site, 
the Principal investigator, the Local Laboratory, the CRO - shall cooperate with the Sponsor to 
allow the fulfilment of such obligations; (c) strict compliance with the applicable data 
protection laws and this section of the protocol is deemed by the Sponsor as an essential 
condition of collaboration with the Site, the Principal investigator, the Local Laboratory, the 
CRO 
 
17.3 Data Controllers and Data Processors 
 
The Sponsor, the Site, the Principal investigator and the CRO - acknowledge that according 
to the applicable privacy laws, Sponsor and Site - will act as independent data controllers 
while CRO and the Principal investigator will act as data processors respectively of the 
Sponsor and of Site. Before the beginning of the study, the Site - will instruct in writing, the 
Principal Investigator - as its data processor. However, if specific local laws or regulations 
mandate a different definition of the privacy roles, the Sponsor, the Site, the Principal 


 
Corporate Medical Department 
 
Identification Number 
Version Number 
State 
Effective date 
FORM-000050125 
2.0, CURRENT 
Effective 
08, Jan 2021 
 
Sponsor: Menarini International Operations Luxembourg SA 
Study Code: MEIN/20/ZoAm-Hyp/001 
Protocol Version 1.0 of 1     23/04/2021 
  
 
Pag. 73 a 91 
 
investigator and the CRO - will implement the relevant legal instruments (e.g. if pursuant to 
the local laws the Site is a data processor of the Sponsor, a Data Processing Agreement will 
be finalised; if pursuant to the local laws Sponsor and Site are join controllers, a Joint 
Controllership Agreement will be finalised).  
 
For clinical trials where the Principal Investigators are the owners of the Site, this provision 
may not apply. In such cases, the Principal Investigator might be considered as a Data 
Controller 
 
17.4 Duties of the Parties involved in the performance of the study 
 
Collection and use of patient’s date will be carried out in full respect of the provisions of the 
information notices submitted to patients, as well as the privacy rights, the fundamental 
freedoms and the dignity of data patients. All the parties involved in this study undertake to 
adopt adequate measures to warrant that data will always be processed securely and in 
compliance with privacy laws. The Site, the Principal investigator, the Sponsor, the CRO 
and the Local Laboratory as well as their appointed staff and service providers, each in its 
respective remit and within the limits of their specific role in the study- use the same 
protocol terminology/definitions], shall implement the following safety measures (physical, 
logical, organizational, technical, electronic, I.T. etc) to ensure adequate protection of the 
personal data of the patients involved in the study. In particular:  
(i) DATA SAFETY. The Site and/or the Principal Investigator shall adopt all the necessary 
measures to prevent or minimise the risks of theft, fire, flooding, partial or total loss, 
accidental disclosure or illegal/unauthorised access to patient’s data or Sponsor’s proprietary 
confidential information; to this extent, before the beginning of the study, the Site and/or the 
Principal Investigator  shall ensure that the actual measures they have implemented are fit-
for purpose and law-compliant, and in particular:  
- in order to minimise the risk of unauthorized access and theft, the hardware on which 
patients’ personal data are stored shall be placed in a restricted-access area, accessible only 
to those individuals who need to retrieve the patients’ personal data included in the database 
for professional purposes; the same safeguards shall be put in place for non-electronic 
databases;  
- any electronic database containing the patients’ personal data shall be password-protected 
by means of a strong password. Systems shall be set so that passwords must be updated at 


 
Corporate Medical Department 
 
Identification Number 
Version Number 
State 
Effective date 
FORM-000050125 
2.0, CURRENT 
Effective 
08, Jan 2021 
 
Sponsor: Menarini International Operations Luxembourg SA 
Study Code: MEIN/20/ZoAm-Hyp/001 
Protocol Version 1.0 of 1     23/04/2021 
  
 
Pag. 74 a 91 
 
least every three months and feature at least 8 characters, with upper-case and lower-case 
recognition, containing at least three "special" characters, such as upper case letters [A-Z], 
lower case letters [a-z], numbers [0-9], symbols [!, #, $, etc.] or other special characters [Á, 
ë, ö etc.]. Passwords shall not include elements which may easily be associated with the 
assignee or information regarding him/her , such as name and year of birth (e.g. 
“johnbrown80”) or easily predictable strings of characters (e.g. “qwerty”, “12345”, “admin”, 
“user”, etc.); 
 - adequate cryptographic protection measures shall be put in place for data “at rest” and “in 
transit” (these include, for example, file system or database cryptography, or any other 
equivalent IT measure which renders data unintelligible to those who are not authorised to 
access them);  
-high level security measures shall be implemented also on the files or databases which 
contain the “key” to match the patients’ personal data (i.e. name, surname, etc.) with their 
respective “Patient IDs” (as defined at point (iv) below);  
- Backup processes and other measures that ensure rapid restoration of business-critical 
systems shall be implemented; 
- Updated Antivirus and firewall programs shall be installed on the IT devices.  
The Site shall, regularly test and update the measures listed above. The Site shall, upon  
request from the Sponsor and/or the CRO, provide detailed written information about the 
measures listed above. The CRO shall ensure that the selected sites for the study have 
implemented the above listed measures.  
 
(ii) TRANSMISSION OF DATA. All the parties that transfer data through internet and/or to 
the centralised database(s) used to process study’s data or to generate statistical analyses 
shall implement secure protocols based on cryptographic standards which make data 
unintelligible to unauthorized individuals.  
 
(iii) SECURITY OF THE CENTRALISED DATA BASE. The centralised database held by 
the Sponsor shall have the following safeguards in place: - appropriate authentication 
methods, which differentiate between different users according to their respective roles so as 
to ensure that access to a specific set of patients' data is permitted exclusively to those for 
whom access to such data is essential in the context of their work for the study; - appropriate 
measures to ensure that the authentication credentials are periodically updated (i.e. password 
change);  


 
Corporate Medical Department 
 
Identification Number 
Version Number 
State 
Effective date 
FORM-000050125 
2.0, CURRENT 
Effective 
08, Jan 2021 
 
Sponsor: Menarini International Operations Luxembourg SA 
Study Code: MEIN/20/ZoAm-Hyp/001 
Protocol Version 1.0 of 1     23/04/2021 
  
 
Pag. 75 a 91 
 
 
(iv) PSEUDONYMIZATION. All personal data that may allow identification of the patients 
involved in the study shall be adequately dissociated from the other data pertaining to the 
study (“pseudo-anonymisation” process). The Principal investigator  shall adequately 
dissociate the identification data of patients from the data pertaining to the study by linking 
results to a an alphanumerical code [“Patient ID”], whose format shall not make it possible 
to identify the patient directly or indirectly, so as to ensure that only anonymous data are 
transmitted to the Sponsor, the Local Laboratory and /or the CRO, Site/Principal 
Investigator shall securely store a separate list (e.g.: identification log) with the 
identification code, together with all signed informed consents, in accordance with the 
security measures as defined above.  
The subject code pairing list (i.e. the list that where the Patient ID is linked to the patients’ 
identification data such as name and surname), shall be archived by the Principal 
Investigator.  
 
(v) TRAINING. The parties shall ensure that any personnel involved in the study have 
received proper training on data protection issues. All actions related to the implementation 
of the afore mentioned measures shall be provided by the Sponsor, the Centre and/or the to 
the competent authorities (including data protection authorities) and Ethics Committees if 
and when requested. If such authorities or the Sponsor consider the implementation of the 
afore mentioned measures insufficient to guarantee an adequate level of protection of the 
patients’ personal data, The Site, the Principal investigator, the CRO and the Local  
Laboratory undertake to adopt all the necessary activities to overcome such remarks to 
assure the full compliance with the data protection laws.  
17.5 Archiving of the clinical trial master file and code pairing list 
 
Unless other EU laws require archiving for a longer period, the Centre and the Principal 
Investigator shall archive the content of the clinical trial master file, including the relevant 
patients’ personal data, for at least 25 years after the end of the clinical trial. However, 
medical records shall be archived in accordance with the national laws of the country where 
the study is performed. The patient code pairing list (i.e. the list that where the Patient ID is 
linked to the patients’ identification data such as name and surname), shall be archived care 
of the Principal Investigator. 
 


 
Corporate Medical Department 
 
Identification Number 
Version Number 
State 
Effective date 
FORM-000050125 
2.0, CURRENT 
Effective 
08, Jan 2021 
 
Sponsor: Menarini International Operations Luxembourg SA 
Study Code: MEIN/20/ZoAm-Hyp/001 
Protocol Version 1.0 of 1     23/04/2021 
  
 
Pag. 76 a 91 
 
The content of the clinical trial master file shall be archived in a way that ensures that it is 
readily available and accessible, upon request, to the competent authorities. 
 
The content of the Investigator’s File shall be archived in a way that ensures that it is readily 
available and accessible, upon request, to the competent authorities.  
If the responsible Investigator retires, relocates, or for other reasons withdraws from the 
responsibility of keeping the study records, custody must be transferred to a person who will 
accept the responsibility.  
The Sponsor must be notified in writing of the name and address of the new custodian. 
Any transfer of ownership of the content of the clinical trial master file shall be documented. 
The new owner shall undertake the responsibilities set out in this protocol. The Sponsor 
appoints Clinical Operations Director as responsible person/s for archives. Access to 
archives shall be restricted to those individuals.Once mandatory data retention time for the 
clinical trials master file has elapsed, the Centre/Principal Investigator shall seek the 
authorisation of the Sponsor to destroy the clinical trial master file.  
Data Breach 
 
Data Breach is an incident regarding personal data security and leading to the accidental or 
unlawful destruction, loss, alteration, unauthorised disclosure of, or access to, personal data 
transmitted, stored or otherwise processed. In particular: destruction of personal data is 
where the data no longer exists, or no longer exists in a form that is of any use to the Site, 
sponsor, CRO, Principal Investigator, Vendor etc data loss is when the data may still exist, 
but the Site, sponsor, CRO, Principal Investigator , Vendor etc has lost control or access to 
it, or no longer has it in its possession; damage is where personal data has been altered, 
corrupted, or is no longer complete; data unavailability is where, following a data incident 
(such as a network outage, a natural or manmade disaster, etc.), personal data become 
temporarily inaccessible to the, Vendor Site, sponsor, CRO, Principal Investigator. 
Anomalous Event is an event that is not part of the standard operational scope of an 
infrastructure, network or service and which affects, or is likely to affect, personal data; this 
may include theft or loss of IT devices and other physical events (e.g. an unauthorised 
access to a locked storage room containing paper files with personal data), and/or 
electronic/IT anomalies (e.g. cyber-attacks, default or hacking of cloud services), which may 
in any way entail loss, unavailability, alteration, theft, copy or dissemination of personal 
data. Whoever becomes aware in any way of an Anomalous Event and/or of a Data Breach 


 
Corporate Medical Department 
 
Identification Number 
Version Number 
State 
Effective date 
FORM-000050125 
2.0, CURRENT 
Effective 
08, Jan 2021 
 
Sponsor: Menarini International Operations Luxembourg SA 
Study Code: MEIN/20/ZoAm-Hyp/001 
Protocol Version 1.0 of 1     23/04/2021 
  
 
Pag. 77 a 91 
 
(see definitions above –) affecting the patients’ personal data and/or personal data collected 
in the context of the study, shall, as appropriate, immediately (and in any case no later than 
24 hours from the knowledge of an Anomalous Event and/or of a Data Breach) inform the 
Menarini Clinical Operations Director  the sponsor’s Data Protection Officer 
(dpo@menarini.com),  the Site and the Biorasi’s Data Protection Officer (DPO@biorasi.co)  
for data breach incidents and shall provide the following information: 
(i) 
Anomalous Event / Data Breach Type (e.g. data loss, unauthorized access, loss of 
company device, etc.). 
(ii) 
Person or source that first reported the Anomalous Event/Data Breach;  
(iii) 
Date and Time when the person who first reported the Anomalous Event / Data Breach 
became aware of it;  
(iv) Anomalous Event / Data Breach Date and Time (actual or presumed);  
(iv) 
Place (specify if actual or alleged) where the Anomalous Event / Data Breach 
occurred;  
(v) 
Anomalous Event / Data Breach Description;  
(vi) 
Indicate the source of the Anomalous Event / Data Breach (e.g. I.P. source) - (if 
relevant);  
(viii) Indicate the affected infrastructure / system / application / cloud/ software / hardware / 
database and their location;  
(ix) List or describe the processing/storage systems affected by the Anomalous Event/Data 
Breach (if relevant);  
(x) Number of data patients involved (if known);  
(xi) Amount of allegedly breached data  
(xii) Other relevant information. 
 Once all the above information have been provided, the Sponsor and/or the Site should have 
a reasonable degree of certainty that a security incident has occurred that has led to personal 
data being compromised.  
Then, as appropriate, Sponsor and Site, each one in its respective remit, shall manage the 
Data Breach in accordance with the applicable data protection regulations.  
For Data Breach affecting personal data of patients enrolled within the European Union, 
Sponsor and Site -autonomously or jointly depending on the circumstances and their privacy 
responsibilities as defined by the Regulation 679/2016- shall:  
1. Collect the necessary evidence and information;  
2. Categorise the breach;  


 
Corporate Medical Department 
 
Identification Number 
Version Number 
State 
Effective date 
FORM-000050125 
2.0, CURRENT 
Effective 
08, Jan 2021 
 
Sponsor: Menarini International Operations Luxembourg SA 
Study Code: MEIN/20/ZoAm-Hyp/001 
Protocol Version 1.0 of 1     23/04/2021 
  
 
Pag. 78 a 91 
 
3. Determine the risk probability and level to the rights and freedom of the concerned 
patients;  
4. Identify and put in place appropriate remedies to minimise the impact of the Data Breach  
5. Determine the notification and communication duties vis à vis the competent supervisory 
authority and/or the concerned patients. 
 
17.6 Information notice on personal data protection and pseudo-anonymisation 
 
Prior to patients’ enrolment in the study, the Principal Investigator and/or the Site  (including 
their personnel) shall provide each patient with adequate, law-compliant “information notices 
and consent forms to process personal data” as included in the ICF (or, as the case may be, 
through a separate, specific form) provided by the Sponsor or delegated CRO and shall collect 
his/her written consent to the processing of personal data according to the actual performance 
conditions in which the study is carried out. The Principal Investigator is responsible to archive 
the signed ICF in accordance with the security measures described above. Among other things, 
the ICF (or the separate form) shall inform patients about:  
(i) the applicable data protection legislation  
(ii) what kind of data shall be collected during the study listing them in detail or by category;  
(iii) the purpose of data processing e.g. performance of the study, pharmacovigilance, 
registration of new drugs and the legal basis;  
(iv) whether granting the consent(s) to process personal data is a necessary or an optional 
condition to take part in the study;  
(v) the use of data for future scientific researches / secondary use of data (if any). In such a case 
the future scientific purposes / secondary use shall include the future/further scientific 
processing activities/purposes (vi) the pseudonymisation procedure and scope;  
(vii) who can access patients’ data and under what circumstances Principal Investigator, Site, 
Sponsor during monitoring activities, audit, etc., regulatory authorities during inspection etc, 
Ethics Committee];  
(viii) the period of data retention/storage as defined in Paragraph 19;  
(ix) to which entities/countries outside the EU patients’ data will be transmitted [list here the 
non-EU countries] (if applicable), as per Paragraph 18.7. 
(x) patients’ data protection rights as defined by the [EU General Data Protection Regulation 
679/2016, and laws applicable in countries where the data patient is based –i.e.., Russian 


 
Corporate Medical Department 
 
Identification Number 
Version Number 
State 
Effective date 
FORM-000050125 
2.0, CURRENT 
Effective 
08, Jan 2021 
 
Sponsor: Menarini International Operations Luxembourg SA 
Study Code: MEIN/20/ZoAm-Hyp/001 
Protocol Version 1.0 of 1     23/04/2021 
  
 
Pag. 79 a 91 
 
privacy laws, particularly Data Protection Act No. 152 FZ dated 27 July 2006 (“DPA”) and 
various regulatory acts adopted to implement the DPA].  
(xi) Data Controllers / Data Processors and the relevant contact details  
(xii) Sponsor’s Data Protection Officer contacts (DPO) 
 
17.7 Genetic Data 
Not applicable 
 
17.8 Transfer of subjects’ data outside the European union 
 
The study performance entails transferring patients ‘personal data (coded data) outside the 
EU. To this extent, the Sponsor, the Site, the Principal investigator, the Local Laboratory, 
the CRO undertake to export such data in compliance with adequate safeguards/legal basis 
as required by the Regulation 679/2016 including the Commission Decisions, the Standard 
Contract Clauses, the Privacy Shield, patients’ specific consent only where permitted under 
Chapter V of the GDPR, on one of the basis set out under art. 49 GDPR.  
 
LIST HERE THE NON-EU COUNTRIES/ENTITIES WHERE DATA CAN BE 
EXPORTED:  
USA,  
RUSSIA 
Nevertheless, if Sponsor registers and markets the: Amlodipine and Zofenopril calcium in non-
EU countries, data may have to be submitted to the Authorities in charge of monitoring the 
safety and reliability of medicines in those countries. The updated list of foreign countries is 
available upon request. 
17.9 Exercise of subjects’ data privacy rights 
 
Each study patient has the right to contact the Sponsor, the Site, the Principal investigator, the 
Local  Laboratory, the CRO to exercise the rights afforded to the patient by the law, including 
the  ones afforded  under articles 15 to 22 of Regulation (EU) 2016/679 or under Data 
Protection Act No. 152 FZ dated 27 July 2006 and implementing acts,, namely: knowing 
whether or not any data referring to his/her is being processed in the context of the study -
access his/her data; verify the data’s content, origin, exactness, location (including, where 


 
Corporate Medical Department 
 
Identification Number 
Version Number 
State 
Effective date 
FORM-000050125 
2.0, CURRENT 
Effective 
08, Jan 2021 
 
Sponsor: Menarini International Operations Luxembourg SA 
Study Code: MEIN/20/ZoAm-Hyp/001 
Protocol Version 1.0 of 1     23/04/2021 
  
 
Pag. 80 a 91 
 
applicable, the non-EU countries where the data might be); obtain a copy of the data including 
their transmission to another entity indicated by the patient; ask that the data are supplemented, 
updated, amended; in the circumstances set forth by the law, ask that the processing of data is 
restricted, that data are anonymised or frozen; oppose to the processing of his/her data for 
legitimate reasons. Each patient- has the right to lodge a complaint with his/her local 
supervisory authority and/or to notify to the Data Protection Officer any use of his/her personal 
data the patient- regards as inappropriate. Each study patient is free to withdraw at any time 
from the study. In such case, each study patient may ask the Sponsor, the Site, the Principal 
investigator, the Local Laboratory, the CRO - to destroy/delete his/her personal data (including 
his/her biological samples), thus preventing any further processing or analysis of his/her data. 
However, data and results of tests that may have been used to determine the results of the study 
shall not be deleted, to avoid altering or impairing altogether the results of the study. If he Site, 
the Principal investigator, the Local Laboratory, the CRO receive a request for data privacy 
rights exercise, the concerned recipient shall immediately inform the Sponsor DPO by email at 
dpo@menarini.com]. The request shall be fulfilled within the term set forth by the applicable 
privacy laws (normally 30 days). The Sponsor, the Site, the Principal investigator, the Local 
Laboratory, the CRO - shall implement adequate organisational measures to reply to patients 
within the above-mentioned deadline 
 
17.10 Future research 
 
In the context of additional research activities, patients’ data will be processed, anonymised 
and transferred abroad, and may be shared with future research partners –this will take place 
in a format that prevents patients’ identification.  
18 PUBLICATION POLICY AND RESULTS 
 
By signing the study protocol, the Investigator (and his / her appointed staff) ensures that 
any information and all the study documents provided by the Sponsor will be maintained 
strictly confidential. 
None of this material may be disclosed to any party not directly involved in the study 
without written permission from the Sponsor. 
All information concerning the study, the drug as well as data and results of the study are 
confidential and property of the Sponsor. 


 
Corporate Medical Department 
 
Identification Number 
Version Number 
State 
Effective date 
FORM-000050125 
2.0, CURRENT 
Effective 
08, Jan 2021 
 
Sponsor: Menarini International Operations Luxembourg SA 
Study Code: MEIN/20/ZoAm-Hyp/001 
Protocol Version 1.0 of 1     23/04/2021 
  
 
Pag. 81 a 91 
 
The Sponsor will prepare the clinical trial report, including the statistical and clinical 
evaluations, and trial results will be posted and made public, according to applicable 
Regulatory Regulations. The Investigator’s agreement and signature will be obtained, and a 
copy will be provided to the Investigator. 
Sponsor reserves the exclusive right to publish and present data and results of the present study 
at scientific meetings, or to submit these clinical trial data to national and international 
Regulatory Authorities. The Investigator may not use the results of this study for publication or 
presentation without written authorization from Sponsor. 
 
19 REFERENCES 
 
1. Chow CK, Teo KK, Rangarajan S, Islam S, Gupta R, Avezum A, et al, PURE Study 
Investigators. Prevalence, awareness, treatment, and control of hypertension in rural and 
urban communities in high-, middle-, and low-income countries. JAMA. 2013; 310:959-68. 
2. Forouzanfar MH, Liu P, Roth GA, Ng M, Biryukov S, Marczak L, et al. Global burden of 
hypertension and systolic blood pressure of at least 110 to 115 mm Hg, 1990-
2015. JAMA. 2017;317:165–82. 
3. Williams B, Mancia G, Spiering W, Agabiti Rosei E, Azizi M, Burnier M, et al. 2018 
ESC/ESH guidelines for the management of arterial hypertension: The Task Force for the 
management of arterial hypertension of the European Society of Cardiology and the 
European Society of Hypertension. J Hypertens. 2018;36:1953-2041. 
4. Ettehad D, Emdin CA, Kiran A, Anderson SG, Callender T, Emberson J, et al. Blood 
pressure lowering for prevention of cardiovascular disease and death: a systematic review 
and meta-analysis. Lancet. 2016;387:957–67. 
5. Thomopoulos C, Parati G, Zanchetti A. Effects of blood pressure lowering on outcome 
incidence in hypertension. Overview, meta-analyses, and meta-regression analyses of 
randomized trials. J Hypertens. 2014;32:2285–95 
6. Mensah GA, Bakris G. Treatment and control of high blood pressure in adults. Cardiol Clin. 
2010;28:609–22 
7. Amlodipine SmPC 
8. Zofenpril SmPC 
9. Borghi C, Omboni S, Reggiardo G, et al. Efficacy of zofenopril in combination with 
amlodipine in patients with acute myocardial infarction: a pooled individual patient data 
analysis of four randomized, double-blind, controlled, prospective studies. Curr Med Res 
Opin. 2018;34(10):1869-1874. 


 
Corporate Medical Department 
 
Identification Number 
Version Number 
State 
Effective date 
FORM-000050125 
2.0, CURRENT 
Effective 
08, Jan 2021 
 
Sponsor: Menarini International Operations Luxembourg SA 
Study Code: MEIN/20/ZoAm-Hyp/001 
Protocol Version 1.0 of 1     23/04/2021 
  
 
Pag. 82 a 91 
 
10. Wright, J. M., Musini, V. M., & Gill, R. (2018). First-line drugs for hypertension. The 
Cochrane 
database 
of 
systematic 
reviews, 
4(4), 
CD001841. 
https://doi.org/10.1002/14651858.CD001841.pub3 
11. Kawalec P, Holko P, Gawin M, Pilc A. Effectiveness of fixed-dose combination therapy in 
hypertension: systematic review and meta-analysis. Arch Med Sci. 2018;14(5):1125-1136. 
doi:10.5114/aoms.2018.77561 
12. Jamerson KA, Nwose O, Jean‐Louis L, et al. Initial angiotensin‐converting enzyme 
inhibitor/calcium channel blocker combination therapy achieves superior blood pressure 
control compared with calcium channel blocker monotherapy in patients with stage 2 
hypertension. Am J Hypertens. 2004; 17: 495– 501. 
13. Bahl, V. K., Jadhav, U. M., & Thacker, H. P. (2009). Management of hypertension with the 
fixed combination of perindopril and amlodipine in daily clinical practice: results from the 
STRONG prospective, observational, multicenter study. American journal of cardiovascular 
drugs: 
drugs, 
devices, 
and 
other 
interventions, 
9(3), 
135–142. 
https://doi.org/10.1007/BF03256570 
14. Frank J. Managing hypertension using combination therapy. Am Fam Physician. 
2008;77(9):1279-1286. 
15. Li, Y., Wei, F. F., Wang, S., Cheng, Y. B., & Wang, J. G. (2014). Cardiovascular risks 
associated with diastolic blood pressure and isolated diastolic hypertension. Current 
hypertension reports, 16(11), 489. https://doi.org/10.1007/s11906-014-0489-x 
16. Volpe M, Rosei EA, Ambrosioni E, et al. 2012 consensus document of the Italian Society of 
Hypertension (SIIA): strategies to improve blood pressure control in Italy: from global 
cardiovascular risk stratification to combination therapy. High Blood Press Cardiovasc Prev. 
2013;20(1):45-52. doi:10.1007/s40292-013-0007-2 
17. Sever PS, Messerli FH. Hypertension management 2011: optimal combination therapy. 
European Heart Journal. 2011 Oct;32(20):2499-2506. DOI: 10.1093/eurheartj/ehr177 
18. Amlodipine IB 
19. Zofenopril IB 
 
 
 
 
 
 


 
COi JH)l'OII MIU/1cal Dq,art,n#Jnl 
ll)entltteatton NUDlber 
Venlon Number 
State 
-
 2.0, CURRENT
lfflllollve 
Bffeettve date 
08, 
jan ,2021 
Spo...,.:.._ .. ...._ .... o,er.ttau,.-..... ,M
si,,+ Cok IIIEINl"JOl'ZIJbt..1/yJIMJ 
Proteeei 
Venlon 
1.0 
of 
1
23AU/lfJJ 
20 PROTOCOL APPROVAL PAGE 
Stm\Y Tttte: Intervcntlonal clinical trial to asseas efficacy and safety of the extemporaneous 
compudion of zofenopril calcium and amlodipino in grade 1-2 hypertcrnaivo padcota versus 
eacbm1onotbenpy (MASOLINO Study) 
C MBIN/20/'loAm-Hyp/001 
EUQRA,CJ' IUUllber: 2021-00074S-40 
De •tllS COlf/l1M tlult tI,,q lltwe Hild IIIUI tl/lJ'1'f)WII die pr6'0Col 
8tust Mdse) l1PSP MAR.CO SALVATORE
Sipeure&Date: L,_ k ii.'<-
O!rqmt• ¥t111n! Qlrrtv(:LORENZ.O MELANI. ___ _ 
Si&Date: 
	 
 • 
FORM-000050125


27 April 2021


 
Corporate Medical Department 
 
Identification Number 
Version Number 
State 
Effective date 
FORM-000050125 
2.0, CURRENT 
Effective 
08, Jan 2021 
 
Sponsor: Menarini International Operations Luxembourg SA 
Study Code: MEIN/20/ZoAm-Hyp/001 
Protocol Version 1.0 of 1     23/04/2021 
  
 
Pag. 84 a 91 
 
21 INVESTIGATOR’S APPROVAL PAGE 
 
I understand that all information concerning the product that Menarini supplied Zofenopril and 
Amlodipine in connection with this study protocol are confidential information. This 
information includes: Protocol, Investigator’s Brochure, Case Report Form etc. 
 
I understand that any change in this study protocol must be approved in writing by Menarini 
International Operations Luxembourg and the Co-ordinating Investigator, submitted to the 
Ethics Committee and Health Authorities before implementation, except where necessary to 
eliminate apparent immediate hazard to patients. 
 
I confirm that I will conduct the study according to this protocol, the Good Clinical Practice 
(GCP), the Declaration of Helsinki and laws and regulations in the Country where the study is 
to be conducted. 
 
I confirm that I will record and report all adverse events occurring during the study, according 
to this protocol. 
 
I confirm that I am informed about the need of data records retention, according to current 
regulations and that no data can be destroyed without the written consent of Menarini 
International Operations Luxembourg 
 
I confirm that I will transfer adequate ownership of my responsibilities for the trial and will 
inform the Sponsor, in case I retire from my PI role. 
 
I confirm that in case the Trial Centre File is stolen or anyhow damaged, I will promptly inform 
the Sponsor and declare it to the Competent Authorities 
 
Principal Investigator: ____________________________________________________ 
 
Signature & Date: _________________________________________________________    
 
 
 
 


 
Corporate Medical Department 
 
Identification Number 
Version Number 
State 
Effective date 
FORM-000050125 
2.0, CURRENT 
Effective 
08, Jan 2021 
 
Sponsor: Menarini International Operations Luxembourg SA 
Study Code: MEIN/20/ZoAm-Hyp/001 
Protocol Version 1.0 of 1     23/04/2021 
  
 
Pag. 85 a 91 
 
 
22 APPENDICES 
 
Appendix 1: Declaration of Helsinki 
 
Adopted by the 18th WMA General Assembly, Helsinki, Finland, June 1964 and amended 
by the: 
 
29th WMA General Assembly, Tokyo, Japan, October 1975 
35th WMA General Assembly, Venice, Italy, October 1983 
41st WMA General Assembly, Hong Kong, September 1989 
48th WMA General Assembly, Somerset West, Republic of South Africa, October 1996 
52nd WMA General Assembly, Edinburgh, Scotland, October 2000 
53rd WMA General Assembly, Washington DC, USA, October 2002 (Note of Clarification 
added) 
55th WMA General Assembly, Tokyo, Japan, October 2004 (Note of Clarification added) 
59th WMA General Assembly, Seoul, Republic of Korea, October 2008 
64th WMA General Assembly, Fortaleza, Brazil, October 2013 
 
Preamble 
1.         The World Medical Association (WMA) has developed the Declaration of Helsinki 
as a statement of ethical principles for medical research involving human subjects, including 
research on identifiable human material and data. 
The Declaration is intended to be read as a whole and each of its constituent paragraphs 
should be applied with consideration of all other relevant paragraphs. 
2.         Consistent with the mandate of the WMA, the Declaration is addressed primarily to 
physicians. The WMA encourages others who are involved in medical research involving 
human subjects to adopt these principles. 
 
General Principles 
3.         The Declaration of Geneva of the WMA binds the physician with the words, “The 
health of my patient will be my first consideration,” and the International Code of Medical 
Ethics declares that, “A physician shall act in the patient’s best interest when providing 
medical care.” 


 
Corporate Medical Department 
 
Identification Number 
Version Number 
State 
Effective date 
FORM-000050125 
2.0, CURRENT 
Effective 
08, Jan 2021 
 
Sponsor: Menarini International Operations Luxembourg SA 
Study Code: MEIN/20/ZoAm-Hyp/001 
Protocol Version 1.0 of 1     23/04/2021 
  
 
Pag. 86 a 91 
 
4.         It is the duty of the physician to promote and safeguard the health, well-being and 
rights of patients, including those who are involved in medical research. The physician’s 
knowledge and conscience are dedicated to the fulfilment of this duty. 
5.         Medical progress is based on research that ultimately must include studies involving 
human subjects. 
6.         The primary purpose of medical research involving human subjects is to understand 
the causes, development and effects of diseases and improve preventive, diagnostic and 
therapeutic interventions (methods, procedures and treatments). Even the best proven 
interventions must be evaluated continually through research for their safety, effectiveness, 
efficiency, accessibility and quality. 
7.         Medical research is subject to ethical standards that promote and ensure respect for 
all human subjects and protect their health and rights. 
8.         While the primary purpose of medical research is to generate new knowledge, this 
goal can never take precedence over the rights and interests of individual research patients. 
9.         It is the duty of physicians who are involved in medical research to protect the life, 
health, dignity, integrity, right to self-determination, privacy, and confidentiality of personal 
information of research patients. The responsibility for the protection of research patients 
must always rest with the physician or other health care professionals and never with the 
research patients, even though they have given consent. 
10.       Physicians must consider the ethical, legal and regulatory norms and standards for 
research involving human subjects in their own countries as well as applicable international 
norms and standards. No national or international ethical, legal or regulatory requirement 
should reduce or eliminate any of the protections for research patients set forth in this 
Declaration. 
11.       Medical research should be conducted in a manner that minimises possible harm to 
the environment. 
12.       Medical research involving human subjects must be conducted only by individuals 
with the appropriate ethics and scientific education, training and qualifications. Research on 
patients or healthy volunteers requires the supervision of a competent and appropriately 
qualified physician or other health care professional. 
13.       Groups that are underrepresented in medical research should be provided appropriate 
access to participation in research. 
14.       Physicians who combine medical research with medical care should involve their 
patients in research only to the extent that this is justified by its potential preventive, 


 
Corporate Medical Department 
 
Identification Number 
Version Number 
State 
Effective date 
FORM-000050125 
2.0, CURRENT 
Effective 
08, Jan 2021 
 
Sponsor: Menarini International Operations Luxembourg SA 
Study Code: MEIN/20/ZoAm-Hyp/001 
Protocol Version 1.0 of 1     23/04/2021 
  
 
Pag. 87 a 91 
 
diagnostic or therapeutic value and if the physician has good reason to believe that 
participation in the research study will not adversely affect the health of the patients who 
serve as research patients. 
15.       Appropriate compensation and treatment for patients who are harmed as a result of 
participating in research must be ensured. 
 
 
Risks, Burdens and Benefits 
16.       In medical practice and in medical research, most interventions involve risks and 
burdens. 
Medical research involving human subjects may only be conducted if the importance of the 
objective outweighs the risks and burdens to the research subjects. 
17.       All medical research involving human subjects must be preceded by careful 
assessment of predictable risks and burdens to the individuals and groups involved in the 
research in comparison with foreseeable benefits to them and to other individuals or groups 
affected by the condition under investigation. 
Measures to minimise the risks must be implemented. The risks must be continuously 
monitored, assessed and documented by the researcher. 
18.       Physicians may not be involved in a research study involving human subjects unless 
they are confident that the risks have been adequately assessed and can be satisfactorily 
managed. 
When the risks are found to outweigh the potential benefits or when there is conclusive 
proof of definitive outcomes, physicians must assess whether to continue, modify or 
immediately stop the study. 
 
Vulnerable Groups and Individuals 
19.       Some groups and individuals are particularly vulnerable and may have an increased 
likelihood of being wronged or of incurring additional harm. 
All vulnerable groups and individuals should receive specifically considered protection. 
20.       Medical research with a vulnerable group is only justified if the research is 
responsive to the health needs or priorities of this group and the research cannot be carried 
out in a non-vulnerable group. In addition, this group should stand to benefit from the 
knowledge, practices or interventions that result from the research. 
 


 
Corporate Medical Department 
 
Identification Number 
Version Number 
State 
Effective date 
FORM-000050125 
2.0, CURRENT 
Effective 
08, Jan 2021 
 
Sponsor: Menarini International Operations Luxembourg SA 
Study Code: MEIN/20/ZoAm-Hyp/001 
Protocol Version 1.0 of 1     23/04/2021 
  
 
Pag. 88 a 91 
 
Scientific Requirements and Research Protocols 
21.       Medical research involving human subjects must conform to generally accepted 
scientific principles, be based on a thorough knowledge of the scientific literature, other 
relevant sources of information, and adequate laboratory and, as appropriate, animal 
experimentation. The welfare of animals used for research must be respected. 
22.       The design and performance of each research study involving human subjects must 
be clearly described and justified in a research protocol. 
The protocol should contain a statement of the ethical considerations involved and should 
indicate how the principles in this Declaration have been addressed. The protocol should 
include information regarding funding, sponsors, institutional affiliations, potential conflicts 
of interest, incentives for subjects and information regarding provisions for treating and/or 
compensating patients who are harmed as a consequence of participation in the research 
study. 
In clinical trials, the protocol must also describe appropriate arrangements for post-trial 
provisions. 
 
Research Ethics Committees 
23.       The research protocol must be submitted for consideration, comment, guidance and 
approval to the concerned research ethics committee before the study begins. This 
committee must be transparent in its functioning, must be independent of the researcher, the 
sponsor and any other undue influence and must be duly qualified. It must take into 
consideration the laws and regulations of the country or countries in which the research is to 
be performed as well as applicable international norms and standards but these must not be 
allowed to reduce or eliminate any of the protections for research patients set forth in this 
Declaration. 
The committee must have the right to monitor ongoing studies. The researcher must provide 
monitoring information to the committee, especially information about any serious adverse 
events. No amendment to the protocol may be made without consideration and approval by 
the committee. After the end of the study, the researchers must submit a final report to the 
committee containing a summary of the study’s findings and conclusions. 
 
Privacy and Confidentiality 
24.       Every precaution must be taken to protect the privacy of research patients and the 
confidentiality of their personal information. 


 
Corporate Medical Department 
 
Identification Number 
Version Number 
State 
Effective date 
FORM-000050125 
2.0, CURRENT 
Effective 
08, Jan 2021 
 
Sponsor: Menarini International Operations Luxembourg SA 
Study Code: MEIN/20/ZoAm-Hyp/001 
Protocol Version 1.0 of 1     23/04/2021 
  
 
Pag. 89 a 91 
 
11 Informed Consent 
25.       Participation by individuals capable of giving informed consent as patients in 
medical research must be voluntary. Although it may be appropriate to consult family 
members or community leaders, no individual capable of giving informed consent may be 
enrolled in a research study unless he or she freely agrees. 
26.       In medical research involving human subjects capable of giving informed consent, 
each potential patient must be adequately informed of the aims, methods, sources of 
funding, any possible conflicts of interest, institutional affiliations of the researcher, the 
anticipated benefits and potential risks of the study and the discomfort it may entail, post-
study provisions and any other relevant aspects of the study. The potential patient must be 
informed of the right to refuse to participate in the study or to withdraw consent to 
participate at any time without reprisal. Special attention should be given to the specific 
information needs of individual potential patients as well as to the methods used to deliver 
the information. 
After ensuring that the potential patient has understood the information, the physician or 
another appropriately qualified individual must then seek the potential patient’s freely-given 
informed consent, preferably in writing. If the consent cannot be expressed in writing, the 
non-written consent must be formally documented and witnessed. 
All medical research patients should be given the option of being informed about the general 
outcome and results of the study. 
27.       When seeking informed consent for participation in a research study the physician 
must be particularly cautious if the potential patient is in a dependent relationship with the 
physician or may consent under duress. In such situations the informed consent must be 
sought by an appropriately qualified individual who is completely independent of this 
relationship. 
28.       For a potential research patient who is incapable of giving informed consent, the 
physician must seek informed consent from the legally authorised representative. These 
individuals must not be included in a research study that has no likelihood of benefit for 
them unless it is intended to promote the health of the group represented by the potential 
patient, the research cannot instead be performed with persons capable of providing 
informed consent, and the research entails only minimal risk and minimal burden. 
29.       When a potential research patient who is deemed incapable of giving informed 
consent is able to give assent to decisions about participation in research, the physician must 


 
Corporate Medical Department 
 
Identification Number 
Version Number 
State 
Effective date 
FORM-000050125 
2.0, CURRENT 
Effective 
08, Jan 2021 
 
Sponsor: Menarini International Operations Luxembourg SA 
Study Code: MEIN/20/ZoAm-Hyp/001 
Protocol Version 1.0 of 1     23/04/2021 
  
 
Pag. 90 a 91 
 
seek that assent in addition to the consent of the legally authorised representative. The 
potential patient’s dissent should be respected. 
30.       Research involving patients who are physically or mentally incapable of giving 
consent, for example, unconscious patients, may be done only if the physical or mental 
condition that prevents giving informed consent is a necessary characteristic of the 
research group. In such circumstances the physician must seek informed consent from the 
legally authorised representative. If no such representative is available and if the research 
cannot be delayed, the study may proceed without informed consent provided that the 
specific reasons for involving patients with a condition that renders them unable to give 
informed consent have been stated in the research protocol and the study has been approved 
by a research ethics committee. Consent to remain in the research must be obtained as soon 
as possible from the patient or a legally authorised representative. 
31.       The physician must fully inform the patient which aspects of their care are related to 
the research. The refusal of a patient to participate in a study or the patient’s decision to 
withdraw from the study must never adversely affect the patient-physician relationship. 
32.       For medical research using identifiable human material or data, such as research on 
material or data contained in biobanks or similar repositories, physicians must seek 
informed consent for its collection, storage and/or reuse. There may be exceptional 
situations where consent would be impossible or impracticable to obtain for such research. 
In such situations the research may be done only after consideration and approval of a 
research ethics committee. 
 
Use of Placebo 
33.       The benefits, risks, burdens and effectiveness of a new intervention must be tested 
against those of the best proven intervention(s), except in the following circumstances: 
Where no proven intervention exists, the use of placebo, or no intervention, is acceptable; or 
Where for compelling and scientifically sound methodological reasons the use of any 
intervention less effective than the best proven one, the use of placebo, or no intervention is 
necessary to determine the efficacy or safety of an intervention 
and the patients who receive any intervention less effective than the best proven one, 
placebo, or no intervention will not be patient to additional risks of serious or irreversible 
harm as a result of not receiving the best proven intervention. 
Extreme care must be taken to avoid abuse of this option. 
 


 
Corporate Medical Department 
 
Identification Number 
Version Number 
State 
Effective date 
FORM-000050125 
2.0, CURRENT 
Effective 
08, Jan 2021 
 
Sponsor: Menarini International Operations Luxembourg SA 
Study Code: MEIN/20/ZoAm-Hyp/001 
Protocol Version 1.0 of 1     23/04/2021 
  
 
Pag. 91 a 91 
 
Post-Trial Provisions 
34.       In advance of a clinical trial, sponsors, researchers and host country governments 
should make provisions for post-trial access for all participants who still need an 
intervention identified as beneficial in the trial. This information must also be disclosed to 
participants during the informed consent process. 
 
Research Registration and Publication and Dissemination of Results 
35.       Every research study involving human subjects must be registered in a publicly 
accessible database before recruitment of the first subject. 
36.       Researchers, authors, sponsors, editors and publishers all have ethical obligations 
with regard to the publication and dissemination of the results of research. Researchers have 
a duty to make publicly available the results of their research on human subjects and are 
accountable for the completeness and accuracy of their reports. All parties should adhere to 
accepted guidelines for ethical reporting. Negative and inconclusive as well as positive 
results must be published or otherwise made publicly available. Sources of funding, 
institutional affiliations and conflicts of interest must be declared in the publication. Reports 
of research not in accordance with the principles of this Declaration should not be accepted 
for publication. 
 
Unproven Interventions in Clinical Practice 
37.       In the treatment of an individual patient, where proven interventions do not exist or 
other known interventions have been ineffective, the physician, after seeking expert advice, 
with informed consent from the patient or a legally authorised representative, may use an 
unproven intervention if in the physician’s judgement it offers hope of saving life, re-
establishing health or alleviating suffering. This intervention should subsequently be made 
the object of research, designed to evaluate its safety and efficacy. In all cases, new 
information must be recorded and, where appropriate, made publicly available. 
 
 
 
 
 
 
 

SAP_001.pdf: 
              
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Protocol Number : 
MEIN/20/ZoAm-Hyp/001 
 
Protocol Version : 
1.0 
 
Protocol Date 
:  
23 April 2021 
 
 
Plan Version 
: 
2.0 
 
Plan Date  
: 
23 May 2022 
 
 
Study Drug 
: 
Extemporaneous combination of Zofenopril (ZOF) 30 mg with  
Amlodipine (AML) 5 mg or Amlodipine (AML) 10 mg 
 
Indication  
: 
Grade 1-2 Hypertension 
 
Statistical Analysis Plan 
Interventional clinical trial to assess efficacy and safety of the 
extemporaneous combination of zofenopril calcium and amlodipine in 
grade 1-2 hypertensive patients versus each monotherapy – (MASOLINO 
Study) 


 
Statistical Analysis Plan  
 
 
 
Confidential | MEIN/20/ZoAm-Hyp/001 | Plan Version No.: 2.0 | Plan Date: 23May2022  
Page 1 of 34 
 
Signature Page 
 
The signatures below indicate that these individuals have reviewed this project-specific Statistical 
Analysis Plan and consent to this document as governing the tasks outlined within. The signatures below 
also indicate that the processes and quality standards set forth by this Statistical Analysis Plan are 
approved for use in this study. 
 
Name 
Title,  
Organization 
Signature 
Date 
Victoria Swaidan 
Biostatistician, 
Biorasi, LLC 
 
 
John Reber 
Biostatistician, 
Biorasi, LLC 
 
 
Hanna 
Lytvynenko 
Statistical Programmer, 
Biorasi, LLC 
 
 
Julia Solovyeva 
Project Manager, 
Biorasi, LLC 
 
 
Paolo Fabrizzi 
Clinical Operations and Medical 
Affairs Director, 
Menarini International Operations 
Luxembourg SA 
 
 
Giorgio 
Reggiardo 
Statistician, 
Menarini International Operations -  
external consultant 
 
 
 
 
 
24 maggio 2022
25 May 2022
24 May 2022
24 May 2022
24 May 2022
24 May 2022


 
Statistical Analysis Plan  
 
 
 
Confidential | MEIN/20/ZoAm-Hyp/001 | Plan Version No.: 2.0 | Plan Date: 23May2022  
Page 2 of 34 
 
Document History 
 
 
Version # 
Issue Date 
Author 
Revisions 
0.1 
10Dec2021 
Victoria Swaidan 
First Draft 
0.2 
22Dec2021 
Victoria Swaidan 
 
Abbreviations table updated 
 
Details on data review meetings added to 
section 5.3 
 
Number of sites updated in section 5.8 
 
Sections 4.6, 6.2, 6.3, 6.5, 7.3, 8.2, 8.7, 9 
updated for clarity 
 
0.3 
05Jan2022 
Victoria Swaidan 
Minor cosmetic/formatting updates 
0.4 
28Jan2022 
Victoria Swaidan 
 
Updated definition of TEAE (section 8.2) to 
include AEs that occur in monotherapy period 
as well as combined therapy period. Updated 
list of corresponding tabulations accordingly. 
 
Addition of e-cigarettes into section 6.3 and 
into corresponding TLF shells. 
0.5 
21Feb2022 
Victoria Swaidan 
 
Added clarifying text to PP Population 
definition 
 
Added additional information into section 8.1.4 
for clarity 
 
Minor updates to TLF shells 
0.6 
23Feb2022 
Victoria Swaidan 
 
Added clarifying text to EFF Population 
definition 
1.0 
25Feb2022 
Victoria Swaidan 
Final/Approved Version 
2.0 
23May2022 
Victoria Swaidan 
 Added clarity to endpoints and analysis 
methods 
 Added clarifying text to Physical 
Examination section 
 
 
 


 
Statistical Analysis Plan  
 
 
 
Confidential | MEIN/20/ZoAm-Hyp/001 | Plan Version No.: 2.0 | Plan Date: 23May2022  
Page 3 of 34 
 
Table of Contents 
 
Signature Page .............................................................................................................................................. 1 
Document History ......................................................................................................................................... 2 
1 
Abbreviations and Definitions............................................................................................................... 6 
2 
Introduction .......................................................................................................................................... 8 
2.1 
Preface .......................................................................................................................................... 8 
2.2 
Purpose of the Analysis ................................................................................................................. 8 
3 
Study Objectives and Endpoints ........................................................................................................... 8 
3.1 
Study Objectives ........................................................................................................................... 8 
3.1.1 
Primary Objectives ................................................................................................................ 8 
3.1.2 
Secondary Objectives ............................................................................................................ 8 
3.1.3 
Exploratory Objectives .......................................................................................................... 9 
3.2 
Endpoints ...................................................................................................................................... 9 
3.2.1 
Primary Endpoints ................................................................................................................. 9 
3.2.2 
Secondary Endpoints ............................................................................................................ 9 
3.2.3 
Exploratory Endpoints ........................................................................................................... 9 
4 
Study Methods .................................................................................................................................... 11 
4.1 
General Study Design and Plan ................................................................................................... 11 
4.2 
Study Schematic .......................................................................................................................... 12 
4.3 
Schedule of Assessments ............................................................................................................ 13 
4.4 
Inclusion-Exclusion Criteria and General Study Population ........................................................ 14 
4.4.1 
Inclusion Criteria ................................................................................................................. 14 
4.4.2 
Exclusion Criteria ................................................................................................................. 15 
4.5 
Randomization and Blinding ....................................................................................................... 15 
4.6 
Sample Size ................................................................................................................................. 15 
5 
General Considerations ....................................................................................................................... 16 
5.1 
Timing of Analyses ...................................................................................................................... 16 
5.2 
Study Variables ........................................................................................................................... 16 
5.2.1 
Baseline ............................................................................................................................... 16 
5.2.2 
First Dose ............................................................................................................................ 16 
5.2.3 
Study Day ............................................................................................................................ 16 
5.2.4 
Visit Windows ..................................................................................................................... 16 
5.3 
Analysis Populations ................................................................................................................... 16 
5.3.1 
Full Analysis Set (FAS) ......................................................................................................... 16 


 
Statistical Analysis Plan  
 
 
 
Confidential | MEIN/20/ZoAm-Hyp/001 | Plan Version No.: 2.0 | Plan Date: 23May2022  
Page 4 of 34 
 
5.3.2 
Safety Population (SAF) ....................................................................................................... 17 
5.3.3 
Efficacy Population (EFF) ..................................................................................................... 17 
5.3.4 
Per Protocol Population (PP) ............................................................................................... 17 
5.4 
Covariates and Subgroups .......................................................................................................... 17 
5.5 
Reporting Conventions ............................................................................................................... 17 
5.6 
Missing Data ................................................................................................................................ 18 
5.6.1 
Imputation of Blood Pressure Data..................................................................................... 18 
5.6.2 
Imputation of Adverse Event Start Dates ........................................................................... 18 
5.6.3 
Imputation of Prior/Concomitant Medication Start and Stop Dates .................................. 19 
5.7 
Interim Analyses and Data Monitoring ....................................................................................... 19 
5.8 
Multi-Center Studies ................................................................................................................... 19 
5.9 
Multiple Testing .......................................................................................................................... 19 
6 
Summary of Study Data ...................................................................................................................... 19 
6.1 
Patient Disposition ...................................................................................................................... 19 
6.2 
Protocol Deviations ..................................................................................................................... 20 
6.3 
Demographic and Baseline Variables.......................................................................................... 20 
6.4 
Medical History ........................................................................................................................... 20 
6.5 
Prior and Concomitant Medications ........................................................................................... 20 
7 
Efficacy Analyses ................................................................................................................................. 21 
7.1 
Efficacy Variable Derivations ...................................................................................................... 21 
7.1.1 
Blood Pressure (BP) Goal (Controlled v Uncontrolled) ....................................................... 21 
7.2 
Primary Efficacy Analyses (Endpoint 1.1) .................................................................................... 21 
7.2.1 
Primary Analysis .................................................................................................................. 21 
7.2.2 
Sensitivity Analyses ............................................................................................................. 22 
7.3 
Secondary Efficacy Analyses ....................................................................................................... 22 
7.3.1 
Mean Change (Endpoints 2.1 and 2.2) ................................................................................ 22 
7.3.2 
Proportion of Patients (Endpoints 2.3 and 2.4) .................................................................. 22 
7.4 
Exploratory Efficacy Analyses ..................................................................................................... 23 
7.4.1 
Mean Change (Endpoints 3.1 and 3.2) ................................................................................ 23 
7.4.1.1 
Model Nonconvergence .................................................................................................. 24 
7.4.2 
Proportion of Patients (Endpoints 3.3 and 3.4) .................................................................. 24 
7.4.2.1 
Model Nonconvergence .................................................................................................. 25 
8 
Safety Analyses (Endpoint 2.5) ........................................................................................................... 25 
8.1 
Study Drug Accountability, Exposure, and Adherence ............................................................... 26 
8.1.1 
Study Medications .............................................................................................................. 26 


 
Statistical Analysis Plan  
 
 
 
Confidential | MEIN/20/ZoAm-Hyp/001 | Plan Version No.: 2.0 | Plan Date: 23May2022  
Page 5 of 34 
 
8.1.2 
Treatment Exposure by Visit ............................................................................................... 26 
8.1.3 
Drug Accountability ............................................................................................................. 26 
8.1.4 
Treatment Adherence ......................................................................................................... 27 
8.1.4.1 
eCRF-Reported Adherence.............................................................................................. 27 
8.1.4.2 
Derived Adherence ......................................................................................................... 27 
8.2 
Adverse Events, Adverse Drug Reactions, and Deaths ............................................................... 28 
8.3 
Clinical Laboratory Evaluations ................................................................................................... 30 
8.4 
Vital Signs .................................................................................................................................... 31 
8.5 
Physical Examination................................................................................................................... 32 
8.6 
Electrocardiogram (ECG) ............................................................................................................. 32 
8.6.1 
ECG Variable Derivations .................................................................................................... 32 
8.6.2 
ECG Variable Analyses ......................................................................................................... 32 
8.7 
Pregnancies ................................................................................................................................. 32 
9 
Technical Details ................................................................................................................................. 33 
10 
Summary of Changes to the Protocol ............................................................................................. 33 
10.1 
Analysis Populations ................................................................................................................... 33 
10.2 
Exploratory Efficacy Analyses ..................................................................................................... 33 
11 
Listing of Tables, Listings, and Figures ............................................................................................ 33 
12 
References ...................................................................................................................................... 34 
 
 
 


 
Statistical Analysis Plan  
 
 
 
Confidential | MEIN/20/ZoAm-Hyp/001 | Plan Version No.: 2.0 | Plan Date: 23May2022  
Page 6 of 34 
 
1 Abbreviations and Definitions 
 
Abbreviations 
Definitions 
ACE-i 
Angiotensin Converting Enzyme Inhibitor 
ADR 
Adverse Drug Reaction 
AE 
Adverse Event 
ALT 
Alanine Transaminase  
AML 
Amlodipine 
AST 
Aspartate Aminotransferase 
ATC 
Anatomic Therapeutic Class 
BMI 
Body Mass Index 
BP 
Blood Pressure 
CCB 
Calcium Channel Blocker 
CI 
Confidence Interval 
eCRF 
Electronic Case Report Form 
CS 
Clinically Significant 
CSR 
Clinical Study Report 
CTMS 
Clinical Trial Management System 
DBP 
Diastolic Blood Pressure 
ECG 
Electrocardiogram 
EFF 
Efficacy Population 
eGFR 
Estimated Glomerular Filtration Rate 
FAS 
Full Analysis Set 
GCP 
Good Clinical Practice 
GGT 
Gamma-Glutamyl Transferase 
HR 
Heart Rate 
IB 
Investigator’s Brochure  
IUD 
Intrauterine Device 
IUS 
Intrauterine Hormone-Releasing System 


 
Statistical Analysis Plan  
 
 
 
Confidential | MEIN/20/ZoAm-Hyp/001 | Plan Version No.: 2.0 | Plan Date: 23May2022  
Page 7 of 34 
 
FAS 
Full Analysis Set 
LS 
Least-Squares 
LOCF 
Last Observation Carried Forward 
Max 
Maximum 
MedDRA 
Medical Dictionary for Regulatory Activities 
Min 
Minimum 
MMRM 
Mixed Model for Repeated Measures  
N 
Sample Size 
NCS 
Not Clinically Significant 
PP 
Per Protocol Population 
PT 
Preferred Term 
RCT 
Randomized Controlled Trial 
RR 
Respiratory Rate 
SAE 
Serious Adverse Event 
SAF 
Safety Population 
SAP 
Statistical Analysis Plan 
SBP 
Systolic Blood Pressure 
SD 
Standard Deviation 
SE 
Standard Error 
SmPCs 
Summary of Product Characteristics  
SOC 
System Organ Class 
TEAE 
Treatment-Emergent Adverse Event 
TESAE 
Treatment-Emergent Serious Adverse Event 
TLFs 
Tables, Listings, and Figures  
VR 
Ventricular Rate 
WHO-DD 
World Health Organization Drug Dictionary  
ZOF 
Zofenopril 
 


 
Statistical Analysis Plan  
 
 
 
Confidential | MEIN/20/ZoAm-Hyp/001 | Plan Version No.: 2.0 | Plan Date: 23May2022  
Page 8 of 34 
 
2 Introduction 
 
2.1 Preface 
Blood Pressure is a multi-regulated variable depending on many compensating pathways. 
Consequently, combinations of drugs, working through different mechanisms, are required to 
reduce BP in most people with hypertension. Thus, monotherapy is likely to be inadequate 
therapy in most patients. Indeed, almost all patients in RCTs have required combinations of 
drugs to control their BP1. 
 
Zofenopril (ZOF) has been widely investigated for the treatment of patients with hypertension and its 
BP lowering effect has been compared with either placebo or with all the classes of 
antihypertensive drugs currently recommended for the treatment of hypertension. Although 
there are data in literature showing an added antihypertensive effect of Amlodipine (AML) or 
Zofenopril to other antihypertensive treatment2, there is scarce evidence at the moment on the 
antihypertensive effect of the extemporaneous combination of ZOF and AML versus each 
monotherapy. The trial will be conducted in compliance with the protocol, GCP and the 
applicable regulatory requirements. 
 
2.2 Purpose of the Analysis 
These analyses will assess the anti-hypertensive efficacy and safety of the extemporaneous combination 
of ZOF 30 mg with AML 5 mg or AML 10 mg. Results will be included in the Clinical Study Report (CSR). 
 
3 Study Objectives and Endpoints 
 
3.1 Study Objectives 
 
3.1.1 Primary Objectives 
 
Objective 1.1: To assess the anti-hypertensive efficacy of the extemporaneous combination of 
ZOF 30 mg with AML 5 mg or AML 10 mg in lowering the sitting diastolic BP between Visit 2 
(Week 0) and Visit 4 (Week 8) in patients with uncontrolled BP previously treated with 
Zofenopril or Amlodipine (5 mg) monotherapies for at least 4 weeks. 
 
3.1.2 Secondary Objectives  
 
Objective 2.1: To assess the antihypertensive efficacy of the extemporaneous combination of 
ZOF 30 mg in combination with AML 5 mg or AML 10 mg in lowering sitting systolic BP (SBP) 
between Visit 2 (Week 0) and Visit 4 (Week 8) in patients with uncontrolled BP previously 
treated with ZOF or AML 5 mg monotherapies for at least 4 weeks. 
 
 
Objective 2.2: To assess the antihypertensive efficacy of the extemporaneous combination of 
ZOF/AML 30/10 mg vs. ZOF/AML 30/5 mg, in lowering sitting DBP and SBP between Visit 3 
(Week 4) and Visit 4 (Week 8) in patients with uncontrolled BP previously treated with ZOF or 
AML 5 mg monotherapies for at least 4 weeks. 
 
 
Objective 2.3: Monotherapy: to evaluate the total number and percentage of patients who 
achieved the BP goal (sitting BP ≤130/80 mmHg) at Visit 2 (Week 0). Combination therapy: to 


 
Statistical Analysis Plan  
 
 
 
Confidential | MEIN/20/ZoAm-Hyp/001 | Plan Version No.: 2.0 | Plan Date: 23May2022  
Page 9 of 34 
 
evaluate the total number and percentage of patients who achieved the BP goal (sitting BP 
≤130/80 mmHg) at Visit 3 (Week 4) and Visit 4 (week 8). 
 
 
Objective 2.4: To assess the compliance to the treatment (percentage of actual doses taken 
versus doses to be taken) at Visit 2 (Week 0), at Visit 3 (Week 4) and at Visit 4 (Week 8). 
 
 
Objective 2.5: To evaluate the safety and tolerability of the monotherapies (ZOF 30 mg and AML 
5 mg) after 4 weeks of therapy and of the extemporaneous combinations (ZOF 30 mg and AML 5 
mg or AML 10 mg) after 8 weeks of treatment. 
 
3.1.3 Exploratory Objectives  
 
Objective 3.1: To assess change in mean sitting SBP and DBP between Visit 1 (Week -4) and Visit 
2 (Week 0), Visit 3 (Week 4) and Visit 4 (Week 8). 
 
 
Objective 3.2: To assess the antihypertensive efficacy at different time points in patients who 
(1) received ZOF or AML monotherapies before the run-in period, (2) received any other ACE-i or 
CCB monotherapies before the run-in period. 
 
3.2 Endpoints 
 
3.2.1 Primary Endpoints 
 
Endpoint 1.1: Change in mean sitting DBP between Visit 2 (Week 0) and Visit 4 (Week 8). 
 
3.2.2 Secondary Endpoints 
 
Endpoint 2.1: Change in mean sitting SBP between Visit 2 (Week 0) and Visit 4 (Week 8). 
 
 
Endpoint 2.2: Change in mean sitting DBP and SBP between Visit 3 (Week 4) and 4 (Week 8) in 
patients on combination of ZOF/AML 30/5 with uncontrolled BP at Visit 3 and up titrated to the 
extemporaneous combination of ZOF/AML 30/10 mg. 
 
 
Endpoint 2.3: Monotherapy: number and proportion of patients achieving the BP goal (sitting 
BP≤130/80 mmHg) at Visit 2 (Week 0). Combination therapy: number and proportion of patients 
achieving the BP goal (sitting BP≤130/80 mmHg) at  Visit 3 (Week 4) and Visit 4 (Week 8). 
 
 
Endpoint 2.4: Adherence to the treatments (percentage (%) of doses taken/ doses to be taken) 
at Visit 2 (Week 0), Visit 3 (Week 4) and Visit 4 (Week 8). 
 
 
Endpoint 2.5: Safety and tolerability of the monotherapies (ZOF 30 mg and AML 5 mg) after 4 
weeks of therapy and of the extemporaneous combination (ZOF 30 mg and AML 5 mg or AML 10 
mg) after eight weeks of treatment. 
 
3.2.3 Exploratory Endpoints 
 
Endpoint 3.1: Change in mean sitting SBP and DBP between Visit 1 (week -4) and Visit 2 (Week 
0), visit 3 (Week 4) and Visit 4 (Week 8): 
o In the group of patients who were on ZOF 30 mg and AML 5 mg at Visit 1 (Week -4) and 
continued the same therapies. 


 
Statistical Analysis Plan  
 
 
 
Confidential | MEIN/20/ZoAm-Hyp/001 | Plan Version No.: 2.0 | Plan Date: 23May2022  
Page 10 of 34 
 
o In the group of patients who switched to ZOF 30 mg or AML 5 mg from any other ACE-i 
or CCBs at Visit 1 (Week -4). 
 
 
Endpoint 3.2: Change in mean sitting SBP and DBP for uncontrolled patients at Visit 3 (Week 4), 
between Visit 2 (Week 0) and Visit 3 (Week 4). 
o In the group of patients who were on ZOF 30 mg and AML 5 mg at Visit 1 (Week -4) and 
continued the same therapies. 
o In the group of patients who switched to ZOF 30 mg or AML 5 mg from any other ACE-i 
or CCBs at Visit 1 (Week -4). 
 
 
Endpoint 3.3:  
o Monotherapy: number and proportion of patients achieving the BP goal (sitting 
BP≤130/80 mmHg) at Visit 2 (Week 0): 
 
In the group of patients who were on ZOF 30 mg and AML 5 mg at Visit 1 (Week 
-4) and continued the same therapies. 
 
In the group of patients who switched to ZOF 30 mg or AML 5 mg from any 
other ACE-i or CCBs at Visit 1 (Week -4). 
o Combination therapy: number and proportion of patients achieving the BP goal (sitting 
BP≤130/80 mmHg) at Visit 3 (Week 4): 
 
In the group of patients who were on ZOF 30 mg and AML 5 mg at Visit 1 (Week 
-4) and continued the same therapies. 
 
In the group of patients who switched to ZOF 30 mg or AML 5 mg from any 
other ACE-i or CCBs at Visit 1 (Week -4). 
 
 
Endpoint 3.4:  
o Monotherapy: number and proportion of patients divided in subgroup by the 
hypertension grade, the presence of diabetes and/or of hypercholesterolemia achieving 
the BP goal (sitting BP ≤130/80 mmHg) at Visit 2 (Week 0): 
 
In the group of patients who were on ZOF 30 mg and AML 5 mg at Visit 1 (Week 
-4) and continued the same therapies. 
 
In the group of patients who switched to ZOF 30 mg or AML 5 mg from any 
other ACE-i or CCBs at Visit 1 (Week -4). 
o Combination therapy: number and proportion of patients divided in subgroup by the 
hypertension grade, the presence of diabetes and/or of hypercholesterolemia achieving 
the BP goal (sitting BP ≤130/80 mmHg) at Visit 3 (Week 4) and Visit 4 (Week 8): 
 
In the group of patients who were on ZOF 30 mg and AML 5 mg at Visit 1 (Week 
-4) and continued the same therapies. 
 
In the group of patients who switched to ZOF 30 mg or AML 5 mg from any 
other ACE-i or CCBs at Visit 1 (Week -4). 
 
 
 
 


 
Statistical Analysis Plan  
 
 
 
Confidential | MEIN/20/ZoAm-Hyp/001 | Plan Version No.: 2.0 | Plan Date: 23May2022  
Page 11 of 34 
 
4 Study Methods 
 
4.1 General Study Design and Plan 
This is a phase IV, open-label, multicenter, multinational study with 2 study periods: a 4-week run-in 
period and an 8-week assessment period. 
 
Approximately 290 patients are planned to be screened to ensure at least 216 patients complete 
the run-in period and start with the assessment period. 
 
Patients with Grade 1-2 hypertensive patients (blood pressure [BP] ranging from ≥140/90 
mmHg to ≤179/109 mmHg) on treatment with any angiotensin converting enzyme inhibitors 
(ACE-i) including Zofenopril 30 mg or with calcium channel blockers (CCBs) including 
Amlodipine 5 mg will be screened for eligibility (Visit 1). 
 
Allowed CCBs: Felodipine, isradipine, lacidipine, lercanidipine, nicardipine, nifedipine, and 
nisoldipine. Patients treated with other dosages of Zofenopril (other than 30 mg) are not 
allowed to be screened. 
 
After screening, on the same day, eligible patients, will enter into a 4-week run-in period, 
during which patients on other ACE-i will be assigned to monotherapy with ZOF 30 mg while 
patients on CCBs will be assigned to monotherapy with AML 5 mg for 4 weeks. Patients with 
on-going treatment zofenopril 30 mg and amlodipine 5mg will continue on the same treatment 
for 4 weeks. 
 
After the run-in period (4 weeks ± 2 days), BP will be further assessed (Visit 2), if BP levels 
are over the defined controlled target goal (sitting SBP/DBP >130/80 mmHg), treatment is 
well tolerated and adherence to the treatments ranges from 80% to 120%, patients will enter the 
assessment period, where they will be assigned to the extemporaneous combination of ZOF 30 
mg and AML 5 mg. At Visit 2 patients with SBP/DBP values classified as Grade 3 (SBP ≥ 180 
or DBP ≥ 110 mmHg) hypertension will be withdrawn from the study. 
 
If patients, at Visit 2, after the run-in period, have a controlled BP (sitting SBP/DBP≤130/80 
mmHg) or do not tolerate the treatment or have an adherence range below 80% or superior to 
120%, they will be withdrawn from the study. 
 
The patients will be assessed for further 8 weeks (assessment period). 
 
After 4 weeks ± 2 days from Visit 2, during the assessment period patients receiving the 
extemporaneous combination of ZOF 30 mg and AML 5 mg, will be further evaluated (Visit 
3): controlled patients (sitting SBP/DBP ≤130/80 mmHg) will continue the same 
extemporaneous combination for additional 4 weeks ± 2 days, while uncontrolled patients 
(sitting SBP/DBP >130/80 mmHg) will be up-titrated from ZOF/AML 30/5 mg to ZOF/AML 
30/10 mg for further 4 weeks ± 2 days. 
 
At Visit 3 patients with SBP/DBP values classified as Grade 3 (SBP ≥ 180 or DBP ≥ 110 
mmHg) hypertension will be withdrawn from the study. 
 


 
Statistical Analysis Plan  
 
 
 
Confidential | MEIN/20/ZoAm-Hyp/001 | Plan Version No.: 2.0 | Plan Date: 23May2022  
Page 12 of 34 
 
If patients at Visit 3, do not tolerate the extemporaneous combination treatment or they have an 
adherence range below 80% or superior to 120%, they will be withdrawn from the study. 
At the end of the assessment period (8 weeks ± 4 days) at Visit 4, the anti-hypertensive effect 
of the extemporaneous combination (ZOF/AML 30/5 mg and ZOF/AML 30/10 mg) will be 
evaluated. 
 
Efforts will be made to achieve 1:1 ratio in the enrolment of patients receiving any ACE-i or 
allowed CCBs. At Visit 2, a minimum of 45% of uncontrolled patients receiving treatment with ZOF 30 mg 
or AML 5 mg are required to enter the assessment period, in order to maintain a balance between the 2 
treatments during the assessment period. 
 
4.2 Study Schematic  
 
 
# There is not a randomization procedure 
 
§ Allowed CCBs at screening: Felodipine, isradipine, lacidipine, lercanidipine, nicardipine, nifedipine, and 
nisoldipine. Patients treated with Amlodipine 10 mg or Zofenopril other than 30 mg will not undergo 
screening procedures. 
 
Grade 1-2 hypertensive patients: Blood pressure (BP) ranging from ≥ 140/90 mmHg to ≤ 179/109 mmHg 
 
Uncontrolled patients with grade 1-2 hypertension: Sitting SBP/DBP > 130/80 mmHg. Patients with 
Grade 3 (SBP ≥ 180 or DBP ≥ 110 mHg) hypertension will be withdrawn from the study at Visit 2 and Visit 
3.  
 
Controlled patients: SBP/DBP ≤ 130/80 mmHg 


 
Statistical Analysis Plan  
 
 
 
Confidential | MEIN/20/ZoAm-Hyp/001 | Plan Version No.: 2.0 | Plan Date: 23May2022  
Page 13 of 34 
 
4.3 Schedule of Assessments 
 
 
a. Patients on ZOF 30 mg or AML 5 mg will continue the same therapy for 4 weeks. Patients on any other 
ACE-i will be assigned to monotherapy with ZOF 30 mg and the patients on other CCBs (the allowed CCBs 
i


 
Statistical Analysis Plan  
 
 
 
Confidential | MEIN/20/ZoAm-Hyp/001 | Plan Version No.: 2.0 | Plan Date: 23May2022  
Page 14 of 34 
 
are: felodipine, isradipine, lacidipine, lercanidipine, nicardipine, nifedipine, and nisoldipine) will be assigned 
to monotherapy with AML 5 mg 
b. Only patients controlled at Visit 3 will receive ZOF/AML 30/5 mg 
c. Only patients uncontrolled at Visit 3 will receive ZOF/AML 30/10 mg. 
d. To ensure patient safety, the patients will be contacted over phone within 24 hours, in case of any 
abnormality and clinically relevant laboratory test according to the Investigator’s judgement at any visit 
e. The Investigator is expected to also record any AE which was ongoing at the last treatment dose and a 
follow-up phone call should be made after 2 weeks from the last study visit. 
In case AE was ongoing, the Investigator is expected to follow-up until the outcome of the AE has been 
determined. 
f. IWRS- Interactive Web Response System 
g. The following procedure is applied only in case of COVID-19 restrictions. 
h. Patients will be provided with an automatic blood pressure device to be used in case they are not able to go 
to the study centre due to Covid-19 pandemic situation. 
i. The patient will return the device at the last visit at the site 
 
4.4 Inclusion-Exclusion Criteria and General Study Population 
 
4.4.1 Inclusion Criteria 
A patient will be considered eligible for inclusion in the study only if all the following criteria 
are met: 
1. Male or female Grade 1-2 hypertensive patients: with mean sitting SBP ≥140 mmHg and ≤179 
mmHg and/or mean sitting DBP ≥ 90 mmHg and ≤109 mmHg at Screening, with ≥18 and ≤65 
years of age, on monotherapy either with ZOF 30 mg or AML 5mg or any other ACE-I or CCBs 
(Felodipine, isradipine, lacidipine, lercanidipine, nicardipine, nifedipine, and nisoldipine) for at 
least 1 month before Visit 1 (Screening). 
2. Patients who are able to understand and give written informed consent at Screening 
3. Patients who are available for the entire trial period and willing to adhere to the protocol 
requirements 
4. Ability to take oral medication and willing to adhere to the drug regimen 
5. Female patients are eligible to participate if not pregnant, or not breastfeeding and must refrain 
from donating or storing eggs. For females of reproductive potential: use of highly effective 
contraception (e.g., method of birth control throughout the study period and for 4 weeks after 
study completion defined as a method which results in a failure rate of less than 1% per year) 
such as: 
a. Combined (estrogen- and progestogen-containing) hormonal contraception associated 
with inhibition of ovulation (oral, intravaginal, transdermal) 
b. Progestogen-only hormonal contraception associated with inhibition of ovulation (oral, 
injectable, implantable) 
c. Intrauterine device (IUD) 
d. Intrauterine hormone-releasing system (IUS) 
e. Bilateral tubal occlusion 
f. Vasectomized partner (performed at least 2 months before screening) (if the partner is 
the sole sexual partner of the trial participant and that the vasectomized partner has 
received medical assessment of the surgical success) 
6. A male patient must agree to use contraception during the whole study period and for at least 1 
week after the last dose of study treatment and refrain from donating sperms during this period 
 


 
Statistical Analysis Plan  
 
 
 
Confidential | MEIN/20/ZoAm-Hyp/001 | Plan Version No.: 2.0 | Plan Date: 23May2022  
Page 15 of 34 
 
4.4.2 Exclusion Criteria  
Any patient who meets any of the following criteria will not qualify for entry into the study: 
1. Known contraindications, presence of not recommended/contraindicated concomitant therapy 
allergies, or significant history of hypersensitivity to zofenopril, amlodipine, other ACE-inhibitors 
or dihydropyridines, or any related products (including excipients of the formulations as 
outlined in the Investigator’s Brochure [IB]), or summary of product characteristics (SmPCs) or 
local package inserts for AML and ZOF 
2. Patients with serious disorders (in the opinion of the Investigator) which may limit the ability to 
evaluate the efficacy or safety of the tested medications, including cerebrovascular, 
cardiovascular, renal, respiratory, hepatic, gastrointestinal, endocrine/ or metabolic, 
haematological, or oncological, neurological, and psychiatric diseases. The same applies for 
immunocompromised and/or neutropenic patients 
3. Patients having a history of the following within the last 6 months: myocardial infarction, 
unstable angina pectoris, percutaneous coronary intervention, bypass surgery, valve 
replacement (transcatheter aortic valve implantation, mitraclip), cerebrovascular accident 
(stroke, heart failure, hypertensive encephalopathy, cerebrovascular accident (stroke), or 
transient ischemic attack. Patients with who have undergone other surgery that in the in the 
opinion of the Investigator may limit the ability to evaluate the efficacy or safety of the tested 
medications. 
4. Patients with secondary hypertension of any aetiology such as renal diseases, 
pheochromocytoma, Cushing’s syndrome hyperaldosteronism, renovascular disease, thyroid 
disorders 
5. Patients with severe heart failure (New York Heart Association classification III-IV), a narrowing 
of the aortic or bicuspid valve, an obstruction of cardiac outflow (obstructive, hypertrophic 
cardiomyopathy) or symptomatic coronary disease 
6. Patients with clinical evidence of renal disease as per the Investigator’s judgement (including 
renovascular occlusive disease, nephrectomy and/or renal transplant, bilateral renal artery 
stenosis or unilateral renal artery stenosis in a solitary kidney, or severe renal impairment) 
7. Patients with history of angioneurotic oedema 
8. Patients with clinically relevant hepatic impairment 
9. Patients with sick sinus syndrome, including sino-atrial block 
10. Patients with second- or third-degree heart block (without a pacemaker) 
11. Participation in any other interventional drug trial or exposure to other investigational agents 
within 30 days before Screening (Visit 1) 
12. Inability to cooperate or any condition that, in the opinion of the Investigator, could increase the 
patient’s risk of participating in the study or confound the outcome of the study  
13. Patients with conditions that, in the opinion of the Investigator, would prevent a careful 
adherence to the protocol 
14. Patients with severe hypotension 
15. Patients who suffer from shock (including cardiogenic shock) 
16. Patients treated with Amlodipine 10 mg and Zofenopril (other than 30 mg) 
 
4.5 Randomization and Blinding 
This is a non-randomized, unblinded study. 
 
4.6 Sample Size 
A total sample size of 216 patients is required to achieve 90% power at a 5% significance level 


 
Statistical Analysis Plan  
 
 
 
Confidential | MEIN/20/ZoAm-Hyp/001 | Plan Version No.: 2.0 | Plan Date: 23May2022  
Page 16 of 34 
 
assuming a difference in mean DBP from baseline (Visit 2) to 8 weeks (Visit 4) of 4 mmHg 
and a standard deviation (SD) for this difference of 10 mmHg. The mean change in DBP for 
the null hypothesis is set equal to 2 mmHg. The alternative hypothesis is that the mean change in DBP is 
greater than 2 mmHg. To achieve this sample size, a total of 290 patients will be enrolled, allowing for a 
25% withdrawal rate.  
 
5 General Considerations 
 
5.1 Timing of Analyses 
No interim analysis is planned for this study. The final analysis will be performed after finalization and 
approval of this Statistical Analysis Plan (SAP) and after database lock.  
 
5.2 Study Variables 
 
5.2.1 Baseline 
Patients are instructed to take the study treatment after all visit evaluations have been performed on 
scheduled visit days. Assessments performed at Visit 2 will be considered Baseline since the first dose 
combination therapy (ZOF/AML) occurs after the completion of Visit 2 assessments. For assessments 
performed at Visit 1 and not Visit 2 (e.g., laboratory and ECG assessments), the Visit 1 assessment will be 
considered Baseline. 
 
5.2.2 First Dose  
First dose is defined as the first administration of the extemporaneous combination of ZOF 30 mg and 
AML 5 mg that occurs on Visit 2 (Baseline). Monotherapies taken prior to Visit 2 should not be 
considered when defining first dose.  
 
5.2.3 Study Day 
Study Day of assessments or events is relative to first study drug dose date and is calculated as:  
 
(Date of assessment – date of first dose + 1) if date of assessment ≥ date of first dose. 
 
(Date of assessment – date of first dose) if date of assessment < date of first dose. 
 
5.2.4 Visit Windows 
It is expected that all visits should occur according to the protocol schedule. All visit data will be 
tabulated per the evaluation visit as recorded in the Electronic Case Report Form (eCRF), even if the 
assessment is outside of the visit window. Early termination visits will be presented in both summary 
tables and data listings, but unscheduled visits will be presented in the data listings only. 
 
5.3 Analysis Populations 
Agreement and authorization of patients included/excluded from each analysis population will be 
conducted prior to database lock of the study.  A data review meeting will be conducted prior to 
database lock and confirm the patients in each analysis set population. Impact of Covid-19 pandemic on 
the missed data, missed visits or dropouts will be assessed during this meeting and appropriate 
decisions on population counts will be taken. 
 
5.3.1 Full Analysis Set (FAS) 
The Full Analysis Set (FAS) includes all study participants who sign informed consent. 


 
Statistical Analysis Plan  
 
 
 
Confidential | MEIN/20/ZoAm-Hyp/001 | Plan Version No.: 2.0 | Plan Date: 23May2022  
Page 17 of 34 
 
 
5.3.2 Safety Population (SAF) 
The Safety Population (SAF) is defined as all study participants in the Full Analysis Set who meet all 
screening criteria, are enrolled, and receive at least one dose of the assigned treatment during the run-
in period. This population will be used for safety analyses.  
 
5.3.3 Efficacy Population (EFF) 
The Efficacy Population (EFF) is defined as all study participants in the Safety Population who complete 
the 4-week run-in period and meet continuation criteria at Visit 2 [uncontrolled BP (sitting SBP/DBP > 
130/80 mmHg), tolerate treatment, and fall within 80-120% treatment adherence] and have at least one 
available post baseline primary efficacy assessment (from Visit 3 or 4). This population will be used for 
efficacy analyses. 
 
5.3.4 Per Protocol Population (PP) 
The Per Protocol Population (PP) is defined as all study participants in the Efficacy Population who were 
dosed according to the protocol (80% - 120% adherence reported for each dosing visit), complete the 
required study visits (Visits 1, 2, 3, 4), and do not experience any major protocol deviations that may 
impact the primary efficacy assessment through end of treatment.  
 
Whether to include or exclude the patients from PP set will be finalized in the data review meeting prior 
to database lock. 
 
5.4 Covariates and Subgroups 
Exploratory endpoints 3.1, 3.2, and 3.4 will be analyzed on the following subgroups: 
 
Patients who were on ZOF 30 mg or AML 5 mg at Visit 1 (Week -4) and continued the same 
therapies. 
 
Patients who switched to ZOF 30 mg or AML 5 mg from any other ACE-i or CCBs at Visit 1 (Week 
-4). 
 
Exploratory endpoint 3.4 will also be analyzed on the following subgroups, such that each subgroup 
above will be further stratified by the subgroups below: 
 
Hypertension grade (Grade 1 or 2) reported at Visit 1  
o Reported in the eCRF at Visit 1 
 
Presence of diabetes and/or hypercholesterolemia at Visit 1 
o Reported as ongoing Medical History event at Visit 1 using MedDRA terms below 
 
Protocol Term 
MedDRA Preferred Term 
Diabetes 
Diabetes mellitus 
Hypercholesterolemia 
Hypercholesterolemia 
 
 
5.5 Reporting Conventions 
The following conventions will be used across all study summaries and analyses, unless otherwise 
specified in the corresponding section. 
 


 
Statistical Analysis Plan  
 
 
 
Confidential | MEIN/20/ZoAm-Hyp/001 | Plan Version No.: 2.0 | Plan Date: 23May2022  
Page 18 of 34 
 
 
Summary statistics will consist of sample size (n), mean, standard deviation (SD), median, 
minimum (min), and maximum (max) values for continuous and some ordinal variables; and 
sample size (n), frequencies, and percentages (%) for categorical and some ordinal variables. 
 
Statistical tests and confidence intervals (CI) will be two-sided unless otherwise specified; 
statistical tests will use an alpha threshold of 0.05 and CIs will use 95% confidence unless 
otherwise specified.  
 
Mixed Models for Repeated Measures (MMRM) will be fit using the unstructured covariance 
matrices. In the event of lack of model convergence, other covariance structures may be used. 
 
P-values will be calculated to three decimal places. P-values less than 0.001 will be presented as 
“< 0.001.” 
 
Unless otherwise specified, descriptive summary tables will be structured with a column for each 
monotherapy group (ZOF 30 mg or AML 5 mg) or combined treatment group (ZOF/AML 30/5 mg or 
ZOF/AML 30/10 mg) and overall (All Patients) and will include the total population size for each group in 
the header. Conversely, inferential summary tables will use only the All Patients column, unless 
otherwise specified, to prevent overinflation of the type I error rate.  
 
For descriptive summary tables, patients will be classified as either ZOF/AML 30/5 mg or ZOF/AML 
30/10 mg such that no patients are counted in both groups. That is, even though patients in the 
ZOF/AML 30/10 mg group are also exposed to the ZOF/AML 30/5 mg treatment, they will only be 
included in the ZOF/AML 30/10 mg and All Patients columns within the summary tables, and not within 
the ZOF/AML 30/5 mg column.   
 
Summary tables will also indicate the number of patients with complete data for each measurement, 
event, or outcome. 
 
Data listings will be sorted by treatment group, patient, and visit (when applicable). 
 
5.6 Missing Data 
 
5.6.1 Imputation of Blood Pressure Data 
Missing blood pressure values that occur after baseline will be imputed for the sensitivity analysis using 
Last Observation Carried Forward (LOCF). Any missing data for blood pressure at baseline will not be 
imputed. No other standard imputations of missing efficacy data will be applied.  
 
5.6.2 Imputation of Adverse Event Start Dates 
Partial start dates for Adverse Events (AEs) are imputed as detailed below in order to classify each AE as 
treatment-emergent, as defined in section 8.2.  
 
Start date:  
 
If start date is completely missing, start date is set to date of first dose.  
 
If (1) year is present and month and day are missing or (2) year and day are present and month 
is missing:  
o If year = year of first dose, then set month and day to month and day of first dose.  
o If year < year of first dose, then set month and day to December 31st. 
o If year > year of first dose, then set month and day to January 1st.  
 
If month and year are present and day is missing:  


 
Statistical Analysis Plan  
 
 
 
Confidential | MEIN/20/ZoAm-Hyp/001 | Plan Version No.: 2.0 | Plan Date: 23May2022  
Page 19 of 34 
 
o If year = year of first dose and  
 
If month = month of first dose, then set day to day of first dose date.  
 
If month < month of first dose, then set day to last day of month. 
 
If month > month of first dose, then set day to 1st day of month. 
o If year < year of first dose, then set day to last day of month.  
o If year > year of first dose, then set day to 1st day of month. 
 
5.6.3 Imputation of Prior/Concomitant Medication Start and Stop Dates 
Partial start and end dates for medications are imputed as detailed below in order to classify each 
medication as either prior or concomitant, as defined in section 6.5.  
 
Start date:  
 
If start date is completely missing, start date will be imputed with the informed consent date.  
 
If year is present and month and day are missing, set month and day to January 1.  
 
If year and day are present and month is missing, set month and day to January 1.  
 
If year and month are present and day is missing, set day to the 1st day of month.  
 
Stop date:  
 
If end date is completely missing, end date will not be imputed and medication will be assumed 
to be ongoing.  
 
If year is present and month and day are missing, set month and day to December 31st.  
 
If year and day are present and month is missing, set month and day to December 31st.  
 
If year and month are present and day is missing, set day to the last day of month.  
 
5.7 Interim Analyses and Data Monitoring 
There will be no interim analyses for this study.   
 
5.8 Multi-Center Studies 
Approximately 31 study centers will be used to enroll patients into this study. All sites will be pooled and 
analyzed collectively, except for the sensitivity analysis for the primary efficacy endpoint which is 
described in section 7.2.2 of this SAP.  
 
5.9 Multiple Testing 
The current study has a single primary efficacy endpoint. The secondary efficacy endpoints are derived 
from the primary objective and will be used to support the conclusion of the primary efficacy endpoint, 
provided that the primary efficacy endpoint is met. Thus, adjustments for multiple testing in the 
secondary efficacy endpoints will not be applied. 
 
6 Summary of Study Data 
 
6.1 Patient Disposition 
Patient disposition parameters including the number of patients screened, screen failures, enrolled, 
completed monotherapy period, completed combined treatment period, completed the study, 
discontinued the study, and reason for discontinuation will be summarized combined treatment group 
(ZOF/AML 30/5 mg or ZOF/AML 30/10 mg) and All Patients for the FAS population. 
 


 
Statistical Analysis Plan  
 
 
 
Confidential | MEIN/20/ZoAm-Hyp/001 | Plan Version No.: 2.0 | Plan Date: 23May2022  
Page 20 of 34 
 
A by-patient data listing of study completion information, entry criteria violations, and the reason for 
study discontinuation will be presented for the FAS population.   
 
6.2 Protocol Deviations 
A list of protocol deviations (PD) will be prepared for the final statistical analysis and protocol deviations 
will be classified as major or minor by the sponsor in coordination with the study statistician based on 
their potential impact on the data quality and integrity. Critical deviations will be classified as Major for 
purposes of defining the PP population. Major protocol deviations will be specified prior to database 
lock and will include protocol deviations that may impact the primary efficacy endpoint. 
 
All protocol deviations will be discussed and reviewed on a case-by-case basis before the DBL. All PDs 
authorized by Sponsor will be documented. 
 
Individual PDs will be presented in a by-patient data listing for the FAS population who have at least one 
deviation. The number and percentage of patients with PDs will be summarized by deviation on the FAS 
population. Additional Major and Minor PDs may be identified during data review and will be reflected 
in the Table and Listing as appropriate. 
 
All PDs will be recorded and classified in Clinical Trial Management System (CTMS). 
 
6.3 Demographic and Baseline Variables 
Demographic and baseline characteristics including study site, age, sex, race, ethnicity, height (cm), 
weight (kg), BMI (kg/m2), smoking status (including e-cigarette use), select medical history 
(hypertension grade 1 or 2, presence/absence of Diabetes, presence/absence of Hypercholesterolemia), 
and treatment at run-in will be summarized by combined treatment group (ZOF/AML 30/5 mg or 
ZOF/AML 30/10 mg) and All Patients for the SAF population. 
 
A by-patient data listing of demographic and baseline characteristics will also be presented for the SAF 
population.  
 
6.4 Medical History 
Medical History will be coded using the Medical Dictionary for Regulatory Activities (MedDRA) version 
24.1 or later. Medical history will be presented in a by-patient data listing for the SAF population and 
will include the System Organ Class (SOC) and Preferred Term (PT) for each medical condition.  
 
6.5 Prior and Concomitant Medications 
Prior and concomitant medications will be coded using the World Health Organization Drug Dictionary 
(WHO-DD) version Sep 2021 or later. Concomitant procedures will be coded using MedDRA version 24.1 
or later. 
 
Prior medication is defined as any medication taken within 30 days prior to the start of the study which 
has a stop date prior to the date of first dose of monotherapy (ZOF 30 mg or AML 5 mg). Concomitant 
medication is defined as any medication with a start date on or before the date of last dose of study 
drug and is ongoing or has a stop date on or after date of first dose of monotherapy (ZOF 30 mg or AML 
5 mg).  
 


 
Statistical Analysis Plan  
 
 
 
Confidential | MEIN/20/ZoAm-Hyp/001 | Plan Version No.: 2.0 | Plan Date: 23May2022  
Page 21 of 34 
 
Prior and concomitant medications will be summarized separately by Anatomic Therapeutic Class (ATC) 
Level 1 and Preferred Term by combined treatment group (ZOF/AML 30/5 mg or ZOF/AML 30/10 mg) 
and All Patients for the SAF population. That is, all patients in the SAF population who took at least one 
prior/concomitant medication will be summarized together in the All Patients column of the 
corresponding summary tables. All patients who take ZOF/AML 30/10 mg will be summarized in the 
ZOF/AML 30/10 mg column, even for medications they took in the monotherapy period or while taking 
the ZOF/AML 30/5 mg regimen. Lastly, all patients who take ZOF/AML 30/5 mg for the duration of the 
combined therapy period will be summarized in the ZOF/AML 30/5 mg column, even for medications 
they took in the monotherapy period. 
 
Patients taking the same medication multiple times will be counted once per medication. Prior and 
concomitant medications as well as concomitant procedures will be presented in by-patient data listings 
for the SAF population. 
 
7 Efficacy Analyses 
All efficacy analyses will be performed on the Efficacy population (EFF) unless otherwise specified.  
Monotherapy: visit 2 (week 0) efficacy analysis (number and proportion of patients achieving the BP goal 
(sitting BP≤130/80 mmHg) at Visit 2) will be performed on the Full Analysis Set (FAS population). 
Results will be presented as described in section 5.5. In addition to the inferential analyses discussed in 
the subsections below, descriptive analyses will be performed to summarize the observed and change 
from baseline values for mean sitting SBP and DBP for all study visits. All blood pressure parameters will 
also be presented in a by-patient data listing for the safety (SAF) population.  
 
7.1 Efficacy Variable Derivations 
 
7.1.1 Blood Pressure (BP) Goal (Controlled v Uncontrolled) 
Multiple endpoints (2.3, 3.3, and 3.4) involve patients meeting the BP goal of sitting BP ≤ 130/80 mmHg 
at Visit 2 (Week 0), Visit 3 (Week 4) and Visit 4 (Week 8).  
 
A patient will be considered to have met the BP goal (controlled BP) if their SBP ≤ 130 mmHg AND their 
DBP ≤ 80 mmHg. If a patient meets one of these criteria but not the other, then they will not be 
considered to have met the BP goal. That is, a patient’s BP is considered uncontrolled if their SBP > 130 
mmHg OR their DBP > 80 mmHg.   
 
7.2 Primary Efficacy Analyses (Endpoint 1.1) 
 
7.2.1 Primary Analysis 
Endpoint 1.1: Change in mean sitting DBP between Visit 2 (Week 0) and Visit 4 (Week 8). 
 
Endpoint 1.1 will be analyzed using a paired t-test with a type I error rate of 0.05 to test the null 
hypothesis that the mean change in DBP is 0 mmHg against a two-sided alternative.  
 
The observed values for sitting DBP will be summarized at Baseline (Visit 2) and Visit 4. The change from 
Baseline to Visit 4 values will be assessed using the paired t-test as described above and will present the 
mean, SD, min, max, critical t-value, degrees of freedom (df), 95% confidence internal (CI) and p-value. If 
resulting p-value ≤ 0.05, the null hypothesis will be rejected, and we will conclude that the mean sitting 
DBP at Visit 4 is significantly different from that at Baseline. Conversely, if p-value > 0.05, then we will 


 
Statistical Analysis Plan  
 
 
 
Confidential | MEIN/20/ZoAm-Hyp/001 | Plan Version No.: 2.0 | Plan Date: 23May2022  
Page 22 of 34 
 
fail to reject the null hypothesis and we cannot conclude a significant difference between mean sitting 
DBP at Baseline and Visit 4. 
 
7.2.2 Sensitivity Analyses 
A sensitivity analysis for the primary endpoint (1.1) will be conducted by replicating the primary 
endpoint analysis under each of the following: 
1. Per-protocol population (PP) 
2. Imputation of missing data using last-observation-carried-forward (LOCF) 
o As described in section 5.6.1 of this SAP 
3. Analysis stratified by study site 
o Approximately 31 sites will be used to enroll patients 
o Sensitivity analysis will be performed on each individual site  
4. Analysis stratified by gender 
o Male 
o Female 
5. Analysis stratified by age group  
o 18-45 years 
o 46-65 years 
 
7.3 Secondary Efficacy Analyses 
The secondary efficacy endpoints are derived from the primary objective and will be used to 
support the conclusion of the primary efficacy endpoint, provided that the primary efficacy 
endpoint is met.  
 
All continuous efficacy variables will be summarized for all study visits using descriptive statistics for both 
actual values and change-from-baseline values. The Efficacy population will be used to analyse the 
secondary endpoints.   
 
7.3.1 Mean Change (Endpoints 2.1 and 2.2) 
 
Endpoint 2.1: Change in mean sitting SBP between Visit 2 (Week 0) and Visit 4 (Week 8).  
 
Endpoint 2.1 will be analyzed using a paired t-test with a type I error rate of 0.05 to test the null 
hypothesis that the mean change in SBP is 0 mmHg from Visit 2 to Visit 4 against a two-sided alternative. 
 
Endpoint 2.2: Change in mean sitting DBP and SBP between Visit 3 (Week 4) and Visit 4 (Week 8) in 
patients uncontrolled at Visit 3 and up titrated to the extemporaneous combination of ZOF/AML 30/10 
mg. 
 
Endpoint 2.2 will be analyzed using paired t-test for DBP and SBP with a type I error rate of 0.05 to test 
the null hypotheses of 0 mmHg mean change from Visit 3 to Visit 4 against a two-sided alternative. 
 
7.3.2 Proportion of Patients (Endpoints 2.3 and 2.4) 
 
Endpoint 2.3: Monotherapy: Number and proportion of patients achieving the BP goal (sitting 
BP≤130/80 mmHg) at Visit 2 (Week 0).  Combination therapy: number and proportion of patients 
achieving the BP goal (sitting BP≤130/80 mmHg) at Visit 3 (Week 4) and Visit 4 (Week 8). 


 
Statistical Analysis Plan  
 
 
 
Confidential | MEIN/20/ZoAm-Hyp/001 | Plan Version No.: 2.0 | Plan Date: 23May2022  
Page 23 of 34 
 
 
Endpoint 2.4: Adherence to the treatments (% of doses taken/doses to be taken) at Visit 2 (Week 0), 
Visit 3 (Week 4) and Visit 4 (Week 8). 
 
Endpoints 2.3 and 2.4 will be analyzed using a 95% binomial confidence interval (CI) for each visit. 
 
A patient who has taken at least 80% and no more than 120% of the required study medication since the 
last visit will be considered as compliant. Treatment adherence will be summarized incrementally rather 
than cumulatively so that changes in adherence over time can be accurately reflected. That is, a patient 
can be compliant between Visits 2 and 3, but non-compliant between Visits 3 and 4, or vice versa.  
 
7.4 Exploratory Efficacy Analyses 
 
Each of the exploratory efficacy analyses described in the subsections below will be performed on the 
following treatment subgroups: 
 
Test Group: Patients who were on ZOF 30 mg or AML 5 mg at Visit 1 (Week -4) and continued the same 
therapies.  
 
Comparison Group: Patients who switched to ZOF 30 mg or AML 5 mg from any other ACE-i or CCBs at 
Visit 1 (Week -4). 
 
7.4.1 Mean Change (Endpoints 3.1 and 3.2) 
 
Endpoint 3.1: Change in mean sitting SBP and DBP between Visit 1 (Week -4) and Visit 2 (Week 0), Visit 3 
(Week 4) and Visit 4 (Week 8). 
 
Endpoint 3.2: Change in mean sitting SBP and DBP for uncontrolled patients at Visit 3 (Week 4), 
between Visit 2 (Week 0) and Visit 3 (Week 4). 
 
Endpoints 3.1 and 3.2 will be analyzed using mixed models for repeated measured (MMRM) to assess 
the mean change in SBP and DBP. The models will be built as follows: 
 
 
Endpoint 3.1  
o Response = change from screening BP 
o Covariates = treatment subgroup, study visit, treatment subgroup-by-visit interaction, 
screening BP values 
o Random effect = patient 
o Covariance matrix = unstructured  
 
In the event of lack of model convergence, other covariance structures may be 
used.  
 
If all MMRM fail to converge, this endpoint will be analyzed as described in 
section 7.4.1.1 below. 
 
 
Endpoint 3.2 
o Response = change from baseline BP 


 
Statistical Analysis Plan  
 
 
 
Confidential | MEIN/20/ZoAm-Hyp/001 | Plan Version No.: 2.0 | Plan Date: 23May2022  
Page 24 of 34 
 
o Covariates = treatment subgroup, study visit, treatment subgroup-by-visit interaction, 
baseline BP values 
o Random effect = patient 
o Covariance matrix = unstructured  
 
In the event of lack of model convergence, other covariance structures may be 
used.  
 
If all MMRM fail to converge, this endpoint will be analyzed as described in 
section 7.4.1.1 below. 
 
Least-squares (LS) means, standard error (SE), and 95% CIs for mean change from screening/baseline for 
BP will be presented by visit and treatment subgroup. The LS-means difference, SE, 95% CI, and two-
sided p-value for the difference between treatment subgroups in mean change from screening/baseline 
for sitting SBP and DBP will be presented where a p-value of ≤ 0.05 indicates a significant difference 
between groups.  
 
7.4.1.1 
Model Nonconvergence  
 
If the above MMRMs fail to converge, endpoints 3.1 and 3.2 will be analyzed using independent sample 
t-tests to compare the mean change in BP in the test group to the comparison group (test/comparison 
groups defined in section 7.4).  
 
7.4.2 Proportion of Patients (Endpoints 3.3 and 3.4) 
 
Endpoint 3.3: Monotherapy: number and proportion of patients achieving the BP goal (sitting BP 
≤130/80 mmHg) at Visit 2 (Week 0).  Combination therapy: number and proportion of patients achieving 
the BP goal (sitting BP ≤130/80 mmHg) at Visit 3 (Week 4). 
 
Endpoint 3.4: Monotherapy: number and proportion of patients divided in subgroup by the 
hypertension grade, the presence of diabetes and/or of hypercholesterolemia achieving the BP goal 
(sitting BP ≤130/80 mmHg) at Visit 2 (Week 0). Combination therapy: number and proportion of patients 
divided in subgroup by the hypertension grade, the presence of diabetes and/or of 
hypercholesterolemia achieving the BP goal (sitting BP ≤130/80 mmHg) at Visit 3 (Week 4) and Visit 4 
(Week 8). 
 
Endpoints 3.3 and 3.4 will be analyzed using a logistic MMRM to assess the proportion of patients 
achieving the BP goal (sitting BP ≤130/80 mmHg). The models will be built as follows: 
 
 
Endpoint 3.3 
o Response = achieving BP goal (sitting BP ≤130/80 mmHg)  
o Covariates = treatment subgroup, study visit, treatment subgroup-by-visit interaction, 
baseline BP values 
o Random effect = patient 
o Covariance matrix = unstructured  
 
In the event of lack of model convergence, other covariance structures may be 
used.  
 
If all logistic MMRM fail to converge, this endpoint will be analyzed as described 
in section 7.4.2.1 below. 
 


 
Statistical Analysis Plan  
 
 
 
Confidential | MEIN/20/ZoAm-Hyp/001 | Plan Version No.: 2.0 | Plan Date: 23May2022  
Page 25 of 34 
 
 
Endpoint 3.4 by hypertension grade 
o Response = achieving BP goal (sitting BP ≤130/80 mmHg)  
o Covariates = treatment subgroup, study visit, treatment subgroup-by-visit interaction, 
baseline BP values 
o Random effect = patient 
o Covariance matrix = unstructured  
 
In the event of lack of model convergence, other covariance structures may be 
used.  
 
If all logistic MMRM fail to converge, this endpoint will be analyzed as described 
in section 7.4.2.1 below. 
o Stratification factor = Baseline hypertension grade 
 
 
Endpoint 3.4 by presence of diabetes and/or of hypercholesterolemia 
o Response = achieving BP goal (sitting BP ≤130/80 mmHg)  
o Covariates = treatment subgroup, study visit, treatment subgroup-by-visit interaction, 
baseline BP values 
o Random effect = patient 
o Covariance matrix = unstructured  
 
In the event of lack of model convergence, other covariance structures may be 
used.  
 
If all logistic MMRM fail to converge, this endpoint will be analyzed as described 
in section 7.4.2.1 below. 
o Stratification factor = presence of diabetes and/or of hypercholesterolemia at baseline 
 
The number (n), proportion (%), and 95% CI of the proportion of patients achieving controlled BP will be 
presented by visit and treatment subgroup. The odds ratio (OR), 95% CI of the OR, and two-sided p-
value for the difference between treatment subgroups in proportion of patients achieving controlled BP 
will be presented where a p-value of ≤ 0.05 indicates a significant difference between groups.  
 
7.4.2.1 
Model Nonconvergence  
 
If the above logistic MMRMs fail to converge, endpoints 3.3 and 3.4 will be analyzed using a 95% 
binomial confidence interval (CI) and Odds Ratio (OR) for each visit to assess the proportion of patients, 
by subgroup, who achieve the BP goal. Subgroups will include those described in section 7.4, as well as 
subgroups for hypertension grade and the presence of diabetes and/or hypercholesterolemia. 
 
8 Safety Analyses (Endpoint 2.5) 
Endpoint 2.5: Safety and tolerability of the monotherapies (ZOF 30 mg and AML 5 mg) after 4 weeks of 
therapy and of the extemporaneous combination (ZOF 30 mg and AML 5 mg or AML 10 mg) after eight 
weeks of treatment. 
 
The variables for endpoint 2.5 are laboratory tests, physical examination, vital signs, 12-lead ECG, and 
incidence of AEs/SAEs, each of which are discussed in the subsections below.  
 
Safety analyses will be performed on the SAF population. Results will be presented as described in 
section 5.5 unless otherwise specified. 
 
 


 
Statistical Analysis Plan  
 
 
 
Confidential | MEIN/20/ZoAm-Hyp/001 | Plan Version No.: 2.0 | Plan Date: 23May2022  
Page 26 of 34 
 
8.1 Study Drug Accountability, Exposure, and Adherence 
 
8.1.1 Study Medications  
Study Medication 
Dose 
Frequency 
Box Details 
Zofenopril calcium (ZOF)  
30 mg 
Once daily  
42 tablets (3 blisters of 14 tablets each) 
Amlodipine (AML)  
5 mg 
Once daily  
42 tablets (3 blisters of 14 tablets each) 
Amlodipine (AML)  
10 mg 
Once daily  
42 tablets (3 blisters of 14 tablets each) 
 
8.1.2 Treatment Exposure by Visit  
At Visit 1 (Week -4), patients on current treatment with AML 5 mg or approved CCBs (see section 4.2 for 
list of approved CCBs) are provided with 1 box of AML 5 mg for the 4-week run-in period. Patients on 
current treatment with ZOF 30 mg or other ACE-i are provided with 1 box of ZOF 30 mg for the 4-week 
run-in period.  
 
At Visit 2 (Week 0), patients with uncontrolled BP (> 130/80 mmHg) will be provided with 1 box of ZOF 
30 and 1 box of AML 5 mg while the following patients will be withdrawn from the study: 
 
Controlled BP (≤ 130/80 mmHg) 
 
Grade 3 Hypertension (SBP ≥ 180 mmHg or DBP ≥ 110 mmHg) 
 
Does not tolerate the treatment 
 
Treatment adherence below 80% or above 120%  
 
At Visit 3 (Week 4), patients with controlled BP (≤ 130/80 mmHg) will continue with ZOF 30 and AML 5 
mg (receiving 1 box of each), patients with uncontrolled BP (> 130/80 mmHg) will be up-titrated to ZOF 
30 and AML 10 mg (receiving 1 box of each), and the following patients will be withdrawn from the 
study: 
 
Grade 3 Hypertension (SBP ≥ 180 mmHg or DBP ≥ 110 mmHg) 
 
Does not tolerate the treatment 
 
Treatment adherence below 80% or above 120%  
 
At Visit 4 (Week 8), the anti-hypertensive effect of the extemporaneous combination (ZOF/AML 30/5 mg 
and ZOF/AML 30/10 mg) will be evaluated. 
 
8.1.3 Drug Accountability 
The number of tablets dispensed and returned for each study medication at each visit is recorded in the 
eCRF and are expected to occur in the amounts detailed below.  
 
Visit 1  
 
Dispensation:  
o 42 tablets of ZOF 30 mg, or 
o 42 tablets of AML 5 mg 
 
Return: 
o Not applicable 
Visit 2 
 
Dispensation:  
o 42 tablets of ZOF 30 mg and 42 tablets of AML 5 mg 
 
Return: 


 
Statistical Analysis Plan  
 
 
 
Confidential | MEIN/20/ZoAm-Hyp/001 | Plan Version No.: 2.0 | Plan Date: 23May2022  
Page 27 of 34 
 
o 14±2 tablets of ZOF 30 mg, or  
o 14±2 tablets of AML 5mg 
Visit 3 
 
Dispensation:  
o 42 tablets of ZOF 30 mg and 42 tablets of AML 5mg, or 
o 42 tablets of ZOF 30 mg and 42 tablets of AML 10 mg 
 
Return: 
o 14±2 tablets of ZOF 30 mg and 14±2 tablets of AML 5 mg 
Visit 4 
 
Dispensation:  
o Not applicable 
 
Return: 
o 14±2 tablets of ZOF 30 mg and 14±2 tablets of AML 5mg, or 
o 14±2 tablets of ZOF 30 mg and 14±2 tablets of AML 10 mg 
 
The average amount of study medication dispensed and returned will be summarized by medication 
type and study visit for the SAF Population. All study drug accountability and exposure details, including 
modified, missed, and interrupted doses, will also presented in by-patient data listings for the SAF 
population. 
 
8.1.4 Treatment Adherence  
Investigators should instruct the patient to take the study drug at the same time every day, in the 
morning. On the days of the patient’s visits, the investigator should instruct the patient to not take the 
study drug at home. 
 
Treatment adherence (eCRF and derived) will be summarized by medication type and study visit for the 
SAF Population. Adherence details will also be presented in a by-patient data listing for the SAF 
Population. 
 
8.1.4.1 
eCRF-Reported Adherence 
Adherence to treatment will be measured through treatment compliance which is 100*(actual doses 
taken/planned dose) and will be reported in the eCRF at each visit. A patient who has taken at least 80% 
and no more than 120% of the required study medication intake since the last visit will be considered as 
compliant.  
 
8.1.4.2 
Derived Adherence  
To ensure accuracy of adherence reported in the eCRF, adherence will also be derived directly for each 
patient at Visits 2, 3, and 4 as outlined below. 
 
Treatment adherence = 100*(actual dose/planned dose) 
 
Actual dose = tablets dispensed at previous visit – tablets returned at current visit.  
 
If a subject fails to return IP, then we assume that all IP was used and return amount will 
be imputed as 0 tablets. This errs on the side of safety, ensuring that subject data is 
included in the safety analyses and that AEs are classified as treatment-emergent if they 
occur after dispensation of IP. 
 


 
Statistical Analysis Plan  
 
 
 
Confidential | MEIN/20/ZoAm-Hyp/001 | Plan Version No.: 2.0 | Plan Date: 23May2022  
Page 28 of 34 
 
Planned dose is 1 dose per day, for the number of days between: 
 
V1 to V2-1 (monotherapy period – approx. 28 days) 
o 1 dose = 1 tablet  
 
V2 to V3-1 (combined period 30/5 – approx. 28 days) 
o 1 dose = 1 tablet of each assigned therapy (2 tablets total per dose) 
 
V3 to V4-1 (combined period 30/5 or 30/10 – approx. 28 days) 
o 1 dose = 1 tablet of each assigned therapy (2 tablets total per dose) 
 
For monotherapy period, adherence will be derived for each individual medication.  
 
For combined therapy periods, adherence will be derived for each individual medication and then those 
individual adherence values will be averaged to get an overall adherence %. 
 
Example 1:  
If a patient has 28 days between V1 to V2-1, and takes 29 ZOF, then adherence is 
 
ZOF = 100*(29/28) = 103.57 
 
 
 
Example 2: 
If patient has 34 days between V3 to V4-1 and takes 34 ZOF but only 30 AML, then adherence is 
 
ZOF = 100*(34/34) = 100  
 
 
 
AML = 100*(30/34) = 88.24 
 
 
 
Total = (100+88.24) / 2 = 94.12   
 
 
Example 3: 
If patient has 14 days between V2 to V3-1 and takes 10 ZOF and 16 AML, then adherence is  
 
ZOF = 100*(10/14) = 71.43 
 
 
 
AML = 100*(16/14) = 114.29 
 
 
 
Total = (71.43+114.29) / 2 = 92.86 
 
 
8.2 Adverse Events, Adverse Drug Reactions, and Deaths 
Adverse Events (AEs) are any untoward medical occurrence in a clinical trial patient administered a 
medicinal product and which does not necessarily have a causal relationship with this treatment.  
 
Treatment Emergent AEs (TEAEs) are defined as AEs that occur only once treatment has started (after 
the first dose of monotherapy of ZOF or AML). Thus, all AEs that occur in both the monotherapy and 
combined therapy periods will be considered treatment-emergent.   
 
Adverse Drug Reactions (ADRs) are defined as AEs that have a relationship of “certain,” “probable,” 
“possible,” or “unassessable.”  
 
All AEs will be coded using the Medical Dictionary for Regulatory Activities (MedDRA) version 24.1 or 
later.  
 
The following tabulations will be produced for the monotherapy period and the combination therapy 
periods for the SAF population: 
 
Monotherapy Period (Day of Visit 1 through day before Day of Visit 2) 
o All treatment-emergent AEs (TEAEs)  


 
Statistical Analysis Plan  
 
 
 
Confidential | MEIN/20/ZoAm-Hyp/001 | Plan Version No.: 2.0 | Plan Date: 23May2022  
Page 29 of 34 
 
o Severe TEAEs 
o Adverse Drug Reactions (ADRs)  
o TEAEs leading to study discontinuation 
o Serious TEAEs (TESAEs) 
o Serious ADRs  
o TESAEs with outcome of death 
 
Combination Therapy Period (Day of Visit 2 through Day of Visit 4) 
o All treatment-emergent AEs (TEAEs) 
o Severe TEAEs 
o Adverse Drug Reactions (ADRs)  
o TEAEs leading to study discontinuation 
o Serious TEAEs (TESAEs) 
o Serious ADRs  
o TESAEs with outcome of death 
 
Key guidelines for counting incidence proportions of AEs/TEAEs/ADRs (collectively referred to as AEs for 
the remainder of this section) are as follows: 
 
When a patient has the same AE reported multiple times during an analysis period based on 
MedDRA terminology (SOC or PT), the patient will only be counted once within a level of 
MedDRA in an AE incidence table. 
 
When assessing investigator reported relationship to study drug of the AEs, if an AE reported 
multiple times changes in causal relationship during an analysis period for a patient, the event 
with highest relatedness will be presented. Related AEs (i.e., ADRs) will include those reported 
as “certain,” “probable,” “possible,” or “unassessable” by the investigator. 
 
When summarizing severity of the AEs (mild, moderate, severe), if there are multiple AEs of the 
same preferred term but different severity during an analysis period for a patient, the AE with 
the maximum severity will be reported. If the AE term (SOC and PT) is reported more than once, 
one of them with missing severity, and at least another with non-missing severity, the maximum 
severity will be chosen from the non-missing severity and the missing severity can be ignored. If 
all are of missing severity, then the AE severity will be summarized with an additional “Missing” 
category. In summary of severe AEs, missing severity will be included in severe category 
following the conservative approach. 
 
All AE tabulations for the monotherapy period will present the incidences separately for the 
monotherapy groups (ZOF 30 mg or AML 5 mg) and All Patients for the SAF population. That is, all 
patients who experienced at least one AE in the monotherapy period will be summarized together in the 
All Patients column of the corresponding summary tables. All patients who take ZOF 30 mg will be 
summarized in the ZOF 30 mg column and all patients who take AML 5 mg will be summarized in the 
AML 5 mg column. 
 
All AE tabulations for the combined therapy period will present the incidences separately for the 
combined treatment groups (ZOF/AML 30/5 mg or ZOF/AML 30/10 mg) and All Patients for the SAF 
population. That is, all patients who experienced at least one AE in the combined therapy period will be 
summarized together in the All Patients column of the corresponding summary tables. All patients who 
take ZOF/AML 30/10 mg will be summarized in the ZOF/AML 30/10 mg column, even for AEs that 
occurred while taking the ZOF/AML 30/5 regimen. Lastly, all patients who take ZOF/AML 30/5 mg for the 
duration of the combined therapy period will be summarized in the ZOF/AML 5 mg column.  
 


 
Statistical Analysis Plan  
 
 
 
Confidential | MEIN/20/ZoAm-Hyp/001 | Plan Version No.: 2.0 | Plan Date: 23May2022  
Page 30 of 34 
 
In summaries by SOC and PT (for both monotherapy and combined therapy periods), AEs will be sorted 
by descending frequency for SOC and PT in the All Patients column. All AEs will also be presented in by-
patient data listings for Adverse Events for the SAF population. 
 
8.3 Clinical Laboratory Evaluations 
For laboratory safety continuous variables, values recorded as “<X” or “≤X” or “>Y” or “≥Y” will be 
imputed by “X” and “Y” respectively for descriptive statistics. This will be documented in a footnote in all 
output where such a replacement was performed. Continuous clinical laboratory observed values and 
change from Baseline (Visit 1) to Visit 4 will be summarized by combined therapy group (ZOF/AML 30/5 
mg or ZOF/AML 30/10 mg) and overall for the SAF population. 
 
Each laboratory result will be classified as Normal, Abnormal Not Clinically Significant (NCS), or 
Abnormal Clinically Significant (CS) at each visit. Shift tables from Baseline (Visit 1) to Visit 4 will be 
provided for each laboratory parameter, summarized by combined therapy group (ZOF/AML 30/5 mg or 
ZOF/AML 30/10 mg) and overall for the SAF population. If a patient has a missing lab parameter value at 
Visit 1 or Visit 4, that patient will be excluded from the shift analysis for that lab parameter but will be 
included in the corresponding by-patient data listing.  
 
All laboratory parameters will also be presented in by-patient data listings for the SAF population.  
 


 
Statistical Analysis Plan  
 
 
 
Confidential | MEIN/20/ZoAm-Hyp/001 | Plan Version No.: 2.0 | Plan Date: 23May2022  
Page 31 of 34 
 
Test 
Visit 
Laboratory Parameters to be Analyzed 
Haematology 
Screening (Visit 1) and Visit 4 
Red blood cell 
White blood cell 
Haemoglobin 
Haematocrit 
Platelets 
Neutrophils 
Lymphocytes 
Monocytes 
Eosinophils 
Basophils 
Neutrophils absolute 
Lymphocytes absolute 
Monocytes absolute 
Eosinophils absolute 
Basophils absolute 
Serum Chemistry 
Screening (Visit 1) and Visit 4 
ALT 
Albumin 
Alkaline phosphatase 
AST 
Direct bilirubin 
Total bilirubin 
Total protein 
Creatinine 
Blood urea nitrogen 
Creatine kinase 
GGT 
Triglycerides 
Cholesterol 
High- and low-density lipoprotein 
Chloride 
eGFR 
Blood glucose 
Potassium 
Uric acid 
 
8.4 Vital Signs 
Vital signs are collected at each study visit and include the following parameters: Systolic Blood Pressure 
(SBP), Diastolic Blood Pressure (DBP), Heart Rate (HR), and Temperature (temp). Vital sign parameters 
will be analyzed for the SAF population as follows: 
 
Monotherapy analysis: observed values and change from Screening (Visit 1) to Baseline (Visit 2) will be 
summarized for each monotherapy group (ZOF 30 mg and AML 5 mg) and for All Patients. 
 
Combined therapy analysis: observed values and change from Baseline (Visit 2) to scheduled post-
baseline visits (Visits 3 and 4) will be summarized for each combined therapy group (ZOF/AML 30/5 mg 
or ZOF/AML 30/10 mg) and for All Patients.  
 
All vital sign parameters will also be presented in a by-patient data listing for the SAF population.  
 


 
Statistical Analysis Plan  
 
 
 
Confidential | MEIN/20/ZoAm-Hyp/001 | Plan Version No.: 2.0 | Plan Date: 23May2022  
Page 32 of 34 
 
8.5 Physical Examination 
Physical examination results for each body system will be classified as Normal or Abnormal (CS or NCS) 
at each visit and will be analyzed as follows:  
 
Monotherapy analysis: shift from Screening (Visit 1) to Baseline (Visit 2) will be summarized (count and 
percentage) for each monotherapy group (ZOF 30 mg and AML 5 mg) and for All Patients. 
 
Combined therapy analysis: shift from Baseline (Visit 2) to scheduled post-baseline visits (Visits 3 and 4) 
will be summarized (count and percentage) for each combined therapy group (ZOF/AML 30/5 mg or 
ZOF/AML 30/10 mg) and for All Patients.  
 
All physical examination details will also be presented in a by-patient data listing for the SAF population.  
 
8.6 Electrocardiogram (ECG) 
Electrocardiograms (ECGs) are performed in triplicate at Screening (Visit 1) and Visit 4 and include the 
following parameters: Ventricular Rate (VR), PR Interval, RR Interval, QRS Interval, QT Interval, QTcF, 
QTcB, Rhythm, and Interpretation. 
 
8.6.1 ECG Variable Derivations 
For continuous ECG parameters, the mean of all 3 measurements will be presented in the summary 
tables. For categorical ECG parameters, the most frequently occurring response across all 3 
measurements will be presented in the summary tables. If the Interpretation results in a unique 
response at each of the 3 measurements, then the most severe (Abnormal, Clinically Significant) will be 
presented in the summary tables. 
 
8.6.2 ECG Variable Analyses 
Continuous ECG observed values and change from Baseline (Visit 1) to Visit 4, as well as the number and 
% of patients in each Rhythm category (Sinusal or Other), will be summarized by combined therapy 
group (ZOF/AML 30/5 mg or ZOF/AML 30/10 mg) and overall for the SAF population. 
 
ECG Interpretations will be classified as Normal, Abnormal Not Clinically Significant (NCS), or Abnormal 
Clinically Significant (CS) at each visit. Shift tables from Baseline (Visit 1) to Visit 4 will be provided the 
EDC Interpretations, summarized by combined therapy group (ZOF/AML 30/5 mg or ZOF/AML 30/10 
mg) and overall for the SAF population. If a patient has a missing ECG Interpretation at Visit 1 or Visit 4, 
that patient will be excluded from the shift analysis but will be included in the corresponding by-patient 
data listing.  
 
All ECG parameters, including individual results from all 3 measurements at each visit, as well as the final 
result used in the summary tables, will be presented in a by-patient data listing for the SAF population.  
 
8.7 Pregnancies 
A urine pregnancy test will be performed in all females of childbearing potential at each study visit. Any 
pregnancy resulting in an abnormal outcome will be reported as an SAE in the eCRF. All pregnancy test 
details, including reason not performed, will be presented in a by-patient data listing for the SAF 
population.   
 


 
Statistical Analysis Plan  
 
 
 
Confidential | MEIN/20/ZoAm-Hyp/001 | Plan Version No.: 2.0 | Plan Date: 23May2022  
Page 33 of 34 
 
9 Technical Details 
All analyses described in this SAP will be generated using SAS version 9.4 or higher, unless otherwise 
specified and includes the following packages: Base SAS, SAS/STAT, SAS/GRAPH, SAS/Secure 168-bit, 
SAS/Secure Windows, SAS Enterprise Guide, SAS/ACCESS Interface to PC Files, SAS Workspace 
Server for Local Access, and High Performance Suite.  
 
10 Summary of Changes to the Protocol 
 
10.1 Analysis Populations 
The Full Analysis Set (FAS) population was added to the SAP for its use to generate tables and listings 
related to enrollment and disposition. 
 
The definition of the Efficacy Population (EFF) was slightly modified to include the enrollment 
continuation requirements at Visit 2 (uncontrolled BP, tolerate treatment, and 80-120% treatment 
adherence). 
 
10.2 Exploratory Efficacy Analyses 
Although not explicitly stated in the protocol, exploratory efficacy endpoint 3.2 [Change in mean sitting 
SBP and DBP for uncontrolled patients at Visit 3 (Week 4), between Visit 2 (Week 0) and Visit 3 (Week 
4)] will be performed on the treatment subgroups described in section 7.4. 
 
11 Listing of Tables, Listings, and Figures 
Please reference document “MEIN-20-ZoAm-Hyp-001 TLF Shells v2.0 16May2022.pdf” for the complete 
list of all tables, listings, and figures (TLFs) as well as corresponding mock shells. Minor changes made to 
the layout or formatting of the TLFs after SAP finalization will not necessitate a modification to the SAP.  
 
 
 


 
Statistical Analysis Plan  
 
 
 
Confidential | MEIN/20/ZoAm-Hyp/001 | Plan Version No.: 2.0 | Plan Date: 23May2022  
Page 34 of 34 
 
12 References 
1. Mensah GA, Bakris G. Treatment and control of high blood pressure in adults. Cardiol Clin. 
2010;28:609–22 
 
2. Borghi C, Omboni S, Reggiardo G, et al. Efficacy of zofenopril in combination with 
amlodipine in patients with acute myocardial infarction: a pooled individual patient data 
analysis of four randomized, double-blind, controlled, prospective studies. Curr Med Res 
Opin. 2018;34(10):1869-1874. 
  
 


               
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Protocol Number : 
MEIN/20/ZoAm-Hyp/001 
 
Protocol Version : 
1.0 
 
Protocol Date 
:  
23 April 2021 
 
 
Plan Version 
: 
2.0 
 
Plan Date  
: 
23 May 2022 
 
 
Study Drug 
: 
Extemporaneous combination of Zofenopril (ZOF) 30 mg with  
Amlodipine (AML) 5 mg or Amlodipine (AML) 10 mg 
 
Indication  
: 
Grade 1-2 Hypertension 
 
Mock TLF Shells 
Interventional clinical trial to assess efficacy and safety of the 
extemporaneous combination of zofenopril calcium and amlodipine in 
grade 1-2 hypertensive patients versus each monotherapy – (MASOLINO 
Study) 


 
Statistical Analysis Plan  
 
 
Confidential | MEIN/20/ZoAm-Hyp/001 | Plan Version No.: 2.0 | Plan Date: 23May2022 
Page 1 of 64 
 
Table of Contents 
 
1 
List of Tables and Listings ...................................................................................................................... 2 
Tables ........................................................................................................................................................ 2 
1.1.1 
Demographic Data  ............................................................................................................... 2 
1.1.2 
Efficacy .................................................................................................................................. 2 
1.1.3 
Safety .................................................................................................................................... 4 
Listings....................................................................................................................................................... 7 
2 
Mock TLF Shells ..................................................................................................................................... 8 
Tables ........................................................................................................................................................ 8 
2.1.1 
Demographic Data ................................................................................................................ 8 
2.1.2 
Efficacy ................................................................................................................................ 15 
2.1.3 
Safety .................................................................................................................................. 29 
Listings..................................................................................................................................................... 44 
 


 
Statistical Analysis Plan  
 
 
Confidential | MEIN/20/ZoAm-Hyp/001 | Plan Version No.: 2.0 | Plan Date: 23May2022 
Page 2 of 64 
 
1 List of Tables and Listings 
Tables 
1.1.1 Demographic Data  
 
Number 
Title 
Population 
Unique/ 
Repeat 
Supporting 
Listing 
14.1.1 
Patient Enrollment and Disposition 
Full Analysis 
Set 
Unique 
16.2.1 
14.1.2 
Analysis Populations and Exclusions 
Full Analysis 
Set 
Unique 
16.2.3 
14.1.3 
Summary of Demographic and Baseline 
Characteristics 
Safety 
Unique 
16.2.4.1, 
16.2.4.2 
14.1.4 
Summary of Protocol Deviations 
Full Analysis 
Set 
Unique 
16.2.2 
 
1.1.2 Efficacy 
 
Number 
Title 
Population 
Unique/ 
Repeat 
Supporting 
Listing 
Endpoint 
Descriptive Summary Analyses 
14.2.1.1 
Summary and Change from Baseline 
for Mean Sitting Diastolic Blood 
Pressure (DBP) by Visit  
EFF 
Unique 
16.2.6 
Descriptive 
Summary 
14.2.1.2 
Summary and Change from Baseline 
for Mean Sitting Systolic Blood 
Pressure (SBP) by Visit  
EFF 
Repeat 
16.2.6 
Descriptive 
Summary 
14.2.1.3 
Summary and Change from Baseline 
for Mean Sitting Diastolic Blood 
Pressure (DBP) by Visit  
PP 
Repeat 
16.2.6 
Descriptive 
Summary 
14.2.1.4 
Summary and Change from Baseline 
for Mean Sitting Systolic Blood 
Pressure (SBP) by Visit  
PP 
Repeat 
16.2.6 
Descriptive 
Summary 
Endpoint Analyses 
14.2.2.1 
Summary of Change in Mean Sitting 
Diastolic Blood Pressure (DBP) from 
Visit 2 to Visit 4  
EFF 
Unique 
16.2.6 
1.1 
14.2.2.2 
Summary of Change in Mean Sitting 
Diastolic Blood Pressure (DBP) from 
Visit 2 to Visit 4 
PP 
Repeat 
16.2.6 
1.1 sensitivity 
14.2.2.3 
Summary of Change in Mean Sitting 
Diastolic Blood Pressure (DBP) from 
Visit 2 to Visit 4 Using LOCF 
EFF 
Repeat 
16.2.6 
1.1 sensitivity 
14.2.2.4 
Summary of Change in Mean Sitting 
Diastolic Blood Pressure (DBP) from 
Visit 2 to Visit 4 by Study Site 
EFF 
Repeat 
16.2.6 
1.1 sensitivity 


 
Statistical Analysis Plan  
 
 
Confidential | MEIN/20/ZoAm-Hyp/001 | Plan Version No.: 2.0 | Plan Date: 23May2022 
Page 3 of 64 
 
14.2.2.5 
Summary of Change in Mean Sitting 
Diastolic Blood Pressure (DBP) from 
Visit 2 to Visit 4 by Gender 
EFF 
Unique 
 
16.2.4.1, 
16.2.6 
1.1 sensitivity 
14.2.2.6 
Summary of Change in Mean Sitting 
Diastolic Blood Pressure (DBP) from 
Visit 2 to Visit 4 by Age Group 
EFF 
Repeat 
16.2.4.1, 
16.2.6 
1.1 sensitivity 
14.2.3.1 
Summary of Change in Mean Sitting 
Systolic Blood Pressure (SBP) from Visit 
2 to Visit 4 
EFF 
Repeat 
16.2.6 
2.1 
14.2.3.2 
Summary of Change in Mean Sitting 
Systolic (SBP) and Diastolic Blood 
Pressure (DBP) from Visit 3 to Visit 4 
for Patients Uncontrolled and Up-
Titrated at Visit 3  
EFF 
Unique 
16.2.6 
2.2 
14.2.3.3 
Proportion of Patients Achieving Sitting 
BP Goal (≤130/80 mmHg) at Visits 2, 3, 
and 4  
FAS, EFF 
Unique 
16.2.6 
2.3 
14.2.3.4 
Proportion of Patients with 80% - 120% 
Adherence to Treatment at Visits 2, 3, 
and 4 
FAS, EFF 
Repeat 
16.2.5.1 
2.4 
14.2.4.1 
Difference in Mean Change for Sitting 
Systolic (SBP) and Diastolic Blood 
Pressure (DBP) from Visit 1 to Visits 2, 
3, and 4 by Treatment Subgroup 
FAS, EFF 
Unique 
16.2.6 
3.1 
14.2.4.2 
Difference in Mean Change for Sitting 
Systolic (SBP) and Diastolic Blood 
Pressure (DBP) from Visit 2 to Visit 3 
for Patients with Uncontrolled BP at 
Visit 3 by Treatment Subgroup 
EFF 
Repeat 
16.2.6 
3.2 
14.2.4.3 
Proportion of Patients Achieving Sitting 
BP Goal (≤130/80 mmHg) at Visits 2, 3, 
and 4 by Treatment Subgroup 
FAS, EFF 
Unique 
16.2.6 
3.3 
14.2.4.4.1 
Proportion of Patients Achieving Sitting 
BP Goal (≤130/80 mmHg) at Visits 2, 3, 
and 4 by Hypertension Grade and 
Treatment Subgroup 
FAS, EFF 
Unique 
16.2.6 
3.4 
14.2.4.4.2 
Proportion of Patients Achieving Sitting 
BP Goal (≤130/80 mmHg) at Visits 2, 3, 
and 4 by Presence of Diabetes and/or 
Hypercholesterolemia and Treatment 
Subgroup 
FAS, EFF 
Repeat 
16.2.6 
3.4 
 
 
 


 
Statistical Analysis Plan  
 
 
Confidential | MEIN/20/ZoAm-Hyp/001 | Plan Version No.: 2.0 | Plan Date: 23May2022 
Page 4 of 64 
 
1.1.3 Safety 
 
Number 
Title 
Population 
Unique/ 
Repeat 
Supporting 
Listing 
Displays of Adverse Events 
14.3.1.1.1 
Overall Summary of Treatment Emergent 
Adverse Events – Monotherapy Period 
Safety 
Unique 
16.2.7.1,  
16.2.7.2, 
16.2.7.3 
14.3.1.1.2 
Overall Summary of Treatment Emergent 
Adverse Events – Combined Therapy 
Period 
Safety 
Repeat 
16.2.7.1,  
16.2.7.2, 
16.2.7.3 
14.3.1.2.1 
Summary of Treatment Emergent 
Adverse Events by System Organ Class 
and Preferred Term – Monotherapy 
Period 
Safety 
Unique 
16.2.7.1,  
16.2.7.2, 
16.2.7.3 
14.3.1.2.2 
Summary of Treatment Emergent 
Adverse Events by System Organ Class 
and Preferred Term – Combined Therapy 
Period 
Safety 
Repeat 
16.2.7.1,  
16.2.7.2, 
16.2.7.3 
14.3.1.3.1 
Summary of Severe Treatment Emergent 
Adverse Events by System Organ Class 
and Preferred Term – Monotherapy 
Period 
Safety 
Repeat 
16.2.7.1,  
16.2.7.2, 
16.2.7.3 
14.3.1.3.2 
Summary of Severe Treatment Emergent 
Adverse Events by System Organ Class 
and Preferred Term – Combined Therapy 
Period 
Safety 
Repeat 
16.2.7.1,  
16.2.7.2, 
16.2.7.3 
14.3.1.4.1 
Summary of Adverse Drug Reactions by 
System Organ Class and Preferred Term – 
Monotherapy Period 
Safety 
Repeat 
16.2.7.1,  
16.2.7.2, 
16.2.7.3 
14.3.1.4.2 
Summary of Adverse Drug Reactions by 
System Organ Class and Preferred Term – 
Combined Therapy Period 
Safety 
Repeat 
16.2.7.1,  
16.2.7.2, 
16.2.7.3 
14.3.1.5.1 
Summary of Treatment Emergent 
Adverse Events Leading to Study 
Discontinuation by System Organ Class 
and Preferred Term – Monotherapy 
Period 
Safety 
Repeat 
16.2.7.1,  
16.2.7.2, 
16.2.7.3 
14.3.1.5.2 
Summary of Treatment Emergent 
Adverse Events Leading to Study 
Discontinuation by System Organ Class 
and Preferred Term – Combined Therapy 
Period 
Safety 
Repeat 
16.2.7.1,  
16.2.7.2, 
16.2.7.3 
Deaths, Other Serious and Certain Other Significant Adverse Events  
14.3.2.1.1 
Summary of Treatment Emergent Serious 
Adverse Events by System Organ Class 
Safety 
Repeat 
16.2.7.1,  
16.2.7.2, 
16.2.7.3 


 
Statistical Analysis Plan  
 
 
Confidential | MEIN/20/ZoAm-Hyp/001 | Plan Version No.: 2.0 | Plan Date: 23May2022 
Page 5 of 64 
 
and Preferred Term – Monotherapy 
Period 
14.3.2.1.2 
Summary of Treatment Emergent Serious 
Adverse Events by System Organ Class 
and Preferred Term – Combined Therapy 
Period 
Safety 
Repeat 
16.2.7.1,  
16.2.7.2, 
16.2.7.3 
14.3.2.2.1 
Summary of Serious Adverse Drug 
Reactions by System Organ Class and 
Preferred Term – Monotherapy Period 
Safety 
Repeat 
16.2.7.1,  
16.2.7.2, 
16.2.7.3 
14.3.2.2.2 
Summary of Serious Adverse Drug 
Reactions by System Organ Class and 
Preferred Term – Combined Therapy 
Period 
Safety 
Repeat 
16.2.7.1,  
16.2.7.2, 
16.2.7.3 
14.3.2.3.1 
Summary of Treatment Emergent Serious 
Adverse Events with Outcome of Death 
by System Organ Class and Preferred 
Term – Monotherapy Period 
Safety 
Repeat 
16.2.7.1,  
16.2.7.2, 
16.2.7.3 
14.3.2.3.2 
Summary of Treatment Emergent Serious 
Adverse Events with Outcome of Death 
by System Organ Class and Preferred 
Term – Combined Therapy Period 
Safety 
Repeat 
16.2.7.1,  
16.2.7.2, 
16.2.7.3 
Abnormal Laboratory Values 
14.3.4.1.1 
Summary and Change from Baseline 
(Visit 1) to Visit 4 for Haematology 
Parameters 
Safety 
Unique 
16.2.8.1 
14.3.4.1.2 
Summary and Change from Baseline 
(Visit 1) to Visit 4 for Serum Chemistry 
Parameters 
Safety 
Repeat 
16.2.8.2 
14.3.4.2.1 
Shift from Baseline (Visit 1) to Visit 4 for 
Haematology Parameters 
Safety 
Unique 
16.2.8.1 
14.3.4.2.2 
Shift from Baseline (Visit 1) to Visit 4 for 
Serum Chemistry Parameters 
Safety 
Repeat 
16.2.8.2 
Other Safety Analyses 
14.3.5 
Summary of Study Drug Accountability, 
Exposure, and Adherence 
Safety 
Unique 
16.2.5.1, 
16.2.5.2, 
16.2.5.3 
14.3.6.1 
Summary and Change from Screening 
(Visit 1) to Baseline (Visit 2) for Vital Sign 
Parameters – Monotherapy Period 
Safety 
Unique 
16.2.9 
14.3.6.2 
Summary and Change from Baseline 
(Visit 2) to Visit 4 for Vital Sign 
Parameters – Combined Therapy Period 
Safety 
Unique 
16.2.9 
14.3.7.1 
Shift from Screening (Visit 1) to Baseline 
(Visit 2) for Physical Examination – 
Monotherapy Period 
Safety 
Unique 
16.2.10 


 
Statistical Analysis Plan  
 
 
Confidential | MEIN/20/ZoAm-Hyp/001 | Plan Version No.: 2.0 | Plan Date: 23May2022 
Page 6 of 64 
 
14.3.7.2 
Shift from Baseline (Visit 2) to Visit 4 for 
Physical Examination – Combined 
Therapy Period 
Safety 
Unique 
16.2.10 
14.3.8.1 
Summary and Change from Baseline 
(Visit 1) to Visit 4 for Electrocardiogram 
(ECG) Parameters 
Safety 
Unique 
16.2.11 
14.3.8.2 
Shift from Baseline (Visit 1) to Visit 4 for 
ECG Interpretation 
Safety 
Unique 
16.2.11 
14.3.9.1 
Summary of Prior Medications by ATC 
Class Level 1 and Preferred Term 
Safety 
Unique 
16.2.12.1 
14.3.9.2 
Summary of Concomitant Medications by 
ATC Class Level 1 and Preferred Term 
Safety 
Repeat 
16.2.12.1 
 
 
 


 
Statistical Analysis Plan  
 
 
Confidential | MEIN/20/ZoAm-Hyp/001 | Plan Version No.: 2.0 | Plan Date: 23May2022 
Page 7 of 64 
 
Listings 
 
Number 
Title 
Population 
Unique/ 
Repeat 
16.2.1 
Patient Enrollment and Disposition  
Full Analysis Set 
Unique 
16.2.2  
Protocol Deviations  
Full Analysis Set 
Unique 
16.2.3 
Patients Excluded from Analysis Populations 
Full Analysis Set 
Unique 
16.2.4.1 
Demographic Characteristics  
Safety 
Unique 
16.2.4.2 
Baseline Characteristics 
Safety 
Unique 
16.2.5.1 
Study Drug Accountability and Adherence 
Safety 
Unique 
16.2.5.2 
Study Drug Exposure 
Safety 
Unique 
16.2.5.3 
Modified, Missing, and Interrupted Doses 
Safety 
Unique 
16.2.6 
Mean Sitting Systolic and Diastolic Blood Pressure 
Details 
Efficacy 
Unique 
16.2.7.1  
Adverse Events 
Safety  
Unique 
16.2.7.2  
Adverse Event Details 
Safety  
Unique 
16.2.7.3 
Deaths  
Safety  
Unique 
16.2.8.1 
Haematology Parameters 
Safety 
Unique 
16.2.8.2 
Serum Chemistry Parameters 
Safety 
Repeat 
16.2.8.3 
Pregnancy Test 
Safety 
Unique 
16.2.9 
Vitals Signs 
Safety 
Unique 
16.2.10 
Physical Examination 
Safety 
Unique 
16.2.11 
Electrocardiogram (ECG) Parameters 
Safety 
Unique 
16.2.12.1 
Prior and Concomitant Medications 
Safety  
Unique 
16.2.12.2 
Non-Drug Treatments/Procedures 
Safety 
Unique 
16.2.13 
Medical History 
Safety  
Unique 
16.2.14 
Blood Pressure Device and Diary Details 
Safety 
Unique 
 
 


 
Statistical Analysis Plan 
 
 
Confidential | MEIN/20/ZoAm-Hyp/001 | Plan Version No.: 2.0 | Plan Date: 23May2022 
Page 8 of 64 
 
2 Mock TLF Shells 
Tables 
2.1.1 Demographic Data 
Table 14.1.1 
Patient Enrollment and Disposition 
(Full Analysis Set) 
 
Disposition [1,2,3] 
Statistic 
ZOF/AML 30/5 mg 
(N=xx) 
ZOF/AML 30/10 mg 
(N=xx) 
All Patients 
(N=xx) 
Total Number of Patients 
     Screened 
     Screen Failures  
     Enrolled 
     Completed Monotherapy 
     Completed Combined Therapy  
     Completed the Study 
     Discontinued the Study 
 
 
n 
n (%) 
n 
n (%) 
n (%) 
n (%) 
n (%) 
 
 
 
 
xx 
xx (xx.x) 
xx (xx.x) 
xx (xx.x) 
xx (xx.x) 
 
 
 
 
xx 
xx (xx.x) 
xx (xx.x) 
xx (xx.x) 
xx (xx.x) 
 
 
xx 
xx (xx.x) 
xx 
xx (xx.x) 
xx (xx.x) 
xx (xx.x) 
xx (xx.x) 
 
Reason for Study Discontinuation 
     Excluded at Visit 2 
     Excluded at Visit 3 
     Meets Exclusion Criteria 
     Adverse Event 
     Study Non-Compliance 
     Withdrawal of Consent 
     Failure to Report to Study Visits 
     Lost to Follow-up                           
     Investigator Decision 
     Lack of Efficacy 
     Pregnancy 
     Protocol Deviation 
     Study Terminated by Sponsor 
     Abnormal Renal Function or Liver Enzyme 
     Death 
     COVID-19 
     Other 
 
 
n (%) 
n (%) 
n (%) 
n (%) 
n (%) 
n (%) 
n (%) 
n (%) 
n (%) 
n (%) 
n (%) 
n (%) 
n (%) 
n (%) 
n (%) 
n (%) 
n (%) 
 
 
xx (xx.x) 
xx (xx.x) 
xx (xx.x) 
xx (xx.x) 
xx (xx.x) 
xx (xx.x) 
xx (xx.x) 
xx (xx.x) 
xx (xx.x) 
xx (xx.x) 
xx (xx.x) 
xx (xx.x) 
xx (xx.x) 
xx (xx.x) 
xx (xx.x) 
xx (xx.x) 
xx (xx.x) 
 
 
 
 
xx (xx.x) 
xx (xx.x) 
xx (xx.x) 
xx (xx.x) 
xx (xx.x) 
xx (xx.x) 
xx (xx.x) 
xx (xx.x) 
xx (xx.x) 
xx (xx.x) 
xx (xx.x) 
xx (xx.x) 
xx (xx.x) 
xx (xx.x) 
xx (xx.x) 
 
 
xx (xx.x) 
xx (xx.x) 
xx (xx.x) 
xx (xx.x) 
xx (xx.x) 
xx (xx.x) 
xx (xx.x) 
xx (xx.x) 
xx (xx.x) 
xx (xx.x) 
xx (xx.x) 
xx (xx.x) 
xx (xx.x) 
xx (xx.x) 
xx (xx.x) 
xx (xx.x) 
xx (xx.x) 
 
[1] Percentages for Screen Failures is based on the number Screened. Percentages for all subsequent percentages are based on the number Enrolled.  
[2] Excluded at Visit 2 = Patients with controlled BP, patients who do not tolerate the treatment, or patients < 80% or > 120% treatment adherence. 
[3] Excluded at Visit 3 = Patients who do not tolerate the extemporaneous combination of treatment, or patients < 80% or > 120% treatment adherence. 


 
Statistical Analysis Plan 
 
 
Confidential | MEIN/20/ZoAm-Hyp/001 | Plan Version No.: 2.0 | Plan Date: 23May2022 
Page 9 of 64 
 
Source: Listing 16.2.1 
Program Name: XXXX.SAS 
Date: DDMMMYYYY 
 
Programming Note: 
 
Patients will be classified as either ZOF/AML 30/5 mg or ZOF/AML 30/10 mg such that no patients are counted in both groups. That is, even though patients in the 
ZOF/AML 30/10 mg group are also exposed to the ZOF/AML 30/5 mg treatment, they will only be included in the ZOF/AML 30/10 mg and All Patients columns, not 
within the ZOF/AML 30/5 mg column.  Patients that do not belong to the ZOF/AML 30/5 mg or ZOF/AML 30/10 mg group will be included only in the All Patients 
column. 
 


 
Statistical Analysis Plan 
 
 
Confidential | MEIN/20/ZoAm-Hyp/001 | Plan Version No.: 2.0 | Plan Date: 23May2022 
Page 10 of 64 
 
Table 14.1.2 
Analysis Populations and Exclusions  
(Full Analysis Set) 
 
Analysis Populations [7] 
Statistic 
All Patients 
(N=xx) 
 
Included in Safety (SAF) [1,4] 
Excluded from Safety (SAF) 
     Did Not Meet all Screening Criteria 
     Did Not Receive At Least One Dose During Run-In 
 
Included in Efficacy (EFF) [2,5] 
Excluded from Efficacy (EFF) 
     Did Not Complete Run-In Period 
     Did Not Meet Continuation Criteria at Visit 2 
     Did Not Complete Visit 3 or 4 
  
Included in Per Protocol (PP) [3,6] 
Excluded from Per Protocol (PP) 
     Not Dosed According to Protocol 
     Did Not Complete Required Study Visits 
     Major Protocol Deviation That May Impact the Primary Efficacy Assessment 
 
 
n (%) 
n (%) 
n (%) 
n (%) 
 
n (%) 
n (%) 
n (%) 
n (%) 
                   n (%) 
 
n (%) 
n (%) 
n (%) 
n (%) 
n (%) 
 
xx (xx.x) 
xx (xx.x) 
xx (xx.x) 
xx (xx.x) 
 
xx (xx.x) 
xx (xx.x) 
xx (xx.x)  
xx (xx.x) 
xx (xx.x) 
 
xx (xx.x) 
xx (xx.x) 
xx (xx.x)  
xx (xx.x) 
xx (xx.x) 
[1] Percentage based on number of All Patients. 
[2] Percentage based on number of subjects included in SAF. 
[3] Percentage based on number of subjects included in EFF. 
[4] Safety Population (SAF): All study participants who sign informed consent, meet all screening criteria, are enrolled, and receive at least one dose of the assigned treatment 
during the run-in period. 
[5] Efficacy Population (EFF): All study participants in the Safety Population who complete the 4-week run-in period and meet continuation criteria at Visit 2 [uncontrolled BP 
(sitting SBP/DBP > 130/80 mmHg), tolerate treatment, and fall within 80-120% treatment adherence] and have at least one available post baseline primary efficacy assessment 
(from Visit 3 or 4). 
[6] Per Protocol Population (PP): All study participants in the Efficacy Population who were dosed according to the protocol (80% - 120% adherence reported for each dosing visit), 
complete the required study visits (Visits 1, 2, 3, 4), and do not experience any major protocol deviations that may impact the primary efficacy assessment through end of 
treatment.   
[7] If subjects are excluded for more than one reason, they will only be counted for the first listed reason. 
Source: Listing 16.2.3 
 
Program Name: XXXX.SAS 
Date: DDMMMYYYY 
 
 
 


 
Statistical Analysis Plan 
 
 
Confidential | MEIN/20/ZoAm-Hyp/001 | Plan Version No.: 2.0 | Plan Date: 23May2022 
Page 11 of 64 
 
Table 14.1.3 
Summary of Demographic and Baseline Characteristics  
(Safety Population) 
 
Parameter 
Statistic 
ZOF/AML 30/5 mg 
(N=xx) 
ZOF/AML 30/10 mg 
(N=xx) 
All Patients 
(N=xx) 
Age (Years) 
 
 
 
Sex 
     Male 
     Female 
     Unknown/Undifferentiated  
 
Ethnicity 
     Hispanic or Latino 
     Not Hispanic or Latino 
     Ashkenazi Jew 
     Sephardic Jew 
     Not Reported/Unknown 
n 
Mean (SD) 
Median 
Min, Max 
 
n (%) 
n (%) 
n (%) 
 
 
n (%) 
n (%) 
n (%) 
n (%) 
n (%) 
xx 
xx.x (xx.xx) 
xx.x 
xx, xx 
 
xx (xx.x) 
xx (xx.x) 
xx (xx.x) 
 
 
xx (xx.x) 
xx (xx.x) 
xx (xx.x) 
xx (xx.x) 
xx (xx.x) 
xx 
xx.x (xx.xx) 
xx.x 
xx, xx 
 
xx (xx.x) 
xx (xx.x) 
xx (xx.x) 
 
 
xx (xx.x) 
xx (xx.x) 
xx (xx.x) 
xx (xx.x) 
xx (xx.x) 
xx 
xx.x (xx.xx) 
xx.x 
xx, xx 
 
xx (xx.x) 
xx (xx.x) 
xx (xx.x) 
 
 
xx (xx.x) 
xx (xx.x) 
xx (xx.x) 
xx (xx.x) 
xx (xx.x) 
 
Race 
     American Indian or Alaska Native  
     Asian 
     Black  
     Native Hawaiian or Other Pacific Islander 
     White 
     Not Applicable 
 
 
n (%) 
n (%) 
n (%) 
n (%) 
n (%) 
n (%) 
 
 
xx (xx.x) 
xx (xx.x) 
xx (xx.x) 
xx (xx.x) 
xx (xx.x) 
xx (xx.x) 
 
 
xx (xx.x) 
xx (xx.x) 
xx (xx.x) 
xx (xx.x) 
xx (xx.x) 
xx (xx.x) 
 
 
xx (xx.x) 
xx (xx.x) 
xx (xx.x) 
xx (xx.x) 
xx (xx.x) 
xx (xx.x) 
     Other 
 
Height (cm) 
 
 
 
 
Weight (kg) 
 
 
 
 
 
n (%) 
 
n 
Mean (SD) 
Median 
Min, Max 
 
n 
Mean (SD) 
Median 
Min, Max 
 
 
xx (xx.x) 
 
xx 
xx.x (xx.xx) 
xx.x 
xx, xx 
 
xx 
xx.x (xx.xx) 
xx.x 
xx, xx 
 
 
xx (xx.x) 
 
xx 
xx.x (xx.xx) 
xx.x 
xx, xx 
 
xx 
xx.x (xx.xx) 
xx.x 
xx, xx 
 
 
xx (xx.x) 
 
xx 
xx.x (xx.xx) 
xx.x 
xx, xx 
 
xx 
xx.x (xx.xx) 
xx.x 
xx, xx 
 
 


 
Statistical Analysis Plan 
 
 
Confidential | MEIN/20/ZoAm-Hyp/001 | Plan Version No.: 2.0 | Plan Date: 23May2022 
Page 12 of 64 
 
BMI (kg/m2) 
 
 
 
Smoking Status 
     Never Tobacco Smoker 
     Former Tobacco Smoker 
          Daily 
          Occasional 
     Current Tobacco Smoker 
          Daily 
          Occasional 
     Undisclosed 
 
e-Cigarettes 
 
Medical History 
     Hypertension Grade 1 
     Hypertension Grade 2 
     Diabetes mellitus 
     Hypercholesterolemia 
 
Treatment at Run-In 
     Zofenopril 30 mg 
     Amlodipine 5 mg 
     Other ACE-i  
     Other CCB 
 
Study Site 
     201 
     202 
     ….. (repeat for all sites) 
                                                                                      
 
n 
Mean (SD) 
Median 
Min, Max 
 
n (%) 
n (%) 
n (%) 
n (%) 
n (%) 
n (%) 
n (%) 
n (%) 
 
n (%) 
 
n (%) 
n (%) 
n (%) 
n (%) 
 
 
n (%) 
n (%) 
n (%) 
n (%) 
 
 
n (%) 
n (%) 
n (%) 
 
xx 
xx.x (xx.xx) 
xx.x 
xx, xx 
 
xx (xx.x) 
xx (xx.x) 
xx (xx.x) 
xx (xx.x) 
xx (xx.x) 
xx (xx.x) 
xx (xx.x) 
xx (xx.x) 
 
xx (xx.x) 
 
xx (xx.x) 
xx (xx.x) 
xx (xx.x) 
xx (xx.x) 
 
 
xx (xx.x) 
xx (xx.x) 
xx (xx.x) 
xx (xx.x) 
 
 
xx (xx.x) 
xx (xx.x) 
xx (xx.x) 
 
xx 
xx.x (xx.xx) 
xx.x 
xx, xx 
 
xx (xx.x) 
xx (xx.x) 
xx (xx.x) 
xx (xx.x) 
xx (xx.x) 
xx (xx.x) 
xx (xx.x) 
xx (xx.x) 
 
xx (xx.x) 
 
xx (xx.x) 
xx (xx.x) 
xx (xx.x) 
xx (xx.x) 
 
 
xx (xx.x) 
xx (xx.x) 
xx (xx.x) 
xx (xx.x) 
 
 
xx (xx.x) 
xx (xx.x) 
xx (xx.x) 
 
xx 
xx.x (xx.xx) 
xx.x 
xx, xx 
 
xx (xx.x) 
xx (xx.x) 
xx (xx.x) 
xx (xx.x) 
xx (xx.x) 
xx (xx.x) 
xx (xx.x) 
xx (xx.x) 
 
xx (xx.x) 
 
xx (xx.x) 
xx (xx.x) 
xx (xx.x) 
xx (xx.x) 
 
 
xx (xx.x) 
xx (xx.x) 
xx (xx.x) 
xx (xx.x) 
 
 
xx (xx.x) 
xx (xx.x) 
xx (xx.x) 
 
Source: Listings 16.2.4.1, 16.2.4.2 
Program Name: XXXX.SAS 
Date: DDMMMYYYY 
 
Programming Note: 
 
Patients will be classified as either ZOF/AML 30/5 mg or ZOF/AML 30/10 mg such that no patients are counted in both groups. That is, even though patients in the 
ZOF/AML 30/10 mg group are also exposed to the ZOF/AML 30/5 mg treatment, they will only be included in the ZOF/AML 30/10 mg and All Patients columns, not 
within the ZOF/AML 30/5 mg column. Patients that do not belong to the ZOF/AML 30/5 mg or ZOF/AML 30/10 mg group will be included only in the All Patients 
column. 


 
Statistical Analysis Plan 
 
 
Confidential | MEIN/20/ZoAm-Hyp/001 | Plan Version No.: 2.0 | Plan Date: 23May2022 
Page 13 of 64 
 
 
In the medical history section, the first two rows (hypertension grade) will come from raw EDC data RUNDIS.RHYPEGRD and the second two rows (diabetes and 
hypercholesterolemia) will come from raw EDC data MH as per usual.  
 
 
 


 
Statistical Analysis Plan 
 
 
Confidential | MEIN/20/ZoAm-Hyp/001 | Plan Version No.: 2.0 | Plan Date: 23May2022 
Page 14 of 64 
 
Table 14.1.4 
Summary of Protocol Deviations 
(Full Analysis Set) 
 
Disposition [1,2] 
Statistic 
ZOF/AML 30/5 mg 
(N=xx) 
ZOF/AML 30/10 mg 
(N=xx) 
All Patients 
(N=xx) 
Subjects with at least one PD 
 
Subjects with at least one Critical PD 
     PD Category 1 
     PD Category 2 
     Etc. 
 
Subjects with at least one Major PD 
     PD Category 1 
     PD Category 2 
     Etc. 
 
 Subjects with at least one Major PD  
that may impact the primary efficacy assessment 
     PD Category 1 
     PD Category 2 
     Etc. 
 
Subjects with at least one Minor PD  
     PD Category 1 
     PD Category 2 
     Etc. 
 
 
n (%) 
 
n (%) 
n (%) 
n (%) 
n (%) 
 
n (%) 
n (%) 
n (%) 
n (%) 
 
 
n (%) 
n (%) 
n (%) 
n (%) 
 
n (%) 
n (%) 
n (%) 
n (%) 
 
xx (xx.x) 
 
xx (xx.x) 
xx (xx.x) 
xx (xx.x) 
xx (xx.x) 
 
xx (xx.x) 
xx (xx.x) 
xx (xx.x) 
xx (xx.x) 
 
 
xx (xx.x) 
xx (xx.x) 
xx (xx.x) 
xx (xx.x) 
 
xx (xx.x) 
xx (xx.x) 
xx (xx.x) 
xx (xx.x) 
 
xx (xx.x) 
 
xx (xx.x) 
xx (xx.x) 
xx (xx.x) 
xx (xx.x) 
 
xx (xx.x) 
xx (xx.x) 
xx (xx.x) 
xx (xx.x) 
 
 
xx (xx.x) 
xx (xx.x) 
xx (xx.x) 
xx (xx.x) 
 
xx (xx.x) 
xx (xx.x) 
xx (xx.x) 
xx (xx.x) 
 
xx (xx.x) 
 
xx (xx.x) 
xx (xx.x) 
xx (xx.x) 
xx (xx.x) 
 
xx (xx.x) 
xx (xx.x) 
xx (xx.x) 
xx (xx.x) 
 
 
xx (xx.x) 
xx (xx.x) 
xx (xx.x) 
xx (xx.x) 
 
xx (xx.x) 
xx (xx.x) 
xx (xx.x) 
xx (xx.x) 
 
[1] PD: Protocol Deviation. 
[2] Critical deviations will be classified as Major for purposes of defining the PP Population but are displayed here as Critical. 
Source: Listing 16.2.2 
Program Name: XXXX.SAS 
Date: DDMMMYYYY 
 
Programming Note: 
 
Patients will be classified as either ZOF/AML 30/5 mg or ZOF/AML 30/10 mg such that no patients are counted in both groups. That is, even though patients in the 
ZOF/AML 30/10 mg group are also exposed to the ZOF/AML 30/5 mg treatment, they will only be included in the ZOF/AML 30/10 mg and All Patients columns, not 
within the ZOF/AML 30/5 mg column.  Patients that do not belong to the ZOF/AML 30/5 mg or ZOF/AML 30/10 mg group will be included only in the All Patients 
column. 
 


 
Statistical Analysis Plan 
 
 
Confidential | MEIN/20/ZoAm-Hyp/001 | Plan Version No.: 2.0 | Plan Date: 23May2022 
Page 15 of 64 
 
2.1.2 Efficacy 
Table 14.2.1.1 
Summary and Change from Baseline for Mean Sitting Diastolic Blood Pressure (DBP) by Visit 
(Efficacy Population) 
 
 
Visit [1] 
Statistic 
ZOF/AML 30/5 mg 
(N=xx) 
ZOF/AML 30/10 mg 
(N=xx) 
All Patients 
(N=xx) 
Screening (Visit 1) 
 
 
 
 
Baseline (Visit 2) 
 
 
 
 
Visit 3 
 
 
 
 
Visit 3 CFB 
 
 
 
 
Visit 4 
 
 
 
 
Visit 4 CFB 
 
 
 
 
n 
Mean (SD) 
Median 
Min, Max 
 
n 
Mean (SD) 
Median 
Min, Max 
 
n 
Mean (SD) 
Median 
Min, Max 
 
n 
Mean (SD) 
Median 
Min, Max 
 
n 
Mean (SD) 
Median 
Min, Max 
 
n 
Mean (SD) 
Median 
Min, Max 
 
xx 
xx.x (xx.xx) 
xx.x 
xx, xx 
 
xx 
xx.x (xx.xx) 
xx.x 
xx, xx 
 
xx 
xx.x (xx.xx) 
xx.x 
xx, xx 
 
xx 
xx.x (xx.xx) 
xx.x 
xx, xx 
 
xx 
xx.x (xx.xx) 
xx.x 
xx, xx 
 
xx 
xx.x (xx.xx) 
xx.x 
xx, xx 
 
xx 
xx.x (xx.xx) 
xx.x 
xx, xx 
 
xx 
xx.x (xx.xx) 
xx.x 
xx, xx 
 
xx 
xx.x (xx.xx) 
xx.x 
xx, xx 
 
xx 
xx.x (xx.xx) 
xx.x 
xx, xx 
 
xx 
xx.x (xx.xx) 
xx.x 
xx, xx 
 
xx 
xx.x (xx.xx) 
xx.x 
xx, xx 
 
xx 
xx.x (xx.xx) 
xx.x 
xx, xx 
 
xx 
xx.x (xx.xx) 
xx.x 
xx, xx 
 
xx 
xx.x (xx.xx) 
xx.x 
xx, xx 
 
xx 
xx.x (xx.xx) 
xx.x 
xx, xx 
 
xx 
xx.x (xx.xx) 
xx.x 
xx, xx 
 
xx 
xx.x (xx.xx) 
xx.x 
xx, xx 
 
[1] CFB = Change from Baseline. 
Source: Listing 16.2.6 
Program Name: XXXX.SAS 
 
Date: DDMMMYYYY 
 


 
Statistical Analysis Plan 
 
 
Confidential | MEIN/20/ZoAm-Hyp/001 | Plan Version No.: 2.0 | Plan Date: 23May2022 
Page 16 of 64 
 
Programming Note: 
 
Patients will be classified as either ZOF/AML 30/5 mg or ZOF/AML 30/10 mg such that no patients are counted in both groups. That is, even though patients in the 
ZOF/AML 30/10 mg group are also exposed to the ZOF/AML 30/5 mg treatment, they will only be included in the ZOF/AML 30/10 mg and All Patients columns, not 
within the ZOF/AML 30/5 mg column. Patients that do not belong to the ZOF/AML 30/5 mg or ZOF/AML 30/10 mg group will be included only in the All Patients 
column. Same for tables in the list below. 
 
Repeat for the following tables:  
o 
14.2.1.2 – Summary of Change from Baseline for Mean Sitting Systolic Blood Pressure (SBP) by Visit – Efficacy Population  
o 
14.2.1.3 – Summary of Change from Baseline for Mean Sitting Diastolic Blood Pressure (DBP) by Visit – Per Protocol Population  
o 
14.2.1.4 – Summary of Change from Baseline for Mean Sitting Systolic Blood Pressure (SBP) by Visit – Per Protocol Population  
 
 


 
Statistical Analysis Plan 
 
 
Confidential | MEIN/20/ZoAm-Hyp/001 | Plan Version No.: 2.0 | Plan Date: 23May2022 
Page 17 of 64 
 
Table 14.2.2.1 
Summary of Change in Mean Sitting Diastolic Blood Pressure (DBP) from Visit 2 to Visit 4 
(Efficacy Population) 
 
 
Visit [1] 
Statistic [2,3] 
All Patients 
(N=xx) 
Baseline (Visit 2) 
 
 
 
 
Visit 4 
 
 
 
 
Visit 4 CFB 
 
 
n 
Mean (SD) 
Median 
Min, Max 
 
n 
Mean (SD) 
Median 
Min, Max 
 
n 
Mean (SD) 
Min, Max 
t-value (df) 
95% CI 
p-value 
 
xx 
xx.x (xx.xx) 
xx.x 
xx, xx 
 
xx 
xx.x (xx.xx) 
xx.x 
xx, xx 
 
xx 
xx.x (xx.xx) 
xx, xx 
x.xx (x) 
(xx.x, xx.x) 
x.xxx 
 
[1] CFB = Change from Baseline. 
[2] SD = Standard Deviation. CI = Confidence Interval. df = degrees of freedom. 
[3] Visit 4 CFB results are generated using paired t-test with alpha = 0.05 to evaluate if 
the mean change in diastolic blood pressure (DBP) from Baseline (Visit 2) to Visit 4 is 
significantly different from 0. 
Source: Listing 16.2.6 
Program Name: XXXX.SAS 
 
Date: DDMMMYYYY 
 
Programming Note: 
 
Repeat for the following tables:  
o 
14.2.2.2 – Summary of Change in Mean Sitting Diastolic Blood Pressure (DBP) from Visit 2 to Visit 4 – Per Protocol Population  
 
Change column header from “EFF” to “PP” 
o 
14.2.2.3 – Summary of Change in Mean Sitting Diastolic Blood Pressure (DBP) from Visit 2 to Visit 4 Using LOCF – Efficacy Population 
 
Add footnote to statistic column “[4] Missing blood pressure (BP) values that occur after Baseline (Visit 2) are imputed using Last Observation 
Carried Forward (LOCF).” 
o 
14.2.2.4 – Summary of Change in Mean Sitting Diastolic Blood Pressure (DBP) from Visit 2 to Visit 4 by Study Site – Efficacy Population 
 
Use of SAS #byar/#byval will produce this table separately for each study site within the same output file. 
o 
14.2.3.1 – Summary of Change in Mean Sitting Systolic Blood Pressure (SBP) from Visit 2 to Visit 4 – Efficacy Population 
 
 


 
Statistical Analysis Plan 
 
 
Confidential | MEIN/20/ZoAm-Hyp/001 | Plan Version No.: 2.0 | Plan Date: 23May2022 
Page 18 of 64 
 
Table 14.2.2.5 
Summary of Change in Mean Sitting Diastolic Blood Pressure (DBP) from Visit 2 to Visit 4 by Gender 
(Efficacy Population) 
 
 
Visit [1] 
Statistic [2,3] 
All Patients (N=xx) 
Male 
Female 
Baseline (Visit 2) 
 
 
 
 
Visit 4 
 
 
 
 
Visit 4 CFB 
 
 
n 
Mean (SD) 
Median 
Min, Max 
 
n 
Mean (SD) 
Median 
Min, Max 
 
n 
Mean (SD) 
Min, Max 
t-value (df) 
95% CI 
p-value 
 
xx 
xx.x (xx.xx) 
xx.x 
xx, xx 
 
xx 
xx.x (xx.xx) 
xx.x 
xx, xx 
 
xx 
xx.x (xx.xx) 
xx, xx 
x.xx (x) 
(xx.x, xx.x) 
x.xxx 
 
xx 
xx.x (xx.xx) 
xx.x 
xx, xx 
 
xx 
xx.x (xx.xx) 
xx.x 
xx, xx 
 
xx 
xx.x (xx.xx) 
xx, xx 
x.xx (x) 
(xx.x, xx.x) 
x.xxx 
 
[1] CFB = Change from Baseline. 
[2] SD = Standard Deviation. CI = Confidence Interval. df = degrees of freedom. 
[3] Visit 4 CFB results are generated using paired t-test with alpha = 0.05 to evaluate if the mean change in systolic 
(SBP; endpoint 2.1) or diastolic blood pressure (DBP; endpoint 1.1) from Baseline (Visit 2) to Visit 4 is significantly 
different from 0. 
Source: Listings 16.2.4.1, 16.2.6 
Program Name: XXXX.SAS 
 
Date: DDMMMYYYY 
 
Programming Note: 
 
Repeat for the following tables:  
o 
14.2.2.6 – Summary of Change in Mean Sitting Diastolic Blood Pressure (DBP) from Visit 2 to Visit 4 by Age Group – Efficacy Population  
 
Change column headers from “Male” and “Female” to “18-45 Years” and “46-65 Years”, respectively 
 
 


 
Statistical Analysis Plan 
 
 
Confidential | MEIN/20/ZoAm-Hyp/001 | Plan Version No.: 2.0 | Plan Date: 23May2022 
Page 19 of 64 
 
 
Table 14.2.3.2 
Summary of Change in Mean Sitting Systolic (SBP) and Diastolic Blood Pressure (DBP) from Visit 3 to Visit 4 for Patients Uncontrolled and Up-Titrated at Visit 3 
(Efficacy Population) 
 
 
Visit [1,2] 
Statistic [3,4] 
All Patients (N=xx) 
SBP 
DBP 
Visit 3 
 
 
 
 
Visit 4 
 
 
 
 
Visit 4 CFV3 
 
 
n 
Mean (SD) 
Median 
Min, Max 
 
n 
Mean (SD) 
Median 
Min, Max 
 
n 
Mean (SD) 
Min, Max 
t-value (df) 
95% CI 
p-value 
 
xx 
xx.x (xx.xx) 
xx.x 
xx, xx 
 
xx 
xx.x (xx.xx) 
xx.x 
xx, xx 
 
xx 
xx.x (xx.xx) 
xx, xx 
x.xx (x) 
(xx.x, xx.x) 
x.xxx 
 
xx 
xx.x (xx.xx) 
xx.x 
xx, xx 
 
xx 
xx.x (xx.xx) 
xx.x 
xx, xx 
 
xx 
xx.x (xx.xx) 
xx, xx 
x.xx (x) 
(xx.x, xx.x) 
x.xxx 
 
[1] CFV3 = Change from Visit 3.  
[2] Patients uncontrolled at Visit 3 are those who have SBP/DBP > 130/80 mmHg. These patients are up-titrated from 
ZOF/AML 30/5 mg to ZOF/AML 30/10 mg.   
[3] SD = Standard Deviation. CI = Confidence Interval. df = degrees of freedom. 
[4] Visit 4 CFV3 results are generated using paired t-test with alpha = 0.05 to evaluate if the mean change in systolic 
(SBP) or diastolic blood pressure (DBP) from Visit 3 to Visit 4 is significantly different from 0 for patients who were 
uncontrolled at Visit 3 and up-titrated (endpoint 2.2). 
Source: Listing 16.2.6 
Program Name: XXXX.SAS 
 
Date: DDMMMYYYY 
 
 


 
Statistical Analysis Plan 
 
 
Confidential | MEIN/20/ZoAm-Hyp/001 | Plan Version No.: 2.0 | Plan Date: 23May2022 
Page 20 of 64 
 
Table 14.2.3.3 
Proportion of Patients Achieving Sitting BP Goal (≤ 130/80 mmHg) at Visits 2, 3, and 4  
(Full Analysis Set and Efficacy Population) 
 
Therapy Type 
 
Visit 
Statistic [1,2,3] 
All Patients 
(N=xx) 
Monotherapy 
 
 
Combined Therapy 
Visit 2 
 
 
Visit 3  
 
 
Visit 4  
 
n/N (Proportion %) 
95% CI 
 
n/N (Proportion %) 
95% CI 
 
n/N (Proportion %) 
95% CI 
 
xx/xx (xx.x) 
(xx.x, xx.x) 
 
xx/xx (xx.x) 
(xx.x, xx.x) 
 
xx/xx (xx.x) 
(xx.x, xx.x) 
 
Note:  The Monotherapy analysis (Visit 2) is performed on the Full Analysis Set. The Combined Therapy analysis (Visits 3 and 4) 
are performed on the Efficacy Population. 
[1] A patient is considered to have met the Blood Pressure (BP) goal (controlled BP) if their SBP ≤ 130 mmHg AND their DBP ≤ 80 
mmHg. 
[2] n = number of patients who have achieved sitting BP goal at that visit. N = number of patients with data at that visit, 
regardless of BP goal status. 
[3] CI = Confidence Interval.  
Source: Listing 16.2.6 
Program Name: XXXX.SAS 
 
Date: DDMMMYYYY 
 
 
 


 
Statistical Analysis Plan 
 
 
Confidential | MEIN/20/ZoAm-Hyp/001 | Plan Version No.: 2.0 | Plan Date: 23May2022 
Page 21 of 64 
 
Table 14.2.3.4 
Proportion of Patients with 80% - 120% Adherence to Treatment at Visits 2, 3, and 4 
(Full Analysis Set and Efficacy Population) 
 
 
 
 
Visit 
Statistic [1,2] 
All Patients 
(N=xx) 
Therapy Type 
eCRF-Reported Adherence 
Derived Adherence 
Monotherapy 
 
 
Combined Therapy 
Visit 2 
 
 
Visit 3  
 
 
Visit 4  
 
n/N (Proportion %) 
95% CI 
 
n/N (Proportion %) 
95% CI 
 
n/N (Proportion %) 
95% CI 
 
xx/xx (xx.x) 
(xx.x, xx.x) 
 
xx/xx (xx.x) 
(xx.x, xx.x) 
 
xx/xx (xx.x) 
(xx.x, xx.x) 
 
xx/xx (xx.x) 
(xx.x, xx.x) 
 
xx/xx (xx.x) 
(xx.x, xx.x) 
 
xx/xx (xx.x) 
(xx.x, xx.x) 
 
Note:  The Monotherapy analysis (Visit 2) is performed on the Full Analysis Set. The Combined Therapy analysis (Visits 3 and 4) are performed on the Efficacy 
Population. 
[1] n = number of patients who met 80% - 120% adherence to treatment at that visit. N = number of patients with data at that visit, regardless of treatment 
adherence status. 
[2] CI = Confidence Interval.  
Source: Listing 16.2.5.1 
Program Name: XXXX.SAS 
 
Date: DDMMMYYYY 
 
 
 


 
Statistical Analysis Plan 
 
 
Confidential | MEIN/20/ZoAm-Hyp/001 | Plan Version No.: 2.0 | Plan Date: 23May2022 
Page 22 of 64 
 
Table 14.2.4.1 
Difference in Mean Change for Sitting Systolic (SBP) and Diastolic Blood Pressure (DBP) From Visit 1 to Visits 2, 3, and 4 
(Full Analysis Set and Efficacy Population) 
 
 
 
 
Visit [1] 
 
 
Statistic Type [2,3] 
Statistic 
SBP 
DBP 
Therapy Type 
ZOF/AML [4] 
(N=xx) 
ACE-i/CCB [5] 
(N=xx) 
ZOF/AML [4] 
(N=xx) 
ACE-i/CCB [5] 
(N=xx) 
Monotherapy 
 
 
 
 
 
 
 
Combined Therapy 
Visit 2 CFS 
 
 
 
 
 
 
 
Visit 3 CFB 
 
 
 
 
 
 
 
Visit 4 CFB 
MMRM 
 
 
 
v. ACE-i/CCB 
 
 
 
MMRM 
 
 
 
v. ACE-i/CCB 
 
 
 
MMRM 
 
 
 
v. ACE-i/CCB 
n 
LSM (SE) 
95% CI 
 
LSM Difference (SE) 
95% CI 
p-value 
 
n 
LSM (SE) 
95% CI 
 
LSM Difference (SE) 
95% CI 
p-value 
 
n 
LSM (SE) 
95% CI 
 
LSM Difference (SE) 
95% CI 
p-value 
 
xx 
xx.x (xx.xxx) 
(xx.x, xx.x) 
 
xx 
xx.x (xx.xxx) 
x.xxx 
 
xx 
xx.x (xx.xxx) 
(xx.x, xx.x) 
 
xx 
xx.x (xx.xxx) 
x.xxx 
 
xx 
xx.x (xx.xxx) 
(xx.x, xx.x) 
 
xx 
xx.x (xx.xxx) 
x.xxx 
xx 
xx.x (xx.xxx) 
(xx.x, xx.x) 
 
 
 
 
 
xx 
xx.x (xx.xxx) 
(xx.x, xx.x) 
 
 
 
 
 
xx 
xx.x (xx.xxx) 
(xx.x, xx.x) 
 
xx 
xx.x (xx.xxx) 
(xx.x, xx.x) 
 
xx 
xx.x (xx.xxx) 
x.xxx 
 
xx 
xx.x (xx.xxx) 
(xx.x, xx.x) 
 
xx 
xx.x (xx.xxx) 
x.xxx 
 
xx 
xx.x (xx.xxx) 
(xx.x, xx.x) 
 
xx 
xx.x (xx.xxx) 
x.xxx 
xx 
xx.x (xx.xxx) 
(xx.x, xx.x) 
 
 
 
 
 
xx 
xx.x (xx.xxx) 
(xx.x, xx.x) 
 
 
 
 
 
xx 
xx.x (xx.xxx) 
(xx.x, xx.x) 
 
Note:  The Monotherapy analysis (Visit 2) is performed on the Full Analysis Set. The Combined Therapy analysis (Visits 3 and 4) are performed on the Efficacy Population. 
[1] CFS = Change from Screening (Visit 1). CFB = Change from Baseline (Visit 2).  
[2] MMRM = Mixed Model Repeated Measures. 
[3] A separate model is used for the monotherapy and combined therapy analyses. The models use an unstructured covariance matrix; change from screening (monotherapy) or 
baseline (combined therapy) for SBP/DBP as the response variable; visit, treatment subgroup, visit*treatment subgroup interaction, and screening (monotherapy) or baseline 
(combined therapy) SBP/DBP as covariates; and a random effect for patient.  
[4] ZOF/AML subgroup: Patients who were on ZOF 30 mg or AML 5 mg at Visit 1 (Week -4) and continued on same therapies. 
[5] ACE-i/CCB subgroup: Patients who switched to ZOF 30 mg or AML 5 mg from any other ACE-i or CCBs at Visit 1 (Week -4).  
Source: Listing 16.2.6 
Program Name: XXXX.SAS 
 
Date: DDMMMYYYY 
 


 
Statistical Analysis Plan 
 
 
Confidential | MEIN/20/ZoAm-Hyp/001 | Plan Version No.: 2.0 | Plan Date: 23May2022 
Page 23 of 64 
 
Programming Note: 
 
If a different covariance structure is used in case of model nonconvergence, footnote 3 should be updated accordingly. 


 
Statistical Analysis Plan 
 
 
Confidential | MEIN/20/ZoAm-Hyp/001 | Plan Version No.: 2.0 | Plan Date: 23May2022 
Page 24 of 64 
 
Table 14.2.4.2 
Difference in Mean Change for Sitting Systolic (SBP) and Diastolic Blood Pressure (DBP) from Visit 2 to Visit 3 for Patients with Uncontrolled BP at Visit 3 
(Efficacy Population) 
 
 
 
Visit [1] 
 
 
Statistic Type [2,3] 
Statistic 
SBP 
DBP 
ZOF/AML [4] 
(N=xx) 
ACE-i/CCB [5] 
(N=xx) 
ZOF/AML [4] 
(N=xx) 
ACE-i/CCB [5] 
(N=xx) 
Visit 3 CFB 
MMRM 
 
 
 
v. ACE-i/CCB 
n 
LSM (SE) 
95% CI 
 
LSM Difference (SE) 
95% CI 
p-value  
 
xx 
xx.x (xx.xxx) 
(xx.x, xx.x) 
 
xx 
xx.x (xx.xxx) 
x.xxx 
 
xx 
xx.x (xx.xxx) 
(xx.x, xx.x) 
 
xx 
xx.x (xx.xxx) 
(xx.x, xx.x) 
 
xx 
xx.x (xx.xxx) 
x.xxx 
 
xx 
xx.x (xx.xxx) 
(xx.x, xx.x) 
 
1] CFB = Change from Baseline (Visit 2). 
[2] MMRM = Mixed Model Repeated Measures. 
[3] Model uses an unstructured covariance matrix; change from baseline for SBP/DBP as the response variable; visit, treatment subgroup, visit*treatment subgroup interaction, 
and baseline SBP/DBP as covariates; and a random effect for patient.   
[4] ZOF/AML subgroup: Patients who were on ZOF 30 mg or AML 5 mg at Visit 1 (Week -4) and continued on same therapies. 
[5] ACE-i/CCB subgroup: Patients who switched to ZOF 30 mg or AML 5 mg from any other ACE-I or CCBs at Visit 1 (Week -4). 
Source: Listing 16.2.6 
Program Name: XXXX.SAS 
 
Date: DDMMMYYYY 
 
Programming Note: 
 
If a different covariance structure is used in case of model nonconvergence, footnote 3 should be updated accordingly. 
 
 
 


 
Statistical Analysis Plan 
 
 
Confidential | MEIN/20/ZoAm-Hyp/001 | Plan Version No.: 2.0 | Plan Date: 23May2022 
Page 25 of 64 
 
 
 
Table 14.2.4.3 
Proportion of Patients Achieving Sitting BP Goal (≤ 130/80 mmHg) at Visits 2, 3, and 4 by Treatment Subgroup 
(Full Analysis Set and Efficacy Population) 
 
 
Therapy Type 
 
Visit 
 
Statistic Type [1,2] 
Statistic [3,4] 
ZOF/AML [5] 
(N=xx) 
ACE-i/CCB [6] 
(N=xx) 
Monotherapy 
 
 
 
 
 
 
Combined Therapy 
Visit 2 
 
 
 
 
 
 
Visit 3 
 
 
 
 
 
 
Visit 4  
 
Logistic MMRM 
 
 
       v. ACE-i/CCB 
 
 
 
Logistic MMRM 
 
 
       v. ACE-i/CCB 
 
 
 
Logistic MMRM 
 
 
       v. ACE-i/CCB 
 
 
 
n/N (Proportion %) 
95% CI 
 
Odds Ratio 
95% CI 
p-value  
 
n/N (Proportion %) 
95% CI 
 
Odds Ratio 
95% CI 
p-value  
 
n/N (Proportion %) 
95% CI 
 
Odds Ratio 
95% CI 
p-value  
 
xx/xx (xx.x) 
(xx.x, xx.x) 
 
x.xx 
(x.xx, x.xx) 
x.xxx 
 
xx/xx (xx.x) 
(xx.x, xx.x) 
 
x.xx 
(x.xx, x.xx) 
x.xxx 
 
xx/xx (xx.x) 
(xx.x, xx.x) 
 
x.xx 
(x.xx, x.xx) 
x.xxx 
 
xx/xx (xx.x) 
(xx.x, xx.x) 
 
 
 
 
 
xx/xx (xx.x) 
(xx.x, xx.x) 
 
 
 
 
 
xx/xx (xx.x) 
(xx.x, xx.x) 
 
 
Note: The Monotherapy analysis (Visit 2) is performed on the Full Analysis Set. The Combined Therapy analysis (Visits 3 and 4) are performed on the Efficacy Population.  
[1] Logistic MMRM = Logistic Mixed Model Repeated Measures. 
[2] A separate model is used for the monotherapy and combined therapy analyses. Models use an unstructured covariance matrix; achieving sitting BP goal as the response 
variable; visit, treatment subgroup, visit*treatment subgroup interaction, and screening (monotherapy) or baseline (combined therapy) SBP/DBP as covariates; and a random 
effect for patient.  
[3] A patient is considered to have met the Blood Pressure (BP) goal (controlled BP) if their SBP ≤ 130 mmHg AND their DBP ≤ 80 mmHg. 
[4] n = number of patients who have achieved sitting BP goal at that visit. N = number of patients with data at that visit, regardless of BP goal status. 
[5] ZOF/AML subgroup: Patients who were on ZOF 30 mg or AML 5 mg at Visit 1 (Week -4) and continued on same therapies. 
[6] ACE-i/CCB subgroup: Patients who switched to ZOF 30 mg or AML 5 mg from any other ACE-I or CCBs at Visit 1 (Week -4).  
Source: Listing 16.2.6 
Program Name: XXXX.SAS 
 
Date: DDMMMYYYY 
 
Programming Note: 


 
Statistical Analysis Plan 
 
 
Confidential | MEIN/20/ZoAm-Hyp/001 | Plan Version No.: 2.0 | Plan Date: 23May2022 
Page 26 of 64 
 
 
If a different covariance structure is used in case of model nonconvergence, footnote 2 should be updated accordingly.  
 


 
Statistical Analysis Plan 
 
 
Confidential | MEIN/20/ZoAm-Hyp/001 | Plan Version No.: 2.0 | Plan Date: 23May2022 
Page 27 of 64 
 
Table 14.2.4.4.1 
Proportion of Patients Achieving Sitting BP Goal (≤ 130/80 mmHg) at Visits 2, 3, and 4 by Hypertension Grade and Treatment Subgroup 
(Full Analysis Set and Efficacy Population) 
 
 
 
 
 
Visit 
 
 
 
Statistic Type [1,2] 
Statistic [3,4] 
Hypertension Grade 1  
(N=xx) 
Hypertension Grade 2  
(N=xx) 
Therapy Type 
ZOF/AML [5]  
(N=xx) 
ACE-i/CCB [6]  
(N=xx) 
ZOF/AML [5] 
(N=xx) 
ACE-i/CCB [6] 
(N=xx) 
Monotherapy 
 
 
 
 
 
 
Combined Therapy 
Visit 2 
 
 
 
 
 
 
Visit 3 
 
 
 
 
 
 
Visit 4 
Logistic MMRM 
 
 
      
v. ACE-i/CCB 
 
 
Logistic MMRM 
 
 
      
v. ACE-i/CCB 
 
 
Logistic MMRM 
 
 
v. ACE-i/CCB 
n/N (Proportion %) 
95% CI 
 
Odds Ratio 
95% CI 
p-value  
 
n/N (Proportion %) 
95% CI 
 
Odds Ratio 
95% CI 
p-value 
 
n/N (Proportion %) 
95% CI 
 
Odds Ratio 
95% CI 
p-value 
xx/xx (xx.x) 
(xx.x, xx.x) 
 
x.xx 
(x.xx, x.xx) 
x.xxx 
 
xx/xx (xx.x) 
(xx.x, xx.x) 
 
x.xx 
(x.xx, x.xx) 
x.xxx 
 
xx/xx (xx.x) 
(xx.x, xx.x) 
 
x.xx 
(x.xx, x.xx) 
x.xxx 
 
xx/xx (xx.x) 
(xx.x, xx.x) 
 
 
 
 
 
xx/xx (xx.x) 
(xx.x, xx.x) 
 
 
 
 
 
xx/xx (xx.x) 
(xx.x, xx.x) 
xx/xx (xx.x) 
(xx.x, xx.x) 
 
x.xx 
(x.xx, x.xx) 
x.xxx 
 
xx/xx (xx.x) 
(xx.x, xx.x) 
 
x.xx 
(x.xx, x.xx) 
x.xxx 
 
xx/xx (xx.x) 
(xx.x, xx.x) 
 
x.xx 
(x.xx, x.xx) 
x.xxx 
xx/xx (xx.x) 
(xx.x, xx.x) 
 
 
 
 
 
xx/xx (xx.x) 
(xx.x, xx.x) 
 
 
 
 
 
xx/xx (xx.x) 
(xx.x, xx.x) 
Note: The Monotherapy analysis (Visit 2) is performed on the Full Analysis Set. The Combined Therapy analysis (Visits 3 and 4) are performed on the Efficacy Population.  
[1] Logistic MMRM = Logistic Mixed Model Repeated Measures. 
[2] A separate model is used for the monotherapy and combined therapy analyses. Models use an unstructured covariance matrix; achieving sitting BP goal as the response 
variable; visit, treatment subgroup, visit*treatment subgroup interaction, and screening (monotherapy) or baseline (combined therapy) SBP/DBP as covariates; and a random 
effect for patient. Analysis will be stratified by Hypertension grade reported at Baseline. 
[3] A patient is considered to have met the Blood Pressure (BP) goal (controlled BP) if their SBP ≤ 130 mmHg AND their DBP ≤ 80 mmHg. 
[4] n is the number of patients who have achieved sitting BP goal at that visit. N is the number of patients with data at that visit, regardless of BP goal status. 
[5] ZOF/AML subgroup: Patients who were on ZOF 30 mg or AML 5 mg at Visit 1 (Week -4) and continued on same therapies. 
[6] ACE-i/CCB subgroup: Patients who switched to ZOF 30 mg or AML 5 mg from any other ACE-I or CCBs at Visit 1 (Week -4).  
Source: Listing 16.2.6 
Program Name: XXXX.SAS 
 
Date: DDMMMYYYY 
 
Programming Note: 


 
Statistical Analysis Plan 
 
 
Confidential | MEIN/20/ZoAm-Hyp/001 | Plan Version No.: 2.0 | Plan Date: 23May2022 
Page 28 of 64 
 
 
If a different covariance structure is used in case of model nonconvergence, footnote 2 should be updated accordingly. Same applies to the table listed below. 
 
Repeat for the following tables:  
o 
14.2.4.4.2 – Proportion of Patients Achieving Sitting BP Goal (≤ 130/80 mmHg) at Visits 2, 3, and 4 by Presence of Diabetes and/or Hypercholesterolemia and 
Treatment Subgroup – Full Analysis Set and Efficacy Population  
 
In the column headers, “Hypertension Grade 1” and “Hypertension Grade 2” will change to “Diabetes/Hypercholesterolemia Present” and 
“Diabetes/Hypercholesterolemia Absent”, respectively. 
 
Footnotes will be as follows: 
 
Note: The Monotherapy analysis (Visit 2) is performed on the Full Analysis Set. The Combined Therapy analysis (Visits 3 and 4) are 
performed on the Efficacy Population. 
 
[1] Logistic MMRM = Logistic Mixed Model Repeated Measures. 
 
[2] A separate model is used for the monotherapy and combined therapy analyses. Models use an unstructured covariance matrix; 
achieving sitting BP goal as the response variable; visit, treatment subgroup, visit*treatment subgroup interaction, and screening 
(monotherapy) or baseline (combined therapy) SBP/DBP as covariates; and a random effect for patient. Analysis will be stratified by 
presence of Diabetes and/or Hypercholesterolemia reported at Baseline. 
 
[3] A patient is considered to have met the Blood Pressure (BP) goal (controlled BP) if their SBP ≤ 130 mmHg AND their DBP ≤ 80 mmHg.  
 
[4] n is the number of patients who have achieved sitting BP goal at that visit. N is the number of patients with data at that visit, 
regardless of BP goal status. 
 
[5] ZOF/AML subgroup: Patients who were on ZOF 30 mg or AML 5 mg at Visit 1 (Week -4) and continued on same therapies. 
 
[6] ACE-i/CCB subgroup: Patients who switched to ZOF 30 mg or AML 5 mg from any other ACE-I or CCBs at Visit 1 (Week -4).  
 
 


 
Statistical Analysis Plan 
 
 
Confidential | MEIN/20/ZoAm-Hyp/001 | Plan Version No.: 2.0 | Plan Date: 23May2022 
Page 29 of 64 
 
 
2.1.3 Safety 
Table 14.3.1.1.1 
Overall Summary of Treatment Emergent Adverse Events – Monotherapy Period 
(Safety Population) 
 
Adverse Events [1,2,3,4] 
Statistic 
ZOF 30 mg 
(N=xx) 
AML 5 mg 
(N=xx) 
All Patients 
(N=xx) 
Total Number of TEAEs  
Total Number of TESAEs 
Total Number of ADRs  
 
Number of Patients with: 
     At Least One TEAE 
     At Least One Severe TEAE 
     At Least One ADR 
     At Least One TEAE Leading to Study Discontinuation 
     At Least One TESAE 
     At Least One Serious ADR  
     At Least One TESAE with Outcome of Death 
 
n 
n 
n 
 
 
n (%) 
n (%) 
n (%) 
n (%) 
n (%) 
n (%) 
n (%) 
xx 
xx 
xx 
 
 
xx (xx.x) 
xx (xx.x) 
xx (xx.x) 
xx (xx.x) 
xx (xx.x) 
xx (xx.x) 
xx (xx.x) 
xx 
xx 
xx 
 
 
xx (xx.x) 
xx (xx.x) 
xx (xx.x) 
xx (xx.x) 
xx (xx.x) 
xx (xx.x) 
xx (xx.x) 
xx 
xx 
xx 
 
 
xx (xx.x) 
xx (xx.x) 
xx (xx.x) 
xx (xx.x) 
xx (xx.x) 
xx (xx.x) 
xx (xx.x) 
[1] AE: Adverse Event. Defined as any untoward medical occurrence in a clinical trial patient administered a medicinal product and which does not necessarily have a causal 
relationship with this treatment. 
[2] TEAE: Treatment Emergent Adverse Event. Defined as AEs that occur after the first dose of monotherapy of ZOF or AML. 
[3] TESAE: Treatment Emergent Serious Adverse Event.  
[4] ADR: Adverse Drug Reaction. Defined as AEs that have a relationship of “certain,” “probable,” “possible,” or “unassessable.” 
Source: Listings 16.2.7.1, 16.2.7.2, 16.2.7.3 
Program Name: XXXX.SAS 
 
Date: DDMMMYYYY 
 
Programming Note: 
 
For the combined therapy period table presented in the list below: Patients will be classified as either ZOF/AML 30/5 mg or ZOF/AML 30/10 mg such that no patients 
are counted in both groups. That is, even though patients in the ZOF/AML 30/10 mg group are also exposed to the ZOF/AML 30/5 mg treatment, they will only be 
included in the ZOF/AML 30/10 mg and All Patients columns, not within the ZOF/AML 30/5 mg column. Patients that do not belong to the ZOF/AML 30/5 mg or 
ZOF/AML 30/10 mg group will be included only in the All Patients column.  
 
Repeat for the following tables:  
o 
14.3.1.1.2 – Overall Summary of Treatment Emergent Adverse Events – Combined Therapy Period – Safety Population  
 
In the column headers, “ZOF 30 mg” and “AML 5mg” will change to “ZOF/AML 30/5 mg” and “ZOF/AML 30/10 mg”, respectively. 
 
 


 
Statistical Analysis Plan 
 
 
Confidential | MEIN/20/ZoAm-Hyp/001 | Plan Version No.: 2.0 | Plan Date: 23May2022 
Page 30 of 64 
 
Table 14.3.1.2.1 
Summary of Treatment Emergent Adverse Events by System Organ Class and Preferred Term – Monotherapy Period 
(Safety Population) 
 
Adverse Events [1,2,3,4] 
Statistic 
ZOF 30 mg 
(N=xx) 
AML 5 mg 
(N=xx) 
All Patients 
(N=xx) 
Total Number of TEAEs 
 
Number of Patients with at Least One TEAE  
 
System Organ Class #1  
     Preferred Term #1 
     Preferred Term #2 
     Preferred Term #3 
     etc. 
 
System Organ Class #2 
     Preferred Term #1 
     Preferred Term #2 
     Preferred Term #3 
     etc. 
n 
 
n (%) 
 
n (%) 
n (%) 
n (%) 
n (%) 
 
 
n (%) 
n (%) 
n (%) 
n (%) 
xx 
 
xx (xx.x) 
 
xx (xx.x) 
xx (xx.x) 
xx (xx.x) 
xx (xx.x) 
 
 
xx (xx.x) 
xx (xx.x) 
xx (xx.x) 
xx (xx.x) 
xx 
 
xx (xx.x) 
 
xx (xx.x) 
xx (xx.x) 
xx (xx.x) 
xx (xx.x) 
 
 
xx (xx.x) 
xx (xx.x) 
xx (xx.x) 
xx (xx.x) 
xx 
 
xx (xx.x) 
 
xx (xx.x) 
xx (xx.x) 
xx (xx.x) 
xx (xx.x) 
 
 
xx (xx.x) 
xx (xx.x) 
xx (xx.x) 
xx (xx.x) 
[1] AE: Adverse Event. Defined as any untoward medical occurrence in a clinical trial patient administered a medicinal product and which does not necessarily have a causal 
relationship with this treatment.  
[2] TEAE: Treatment Emergent Adverse Event. Defined as AEs that occur after the first dose of monotherapy of ZOF or AML. 
[3] Patients will be counted once per System Organ Class/Preferred Term (SOC/PT). 
[4] MedDRA Dictionary version XX.X was used to code adverse events. 
Source: Listings 16.2.7.1, 16.2.7.2, 16.2.7.3 
Program Name: XXXX.SAS 
 
Date: DDMMMYYYY 
 
Programming Note: 
 
For the combined therapy period tables presented in the list below: Patients will be classified as either ZOF/AML 30/5 mg or ZOF/AML 30/10 mg such that no patients 
are counted in both groups. That is, even though patients in the ZOF/AML 30/10 mg group are also exposed to the ZOF/AML 30/5 mg treatment, they will only be 
included in the ZOF/AML 30/10 mg and All Patients columns, not within the ZOF/AML 30/5 mg column. Patients that do not belong to the ZOF/AML 30/5 mg or 
ZOF/AML 30/10 mg group will be included only in the All Patients column.  
 
Repeat for the following tables:  
o 
14.3.1.2.2 – Summary of Treatment Emergent Adverse Events by System Organ Class and Preferred Term – Combined Therapy Period – Safety Population  
 
In the column headers, “ZOF 30 mg” and “AML 5mg” will change to “ZOF/AML 30/5 mg [4]” and “ZOF/AML 30/10 mg [4]”, respectively. 
o 
14.3.1.3.1 – Summary of Treatment Emergent Severe Adverse Events by System Organ Class and Preferred Term – Monotherapy Period – Safety Population  
 
Rows 1 and 2 will change from TEAE(s) to Severe TEAE(s). 
o 
14.3.1.3.2 – Summary of Treatment Emergent Severe Adverse Events by System Organ Class and Preferred Term – Combined Therapy Period – Safety 
Population  


 
Statistical Analysis Plan 
 
 
Confidential | MEIN/20/ZoAm-Hyp/001 | Plan Version No.: 2.0 | Plan Date: 23May2022 
Page 31 of 64 
 
 
Rows 1 and 2 will change from TEAE(s) to Severe TEAE(s). 
 
In the column headers, “ZOF 30 mg” and “AML 5mg” will change to “ZOF/AML 30/5 mg [4]” and “ZOF/AML 30/10 mg [4]”, respectively. 
o 
14.3.1.4.1 – Summary of Adverse Drug Reactions by System Organ Class and Preferred Term – Monotherapy Period – Safety Population 
 
Rows 1 and 2 will change from TEAE(s) to ADR(s). 
 
In the column headers, “ZOF 30 mg” and “AML 5mg” will change to “ZOF/AML 30/5 mg [4]” and “ZOF/AML 30/10 mg [4]”, respectively. 
 
Footnote [2] will change to [ADR: Adverse Drug Reaction. Defined as AEs that have a relationship of “certain,” “probable,” “possible,” or 
“unassessable.”] 
o 
14.3.1.4.2 – Summary of Adverse Drug Reactions by System Organ Class and Preferred Term – Combined Therapy Period – Safety Population 
 
Rows 1 and 2 will change from TEAE(s) to ADR(s). 
 
In the column headers, “ZOF 30 mg” and “AML 5mg” will change to “ZOF/AML 30/5 mg [4]” and “ZOF/AML 30/10 mg [4]”, respectively. 
 
Footnote [2] will change to [ADR: Adverse Drug Reaction. Defined as AEs that have a relationship of “certain,” “probable,” “possible,” or 
“unassessable.”] 
o 
14.3.1.5.1 – Summary of Treatment Emergent Adverse Events Leading to Study Discontinuation by System Organ Class and Preferred Term – Monotherapy 
Period – Safety Population  
 
Rows 1 and 2 will change from TEAE(s) to TEAE(s) Leading to Study Discontinuation. 
o 
14.3.1.5.2 – Summary of Treatment Emergent Adverse Events Leading to Study Discontinuation by System Organ Class and Preferred Term – Combined 
Therapy Period – Safety Population  
 
Rows 1 and 2 will change from TEAE(s) to TEAE(s) Leading to Study Discontinuation. 
 
In the column headers, “ZOF 30 mg” and “AML 5mg” will change to “ZOF/AML 30/5 mg [4]” and “ZOF/AML 30/10 mg [4]”, respectively. 
o 
14.3.2.1.1 – Summary of Treatment Emergent Serious Adverse Events by System Organ Class and Preferred Term – Monotherapy Period – Safety Population 
 
Rows 1 and 2 will change from TEAE(s) to TESAE(s). 
 
Footnote [2] will change to “TESAE: Treatment Emergent Serious Adverse Event.” 
o 
14.3.2.1.2 – Summary of Treatment Emergent Serious Adverse Events by System Organ Class and Preferred Term – Combined Therapy Period – Safety 
Population 
 
Rows 1 and 2 will change from TEAE(s) to TESAE(s). 
 
In the column headers, “ZOF 30 mg” and “AML 5mg” will change to “ZOF/AML 30/5 mg [4]” and “ZOF/AML 30/10 mg [4]”, respectively. 
 
Footnote [2] will change to “TESAE: Treatment Emergent Serious Adverse Event.” 
o 
14.3.2.2.1 – Summary of Serious Adverse Drug Reactions by System Organ Class and Preferred Term – Monotherapy Period – Safety Population 
 
Rows 1 and 2 will change from TEAE(s) to Serious ADR(s). 
 
Footnote [2] will change to [Serious ADR: Serious Adverse Drug Reaction. Defined as SAEs that have a relationship of “certain,” “probable,” 
“possible,” or “unassessable.”] 
o 
14.3.2.2.2 – Summary of Serious Adverse Drug Reactions by System Organ Class and Preferred Term – Combined Therapy Period – Safety Population 
 
Rows 1 and 2 will change from TEAE(s) to Serious ADR(s). 
 
In the column headers, “ZOF 30 mg” and “AML 5mg” will change to “ZOF/AML 30/5 mg [4]” and “ZOF/AML 30/10 mg [4]”, respectively. 
 
Footnote [2] will change to [Serious ADR: Serious Adverse Drug Reaction. Defined as SAEs that have a relationship of “certain,” “probable,” 
“possible,” or “unassessable.”] 
o 
14.3.2.3.1 – Summary of Treatment Emergent Serious Adverse Events with Outcome of Death by System Organ Class and Preferred Term – Monotherapy 
Period – Safety Population 
 
Rows 1 and 2 will change from TEAE(s) to TESAE(s) with Outcome of Death. 
 
Footnote [2] will change to “TESAE: Treatment-Emergent Serious Adverse Event.” 
o 
14.3.2.3.2 – Summary of Treatment Emergent Serious Adverse Events with Outcome of Death by System Organ Class and Preferred Term – Combined 
Therapy Period – Safety Population 


 
Statistical Analysis Plan 
 
 
Confidential | MEIN/20/ZoAm-Hyp/001 | Plan Version No.: 2.0 | Plan Date: 23May2022 
Page 32 of 64 
 
 
Rows 1 and 2 will change from TEAE(s) to TESAE(s) with Outcome of Death. 
 
In the column headers, “ZOF 30 mg” and “AML 5mg” will change to “ZOF/AML 30/5 mg [4]” and “ZOF/AML 30/10 mg [4]”, respectively. 
 
Footnote [2] will change to “TESAE: Treatment-Emergent Serious Adverse Event.” 


 
Statistical Analysis Plan 
 
 
Confidential | MEIN/20/ZoAm-Hyp/001 | Plan Version No.: 2.0 | Plan Date: 23May2022 
Page 33 of 64 
 
Table 14.3.4.1.1 
Summary and Change from Baseline (Visit 1) to Visit 4 for Haematology Parameters 
(Safety Population) 
 
 
Parameter (Unit)  
 
Visit [1] 
Statistic 
ZOF/AML 30/5 mg  
(N=xx) 
ZOF/AML 30/10 mg  
(N=xx) 
All Patients 
(N=xx) 
xxxxxxx (xxx) 
 
 
 
 
 
 
 
 
 
 
 
 
Repeat for All Parameters  
Baseline (Visit 1) 
 
 
 
 
Visit 4 
 
 
 
 
Visit 4 CFB 
 
 
 
n 
Mean (SD) 
Median 
Min, Max 
 
n 
Mean (SD) 
Median 
Min, Max 
 
n 
Mean (SD) 
Median 
Min, Max 
 
xx 
xx.x (xx.xx) 
xx.x 
xx, xx 
 
xx 
xx.x (xx.xx) 
xx.x 
xx, xx 
 
xx 
xx.x (xx.xx) 
xx.x 
xx, xx 
 
xx 
xx.x (xx.xx) 
xx.x 
xx, xx 
 
xx 
xx.x (xx.xx) 
xx.x 
xx, xx 
 
xx 
xx.x (xx.xx) 
xx.x 
xx, xx 
 
xx 
xx.x (xx.xx) 
xx.x 
xx, xx 
 
xx 
xx.x (xx.xx) 
xx.x 
xx, xx 
 
xx 
xx.x (xx.xx) 
xx.x 
xx, xx 
 
[1] CFB = Change from Baseline. Visit 1 values will serve as Baseline since laboratory parameters are not assessed at Visit 2.  
Source: Listing 16.2.8.1 
Program Name: XXXX.SAS 
 
Date: DDMMMYYYY 
 
Programming Note: 
 
Patients will be classified as either ZOF/AML 30/5 mg or ZOF/AML 30/10 mg such that no patients are counted in both groups. That is, even though patients in the 
ZOF/AML 30/10 mg group are also exposed to the ZOF/AML 30/5 mg treatment, they will only be included in the ZOF/AML 30/10 mg and All Patients columns, not 
within the ZOF/AML 30/5 mg column. Same for table in the list below. 
 
Repeat for the following tables: 
o 
14.3.4.1.2 – Summary and Change from Baseline (Visit 1) to Visit 4 for Serum Chemistry Parameters – Safety Population 
 
Footnote for Source will change to “Source: Listing 16.2.8.2” 
 
Source will change to Listing 16.2.8.2 
 
 
 


 
Statistical Analysis Plan 
 
 
Confidential | MEIN/20/ZoAm-Hyp/001 | Plan Version No.: 2.0 | Plan Date: 23May2022 
Page 34 of 64 
 
Table 14.3.4.2.1 
Shift from Baseline (Visit 1) to Visit 4 for Haematology Parameters 
(Safety Population) 
 
 
 
Baseline (Visit 1) Value 
Parameter (Unit) 
Combined Therapy Group 
Visit 4 Value  
Statistic 
Normal 
Abnormal, NCS 
Abnormal, CS 
xxxxxxx (xxx) 
 
 
 
 
 
 
 
 
Repeat for All  
Parameters  
ZOF/AML 30/5 mg (N=xxx) 
 
 
 
ZOF/AML 30/10 mg (N=xxx) 
 
 
 
All Patients (N=xxx) 
Normal 
Abnormal, NCS 
Abnormal, CS 
 
Normal 
Abnormal, NCS 
Abnormal, CS 
 
Normal 
Abnormal, NCS 
Abnormal, CS 
 
n (%) 
n (%) 
n (%) 
 
n (%) 
n (%) 
n (%) 
 
n (%) 
n (%) 
n (%) 
 
xx (xx.x) 
xx (xx.x) 
xx (xx.x) 
 
xx (xx.x) 
xx (xx.x) 
xx (xx.x) 
 
xx (xx.x) 
xx (xx.x) 
xx (xx.x) 
 
xx (xx.x) 
xx (xx.x) 
xx (xx.x) 
 
xx (xx.x) 
xx (xx.x) 
xx (xx.x) 
 
xx (xx.x) 
xx (xx.x) 
xx (xx.x) 
 
xx (xx.x) 
xx (xx.x) 
xx (xx.x) 
 
xx (xx.x) 
xx (xx.x) 
xx (xx.x) 
 
xx (xx.x) 
xx (xx.x) 
xx (xx.x) 
 
Source: Listing 16.2.8.1 
Program Name: XXXX.SAS 
 
Date: DDMMMYYYY 
 
Programming Note: 
 
Patients will be classified as either ZOF/AML 30/5 mg or ZOF/AML 30/10 mg such that no patients are counted in both groups. That is, even though patients in the 
ZOF/AML 30/10 mg group are also exposed to the ZOF/AML 30/5 mg treatment, they will only be included in the ZOF/AML 30/10 mg and All Patients sections, not 
within the ZOF/AML 30/5 mg section. Same for table in the list below. 
 
Repeat for the following tables:  
o 
14.3.4.2.2 – Shift from Baseline (Visit 1) to Visit 4 for Serum Chemistry Parameters – Safety Population 
 
Source will change to Listing 16.2.8.2 
 
 


 
Statistical Analysis Plan 
 
 
Confidential | MEIN/20/ZoAm-Hyp/001 | Plan Version No.: 2.0 | Plan Date: 23May2022 
Page 35 of 64 
 
Table 14.3.5 
Summary of Study Drug Accountability, Exposure, and Adherence 
(Safety Population) 
 
 
Visit 
Parameter [1,2,3] 
Statistic 
ZOF 30 mg 
AML 5 mg 
AML 10 mg 
Visit 1 (Week -4) 
 
 
 
 
Visit 2 (Week 0) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Visit 3 (Week 4) 
 
 
 
 
 
 
 
 
 
 
 
IP Dispensed (tablets) 
 
 
 
 
IP Dispensed (tablets) 
 
 
 
 
IP Returned (tablets) 
 
 
 
 
Adherence (%) Derived 
 
 
 
Adherence (%) CRF 
     < 80% 
     ≥ 80% and ≤ 120% 
     > 120%  
 
IP Dispensed (tablets) 
 
 
 
 
IP Returned (tablets) 
 
 
 
 
 
 
n 
Mean (SD) 
Median 
Min, Max 
 
n 
Mean (SD) 
Median 
Min, Max 
 
n 
Mean (SD) 
Median 
Min, Max 
 
n 
Mean (SD) 
Median 
Min, Max 
 
n/N (%) 
n/N (%) 
n/N (%) 
 
n 
Mean (SD) 
Median 
Min, Max 
 
n 
Mean (SD) 
Median 
Min, Max 
 
 
 
xx 
xx.x (xx.xx) 
xx.x 
xx, xx 
 
xx 
xx.x (xx.xx) 
xx.x 
xx, xx 
 
xx 
xx.x (xx.xx) 
xx.x 
xx, xx 
 
xx 
xx.x (xx.xx) 
xx.x 
xx, xx 
 
xx/xx (xx.x) 
xx/xx (xx.x) 
xx/xx (xx.x) 
 
xx 
xx.x (xx.xx) 
xx.x 
xx, xx 
 
xx 
xx.x (xx.xx) 
xx.x 
xx, xx 
 
 
 
xx 
xx.x (xx.xx) 
xx.x 
xx, xx 
 
xx 
xx.x (xx.xx) 
xx.x 
xx, xx 
 
xx 
xx.x (xx.xx) 
xx.x 
xx, xx 
 
xx 
xx.x (xx.xx) 
xx.x 
xx, xx 
 
xx/xx (xx.x) 
xx/xx (xx.x) 
xx/xx (xx.x) 
 
xx 
xx.x (xx.xx) 
xx.x 
xx, xx 
 
xx 
xx.x (xx.xx) 
xx.x 
xx, xx 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
xx 
xx.x (xx.xx) 
xx.x 
xx, xx 
 
 
 
 
 
 
 
 


 
Statistical Analysis Plan 
 
 
Confidential | MEIN/20/ZoAm-Hyp/001 | Plan Version No.: 2.0 | Plan Date: 23May2022 
Page 36 of 64 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Visit 4 (Week 8) 
Adherence (%) Derived 
     Individual IP 
 
 
 
 
     Combined IP (ZOF/AML) 
 
 
 
Adherence (%) CRF 
     < 80% 
     ≥ 80% and ≤ 120% 
     > 120%  
 
IP Returned (tablets) 
 
 
 
 
Adherence (%) Derived 
     Individual IP 
 
 
 
 
     Combined IP (ZOF/AML) 
 
 
 
Adherence (%) CRF 
     < 80% 
     ≥ 80% and ≤ 120% 
     > 120%  
 
 
n 
Mean (SD) 
Median 
Min, Max 
 
n 
Mean (SD) 
Median 
Min, Max 
 
n/N (%) 
n/N (%) 
n/N (%) 
 
n 
Mean (SD) 
Median 
Min, Max 
 
 
n 
Mean (SD) 
Median 
Min, Max 
 
n 
Mean (SD) 
Median 
Min, Max 
 
n/N (%) 
n/N (%) 
n/N (%) 
 
 
xx 
xx.x (xx.xx) 
xx.x 
xx, xx 
 
 
 
 
 
 
 
 
 
 
xx 
xx.x (xx.xx) 
xx.x 
xx, xx 
 
 
xx 
xx.x (xx.xx) 
xx.x 
xx, xx 
 
 
 
 
 
 
 
 
xx 
xx.x (xx.xx) 
xx.x 
xx, xx 
 
xx 
xx.x (xx.xx) 
xx.x 
xx, xx 
 
xx/xx (xx.x) 
xx/xx (xx.x) 
xx/xx (xx.x) 
 
xx 
xx.x (xx.xx) 
xx.x 
xx, xx 
 
 
xx 
xx.x (xx.xx) 
xx.x 
xx, xx 
 
xx 
xx.x (xx.xx) 
xx.x 
xx, xx 
 
xx/xx (xx.x) 
xx/xx (xx.x) 
xx/xx (xx.x) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
xx 
xx.x (xx.xx) 
xx.x 
xx, xx 
 
 
xx 
xx.x (xx.xx) 
xx.x 
xx, xx 
 
xx 
xx.x (xx.xx) 
xx.x 
xx, xx 
 
xx/xx (xx.x) 
xx/xx (xx.x) 
xx/xx (xx.x) 
 
[1] Adherence is reported in the CRF and derived directly for each patient using the following formula: Adherence (%)=100*(actual doses taken/planned dose). 
[2] A patient who has taken at least 80% and no more than 120% of the required study medication intake since the last visit will be considered as compliant. 
[3] Values for Adherence CRF and Adherence Derived for Combined IP (ZOF/AML) are presented at Visits 3 and 4 under the corresponding AML columns (AML 5 mg at Visit 3, 
AML 5 mg at Visit 4 for patients on the ZOF/AML 30/5 mg regimen, and AML 10 mg at Visit 4 for patients up-titrated to the ZOF/AML 30/10 mg regimen). 
Source: Listings 16.2.5.1, 16.2.5.2, 16.2.5.3 
Program Name: XXXX.SAS 
 
Date: DDMMMYYYY 


 
Statistical Analysis Plan 
 
 
Confidential | MEIN/20/ZoAm-Hyp/001 | Plan Version No.: 2.0 | Plan Date: 23May2022 
Page 37 of 64 
 
Table 14.3.6.1 
Summary and Change from Screening (Visit 1) to Baseline (Visit 2) for Vital Sign Parameters – Monotherapy Period 
(Safety Population) 
 
 
Parameter (Unit)  
 
Visit [1] 
Statistic 
ZOF 30 mg  
(N=xx) 
AML 5 mg  
(N=xx) 
All Patients 
(N=xx) 
xxxxxxx (xxx) 
 
 
 
 
 
 
 
 
 
 
 
Repeat for All Vital Sign 
Parameters  
Screening (Visit 1) 
 
 
 
 
Baseline (Visit 2) 
 
 
 
 
Baseline (Visit 2) 
CFS 
 
 
n 
Mean (SD) 
Median 
Min, Max 
 
n 
Mean (SD) 
Median 
Min, Max 
 
n 
Mean (SD) 
Median 
Min, Max 
 
xx 
xx.x (xx.xx) 
xx.x 
xx, xx 
 
xx 
xx.x (xx.xx) 
xx.x 
xx, xx 
 
xx 
xx.x (xx.xx) 
xx.x 
xx, xx 
 
xx 
xx.x (xx.xx) 
xx.x 
xx, xx 
 
xx 
xx.x (xx.xx) 
xx.x 
xx, xx 
 
xx 
xx.x (xx.xx) 
xx.x 
xx, xx 
 
xx 
xx.x (xx.xx) 
xx.x 
xx, xx 
 
xx 
xx.x (xx.xx) 
xx.x 
xx, xx 
 
xx 
xx.x (xx.xx) 
xx.x 
xx, xx 
 
[1] CFS = Change from Screening (Visit 1). 
Source: Listing 16.2.9 
Program Name: XXXX.SAS 
 
Date: DDMMMYYYY 
 
 


 
Statistical Analysis Plan 
 
 
Confidential | MEIN/20/ZoAm-Hyp/001 | Plan Version No.: 2.0 | Plan Date: 23May2022 
Page 38 of 64 
 
Table 14.3.6.2 
Summary and Change from Baseline (Visit 2) to Visit 4 for Vital Sign Parameters – Combined Therapy Period 
(Safety Population) 
 
 
Parameter (Unit)  
 
Visit [1] 
Statistic 
ZOF/AML 30/5 mg  
(N=xx) 
ZOF/AML 30/10 mg  
(N=xx) 
All Patients 
(N=xx) 
xxxxxxx (xxx) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Repeat for All Vital Sign 
Parameters  
Baseline (Visit 2) 
 
 
 
 
Visit 3 
 
 
 
 
Visit 3 CFB 
 
 
 
 
Visit 4 
 
 
 
 
Visit 4 CFB 
 
 
n 
Mean (SD) 
Median 
Min, Max 
 
n 
Mean (SD) 
Median 
Min, Max 
 
n 
Mean (SD) 
Median 
Min, Max 
 
n 
Mean (SD) 
Median 
Min, Max 
 
n 
Mean (SD) 
Median 
Min, Max 
 
xx 
xx.x (xx.xx) 
xx.x 
xx, xx 
 
xx 
xx.x (xx.xx) 
xx.x 
xx, xx 
 
xx 
xx.x (xx.xx) 
xx.x 
xx, xx 
 
xx 
xx.x (xx.xx) 
xx.x 
xx, xx 
 
xx 
xx.x (xx.xx) 
xx.x 
xx, xx 
 
xx 
xx.x (xx.xx) 
xx.x 
xx, xx 
 
xx 
xx.x (xx.xx) 
xx.x 
xx, xx 
 
xx 
xx.x (xx.xx) 
xx.x 
xx, xx 
 
xx 
xx.x (xx.xx) 
xx.x 
xx, xx 
 
xx 
xx.x (xx.xx) 
xx.x 
xx, xx 
 
xx 
xx.x (xx.xx) 
xx.x 
xx, xx 
 
xx 
xx.x (xx.xx) 
xx.x 
xx, xx 
 
xx 
xx.x (xx.xx) 
xx.x 
xx, xx 
 
xx 
xx.x (xx.xx) 
xx.x 
xx, xx 
 
xx 
xx.x (xx.xx) 
xx.x 
xx, xx 
 
[1] CFB = Change from Baseline (Visit 2).   
Source: Listing 16.2.9 
Program Name: XXXX.SAS 
 
Date: DDMMMYYYY 
 
Programming Note:  
 
Patients will be classified as either ZOF/AML 30/5 mg or ZOF/AML 30/10 mg such that no patients are counted in both groups. That is, even though patients in the 
ZOF/AML 30/10 mg group are also exposed to the ZOF/AML 30/5 mg treatment, they will only be included in the ZOF/AML 30/10 mg and All Patients columns, not 
within the ZOF/AML 30/5 mg column.  
 
 


 
Statistical Analysis Plan 
 
 
Confidential | MEIN/20/ZoAm-Hyp/001 | Plan Version No.: 2.0 | Plan Date: 23May2022 
Page 39 of 64 
 
Table 14.3.7.1 
Shift from Screening (Visit 1) to Baseline (Visit 2) for Physical Examination – Monotherapy Period 
(Safety Population) 
 
 
 
Baseline (Visit 2) Value  
Screening (Visit 1) Value 
Body System 
Monotherapy Group 
Statistic 
Normal 
Abnormal, NCS 
Abnormal, CS 
xxxxxxx  
 
 
 
 
 
 
 
 
Repeat for All  
Body Systems  
ZOF 30 mg (N=xxx) 
 
 
 
AML 5 mg (N=xxx) 
 
 
 
All Patients (N=xxx) 
Normal 
Abnormal, NCS 
Abnormal, CS 
 
Normal 
Abnormal, NCS 
Abnormal, CS 
 
Normal 
Abnormal, NCS 
Abnormal, CS 
 
n (%) 
n (%) 
n (%) 
 
n (%) 
n (%) 
n (%) 
 
n (%) 
n (%) 
n (%) 
 
xx (xx.x) 
xx (xx.x) 
xx (xx.x) 
 
xx (xx.x) 
xx (xx.x) 
xx (xx.x) 
 
xx (xx.x) 
xx (xx.x) 
xx (xx.x) 
 
xx (xx.x) 
xx (xx.x) 
xx (xx.x) 
 
xx (xx.x) 
xx (xx.x) 
xx (xx.x) 
 
xx (xx.x) 
xx (xx.x) 
xx (xx.x) 
 
xx (xx.x) 
xx (xx.x) 
xx (xx.x) 
 
xx (xx.x) 
xx (xx.x) 
xx (xx.x) 
 
xx (xx.x) 
xx (xx.x) 
xx (xx.x) 
 
Source: Listing 16.2.10 
Program Name: XXXX.SAS 
 
Date: DDMMMYYYY 
 
 


 
Statistical Analysis Plan 
 
 
Confidential | MEIN/20/ZoAm-Hyp/001 | Plan Version No.: 2.0 | Plan Date: 23May2022 
Page 40 of 64 
 
Table 14.3.7.2 
Shift from Baseline (Visit 2) to Visit 4 for Physical Examination – Combined Therapy Period 
(Safety Population) 
 
 
 
 
Visit Value  
Baseline (Visit 2) Value 
Body System 
Combined Therapy Group 
Visit 
Statistic 
Normal 
Abnormal, NCS 
Abnormal, CS 
xxxxxxx  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Repeat for All  
Body Systems  
ZOF/AML 30/5 mg (N=xxx) 
 
 
 
 
 
 
 
ZOF/AML 30/10 mg (N=xxx) 
 
 
 
 
 
 
 
All Patients (N=xxx) 
 
 
Visit 3 
 
 
 
Visit 4 
 
 
 
Visit 3 
 
 
 
Visit 4 
 
 
 
Visit 3 
 
 
 
Visit 4 
Normal 
Abnormal, NCS 
Abnormal, CS 
 
Normal 
Abnormal, NCS 
Abnormal, CS 
 
Normal 
Abnormal, NCS 
Abnormal, CS 
 
Normal 
Abnormal, NCS 
Abnormal, CS 
 
Normal 
Abnormal, NCS 
Abnormal, CS 
 
Normal 
Abnormal, NCS 
Abnormal, CS 
 
n (%) 
n (%) 
n (%) 
 
n (%) 
n (%) 
n (%) 
 
n (%) 
n (%) 
n (%) 
 
n (%) 
n (%) 
n (%) 
 
n (%) 
n (%) 
n (%) 
 
n (%) 
n (%) 
n (%) 
 
xx (xx.x) 
xx (xx.x) 
xx (xx.x) 
 
xx (xx.x) 
xx (xx.x) 
xx (xx.x) 
 
xx (xx.x) 
xx (xx.x) 
xx (xx.x) 
 
xx (xx.x) 
xx (xx.x) 
xx (xx.x) 
 
xx (xx.x) 
xx (xx.x) 
xx (xx.x) 
 
xx (xx.x) 
xx (xx.x) 
xx (xx.x) 
 
xx (xx.x) 
xx (xx.x) 
xx (xx.x) 
 
xx (xx.x) 
xx (xx.x) 
xx (xx.x) 
 
xx (xx.x) 
xx (xx.x) 
xx (xx.x) 
 
xx (xx.x) 
xx (xx.x) 
xx (xx.x) 
 
xx (xx.x) 
xx (xx.x) 
xx (xx.x) 
 
xx (xx.x) 
xx (xx.x) 
xx (xx.x) 
 
xx (xx.x) 
xx (xx.x) 
xx (xx.x) 
 
xx (xx.x) 
xx (xx.x) 
xx (xx.x) 
 
xx (xx.x) 
xx (xx.x) 
xx (xx.x) 
 
xx (xx.x) 
xx (xx.x) 
xx (xx.x) 
 
xx (xx.x) 
xx (xx.x) 
xx (xx.x) 
 
xx (xx.x) 
xx (xx.x) 
xx (xx.x) 
 
Source: Listing 16.2.10 
Program Name: XXXX.SAS 
 
Date: DDMMMYYYY 
 
Programming Note:  
 
Patients will be classified as either ZOF/AML 30/5 mg or ZOF/AML 30/10 mg such that no patients are counted in both groups. That is, even though patients in the 
ZOF/AML 30/10 mg group are also exposed to the ZOF/AML 30/5 mg treatment, they will only be included in the ZOF/AML 30/10 mg and All Patients sections, not 
within the ZOF/AML 30/5 mg section.  
 
 
 
 


 
Statistical Analysis Plan 
 
 
Confidential | MEIN/20/ZoAm-Hyp/001 | Plan Version No.: 2.0 | Plan Date: 23May2022 
Page 41 of 64 
 
Table 14.3.8.1 
Summary and Change from Baseline (Visit 1) to Visit 4 for Electrocardiogram (ECG) Parameters 
(Safety Population) 
 
Parameter (Unit) 
Visit [1] 
Statistic 
ZOF/AML 30/5 mg  
(N=xx) 
ZOF/AML 30/10 mg  
(N=xx) 
All Patients 
(N=xx) 
Rhythm 
     Sinusal 
     Other 
 
 
 
 
xxxxxxx (xxx) 
 
 
 
 
 
 
 
 
 
 
 
Repeat for All  
Parameters 
 
Baseline (Visit 1) 
 
 
Visit 4  
 
 
 
Baseline (Visit 1) 
 
 
 
 
Visit 4 
 
 
 
 
Visit 4 CFB 
 
 
 
 
n (%) 
n (%) 
 
n (%) 
n (%) 
 
n 
Mean (SD) 
Median 
Min, Max 
 
n 
Mean (SD) 
Median 
Min, Max 
 
n 
Mean (SD) 
Median 
Min, Max 
 
 
xx (xx.x) 
xx (xx.x) 
 
xx (xx.x) 
xx (xx.x) 
 
xx 
xx.x (xx.xx) 
xx.x 
xx, xx 
 
xx 
xx.x (xx.xx) 
xx.x 
xx, xx 
 
xx 
xx.x (xx.xx) 
xx.x 
xx, xx 
 
 
xx (xx.x) 
xx (xx.x) 
 
xx (xx.x) 
xx (xx.x) 
 
xx 
xx.x (xx.xx) 
xx.x 
xx, xx 
 
xx 
xx.x (xx.xx) 
xx.x 
xx, xx 
 
xx 
xx.x (xx.xx) 
xx.x 
xx, xx 
 
 
xx (xx.x) 
xx (xx.x) 
 
xx (xx.x) 
xx (xx.x) 
 
xx 
xx.x (xx.xx) 
xx.x 
xx, xx 
 
xx 
xx.x (xx.xx) 
xx.x 
xx, xx 
 
xx 
xx.x (xx.xx) 
xx.x 
xx, xx 
 
[1] CFB: Change from Baseline. Visit 1 values will serve as Baseline since ECG parameters are not assessed at Visit 2. 
Source: Listing 16.2.11 
Program Name: XXXX.SAS 
 
Date: DDMMMYYYY 
 
Programming Note: 
 
Patients will be classified as either ZOF/AML 30/5 mg or ZOF/AML 30/10 mg such that no patients are counted in both groups. That is, even though patients in the 
ZOF/AML 30/10 mg group are also exposed to the ZOF/AML 30/5 mg treatment, they will only be included in the ZOF/AML 30/10 mg and All Patients columns, not 
within the ZOF/AML 30/5 mg column. 
 
 


 
Statistical Analysis Plan 
 
 
Confidential | MEIN/20/ZoAm-Hyp/001 | Plan Version No.: 2.0 | Plan Date: 23May2022 
Page 42 of 64 
 
Table 14.3.8.2 
Shift from Baseline (Visit 1) to Visit 4 for ECG Interpretation 
(Safety Population) 
 
 
 
Baseline (Visit 1) Value 
Parameter  
Combined Therapy Group 
Visit 4 Value  
Statistic 
Normal 
Abnormal, NCS 
Abnormal, CS 
Interpretation 
 
 
 
 
 
 
 
 
  
ZOF/AML 30/5 mg (N=xxx) 
 
 
 
ZOF/AML 30/10 mg (N=xxx) 
 
 
 
All Patients (N=xxx) 
Normal 
Abnormal, NCS 
Abnormal, CS 
 
Normal 
Abnormal, NCS 
Abnormal, CS 
 
Normal 
Abnormal, NCS 
Abnormal, CS 
 
n (%) 
n (%) 
n (%) 
 
n (%) 
n (%) 
n (%) 
 
n (%) 
n (%) 
n (%) 
 
xx (xx.x) 
xx (xx.x) 
xx (xx.x) 
 
xx (xx.x) 
xx (xx.x) 
xx (xx.x) 
 
xx (xx.x) 
xx (xx.x) 
xx (xx.x) 
 
xx (xx.x) 
xx (xx.x) 
xx (xx.x) 
 
xx (xx.x) 
xx (xx.x) 
xx (xx.x) 
 
xx (xx.x) 
xx (xx.x) 
xx (xx.x) 
 
xx (xx.x) 
xx (xx.x) 
xx (xx.x) 
 
xx (xx.x) 
xx (xx.x) 
xx (xx.x) 
 
xx (xx.x) 
xx (xx.x) 
xx (xx.x) 
 
Source: Listing 16.2.11 
Program Name: XXXX.SAS 
 
Date: DDMMMYYYY 
 
Programming Note: 
 
Patients will be classified as either ZOF/AML 30/5 mg or ZOF/AML 30/10 mg such that no patients are counted in both groups. That is, even though patients in the 
ZOF/AML 30/10 mg group are also exposed to the ZOF/AML 30/5 mg treatment, they will only be included in the ZOF/AML 30/10 mg and All Patients sections, not 
within the ZOF/AML 30/5 mg section. 
 
 
 
 
 
 
 
 


 
Statistical Analysis Plan 
 
 
Confidential | MEIN/20/ZoAm-Hyp/001 | Plan Version No.: 2.0 | Plan Date: 23May2022 
Page 43 of 64 
 
Table 14.3.9.1 
Summary of Prior Medications by ATC Class Level 1 and Preferred Term 
(Safety Population) 
 
Medication Name [1,2,3] 
Statistic 
ZOF/AML 30/5 mg  
(N=xx) 
ZOF/AML 30/10 mg  
(N=xx) 
All Patients 
(N=xx) 
Number of Patients with at Least One Prior Medication  
 
ATC Class Level 1 #1  
     Preferred Term #1 
     Preferred Term #2 
     Preferred Term #3 
     etc. 
 
ATC Class Level 1 #2 
     Preferred Term #1 
     Preferred Term #2 
     Preferred Term #3 
     etc. 
n (%) 
 
n (%) 
n (%) 
n (%) 
n (%) 
 
 
n (%) 
n (%) 
n (%) 
n (%) 
xx (xx.x) 
 
xx (xx.x) 
xx (xx.x) 
xx (xx.x) 
xx (xx.x) 
 
 
xx (xx.x) 
xx (xx.x) 
xx (xx.x) 
xx (xx.x) 
xx (xx.x) 
 
xx (xx.x) 
xx (xx.x) 
xx (xx.x) 
xx (xx.x) 
 
 
xx (xx.x) 
xx (xx.x) 
xx (xx.x) 
xx (xx.x) 
xx (xx.x) 
 
xx (xx.x) 
xx (xx.x) 
xx (xx.x) 
xx (xx.x) 
 
 
xx (xx.x) 
xx (xx.x) 
xx (xx.x) 
xx (xx.x) 
[1] Patients will be counted once per ATC Class/Preferred Term. 
[2] WHO Drug Dictionary version Sep 2020 was used to code medication names. 
[3] Prior medication is defined as any medication taken within 30 days prior to the start of the study which has a stop date prior to the date of first dose of monotherapy (ZOF 30 
mg or AML 5 mg). 
Source: Listing 16.2.12.1 
Program Name: XXXX.SAS 
 
Date: DDMMMYYYY 
 
Programming Note: 
 
Patients will be classified as either ZOF/AML 30/5 mg or ZOF/AML 30/10 mg such that no patients are counted in both groups. That is, even though patients in the 
ZOF/AML 30/10 mg group are also exposed to the ZOF/AML 30/5 mg treatment, they will only be included in the ZOF/AML 30/10 mg and All Patients columns, not 
within the ZOF/AML 30/5 mg column. 
 
Repeat for 14.3.9.2 – Summary of Concomitant Medications by ATC Class Level 1 and Preferred Term – Safety Population 
o 
First row text will change from “…Prior Medication” to “…Concomitant Medication”  
o 
Footnote [3] will change to “Concomitant medication is defined as any medication with a start date on or before the date of last dose of study drug and is 
ongoing or has a stop date on or after date of first dose of monotherapy (ZOF 30 mg or AML 5 mg).


 
Statistical Analysis Plan 
 
 
Confidential | MEIN/20/ZoAm-Hyp/001 | Plan Version No.: 2.0 | Plan Date: 23May2022 
Page 44 of 64 
 
 
 
Listings  
Listing 16.2.1 
Patient Enrollment and Disposition 
(Full Analysis Set) 
 
 
Patient ID 
Analysis  
Population [1] 
Disposition 
Completed Monotherapy/ 
Completed Combined Therapy 
 
Date of Last Monotherapy/ 
Date of Last Combined Therapy 
Date of Study 
Completion  
or Discontinuation 
Reason for Study  
Discontinuation  
or Screen Failure 
xxxxxx 
 
SAF, 
EFF, 
PP 
 
Screen Failure,  
Completed,  
Discontinued  
 
Yes, No/ 
Yes, No 
 
DDMMMYYYY/ 
DDMMMYYYY 
DDMMMYYYY 
xxxxxxxx 
 
[1] SAF: Safety Population. EFF: Efficacy Population. PP: Per Protocol Population.  
Source: SDTM.XXXX or ADaM.XXXX 
Program Name: XXXX.SAS 
 
Date: DDMMMYYYY 
 
Programming Note: 
 
Analysis Population column should list all populations to which the patient belongs. 
 
 
 
 


 
Statistical Analysis Plan 
 
 
Confidential | MEIN/20/ZoAm-Hyp/001 | Plan Version No.: 2.0 | Plan Date: 23May2022 
Page 45 of 64 
 
 
 
Listing 16.2.2 
Protocol Deviations  
(Full Analysis Set) 
 
Patient ID 
Analysis  
Population [1] 
 
Date of Deviation 
Deviation Grade [2] 
 
Deviation Category 
Deviation Description 
xxxxxx 
 
SAF, 
EFF, 
PP 
 
DDMMMYYYY 
Critical, 
Major, 
Minor 
 
xxxxxxxx 
xxxxxxxx 
 
[1] SAF: Safety Population. EFF: Efficacy Population. PP: Per Protocol Population.  
[2] Critical deviations will be classified as Major for purposes of defining the PP Population but are displayed here as Critical. 
Source: SDTM.XXXX or ADaM.XXXX 
Program Name: XXXX.SAS 
 
Date: DDMMMYYYY 
 
Programming Note: 
 
Analysis Population column should list all populations to which the patient belongs. 
 
 
 
 
 


 
Statistical Analysis Plan 
 
 
Confidential | MEIN/20/ZoAm-Hyp/001 | Plan Version No.: 2.0 | Plan Date: 23May2022 
Page 46 of 64 
 
 
 
Listing 16.2.3 
Patients Excluded from Analysis Populations 
(Full Analysis Set) 
 
Patient ID 
Safety Population [1] 
Efficacy  
Population [2] 
Per Protocol  
Population [3] 
 
Reason for Exclusion 
xxxxxx 
 
Yes, 
No 
 
Yes, 
No 
Yes, 
No 
Did Not Meet all Screening Criteria/Did Not Enroll 
Did Not Receive At Least One Dose During Run-In 
Did Not Complete Run-In Period 
Did Not Complete V2 BP Assessment  
Not Dosed According to Protocol 
Did Not Complete Required Study Visits 
Major Protocol Deviation That May Impact the Primary 
Efficacy Assessment 
 
[1] Safety Population (SAF): All study participants who sign informed consent, meet all screening criteria, are enrolled, and receive at least one dose of the assigned treatment 
during the run-in period. 
[2] Efficacy Population (EFF): All study participants in the Safety Population who complete the 4-week run-in period and the Visit 2 blood pressure assessment.  
[3] Per Protocol Population (PP): All study participants in the Efficacy Population who were dosed according to the protocol, complete the required study visits, and do not 
experience any major protocol deviations that may impact the primary efficacy assessment through end of treatment.   
Source: SDTM.XXXX or ADaM.XXXX 
Program Name: XXXX.SAS 
 
Date: DDMMMYYYY 
 
 
 
 


 
Statistical Analysis Plan 
 
 
Confidential | MEIN/20/ZoAm-Hyp/001 | Plan Version No.: 2.0 | Plan Date: 23May2022 
Page 47 of 64 
 
 
 
Listing 16.2.4.1 
Demographic Characteristics 
(Safety Population) 
 
Patient ID 
Analysis 
Population [1] 
Age  
(Years) 
 
Sex 
Ethnicity 
 
Race 
Height 
(cm) 
Weight 
(kg) 
BMI 
(kg/m2) 
xxxxxx 
 
SAF, 
EFF, 
PP 
 
xx 
 
Male, 
Female, 
Unknown/ 
Undifferentiated 
Hispanic or Latino, 
Not Hispanic or Latino, 
Not Reported, 
Unknown 
 
American Indian or Alaska Native, 
Asian, 
Black or African American, 
Native Hawaiian or Other Pacific Islander, 
White, 
Other (Specify) 
 
xxx.xx 
xxx.xx 
xx.xx 
[1] SAF: Safety Population. EFF: Efficacy Population. PP: Per Protocol Population.  
Source: SDTM.XXXX or ADaM.XXXX 
Program Name: XXXX.SAS 
 
Date: DDMMMYYYY 
 
Programming Note: 
 
Analysis Population column should list all populations to which the patient belongs. 
 
 
 


 
Statistical Analysis Plan 
 
 
Confidential | MEIN/20/ZoAm-Hyp/001 | Plan Version No.: 2.0 | Plan Date: 23May2022 
Page 48 of 64 
 
 
 
Listing 16.2.4.2 
Baseline Characteristics 
(Safety Population) 
 
Patient ID 
Analysis 
Population [1] 
Smoking Status 
 
Smoking Frequency 
 
e-Cigarette Details 
Medical History 
 
Treatment at Run-In 
 
Study Site 
xxxxxx 
 
SAF, 
EFF, 
PP 
 
Never Tobacco Smoker, 
Former Tobacco Smoker, 
Current Tobacco Smoker, 
Undisclosed 
 
Daily, 
Occasional 
xxxxx 
Hypertension Grade 1, 
Hypertension Grade 2, 
Diabetes mellitus, 
Hypercholesterolemia 
Zofenopril 30 mg, 
Amlodipine 5 mg, 
Other ACE-i, 
Other CCB 
 
201, 
202, 
etc. 
[1] SAF: Safety Population. EFF: Efficacy Population. PP: Per Protocol Population.  
Source: SDTM.XXXX or ADaM.XXXX 
Program Name: XXXX.SAS 
 
Date: DDMMMYYYY 
 
Programming Note: 
 
Analysis Population column should list all populations to which the patient belongs. 
 
Smoking Frequency should only be populated when Smoking Status is “Former Tobacco Smoker” or “Current Tobacco Smoker.”  
 
E-Cigarette details should only be populated if the checkbox for e-cigarette use is checked in the EDC (raw.dm.smkesig). 
 
 
 


 
Statistical Analysis Plan 
 
 
Confidential | MEIN/20/ZoAm-Hyp/001 | Plan Version No.: 2.0 | Plan Date: 23May2022 
Page 49 of 64 
 
 
 
Listing 16.2.5.1 
Study Drug Accountability and Adherence 
(Safety Population) 
 
Patient 
ID 
Analysis 
Population [1] 
 
Visit [2] 
Dispensed/ 
Returned 
Date/Time of 
Dispensation/Return 
Medication  
Type 
CTM 
Code 
 
IP Amount 
Uncontrolled  
Sitting BP [3] 
Tx Well  
Tolerated [4] 
Adherence (%) Derived/ 
Adherence (%) CRF [5] 
xxxxxx 
 
SAF, 
EFF, 
PP 
 
Visit 1 
 
 
Visit 2 
 
 
 
 
Visit 3 
 
 
 
 
Visit 4 
Dispensed 
 
 
Dispensed 
 
Returned 
 
 
Dispensed 
 
Returned 
 
 
Returned 
 
DDMMMYYYY/HH:MM 
 
 
DDMMMYYYY/HH:MM 
 
DDMMMYYYY/HH:MM 
 
 
DDMMMYYYY/HH:MM 
 
DDMMMYYYY/HH:MM 
 
 
DDMMMYYYY/HH:MM 
ZOF 30 mg or  
AML 5mg 
 
ZOF 30 mg 
AML 5 mg 
ZOF 30 mg or  
AML 5mg 
 
ZOF 30 mg 
AML x mg  
ZOF 30 mg 
AML 5 mg 
 
ZOF 30 mg 
AML x mg  
 
xxxxxxx 
 
 
xxxxxxx 
xxxxxxx 
xxxxxxx 
 
 
xxxxxxx 
xxxxxxx 
xxxxxxx 
xxxxxxx 
 
xxxxxxx 
xxxxxxx 
xx tablets 
 
 
xx tablets 
xx tablets 
xx tablets 
 
 
xx tablets 
xx tablets 
xx tablets 
xx tablets 
 
xx tablets 
xx tablets 
 
 
 
Yes, No 
 
 
 
 
Yes, No 
 
 
 
 
 
 
 
 
Yes, No 
 
 
 
 
Yes, No 
 
 
 
xx.x/ 
< 80%, 
≥ 80% and ≤ 120%, 
> 120%  
 
xx.x/ 
< 80%, 
≥ 80% and ≤ 120%, 
> 120% 
 
xx.x/ 
< 80%, 
≥ 80% and ≤ 120%, 
> 120% 
 
[1] SAF: Safety Population. EFF: Efficacy Population. PP: Per Protocol Population.  
[2] Visit 1 is Week -4. Visit 2 is Week 0. Visit 3 is Week 4. Visit 4 is Week 8. 
[3] Uncontrolled sitting BP = SBP/DBP > 130/80mmHg. 
[4] Tx = Treatment. 
[5] Adherence is reported in the CRF and derived directly for each patient using the following formula: Adherence (%)=100*(actual doses taken/planned dose). 
Source: SDTM.XXXX or ADaM.XXXX 
Program Name: XXXX.SAS 
 
Date: DDMMMYYYY 
 
 
 


 
Statistical Analysis Plan 
 
 
Confidential | MEIN/20/ZoAm-Hyp/001 | Plan Version No.: 2.0 | Plan Date: 23May2022 
Page 50 of 64 
 
 
 
Listing 16.2.5.2 
Study Drug Exposure 
(Safety Population) 
 
Patient ID 
Analysis  
Population [1] 
 
Visit [2] 
 
Therapy Type 
 
Medication Type 
 
Start Date/Time 
 
End Date/Time  
xxxxxx 
 
SAF, 
EFF, 
PP 
 
Visit 1 
 
 
Visit 2 
 
 
Visit 3 
 
 
Monotherapy 
 
 
Combination  
 
 
Combination  
 
 
ZOF 30 mg or 
AML 5 mg 
 
ZOF 30 mg 
AML 5 mg 
 
ZOF 30 mg 
AML x mg 
 
DDMMMYYYY/HH:MM 
 
 
DDMMMYYYY/HH:MM 
DDMMMYYYY/HH:MM 
 
DDMMMYYYY/HH:MM 
DDMMMYYYY/HH:MM 
 
DDMMMYYYY/HH:MM or 
DDMMMYYYY/HH:MM 
 
DDMMMYYYY/HH:MM 
DDMMMYYYY/HH:MM 
 
DDMMMYYYY/HH:MM 
DDMMMYYYY/HH:MM 
 
[1] SAF: Safety Population. EFF: Efficacy Population. PP: Per Protocol Population.  
[2] Visit 1 is Week -4. Visit 2 is Week 0. Visit 3 is Week 4. Visit 4 is Week 8. 
Source: SDTM.XXXX or ADaM.XXXX 
Program Name: XXXX.SAS 
 
Date: DDMMMYYYY 
 
 
 


 
Statistical Analysis Plan 
 
 
Confidential | MEIN/20/ZoAm-Hyp/001 | Plan Version No.: 2.0 | Plan Date: 23May2022 
Page 51 of 64 
 
 
 
Listing 16.2.5.3 
Modified, Missing, and Interrupted Doses 
(Safety Population) 
 
Patient 
ID 
 
Analysis  
Populat
ion [1] 
 
 
Visit [2] 
 
 
Type 
 
 
Dose Modification 
 
Dose Missed/ 
Interrupted 
 
Missed/ 
Interrupted by 
Interruption 
Start Date/Time 
Restart Date/Time 
Reason for Dose 
Modified, 
Missing, Interrupted 
 
 
AE # 
xxxxxx 
 
SAF, 
EFF, 
PP 
 
Visit 2 
Visit 3 
Visit 4 
Modification 
Missed Dose 
Interruption 
 
Dose Increased, 
Dose Reduced, 
Drug Withdrawal, 
Unknown 
 
 
ZOF 30 mg, 
AML 5 mg, 
AML 10 mg, 
ZOF/AML 30/5 mg, 
ZOF/AML 30/10 mg 
 
Investigator, 
Patient 
 
DDMMMYYYY/HH:MM 
DDMMMYYYY/HH:MM 
 
 
 
Adverse Event, 
Other, Specify 
 
 
xx 
[1] SAF: Safety Population. EFF: Efficacy Population. PP: Per Protocol Population.  
[2] Visit 2 is Week 0. Visit 3 is Week 4. Visit 4 is Week 8. Visit reflects when the missing/interrupted dose was reported, not necessarily when the dose was missed/interrupted. 
Source: SDTM.XXXX or ADaM.XXXX 
Program Name: XXXX.SAS 
 
Date: DDMMMYYYY 
 
 
 


 
Statistical Analysis Plan 
 
 
Confidential | MEIN/20/ZoAm-Hyp/001 | Plan Version No.: 2.0 | Plan Date: 23May2022 
Page 52 of 64 
 
 
 
Listing 16.2.6 
Mean Sitting Systolic and Diastolic Blood Pressure Details 
(Efficacy Population) 
 
Patient ID 
Analysis 
Population [1] 
Treatment 
Subgroup [2] 
 
Visit [3]  
Date/Time of  
Assessment 
 
Parameter (Unit) 
 
Result [4] 
Normality and  
Clinical Significance 
Met BP  
Goal [5] 
Up-Titrated  
at Visit 3 [6] 
xxxxxx 
SAF, 
EFF, 
PP 
 
ZOF/AML, 
ACE-i/CCB 
Visit 1, 
Visit 2, 
Visit 3, 
Visit 4 
DDMMMYYYY/HH:MM 
SBP (mmHg), 
DBP (mmHg) 
xx.x, 
xx.x* 
Normal, 
Abnormal NCS, 
Abnormal CS 
Yes, No 
Yes, No 
[1] SAF: Safety Population. EFF: Efficacy Population. PP: Per Protocol Population.  
[2] ZOF/AML subgroup: Patients who were on ZOF 30 mg or AML 5 mg at Visit 1 (Week -4) and continued on same therapies. ACE-i/CCB subgroup: Patients who switched to ZOF 
30 mg or AML 5 mg from any other ACE-I or CCBs at Visit 1 (Week -4). 
[3] Visit 1 is Week -4. Visit 2 is Week 0. Visit 3 is Week 4. Visit 4 is Week 8. 
[4] Results imputed using Last Observation Carried Forward (LOCF) are noted with *. 
[5] A patient is considered to have met the Blood Pressure (BP) goal (controlled BP) if their SBP ≤ 130 mmHg AND their DBP ≤ 80 mmHg. 
[6] Patients uncontrolled at Visit 3 are those who have SBP/DBP > 130/80 mmHg. These patients are up-titrated from ZOF/AML 30/5 mg to ZOF/AML 30/10 mg.   
Source: SDTM.XXXX or ADaM.XXXX 
Program Name: XXXX.SAS 
 
Date: DDMMMYYYY 
 
Programming Note: 
 
Analysis Population column should list all populations to which the patient belongs. 
 
 


 
Statistical Analysis Plan 
 
 
Confidential | MEIN/20/ZoAm-Hyp/001 | Plan Version No.: 2.0 | Plan Date: 23May2022 
Page 53 of 64 
 
 
 
 
Listing 16.2.7.1 
Adverse Events 
(Safety Population) 
 
Patient ID 
Analysis  
Population [1] 
System Organ Class/ 
     Preferred Term [2] 
 
AE # 
 
CM # 
 
Start Date 
End Date/ 
Ongoing 
Serious 
 
SAE Criteria 
Treatment 
Emergent [3] 
Therapy  
Period [4] 
xxxxxx 
 
SAF, 
EFF, 
PP 
 
xxxxxxx/ 
      xxxxxxxx 
 
xxx 
xxx 
DDMMMYYYY 
 
DDMMMYYYY, 
Ongoing 
Yes, No 
 
xxxxx  
Yes, No 
M, C 
[1] SAF: Safety Population. EFF: Efficacy Population. PP: Per Protocol Population.  
[2] MedDRA Dictionary version XX.X was used to code adverse events. 
[3] Treatment-Emergent Adverse Event. Defined as AEs that occur after the first dose of monotherapy of ZOF or AML. 
[4] M: Monotherapy Period. C: Combined Therapy Period. 
Source: SDTM.XXXX or ADaM.XXXX 
Program Name: XXXX.SAS 
 
Date: DDMMMYYYY 
 
Programming Note: 
 
Analysis Population column should list all populations to which the patient belongs. 
 
 
 


 
Statistical Analysis Plan 
 
 
Confidential | MEIN/20/ZoAm-Hyp/001 | Plan Version No.: 2.0 | Plan Date: 23May2022 
Page 54 of 64 
 
 
 
Listing 16.2.7.2 
Adverse Event Details 
(Safety Population) 
 
Patient ID 
Analysis  
Population [1] 
System Organ Class/ 
Preferred Term [2] 
 
AE # 
 
Severity 
 
Relationship 
 
Outcome 
 
Action Taken 
Led to Study 
Discontinuation 
xxxxxx 
 
SAF, 
EFF, 
PP 
 
xxxxxxx/ 
      xxxxxxxx 
 
xxx 
Mild, 
Moderate, 
Severe 
Not Related, 
Unlikely, 
Possible, 
Probable, 
Certain, 
Un-assessable 
Resolved, 
Resolving,  
Not Resolved, 
Resolved with Sequelae, 
Fatal, 
Unknown 
 
Withdrawn, 
Dose Reduced, 
Increased, 
Not Changed, 
Unknown, 
Not Applicable 
Yes, No 
[1] SAF: Safety Population. EFF: Efficacy Population. PP: Per Protocol Population.  
[2] MedDRA Dictionary version XX.X was used to code adverse events. 
Source: SDTM.XXXX or ADaM.XXXX 
Program Name: XXXX.SAS 
 
Date: DDMMMYYYY 
 
Programming Note: 
 
Analysis Population column should list all populations to which the patient belongs. 
 
 
 


 
Statistical Analysis Plan 
 
 
Confidential | MEIN/20/ZoAm-Hyp/001 | Plan Version No.: 2.0 | Plan Date: 23May2022 
Page 55 of 64 
 
 
 
Listing 16.2.7.3 
Deaths 
(Safety Population) 
 
Patient ID 
Analysis  
Population [1] 
Date/Time of First Dose 
Date/Time of Last Dose 
 
Date of Death 
System Organ Class/ 
Preferred Term [2] 
 
AE # 
xxxxxx 
 
SAF, 
EFF, 
PP 
 
DDMMMYYYY/HH:MM 
DDMMMYYYY/HH:MM 
DDMMMYYYY 
xxxxxxx/ 
      xxxxxxxx 
 
xxx 
[1] SAF: Safety Population. EFF: Efficacy Population. PP: Per Protocol Population.  
[2] MedDRA Dictionary version XX.X was used to code adverse events. 
Source: SDTM.XXXX or ADaM.XXXX 
Program Name: XXXX.SAS  
Date: DDMMMYYYY 
 
Programming Note: 
 
Analysis Population column should list all populations to which the patient belongs. 
 
 
 


 
Statistical Analysis Plan 
 
 
Confidential | MEIN/20/ZoAm-Hyp/001 | Plan Version No.: 2.0 | Plan Date: 23May2022 
Page 56 of 64 
 
 
 
Listing 16.2.8.1 
Haematology Parameters 
(Safety Population) 
 
Patient ID 
Analysis Population 
[1] 
 
Visit [2] 
 
Date/Time of Assessment 
 
Parameter (Unit) 
 
Result 
 
Normality 
Clinically 
Significant 
xxxxxx 
 
SAF, 
EFF, 
PP 
 
Visit 1, 
Visit 4 
 
DDMMMYYYY/HH:MM 
xxxxxxxx (xxx) 
 
xx.x 
Normal, 
Abnormal 
Yes, No 
[1] SAF: Safety Population. EFF: Efficacy Population. PP: Per Protocol Population.  
[2] Visit 1 is Week -4. Visit 4 is Week 8.  
Source: SDTM.XXXX or ADaM.XXXX 
Program Name: XXXX.SAS 
 
Date: DDMMMYYYY 
 
Programming Note: 
 
Analysis Population column should list all populations to which the patient belongs. 
 
Repeat for 16.2.8.2 – Serum Chemistry Parameters – Safety Population 
 
 
 


 
Statistical Analysis Plan 
 
 
Confidential | MEIN/20/ZoAm-Hyp/001 | Plan Version No.: 2.0 | Plan Date: 23May2022 
Page 57 of 64 
 
 
 
Listing 16.2.8.3 
Pregnancy Test 
(Safety Population) 
 
Patient ID 
Analysis  
Population [1] 
 
Visit [2] 
 
Date of Assessment 
 
Result  
 
Reason Not Done 
xxxxxx 
 
SAF, 
EFF, 
PP 
 
Visit 1, 
Visit 2, 
Visit 3, 
Visit 4 
 
DDMMMYYYY 
Not Done, 
Positive, 
Negative 
 
Subject is surgically sterile, 
Subject is post-menopausal, 
Other (specify) 
 
[1] SAF: Safety Population. EFF: Efficacy Population. PP: Per Protocol Population.  
[2] Visit 1 is Week -4. Visit 2 is Week 0. Visit 3 is Week 4. Visit 4 is Week 8. 
Source: SDTM.XXXX or ADaM.XXXX 
Program Name: XXXX.SAS 
 
Date: DDMMMYYYY 
 
Programming Note: 
 
Analysis Population column should list all populations to which the patient belongs. 
 
 
 


 
Statistical Analysis Plan 
 
 
Confidential | MEIN/20/ZoAm-Hyp/001 | Plan Version No.: 2.0 | Plan Date: 23May2022 
Page 58 of 64 
 
 
 
Listing 16.2.9 
Vital Signs 
(Safety Population) 
 
Patient ID 
Analysis  
Population [1] 
 
Visit [2] 
 
Date/Time of Assessment 
 
Parameter (Unit) 
 
Result 
 
Normality 
Clinically  
Significant 
 
Position 
 
Arm 
xxxxxx 
 
SAF, 
EFF, 
PP 
 
Visit 1, 
Visit 2, 
Visit 3, 
Visit 4 
 
DDMMMYYYY/HH:MM 
xxxxxxxx (xxx) 
 
xx.x 
Normal, 
Abnormal 
Yes, No 
Sitting, 
Standing 
Left, 
Right 
[1] SAF: Safety Population. EFF: Efficacy Population. PP: Per Protocol Population.  
[2] Visit 1 is Week -4. Visit 2 is Week 0. Visit 3 is Week 4. Visit 4 is Week 8. 
Source: SDTM.XXXX or ADaM.XXXX 
Program Name: XXXX.SAS 
 
Date: DDMMMYYYY 
 
Programming Note: 
 
Analysis Population column should list all populations to which the patient belongs. 
 
Last 2 columns will only be populated for blood pressure parameters. 
 
 


 
Statistical Analysis Plan 
 
 
Confidential | MEIN/20/ZoAm-Hyp/001 | Plan Version No.: 2.0 | Plan Date: 23May2022 
Page 59 of 64 
 
 
 
Listing 16.2.10 
Physical Examination 
(Safety Population) 
 
Patient ID 
 
Analysis Population [1] 
 
Visit [2] 
 
Date/Time of Assessment 
 
Body System 
 
Result 
Clinically 
Significant 
 
Specify Abnormality 
xxxxxx 
 
SAF, 
EFF, 
PP 
 
Visit 1, 
Visit 2, 
Visit 3, 
Visit 4 
 
DDMMMYYYY/HH:MM 
xxxxxxxx 
 
Normal, 
Abnormal 
Yes, No 
xxxxxxxx 
 
[1] SAF: Safety Population. EFF: Efficacy Population. PP: Per Protocol Population.  
[2] Visit 1 is Week -4. Visit 2 is Week 0. Visit 3 is Week 4. Visit 4 is Week 8. 
Source: SDTM.XXXX or ADaM.XXXX 
Program Name: XXXX.SAS 
 
Date: DDMMMYYYY 
 
Programming Note: 
 
Analysis Population column should list all populations to which the patient belongs. 
 
Height (cm), weight (kg), and BMI (kg/m2) are all presented in 16.2.4.1 and thus are not presented here. 
 
 
 


 
Statistical Analysis Plan 
 
 
Confidential | MEIN/20/ZoAm-Hyp/001 | Plan Version No.: 2.0 | Plan Date: 23May2022 
Page 60 of 64 
 
 
 
Listing 16.2.11 
Electrocardiogram (ECG) Parameters 
(Safety Population) 
 
Patient ID 
Analysis  
Population [1] 
 
Visit [2] 
 
ECG Number 
 
Date/Time of Assessment 
 
Parameter (Unit) 
 
Result 
Describe CS 
Interpretation 
xxxxxx 
 
SAF, 
EFF, 
PP 
 
Visit 1, 
Visit 4 
 
1, 2, 3 
DDMMMYYYY/HH:MM 
xxxxxxxx (xxx), 
Rhythm, 
Interpretation 
 
xx.x, 
Sinusal or Other (Specify), 
Normal, Abnormal NCS, or 
Abnormal CS 
 
 
 
xxxxxx 
[1] SAF: Safety Population. EFF: Efficacy Population. PP: Per Protocol Population.  
[2] Visit 1 is Week -4. Visit 4 is Week 8. 
Source: SDTM.XXXX or ADaM.XXXX 
Program Name: XXXX.SAS 
 
Date: DDMMMYYYY 
 
Programming Note: 
 
Analysis Population column should list all populations to which the patient belongs. 
 
Interpretation and Rhythm will be included as a separate parameter for each ECG number. 
 
 


 
Statistical Analysis Plan 
 
 
Confidential | MEIN/20/ZoAm-Hyp/001 | Plan Version No.: 2.0 | Plan Date: 23May2022 
Page 61 of 64 
 
 
 
Listing 16.2.12.1 
Prior and Concomitant Medications 
(Safety Population) 
 
Patient 
ID 
Analysis  
Population [1] 
ATC Class Level 1/ 
     Preferred Term [2] 
 
CM # 
Start Date / 
End Date or Ongoing 
Indication 
Dose 
(Unit) 
 
Form 
 
Frequency 
 
Route 
Prior 
Med [3,4] 
Treatment  
Given For 
xxxxxx 
 
SAF, 
EFF, 
PP 
 
xxxxxxx/ 
      xxxxxxxx 
 
xxx 
DDMMMYYYY/ 
DDMMMYYYY or 
Ongoing 
xxx 
 
xxx 
(xxx)  
xxx 
xxx 
xxx 
Yes, 
No 
MH #, 
AE #, 
Prophylactically, 
Other (Specify) 
[1] SAF: Safety Population. EFF: Efficacy Population. PP: Per Protocol Population.  
[2] WHO Drug Dictionary version YYYYMMM was used to code medication names. 
[3] Prior medication is defined as any medication taken within 30 days prior to the start of the study which has a stop date prior to the date of first dose of monotherapy. 
[4] Concomitant medication is defined as any medication with a start date on or before the date of last dose of study drug and is ongoing or has a stop date on or after date of 
first dose of monotherapy.  
Source: SDTM.XXXX or ADaM.XXXX 
Program Name: XXXX.SAS 
 
Date: DDMMMYYYY 
 
Programming Note: 
 
Analysis Population column should list all populations to which the patient belongs. 
 
 


 
Statistical Analysis Plan 
 
 
Confidential | MEIN/20/ZoAm-Hyp/001 | Plan Version No.: 2.0 | Plan Date: 23May2022 
Page 62 of 64 
 
 
 
Listing 16.2.12.2 
Non-Drug Treatments/Procedures 
(Safety Population) 
 
Patient ID 
Analysis  
Population [1] 
System Organ Class/ 
Preferred Term [2] 
 
PR # 
 
Procedure Date 
 
Indication 
Treatment  
Given For 
xxxxxx 
 
SAF, 
EFF, 
PP 
 
xxxxxxx/ 
      xxxxxxxx 
 
xxx 
DDMMMYYYY 
 
xxx 
MH #, 
AE #, 
Prophylactically, 
Other (Specify) 
 
[1] SAF: Safety Population. EFF: Efficacy Population. PP: Per Protocol Population.  
[2] MedDRA Dictionary version XX.X was used to code non-drug treatments/procedures.  
Source: SDTM.XXXX or ADaM.XXXX 
Program Name: XXXX.SAS 
 
Date: DDMMMYYYY 
 
Programming Note: 
 
Analysis Population column should list all populations to which the patient belongs. 
 
 
 


 
Statistical Analysis Plan 
 
 
Confidential | MEIN/20/ZoAm-Hyp/001 | Plan Version No.: 2.0 | Plan Date: 23May2022 
Page 63 of 64 
 
 
 
Listing 16.2.13 
Medical History 
(Safety Population) 
 
Patient ID 
Analysis  
Population [1] 
System Organ Class/ 
     Preferred Term [2] 
 
MH # 
 
Start Date  
Current  
Treatment 
 
CM # 
xxxxxx 
 
SAF, 
EFF, 
PP 
 
xxxxxxx/ 
      xxxxxxxx 
 
xxx 
DDMMMYYYY  
 
Yes, No 
 
xxx 
[1] SAF: Safety Population. EFF: Efficacy Population. PP: Per Protocol Population.  
[2] MedDRA Dictionary version XX.X was used to code medical history events. 
Source: SDTM.XXXX or ADaM.XXXX 
Program Name: XXXX.SAS 
 
Date: DDMMMYYYY 
 
Programming Note: 
 
Analysis Population column should list all populations to which the patient belongs. 
 
 
 


 
Statistical Analysis Plan 
 
 
Confidential | MEIN/20/ZoAm-Hyp/001 | Plan Version No.: 2.0 | Plan Date: 23May2022 
Page 64 of 64 
 
 
 
Listing 16.2.14 
Blood Pressure Device and Diary Details 
(Safety Population) 
 
Patient ID 
Analysis  
Population [1] 
Date of BP Device Dispense 
 
Date of BP Device Return 
 
Date of Diary Dispense 
 
Date of Diary Return 
xxxxxx 
 
SAF, 
EFF, 
PP 
 
DDMMMYYYY  
 
DDMMMYYYY  
 
DDMMMYYYY  
 
DDMMMYYYY 
[1] SAF: Safety Population. EFF: Efficacy Population. PP: Per Protocol Population.  
Source: SDTM.XXXX or ADaM.XXXX 
Program Name: XXXX.SAS 
 
Date: DDMMMYYYY 
 
Programming Note: 
 
Analysis Population column should list all populations to which the patient belongs. 


Certificate Of Completion
Envelope Id: 79F9064851814C909135C1D8212CA44F
Status: Completed
Subject: Please DocuSign: MEIN-20-ZoAm-Hyp-001 Statistical Analysis Plan v2.0 23May2022_clean.docx, MEIN...
Sponsor Project Code: 169-1
Quality Document Type: Not Applicable
Source Envelope: 
Document Pages: 100
Signatures: 6
Envelope Originator: 
Certificate Pages: 6
Initials: 0
Victoria Swaidan
AutoNav: Enabled
EnvelopeId Stamping: Disabled
Time Zone: (UTC-08:00) Pacific Time (US & Canada)
18851 NE 29th Ave #800
Aventura, FL  33180
vswaidan@biorasi.com
IP Address: 98.55.173.86   
Record Tracking
Status: Original
             5/24/2022 8:33:07 AM
Holder: Victoria Swaidan
             vswaidan@biorasi.com
Location: DocuSign
Signer Events
Signature
Timestamp
Giorgio Reggiardo
giorgioreggiardo@cvbf.net
Security Level: Email, Account Authentication 
(Required)
Signature Adoption: Pre-selected Style
Signed by link sent to giorgioreggiardo@cvbf.net
Signature ID: 
55ABF8D8-F49E-4652-84E3-30F8AB1E18C8
Using IP Address: 93.32.76.148
With Signing Authentication via DocuSign password
With Signing Reasons (on each tab): 
   Approvo il documento
Sent: 5/24/2022 8:38:07 AM
Viewed: 5/24/2022 9:56:22 PM 
Signed: 5/24/2022 9:57:13 PM
Electronic Record and Signature Disclosure: 
      Accepted: 5/24/2022 9:56:22 PM
      ID: b8ba5121-ed9e-4f6d-ad89-fdd48ee3aaa3
Hanna Lytvynenko
hlytvynenko@biorasi.com
Security Level: Email, Account Authentication 
(Required)
Signature Adoption: Pre-selected Style
Signed by link sent to hlytvynenko@biorasi.com
Signature ID: 
3BBBAE2E-DC07-497E-965F-70C9C798DB1D
Using IP Address: 176.113.166.5
With Signing Authentication via DocuSign password
With Signing Reasons (on each tab): 
   I approve this document
Sent: 5/24/2022 8:38:05 AM
Viewed: 5/25/2022 2:34:25 AM 
Signed: 5/25/2022 2:34:52 AM
Electronic Record and Signature Disclosure: 
      Not Offered via DocuSign


Signer Events
Signature
Timestamp
John Reber
jreber@biorasi.com
Security Level: Email, Account Authentication 
(Required)
Signature Adoption: Pre-selected Style
Signed by link sent to jreber@biorasi.com
Signature ID: 
CC5A8051-CACD-4A8C-AFD6-A96A3092CB46
Using IP Address: 66.228.227.97
With Signing Authentication via DocuSign password
With Signing Reasons (on each tab): 
   I approve this document
Sent: 5/24/2022 8:38:05 AM
Viewed: 5/24/2022 8:41:36 AM 
Signed: 5/24/2022 8:41:46 AM
Electronic Record and Signature Disclosure: 
      Accepted: 2/14/2021 9:23:55 AM
      ID: 7ebbb550-6705-417a-af0e-7c752602df9c
Julia Solovyeva
jsolovyeva@biorasi.com
Project Manager II
Biorasi
Security Level: Email, Account Authentication 
(Required)
Signature Adoption: Pre-selected Style
Signed by link sent to jsolovyeva@biorasi.com
Signature ID: 
E17D0303-84C0-43B8-93BD-F491C8A6193A
Using IP Address: 80.250.209.54
With Signing Authentication via DocuSign password
With Signing Reasons (on each tab): 
   I approve this document
Sent: 5/24/2022 8:38:06 AM
Viewed: 5/24/2022 8:42:28 AM 
Signed: 5/24/2022 8:42:46 AM
Electronic Record and Signature Disclosure: 
      Not Offered via DocuSign
Paolo Fabrizzi
pfabrizzi@menarini.it
Paolo Fabrizzi
Security Level: Email, Account Authentication 
(Required)
Signature Adoption: Pre-selected Style
Signed by link sent to pfabrizzi@menarini.it
Signature ID: 
9D1DC95A-F30F-4AA9-B407-09F91A9C3C83
Using IP Address: 151.11.86.7
With Signing Authentication via DocuSign password
With Signing Reasons (on each tab): 
   I approve this document
Sent: 5/24/2022 8:38:06 AM
Viewed: 5/24/2022 10:31:46 AM 
Signed: 5/24/2022 10:32:02 AM
Electronic Record and Signature Disclosure: 
      Accepted: 8/13/2021 10:05:10 AM
      ID: 23af8ef9-0ece-4677-92ca-1fb5d97b1ff9


Signer Events
Signature
Timestamp
Victoria Swaidan
vswaidan@biorasi.com
Biorasi
Security Level: Email, Account Authentication 
(Required)
Signature Adoption: Pre-selected Style
Signed by link sent to vswaidan@biorasi.com
Signature ID: 
F18BA1C2-BF7C-48A4-B775-BE54652AC840
Using IP Address: 98.55.173.86
With Signing Authentication via DocuSign password
With Signing Reasons (on each tab): 
   I am the author of this document
Sent: 5/24/2022 8:38:05 AM
Viewed: 5/24/2022 8:38:25 AM 
Signed: 5/24/2022 8:38:38 AM
Electronic Record and Signature Disclosure: 
      Accepted: 6/24/2020 9:03:50 AM
      ID: 42b1d68e-a4bb-4cee-b689-c158e740ba19
In Person Signer Events
Signature
Timestamp
Editor Delivery Events
Status
Timestamp
Agent Delivery Events
Status
Timestamp
Intermediary Delivery Events
Status
Timestamp
Certified Delivery Events
Status
Timestamp
Carbon Copy Events
Status
Timestamp
Witness Events
Signature
Timestamp
Notary Events
Signature
Timestamp
Envelope Summary Events
Status
Timestamps
Envelope Sent
Hashed/Encrypted
5/24/2022 8:38:07 AM
Certified Delivered
Security Checked
5/24/2022 8:38:25 AM
Signing Complete
Security Checked
5/24/2022 8:38:38 AM
Completed
Security Checked
5/25/2022 2:34:52 AM
Payment Events
Status
Timestamps
Electronic Record and Signature Disclosure


ELECTRONIC RECORD AND SIGNATURE DISCLOSURE  
From time to time, Biorasi, LLC (we, us or Company) may be required by law to provide to you 
certain written notices or disclosures. Described below are the terms and conditions for providing 
to you such notices and disclosures electronically through the DocuSign system. Please read the 
information below carefully and thoroughly, and if you can access this information electronically 
to your satisfaction and agree to this Electronic Record and Signature Disclosure (ERSD), please 
confirm your agreement by selecting the check-box next to ‘I agree to use electronic records and 
signatures’ before clicking ‘CONTINUE’ within the DocuSign system. 
 
Getting paper copies  
At any time, you may request from us a paper copy of any record provided or made available 
electronically to you by us. You will have the ability to download and print documents we send 
to you through the DocuSign system during and immediately after the signing session and, if you 
elect to create a DocuSign account, you may access the documents for a limited period of time 
(usually 30 days) after such documents are first sent to you. After such time, if you wish for us to 
send you paper copies of any such documents from our office to you, you will be charged a 
$0.00 per-page fee. You may request delivery of such paper copies from us by following the 
procedure described below. 
 
Withdrawing your consent  
If you decide to receive notices and disclosures from us electronically, you may at any time 
change your mind and tell us that thereafter you want to receive required notices and disclosures 
only in paper format. How you must inform us of your decision to receive future notices and 
disclosure in paper format and withdraw your consent to receive notices and disclosures 
electronically is described below. 
 
Consequences of changing your mind  
If you elect to receive required notices and disclosures only in paper format, it will slow the 
speed at which we can complete certain steps in transactions with you and delivering services to 
you because we will need first to send the required notices or disclosures to you in paper format, 
and then wait until we receive back from you your acknowledgment of your receipt of such 
paper notices or disclosures. Further, you will no longer be able to use the DocuSign system to 
receive required notices and consents electronically from us or to sign electronically documents 
from us. 
 
All notices and disclosures will be sent to you electronically  
Electronic Record and Signature Disclosure created on: 3/20/2020 6:43:22 PM
Parties agreed to: Giorgio Reggiardo, John Reber, Paolo Fabrizzi, Victoria Swaidan


Unless you tell us otherwise in accordance with the procedures described herein, we will provide 
electronically to you through the DocuSign system all required notices, disclosures, 
authorizations, acknowledgements, and other documents that are required to be provided or made 
available to you during the course of our relationship with you. To reduce the chance of you 
inadvertently not receiving any notice or disclosure, we prefer to provide all of the required 
notices and disclosures to you by the same method and to the same address that you have given 
us. Thus, you can receive all the disclosures and notices electronically or in paper format through 
the paper mail delivery system. If you do not agree with this process, please let us know as 
described below. Please also see the paragraph immediately above that describes the 
consequences of your electing not to receive delivery of the notices and disclosures 
electronically from us. 
 
How to contact Biorasi, LLC:  
You may contact us to let us know of your changes as to how we may contact you electronically, 
to request paper copies of certain information from us, and to withdraw your prior consent to 
receive notices and disclosures electronically as follows: 
To contact us by email send messages to: mrudolph@biorasi.com 
 
To advise Biorasi, LLC of your new email address  
To let us know of a change in your email address where we should send notices and disclosures 
electronically to you, you must send an email message to us at mrudolph@biorasi.com and in the 
body of such request you must state: your previous email address, your new email address.  We 
do not require any other information from you to change your email address.  
If you created a DocuSign account, you may update it with your new email address through your 
account preferences.  
 
To request paper copies from Biorasi, LLC  
To request delivery from us of paper copies of the notices and disclosures previously provided 
by us to you electronically, you must send us an email to mrudolph@biorasi.com and in the body 
of such request you must state your email address, full name, mailing address, and telephone 
number. We will bill you for any fees at that time, if any. 
 
To withdraw your consent with Biorasi, LLC  
To inform us that you no longer wish to receive future notices and disclosures in electronic 
format you may: 


i. decline to sign a document from within your signing session, and on the subsequent page, 
select the check-box indicating you wish to withdraw your consent, or you may; 
ii. send us an email to mrudolph@biorasi.com and in the body of such request you must state 
your email, full name, mailing address, and telephone number. We do not need any other 
information from you to withdraw consent..  The consequences of your withdrawing consent for 
online documents will be that transactions may take a longer time to process.. 
 
Required hardware and software  
The minimum system requirements for using the DocuSign system may change over time. The 
current system requirements are found here: https://support.docusign.com/guides/signer-guide-
signing-system-requirements.  
 
Acknowledging your access and consent to receive and sign documents electronically  
To confirm to us that you can access this information electronically, which will be similar to 
other electronic notices and disclosures that we will provide to you, please confirm that you have 
read this ERSD, and (i) that you are able to print on paper or electronically save this ERSD for 
your future reference and access; or (ii) that you are able to email this ERSD to an email address 
where you will be able to print on paper or save it for your future reference and access. Further, 
if you consent to receiving notices and disclosures exclusively in electronic format as described 
herein, then select the check-box next to ‘I agree to use electronic records and signatures’ before 
clicking ‘CONTINUE’ within the DocuSign system. 
By selecting the check-box next to ‘I agree to use electronic records and signatures’, you confirm 
that: 
 
You can access and read this Electronic Record and Signature Disclosure; and 
 
You can print on paper this Electronic Record and Signature Disclosure, or save or send 
this Electronic Record and Disclosure to a location where you can print it, for future 
reference and access; and 
 
Until or unless you notify Biorasi, LLC as described above, you consent to receive 
exclusively through electronic means all notices, disclosures, authorizations, 
acknowledgements, and other documents that are required to be provided or made 
available to you by Biorasi, LLC during the course of your relationship with Biorasi, 
LLC.